PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
29456664-6	2018	HDAC2 expression was markedly reduced in the lung tissue of the COPD group compared with the control group, and treatment with Jinwei Tang + budesonide or theophylline + budesonide resulted in significant attenuation of the reduction of HDAC2 expression in the lungs (P<0.05).	Budesonide	141-151	histone deacetylase 2	Rattus norvegicus	0-5
29456664-6	2018	HDAC2 expression was markedly reduced in the lung tissue of the COPD group compared with the control group, and treatment with Jinwei Tang + budesonide or theophylline + budesonide resulted in significant attenuation of the reduction of HDAC2 expression in the lungs (P<0.05).	Budesonide	141-151	histone deacetylase 2	Rattus norvegicus	237-242
29456664-6	2018	HDAC2 expression was markedly reduced in the lung tissue of the COPD group compared with the control group, and treatment with Jinwei Tang + budesonide or theophylline + budesonide resulted in significant attenuation of the reduction of HDAC2 expression in the lungs (P<0.05).	Budesonide	170-180	histone deacetylase 2	Rattus norvegicus	0-5
29456664-6	2018	HDAC2 expression was markedly reduced in the lung tissue of the COPD group compared with the control group, and treatment with Jinwei Tang + budesonide or theophylline + budesonide resulted in significant attenuation of the reduction of HDAC2 expression in the lungs (P<0.05).	Budesonide	170-180	histone deacetylase 2	Rattus norvegicus	237-242
29456664-8	2018	In the Jinwei Tang + budesonide and theophylline + budesonide groups, IL-8 and TNF-alpha expression was significantly decreased (P<0.05) and the HDAC2 level increased (P<0.05) compared with that in the COPD group.	Budesonide	21-31	tumor necrosis factor	Rattus norvegicus	79-88
29456664-8	2018	In the Jinwei Tang + budesonide and theophylline + budesonide groups, IL-8 and TNF-alpha expression was significantly decreased (P<0.05) and the HDAC2 level increased (P<0.05) compared with that in the COPD group.	Budesonide	21-31	histone deacetylase 2	Rattus norvegicus	148-153
29456664-8	2018	In the Jinwei Tang + budesonide and theophylline + budesonide groups, IL-8 and TNF-alpha expression was significantly decreased (P<0.05) and the HDAC2 level increased (P<0.05) compared with that in the COPD group.	Budesonide	51-61	tumor necrosis factor	Rattus norvegicus	79-88
29489916-10	2018	The combination of tiotropium with budesonide inhibits cadmium-induced inflammatory injuries with a synergistic interaction on MMP-2 and MMP-9 activity and airway hyper-responsiveness.	Budesonide	35-45	matrix metallopeptidase 2	Rattus norvegicus	127-132
29489916-10	2018	The combination of tiotropium with budesonide inhibits cadmium-induced inflammatory injuries with a synergistic interaction on MMP-2 and MMP-9 activity and airway hyper-responsiveness.	Budesonide	35-45	matrix metallopeptidase 9	Rattus norvegicus	137-142
29416153-0	2018	Effect of inhaled budesonide suspension, administered using a metered dose inhaler, on post-operative sore throat, hoarseness of voice and cough.	Budesonide	18-28	solute carrier family 35 member G1	Homo sapiens	87-91
29416153-2	2018	This study was performed to compare the effect of inhaled budesonide suspension, administered using a metered dose inhaler, on the incidence and severity of POST.	Budesonide	58-68	solute carrier family 35 member G1	Homo sapiens	157-161
29416153-12	2018	Conclusion: Inhaled budesonide suspension is effective in significantly reducing the incidence and severity of POST.	Budesonide	20-30	solute carrier family 35 member G1	Homo sapiens	111-115
29246209-9	2017	CONCLUSIONS: Our findings suggests that AACs (especially instillation of budesonide using surfactant as a vehicle) are an effective and safe option for preventing BPD in preterm infants.	Budesonide	73-83	acetoacetyl-CoA synthetase	Homo sapiens	40-44
29649811-11	2018	Moreover, budesonide decreased CDK9 phosphorylation and markedly inhibited IL-17F-induced IL-8 production.	Budesonide	10-20	cyclin dependent kinase 9	Homo sapiens	31-35
29649811-11	2018	Moreover, budesonide decreased CDK9 phosphorylation and markedly inhibited IL-17F-induced IL-8 production.	Budesonide	10-20	interleukin 17F	Homo sapiens	75-81
29649811-11	2018	Moreover, budesonide decreased CDK9 phosphorylation and markedly inhibited IL-17F-induced IL-8 production.	Budesonide	10-20	C-X-C motif chemokine ligand 8	Homo sapiens	90-94
29075337-7	2017	Expression of OMP in the olfactory epithelium was upregulated in the budesonide group A and betamethasone group A compared with the medicine-free group, whereas the expression of OMP in the olfactory epithelium of budesonide group A or betamethasone group A was not significantly different from the control group.	Budesonide	69-79	olfactory marker protein	Mus musculus	14-17
29255358-0	2017	Metabolic changes of different high-resolution computed tomography phenotypes of COPD after budesonide-formoterol treatment.	Budesonide	92-102	COPD	Homo sapiens	81-85
29611642-0	2017	The effect of budesonide on the expression of Ki-67 and PCNA and the apoptotic index in dogs with inflammatory bowel disease.	Budesonide	14-24	proliferating cell nuclear antigen	Canis lupus familiaris	56-60
29611642-1	2017	The aim of this study was to determine the effect of budesonide on the expression of Ki-67 and PCNA proliferative antigens and the apoptotic index in the course of inflammatory bowel disease (IBD) and to evaluate the applicability of these markers in monitoring IBD treatment in dogs.	Budesonide	53-63	proliferating cell nuclear antigen	Canis lupus familiaris	95-99
29075337-7	2017	Expression of OMP in the olfactory epithelium was upregulated in the budesonide group A and betamethasone group A compared with the medicine-free group, whereas the expression of OMP in the olfactory epithelium of budesonide group A or betamethasone group A was not significantly different from the control group.	Budesonide	214-224	olfactory marker protein	Mus musculus	14-17
29075337-8	2017	Moreover, the expression of OMP in the budesonide group B was similar to budesonide group A, and expression of OMP in betamethasone group B was similar to betamethasone group A.	Budesonide	39-49	olfactory marker protein	Mus musculus	28-31
29140131-3	2017	This study was to investigate the effects and potential mechanisms of inhaled budesonide on the expressions of LIGHT and its receptors (LTbetaR and HVEM) of lung tissues in ovalbumin-sensitized mice.	Budesonide	78-88	lymphotoxin B receptor	Mus musculus	136-143
29140131-3	2017	This study was to investigate the effects and potential mechanisms of inhaled budesonide on the expressions of LIGHT and its receptors (LTbetaR and HVEM) of lung tissues in ovalbumin-sensitized mice.	Budesonide	78-88	tumor necrosis factor receptor superfamily, member 14 (herpesvirus entry mediator)	Mus musculus	148-152
29140131-9	2017	RESULTS: Inhaled budesonide significantly reduced protein and mRNA levels of lung LIGHT, LTbetaR, and HVEM in asthmatic mice.	Budesonide	17-27	lymphotoxin B receptor	Mus musculus	89-96
29140131-9	2017	RESULTS: Inhaled budesonide significantly reduced protein and mRNA levels of lung LIGHT, LTbetaR, and HVEM in asthmatic mice.	Budesonide	17-27	tumor necrosis factor receptor superfamily, member 14 (herpesvirus entry mediator)	Mus musculus	102-106
29140131-10	2017	Correspondingly, the number of eosinophils and neutrophils and IL-6 levels in BALF after budesonide treatment were found to be decreased, whereas the IFN-gamma levels in BALF were increased.	Budesonide	89-99	interleukin 6	Mus musculus	63-67
29140131-12	2017	CONCLUSIONS: Inhaled budesonide can down-regulate the expressions of LIGHT, LTbetaR, and HVEM in the lungs of asthmatic mice, and LIGHT/LTbetaR/HVEM interactions may be a potentially key target for asthma treatment.	Budesonide	21-31	lymphotoxin B receptor	Mus musculus	76-83
29140131-12	2017	CONCLUSIONS: Inhaled budesonide can down-regulate the expressions of LIGHT, LTbetaR, and HVEM in the lungs of asthmatic mice, and LIGHT/LTbetaR/HVEM interactions may be a potentially key target for asthma treatment.	Budesonide	21-31	tumor necrosis factor receptor superfamily, member 14 (herpesvirus entry mediator)	Mus musculus	89-93
29140131-12	2017	CONCLUSIONS: Inhaled budesonide can down-regulate the expressions of LIGHT, LTbetaR, and HVEM in the lungs of asthmatic mice, and LIGHT/LTbetaR/HVEM interactions may be a potentially key target for asthma treatment.	Budesonide	21-31	lymphotoxin B receptor	Mus musculus	136-143
29140131-12	2017	CONCLUSIONS: Inhaled budesonide can down-regulate the expressions of LIGHT, LTbetaR, and HVEM in the lungs of asthmatic mice, and LIGHT/LTbetaR/HVEM interactions may be a potentially key target for asthma treatment.	Budesonide	21-31	tumor necrosis factor receptor superfamily, member 14 (herpesvirus entry mediator)	Mus musculus	144-148
28264206-7	2017	The observed effects on protein release were comparable to the effect of budesonide, which decreased TNFalpha and CXCL13 and enhanced interleukin-10 release.The components of the herbal medicinal product influence the activity of activated human macrophages on both gene and protein level.	Budesonide	73-83	tumor necrosis factor	Homo sapiens	101-109
27929704-5	2017	With TBH, the plot of drug release vs. PIF either at level or at tilted position scattered along approximately the same regression lines.	Budesonide	5-8	PIF1 5'-to-3' DNA helicase	Homo sapiens	39-42
28832630-0	2017	Long-term treatment with budesonide/formoterol attenuates circulating CRP levels in chronic obstructive pulmonary disease patients of group D. BACKGROUND: The systemic inflammation is associated with clinical outcome and mortality in chronic obstructive pulmonary disease (COPD) patients.	Budesonide	25-35	C-reactive protein	Homo sapiens	70-73
28764781-12	2017	RESULTS: Extracts, budesonide and Co-administration significantly reduced allergen-induced increases in the serum levels of IL-4, IL-5 and IgE, the number of eosinophils in BALF, goblet cell hyperplasia, Collagen III integral optical density (IOD) and the mRNA expression of TGF-beta2 and Smad2.	Budesonide	19-29	interleukin 4	Rattus norvegicus	124-128
28764781-12	2017	RESULTS: Extracts, budesonide and Co-administration significantly reduced allergen-induced increases in the serum levels of IL-4, IL-5 and IgE, the number of eosinophils in BALF, goblet cell hyperplasia, Collagen III integral optical density (IOD) and the mRNA expression of TGF-beta2 and Smad2.	Budesonide	19-29	interleukin 5	Rattus norvegicus	130-134
28264206-7	2017	The observed effects on protein release were comparable to the effect of budesonide, which decreased TNFalpha and CXCL13 and enhanced interleukin-10 release.The components of the herbal medicinal product influence the activity of activated human macrophages on both gene and protein level.	Budesonide	73-83	C-X-C motif chemokine ligand 13	Homo sapiens	114-120
28264206-7	2017	The observed effects on protein release were comparable to the effect of budesonide, which decreased TNFalpha and CXCL13 and enhanced interleukin-10 release.The components of the herbal medicinal product influence the activity of activated human macrophages on both gene and protein level.	Budesonide	73-83	interleukin 10	Homo sapiens	134-148
27746241-12	2017	Stimulation of primary bronchial epithelial cells with IL-17A enhanced mRNA expression of IL-17RA and increased release of IL-8, even in the presence of budesonide.	Budesonide	153-163	interleukin 17A	Homo sapiens	55-61
28301431-3	2017	Our aim was to elucidate the activity of CYP3A4 and P-gp in subjects with Crohn"s disease (CD) and to evaluate their influence on budesonide pharmacokinetics.	Budesonide	130-140	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	41-47
28301431-4	2017	METHODS: A detailed pharmacokinetic assessment was conducted in 8 individuals diagnosed with CD on stable doses of oral budesonide, a putative shared CYP3A4, and P-gp substrate, where hepatic and intestinal CYP3A4 activity were also assessed using intravenous and oral midazolam.	Budesonide	120-130	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	150-156
28301431-4	2017	METHODS: A detailed pharmacokinetic assessment was conducted in 8 individuals diagnosed with CD on stable doses of oral budesonide, a putative shared CYP3A4, and P-gp substrate, where hepatic and intestinal CYP3A4 activity were also assessed using intravenous and oral midazolam.	Budesonide	120-130	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	207-213
28039105-2	2017	In human bronchial epithelial, BEAS-2B, cells, expression of TNFalpha-induced protein-3 (TNFAIP3), or A20, a dual-ubiquitin ligase that provides feedback inhibition of NF-kappaB, was induced by budesonide, an ICS, and formoterol, a LABA, and was further enhanced by budesonide-formoterol combination.	Budesonide	266-276	TNF alpha induced protein 3	Homo sapiens	61-87
28358425-9	2017	Expression levels of ORMDL3, phosphorylated (p)-ERK and MMP-9 were significantly greater in the asthma-model group; however, in the group pretreated with budesonide their expression was reduced.	Budesonide	154-164	ORM1-like 3 (S. cerevisiae)	Mus musculus	21-27
28358425-9	2017	Expression levels of ORMDL3, phosphorylated (p)-ERK and MMP-9 were significantly greater in the asthma-model group; however, in the group pretreated with budesonide their expression was reduced.	Budesonide	154-164	mitogen-activated protein kinase 1	Mus musculus	48-51
28358425-9	2017	Expression levels of ORMDL3, phosphorylated (p)-ERK and MMP-9 were significantly greater in the asthma-model group; however, in the group pretreated with budesonide their expression was reduced.	Budesonide	154-164	matrix metallopeptidase 9	Mus musculus	56-61
27324471-11	2017	Enteric budesonide targeting Peyer"s patches at the ileocecal junction is an interesting option that has provided some preliminary favorable results in IgAN.	Budesonide	8-18	IGAN1	Homo sapiens	152-156
28039105-2	2017	In human bronchial epithelial, BEAS-2B, cells, expression of TNFalpha-induced protein-3 (TNFAIP3), or A20, a dual-ubiquitin ligase that provides feedback inhibition of NF-kappaB, was induced by budesonide, an ICS, and formoterol, a LABA, and was further enhanced by budesonide-formoterol combination.	Budesonide	266-276	TNF alpha induced protein 3	Homo sapiens	89-96
28039105-4	2017	Whereas subsequent budesonide treatment enhanced TNF-induced TNFAIP3 and reduced TNF expression, formoterol amplified these differential effects.	Budesonide	19-29	tumor necrosis factor	Homo sapiens	49-52
28039105-4	2017	Whereas subsequent budesonide treatment enhanced TNF-induced TNFAIP3 and reduced TNF expression, formoterol amplified these differential effects.	Budesonide	19-29	TNF alpha induced protein 3	Homo sapiens	61-68
28039105-4	2017	Whereas subsequent budesonide treatment enhanced TNF-induced TNFAIP3 and reduced TNF expression, formoterol amplified these differential effects.	Budesonide	19-29	tumor necrosis factor	Homo sapiens	61-64
28039105-8	2017	RELA binding was reduced by budesonide, was further reduced by formoterol cotreatment, and was associated with reduced RNA polymerase II recruitment to the TNF gene.	Budesonide	28-38	RELA proto-oncogene, NF-kB subunit	Homo sapiens	0-4
28039105-10	2017	TNFAIP3 knockdown enhanced TNF expression in the presence of TNF, TNF plus budesonide, and TNF plus budesonide-formoterol combination and confirms feedback inhibition.	Budesonide	75-85	TNF alpha induced protein 3	Homo sapiens	0-7
28039105-10	2017	TNFAIP3 knockdown enhanced TNF expression in the presence of TNF, TNF plus budesonide, and TNF plus budesonide-formoterol combination and confirms feedback inhibition.	Budesonide	75-85	tumor necrosis factor	Homo sapiens	0-3
28039105-10	2017	TNFAIP3 knockdown enhanced TNF expression in the presence of TNF, TNF plus budesonide, and TNF plus budesonide-formoterol combination and confirms feedback inhibition.	Budesonide	75-85	tumor necrosis factor	Homo sapiens	27-30
28039105-10	2017	TNFAIP3 knockdown enhanced TNF expression in the presence of TNF, TNF plus budesonide, and TNF plus budesonide-formoterol combination and confirms feedback inhibition.	Budesonide	75-85	tumor necrosis factor	Homo sapiens	27-30
28039105-10	2017	TNFAIP3 knockdown enhanced TNF expression in the presence of TNF, TNF plus budesonide, and TNF plus budesonide-formoterol combination and confirms feedback inhibition.	Budesonide	75-85	tumor necrosis factor	Homo sapiens	27-30
28039105-10	2017	TNFAIP3 knockdown enhanced TNF expression in the presence of TNF, TNF plus budesonide, and TNF plus budesonide-formoterol combination and confirms feedback inhibition.	Budesonide	100-110	TNF alpha induced protein 3	Homo sapiens	0-7
28039105-10	2017	TNFAIP3 knockdown enhanced TNF expression in the presence of TNF, TNF plus budesonide, and TNF plus budesonide-formoterol combination and confirms feedback inhibition.	Budesonide	100-110	tumor necrosis factor	Homo sapiens	0-3
28039105-10	2017	TNFAIP3 knockdown enhanced TNF expression in the presence of TNF, TNF plus budesonide, and TNF plus budesonide-formoterol combination and confirms feedback inhibition.	Budesonide	100-110	tumor necrosis factor	Homo sapiens	27-30
28039105-10	2017	TNFAIP3 knockdown enhanced TNF expression in the presence of TNF, TNF plus budesonide, and TNF plus budesonide-formoterol combination and confirms feedback inhibition.	Budesonide	100-110	tumor necrosis factor	Homo sapiens	27-30
28039105-10	2017	TNFAIP3 knockdown enhanced TNF expression in the presence of TNF, TNF plus budesonide, and TNF plus budesonide-formoterol combination and confirms feedback inhibition.	Budesonide	100-110	tumor necrosis factor	Homo sapiens	27-30
28039105-12	2017	Repression of reporter activity by budesonide was increased by formoterol and involved TNFAIP3.	Budesonide	35-45	TNF alpha induced protein 3	Homo sapiens	87-94
27623823-11	2017	However, western blotting showed that budesonide can significantly up-regulate the H1R, M1R and M3R level while azelastine had opposite effects.	Budesonide	38-48	histamine receptor H1	Homo sapiens	83-86
27822702-4	2017	A prescription of budesonide aqueous nasal spray 128 microg bid was given to all the subjects.	Budesonide	18-28	BH3 interacting domain death agonist	Homo sapiens	60-63
27623823-12	2017	Histamine and methacholine stimulated MUC5AC secretion was greater in cells treated with budesonide but was lesser in those treated with azelastine, as compared to controls.	Budesonide	89-99	mucin 5AC, oligomeric mucus/gel-forming	Homo sapiens	38-44
27623823-14	2017	Long-term use of budesonide might amplify histamine signaling and result in airway hyperreactivity to stimulants by enhancing H1R, M1R and M3R expression while azelastine can oppose this effect.	Budesonide	17-27	histamine receptor H1	Homo sapiens	126-129
28217046-7	2017	Furthermore, TNF-alpha, IL-1beta, and IL-6 were significantly reduced after budesonide nebulizations.	Budesonide	76-86	interleukin 1 beta	Homo sapiens	24-32
28352347-8	2017	Dexamethasone and budesonide groups exhibited significant protein and mRNA reductions in IL-25, as compared with the asthma group after excitation (P<0.05), whereas these two groups significantly increased levels compared with the normal group after excitation (P<0.05).	Budesonide	18-28	interleukin 25	Mus musculus	89-94
28039105-2	2017	In human bronchial epithelial, BEAS-2B, cells, expression of TNFalpha-induced protein-3 (TNFAIP3), or A20, a dual-ubiquitin ligase that provides feedback inhibition of NF-kappaB, was induced by budesonide, an ICS, and formoterol, a LABA, and was further enhanced by budesonide-formoterol combination.	Budesonide	194-204	TNF alpha induced protein 3	Homo sapiens	61-87
28039105-2	2017	In human bronchial epithelial, BEAS-2B, cells, expression of TNFalpha-induced protein-3 (TNFAIP3), or A20, a dual-ubiquitin ligase that provides feedback inhibition of NF-kappaB, was induced by budesonide, an ICS, and formoterol, a LABA, and was further enhanced by budesonide-formoterol combination.	Budesonide	194-204	TNF alpha induced protein 3	Homo sapiens	89-96
29236548-10	2017	Furthermore, treatment with budesonide significantly decreased the levels of MDA, MPO, and XO in the lung and the levels of TNF-alpha, IL-1beta, IL-6, and neutrophil elastase, but increased IL-10 in the BALF, accompanied by significantly reduced levels of serum P-selectin and LFA-1 in rats.	Budesonide	28-38	myeloperoxidase	Rattus norvegicus	82-85
29236548-10	2017	Furthermore, treatment with budesonide significantly decreased the levels of MDA, MPO, and XO in the lung and the levels of TNF-alpha, IL-1beta, IL-6, and neutrophil elastase, but increased IL-10 in the BALF, accompanied by significantly reduced levels of serum P-selectin and LFA-1 in rats.	Budesonide	28-38	tumor necrosis factor	Rattus norvegicus	124-133
29236548-10	2017	Furthermore, treatment with budesonide significantly decreased the levels of MDA, MPO, and XO in the lung and the levels of TNF-alpha, IL-1beta, IL-6, and neutrophil elastase, but increased IL-10 in the BALF, accompanied by significantly reduced levels of serum P-selectin and LFA-1 in rats.	Budesonide	28-38	interleukin 1 beta	Rattus norvegicus	135-143
29236548-10	2017	Furthermore, treatment with budesonide significantly decreased the levels of MDA, MPO, and XO in the lung and the levels of TNF-alpha, IL-1beta, IL-6, and neutrophil elastase, but increased IL-10 in the BALF, accompanied by significantly reduced levels of serum P-selectin and LFA-1 in rats.	Budesonide	28-38	interleukin 6	Rattus norvegicus	145-149
29236548-10	2017	Furthermore, treatment with budesonide significantly decreased the levels of MDA, MPO, and XO in the lung and the levels of TNF-alpha, IL-1beta, IL-6, and neutrophil elastase, but increased IL-10 in the BALF, accompanied by significantly reduced levels of serum P-selectin and LFA-1 in rats.	Budesonide	28-38	elastase, neutrophil expressed	Rattus norvegicus	155-174
29236548-10	2017	Furthermore, treatment with budesonide significantly decreased the levels of MDA, MPO, and XO in the lung and the levels of TNF-alpha, IL-1beta, IL-6, and neutrophil elastase, but increased IL-10 in the BALF, accompanied by significantly reduced levels of serum P-selectin and LFA-1 in rats.	Budesonide	28-38	interleukin 10	Rattus norvegicus	190-195
29236548-10	2017	Furthermore, treatment with budesonide significantly decreased the levels of MDA, MPO, and XO in the lung and the levels of TNF-alpha, IL-1beta, IL-6, and neutrophil elastase, but increased IL-10 in the BALF, accompanied by significantly reduced levels of serum P-selectin and LFA-1 in rats.	Budesonide	28-38	selectin P	Rattus norvegicus	262-272
29236548-10	2017	Furthermore, treatment with budesonide significantly decreased the levels of MDA, MPO, and XO in the lung and the levels of TNF-alpha, IL-1beta, IL-6, and neutrophil elastase, but increased IL-10 in the BALF, accompanied by significantly reduced levels of serum P-selectin and LFA-1 in rats.	Budesonide	28-38	integrin subunit alpha L	Rattus norvegicus	277-282
28731412-5	2017	RESULTS: Prior to treatment with budesonide, the E/I MF was significantly correlated with respiratory function, airway hyperresponsiveness, FeNO, and sputum eosinophil percentage.	Budesonide	33-43	MyoD family inhibitor	Homo sapiens	51-55
28731412-7	2017	With respect to the reference value, the E/I MF improved significantly in patients whose respiratory function and FeNO benefited from therapy with budesonide compared with patients whose respiratory function did not benefit from budesonide (odds ratios of 6.39 and 4.78, respectively).	Budesonide	147-157	MyoD family inhibitor	Homo sapiens	43-47
28217046-7	2017	Furthermore, TNF-alpha, IL-1beta, and IL-6 were significantly reduced after budesonide nebulizations.	Budesonide	76-86	tumor necrosis factor	Homo sapiens	13-22
28217046-7	2017	Furthermore, TNF-alpha, IL-1beta, and IL-6 were significantly reduced after budesonide nebulizations.	Budesonide	76-86	interleukin 6	Homo sapiens	38-42
28217046-9	2017	CONCLUSION: Nebulized budesonide improved oxygenation, peak, and plateau airway pressures and significantly reduced inflammatory markers (TNF-alpha, IL-1beta and IL-6) without affecting hemodynamics.	Budesonide	22-32	tumor necrosis factor	Homo sapiens	138-147
28217046-9	2017	CONCLUSION: Nebulized budesonide improved oxygenation, peak, and plateau airway pressures and significantly reduced inflammatory markers (TNF-alpha, IL-1beta and IL-6) without affecting hemodynamics.	Budesonide	22-32	interleukin 1 beta	Homo sapiens	149-157
28217046-9	2017	CONCLUSION: Nebulized budesonide improved oxygenation, peak, and plateau airway pressures and significantly reduced inflammatory markers (TNF-alpha, IL-1beta and IL-6) without affecting hemodynamics.	Budesonide	22-32	interleukin 6	Homo sapiens	162-166
26885197-11	2015	We conclude that erythromycin can enhance the anti-inflammatory activity of budesonide in COPD model rats, possibly through inhibiting the PI3K/AKT pathway and enhancing the activity of HDAC2.	Budesonide	76-86	AKT serine/threonine kinase 1	Rattus norvegicus	144-147
28119748-5	2017	METHODS: Effects of MF and budesonide (BUD) on the phorbol-12-myristate-13-acetate (PMA)-induction of mucin and TNF-alpha in human airway epithelial cells (NCI-H292) were investigated in the present study.	Budesonide	27-37	LOC100508689	Homo sapiens	102-107
28119748-5	2017	METHODS: Effects of MF and budesonide (BUD) on the phorbol-12-myristate-13-acetate (PMA)-induction of mucin and TNF-alpha in human airway epithelial cells (NCI-H292) were investigated in the present study.	Budesonide	27-37	tumor necrosis factor	Homo sapiens	112-121
28119748-5	2017	METHODS: Effects of MF and budesonide (BUD) on the phorbol-12-myristate-13-acetate (PMA)-induction of mucin and TNF-alpha in human airway epithelial cells (NCI-H292) were investigated in the present study.	Budesonide	39-42	LOC100508689	Homo sapiens	102-107
28119748-5	2017	METHODS: Effects of MF and budesonide (BUD) on the phorbol-12-myristate-13-acetate (PMA)-induction of mucin and TNF-alpha in human airway epithelial cells (NCI-H292) were investigated in the present study.	Budesonide	39-42	tumor necrosis factor	Homo sapiens	112-121
28511169-8	2017	AIM: To compare the impact of tofacitinib and budesonid on the mucous membrane of NUC patients.	Budesonide	46-55	nucleobindin 1	Homo sapiens	82-85
27281349-5	2016	Budesonide suppressed secreted chemokines IL-8 and CCL2 (MCP-1) within 4 hours, reaching a 90% decrease at 12 hours, which was fully reversed 72 hours after removal of the steroid.	Budesonide	0-10	C-X-C motif chemokine ligand 8	Homo sapiens	42-46
27281349-5	2016	Budesonide suppressed secreted chemokines IL-8 and CCL2 (MCP-1) within 4 hours, reaching a 90% decrease at 12 hours, which was fully reversed 72 hours after removal of the steroid.	Budesonide	0-10	C-C motif chemokine ligand 2	Homo sapiens	51-55
27281349-5	2016	Budesonide suppressed secreted chemokines IL-8 and CCL2 (MCP-1) within 4 hours, reaching a 90% decrease at 12 hours, which was fully reversed 72 hours after removal of the steroid.	Budesonide	0-10	C-C motif chemokine ligand 2	Homo sapiens	57-62
27527926-3	2016	We also designed a long-acting polyethylene glycol (PEG)-modified IL-2 and demonstrated that the optimal dosage form is IL-2(PEG) plus budesonide, which can upregulate Treg cells and ameliorate asthma at a lower dose.	Budesonide	135-145	interleukin 2	Mus musculus	66-70
27003559-3	2016	OBJECTIVE: To evaluate health care costs and utilization among COPD patients newly initiating ICS/LABA combination therapy with budesonide/formoterol (BFC) or fluticasone/salmeterol (FSC) in a managed care system.	Budesonide	128-138	COPD	Homo sapiens	63-67
27784958-7	2016	MCi presents clinical characteristics indistinguishable from complete MC with a good response to budesonide and cholestiramine.	Budesonide	97-107	multiciliate differentiation and DNA synthesis associated cell cycle protein	Homo sapiens	0-3
27498916-9	2016	The expression of Mac-1 and L-selectin decreased by 51.0% (P< .01) and 30.9% (P= .02), respectively, following face mask inhalation of budesonide and by 39.8% (P= .01) and 17.4% (P= .17), respectively, following inhalation of fluticasone.	Budesonide	138-148	integrin subunit alpha M	Homo sapiens	18-23
27498916-9	2016	The expression of Mac-1 and L-selectin decreased by 51.0% (P< .01) and 30.9% (P= .02), respectively, following face mask inhalation of budesonide and by 39.8% (P= .01) and 17.4% (P= .17), respectively, following inhalation of fluticasone.	Budesonide	138-148	selectin L	Homo sapiens	28-38
27635174-9	2016	Adjusted models demonstrated that receiving outpatient budesonide from 1 to 90 days and for > 90 days was associated with a lower likelihood of being admitted for a CD exacerbation (1 - 90 days: IRR 0.85; 95% CI 0.65 - 1.10; > 90 days: IRR 0.71; 95% CI 0.56 - 0.91).	Budesonide	55-65	insulin receptor related receptor	Homo sapiens	198-201
27635174-9	2016	Adjusted models demonstrated that receiving outpatient budesonide from 1 to 90 days and for > 90 days was associated with a lower likelihood of being admitted for a CD exacerbation (1 - 90 days: IRR 0.85; 95% CI 0.65 - 1.10; > 90 days: IRR 0.71; 95% CI 0.56 - 0.91).	Budesonide	55-65	insulin receptor related receptor	Homo sapiens	242-245
26971626-4	2016	RESULTS: We found that anti-inflammatory glucocorticoids, such as mometasone, budesonide, and fluticasone, increased mutant CFTR function.	Budesonide	78-88	CF transmembrane conductance regulator	Homo sapiens	124-128
27317302-0	2016	Budesonide, but not dexamethasone, blunted the response of aldosterone to renin elevation by suppressing angiotensin converting enzyme upon high-altitude exposure.	Budesonide	0-10	renin	Homo sapiens	74-79
27317302-3	2016	We aimed to investigate the effects of budesonide and dexamethasone on renin-angiotensin-aldosterone system in AMS prevention.	Budesonide	39-49	renin	Homo sapiens	71-76
27317302-9	2016	CONCLUSIONS: Upon acute high-altitude exposure, budesonide, but not dexamethasone, blunted the response of aldosterone to renin elevation by suppressing angiotensin converting enzyme.	Budesonide	48-58	renin	Homo sapiens	122-127
27260506-7	2016	The lung wet-to-dry weight ratio, total protein, neutrophil elastase level, and neutrophilcount in BALF were decreased in the budesonide group.	Budesonide	126-136	elastase, neutrophil expressed	Homo sapiens	49-68
27260506-11	2016	Bax, caspase-3, and cleaved caspase-3 were down-regulated, and Bcl-2 was up-regulated by budesonide.	Budesonide	89-99	BCL2 apoptosis regulator	Homo sapiens	63-68
26996478-0	2016	Effect of Inhaled Budesonide on Interleukin-4 and Interleukin-6 in Exhaled Breath Condensate of Asthmatic Patients.	Budesonide	18-28	interleukin 4	Homo sapiens	32-45
26996478-0	2016	Effect of Inhaled Budesonide on Interleukin-4 and Interleukin-6 in Exhaled Breath Condensate of Asthmatic Patients.	Budesonide	18-28	interleukin 6	Homo sapiens	50-63
26342671-7	2016	The number of cells CD3(+)CD8(-) and CD3(+)CD8(+) expressing of CXCR1 was significantly lower in the group of patients using more than 800mug of budesonide daily than in the group of patients using less than 400mug of budesonide.	Budesonide	145-155	CD8a molecule	Homo sapiens	26-29
26342671-7	2016	The number of cells CD3(+)CD8(-) and CD3(+)CD8(+) expressing of CXCR1 was significantly lower in the group of patients using more than 800mug of budesonide daily than in the group of patients using less than 400mug of budesonide.	Budesonide	145-155	CD8a molecule	Homo sapiens	43-46
26342671-7	2016	The number of cells CD3(+)CD8(-) and CD3(+)CD8(+) expressing of CXCR1 was significantly lower in the group of patients using more than 800mug of budesonide daily than in the group of patients using less than 400mug of budesonide.	Budesonide	145-155	C-X-C motif chemokine receptor 1	Homo sapiens	64-69
26342671-7	2016	The number of cells CD3(+)CD8(-) and CD3(+)CD8(+) expressing of CXCR1 was significantly lower in the group of patients using more than 800mug of budesonide daily than in the group of patients using less than 400mug of budesonide.	Budesonide	218-228	C-X-C motif chemokine receptor 1	Homo sapiens	64-69
26885197-11	2015	We conclude that erythromycin can enhance the anti-inflammatory activity of budesonide in COPD model rats, possibly through inhibiting the PI3K/AKT pathway and enhancing the activity of HDAC2.	Budesonide	76-86	histone deacetylase 2	Rattus norvegicus	186-191
26547326-9	2015	Budesonide can partially suppress airway remodeling and inflammation by regulating the expression of TRPC1.	Budesonide	0-10	short transient receptor potential channel 1	Cavia porcellus	101-106
25956681-14	2015	TNF-alpha, IL-1beta, and IL-8 levels decreased in BALF, while IL-10 levels increased in the budesonide group.	Budesonide	92-102	interleukin-10	Oryctolagus cuniculus	62-67
26496719-7	2015	RESULTS: Cathepsin-dependent fluorescence in DRA-sensitized mice resulted significantly increased at 6 and 8 weeks, and was markedly inhibited by budesonide.	Budesonide	146-156	solute carrier family 26, member 3	Mus musculus	45-48
26147243-1	2015	The aim of this study was to investigate the changes in transport and effectiveness of salbutamol sulfate (SAL) and budesonide (BD) following stimulation with transforming growth factor-beta (TGF-beta) in mono- and coculture models of bronchial and alveolar epithelium.	Budesonide	116-126	transforming growth factor beta 1	Homo sapiens	159-190
26147243-1	2015	The aim of this study was to investigate the changes in transport and effectiveness of salbutamol sulfate (SAL) and budesonide (BD) following stimulation with transforming growth factor-beta (TGF-beta) in mono- and coculture models of bronchial and alveolar epithelium.	Budesonide	116-126	transforming growth factor beta 1	Homo sapiens	192-200
25700603-6	2015	The administration of dexamethasone or budesonide to mice significantly decreased the mRNA expression of proglucagon in the ileum and partially decreased glucose-stimulated GLP-1 secretion.	Budesonide	39-49	glucagon	Mus musculus	173-178
25672589-7	2015	Furthermore, treatment with the glucocorticoid, budesonide, and the PLC inhibitor, U73,122, significantly suppressed the formoterol-induced upregulated protein expression levels of M3R and PLCbeta1 and production of IP3.	Budesonide	48-58	phospholipase C beta 1	Rattus norvegicus	189-197
25722071-0	2015	Budesonide increases TLR4 and TLR2 expression in Treg lymphocytes of allergic asthmatics.	Budesonide	0-10	toll like receptor 4	Homo sapiens	21-25
25722071-0	2015	Budesonide increases TLR4 and TLR2 expression in Treg lymphocytes of allergic asthmatics.	Budesonide	0-10	toll like receptor 2	Homo sapiens	30-34
25722071-2	2015	OBJECTIVES: In this study the effect of budesonide on the expression of TLR4 and TLR2 in T regulatory lymphocyte sub-population was assessed.	Budesonide	40-50	toll like receptor 4	Homo sapiens	72-76
25722071-2	2015	OBJECTIVES: In this study the effect of budesonide on the expression of TLR4 and TLR2 in T regulatory lymphocyte sub-population was assessed.	Budesonide	40-50	toll like receptor 2	Homo sapiens	81-85
25722071-4	2015	The in vitro effects of budesonide in modulating: TLR4 and TLR2 expression in controls and in asthmatics; IL-10 expression and cytokine release (IL-6 and TNF-alpha selected by a multiplex assay) in asthmatics were also explored.	Budesonide	24-34	toll like receptor 4	Homo sapiens	50-54
25722071-4	2015	The in vitro effects of budesonide in modulating: TLR4 and TLR2 expression in controls and in asthmatics; IL-10 expression and cytokine release (IL-6 and TNF-alpha selected by a multiplex assay) in asthmatics were also explored.	Budesonide	24-34	toll like receptor 2	Homo sapiens	59-63
25722071-4	2015	The in vitro effects of budesonide in modulating: TLR4 and TLR2 expression in controls and in asthmatics; IL-10 expression and cytokine release (IL-6 and TNF-alpha selected by a multiplex assay) in asthmatics were also explored.	Budesonide	24-34	interleukin 10	Homo sapiens	106-111
25722071-7	2015	Budesonide was able to increase the expression of TLR4, TLR2 and IL-10 in CD4+/CD25 highly+ cells from asthmatics.	Budesonide	0-10	toll like receptor 4	Homo sapiens	50-54
25722071-7	2015	Budesonide was able to increase the expression of TLR4, TLR2 and IL-10 in CD4+/CD25 highly+ cells from asthmatics.	Budesonide	0-10	toll like receptor 2	Homo sapiens	56-60
25722071-7	2015	Budesonide was able to increase the expression of TLR4, TLR2 and IL-10 in CD4+/CD25 highly+ cells from asthmatics.	Budesonide	0-10	interleukin 10	Homo sapiens	65-70
25722071-7	2015	Budesonide was able to increase the expression of TLR4, TLR2 and IL-10 in CD4+/CD25 highly+ cells from asthmatics.	Budesonide	0-10	interleukin 2 receptor subunit alpha	Homo sapiens	79-83
25722071-9	2015	Budesonide was also able to reduce the release of IL-6 and TNF-alpha by PBMC of asthmatics.	Budesonide	0-10	interleukin 6	Homo sapiens	50-54
25722071-9	2015	Budesonide was also able to reduce the release of IL-6 and TNF-alpha by PBMC of asthmatics.	Budesonide	0-10	tumor necrosis factor	Homo sapiens	59-68
25722071-10	2015	CONCLUSIONS: Budesonide potentiates the activity of Treg by increasing TLR4, TLR2 and IL-10 expression.	Budesonide	13-23	toll like receptor 4	Homo sapiens	71-75
25722071-10	2015	CONCLUSIONS: Budesonide potentiates the activity of Treg by increasing TLR4, TLR2 and IL-10 expression.	Budesonide	13-23	toll like receptor 2	Homo sapiens	77-81
25722071-10	2015	CONCLUSIONS: Budesonide potentiates the activity of Treg by increasing TLR4, TLR2 and IL-10 expression.	Budesonide	13-23	interleukin 10	Homo sapiens	86-91
25722071-11	2015	This event is associated to the decreased release of IL-6 and TNF-alpha in PBMC treated with budesonide.	Budesonide	93-103	interleukin 6	Homo sapiens	53-57
25722071-11	2015	This event is associated to the decreased release of IL-6 and TNF-alpha in PBMC treated with budesonide.	Budesonide	93-103	tumor necrosis factor	Homo sapiens	62-71
26108327-1	2015	OBJECTIVE: To determine the changes in the expression of leptin and its receptor in the lungs of mice with varying degrees of asthma before and after budesonide treatment.	Budesonide	150-160	leptin	Mus musculus	57-63
26108327-13	2015	Budesonide can increase the expression of leptin receptor, but has no significant impact on the expression of leptin.	Budesonide	0-10	leptin	Mus musculus	42-48
26191209-0	2015	Budesonide ameliorates lung function of the cigarette smoke-exposed rats through reducing matrix metalloproteinase-1 content.	Budesonide	0-10	matrix metallopeptidase 1	Rattus norvegicus	90-116
26191209-8	2015	Treatment with budesonide resulted in an obvious decrease in the MMP-1 but not MMP-2 and TIMP-2 productions (P<0.05).	Budesonide	15-25	matrix metallopeptidase 1	Rattus norvegicus	65-70
26191209-8	2015	Treatment with budesonide resulted in an obvious decrease in the MMP-1 but not MMP-2 and TIMP-2 productions (P<0.05).	Budesonide	15-25	matrix metallopeptidase 2	Rattus norvegicus	79-84
26191209-8	2015	Treatment with budesonide resulted in an obvious decrease in the MMP-1 but not MMP-2 and TIMP-2 productions (P<0.05).	Budesonide	15-25	TIMP metallopeptidase inhibitor 2	Rattus norvegicus	89-95
26191209-9	2015	CONCLUSION: Inhaled budesonide mitigates the ongoing inflammatory process in the smoked lungs and ameliorates declining lung function through reducing MMP-1 content.	Budesonide	20-30	matrix metallopeptidase 1	Rattus norvegicus	151-156
26131096-0	2015	Budesonide mitigates pathological changes in animal model Of COPD through reducing neutrophil elastase expression.	Budesonide	0-10	elastase, neutrophil expressed	Rattus norvegicus	83-102
26103669-9	2015	In addition, intranasal budesonide reduced MMP-9 in the nasal of AR mice.	Budesonide	24-34	matrix metallopeptidase 9	Mus musculus	43-48
25831061-5	2015	DNMT inhibitor 5-azacytidine (2 muM) and the methylating agent budesonide (2 muM) were used to compare their demethylation/methylation effects with phytoestrogens.	Budesonide	63-73	latexin	Homo sapiens	77-80
25060977-7	2015	Azelastine and budesonide additively increased MKP-1 expression and inhibited ICAM-1 expression in vitro.	Budesonide	15-25	dual specificity phosphatase 1	Homo sapiens	47-52
25060977-7	2015	Azelastine and budesonide additively increased MKP-1 expression and inhibited ICAM-1 expression in vitro.	Budesonide	15-25	intercellular adhesion molecule 1	Homo sapiens	78-84
25060977-8	2015	After treatment for two consecutive weeks, combined azelastine and budesonide nasal spray significantly decreased nasal ICAM-1 level and TNSS in six uncontrolled AR patients.	Budesonide	67-77	intercellular adhesion molecule 1	Homo sapiens	120-126
25060977-9	2015	Our findings suggested that azelastine is able to additively enhance the anti-inflammatory effect of budesonide by modulating MKP-1 expression, which may implicate in the treatment of uncontrolled severe AR.	Budesonide	101-111	dual specificity phosphatase 1	Homo sapiens	126-131
26273338-8	2015	miR-16 in the miRNA-mRNA-drug network of SCLC is significant and we acquired 11 potential drugs, such as dexamethasone and budesonide.	Budesonide	123-133	glycerophosphodiester phosphodiesterase 1	Homo sapiens	0-6
25849971-13	2015	Both dietary intervention with 1% GOS or budesonide treatment significantly decreased the HDM-induced increased concentrations of CCL5 and IL-13 in lung tissue, while budesonide also reduced the HDM-enhanced concentrations of IL-6 and CCL17 in lung tissue.	Budesonide	41-51	chemokine (C-C motif) ligand 5	Mus musculus	130-134
25849971-13	2015	Both dietary intervention with 1% GOS or budesonide treatment significantly decreased the HDM-induced increased concentrations of CCL5 and IL-13 in lung tissue, while budesonide also reduced the HDM-enhanced concentrations of IL-6 and CCL17 in lung tissue.	Budesonide	41-51	interleukin 13	Mus musculus	139-144
25849971-13	2015	Both dietary intervention with 1% GOS or budesonide treatment significantly decreased the HDM-induced increased concentrations of CCL5 and IL-13 in lung tissue, while budesonide also reduced the HDM-enhanced concentrations of IL-6 and CCL17 in lung tissue.	Budesonide	167-177	interleukin 6	Mus musculus	226-230
25849971-13	2015	Both dietary intervention with 1% GOS or budesonide treatment significantly decreased the HDM-induced increased concentrations of CCL5 and IL-13 in lung tissue, while budesonide also reduced the HDM-enhanced concentrations of IL-6 and CCL17 in lung tissue.	Budesonide	167-177	chemokine (C-C motif) ligand 17	Mus musculus	235-240
25925924-8	2015	Patients who are nonresponsive, dependent or who experience side effects on budesonide may benefit from thiopurine or anti-TNF treatment, but these options are still experimental.	Budesonide	76-86	tumor necrosis factor	Homo sapiens	123-126
26012304-0	2015	[Effect of budesonide on the expression of IL-12 in animal model of minimal persistent inflammation of allergic rhinitis in rats].	Budesonide	11-21	interleukin 12B	Rattus norvegicus	43-48
26012304-14	2015	CONCLUSION: Budesonide significantly inhibited the late reaction of animal model of minimal persistent inflammation (MPI) of allergic rhinitis in rats and increase the expression of IL-12 in MPI model.	Budesonide	12-22	interleukin 12B	Rattus norvegicus	182-187
25670896-2	2015	We aimed to derive this by analyzing data from three existing COPD clinical trials of budesonide/formoterol, formoterol, or placebo in patients with moderate-to-very-severe COPD and a history of exacerbations in the previous year.	Budesonide	86-96	COPD	Homo sapiens	62-66
25670896-2	2015	We aimed to derive this by analyzing data from three existing COPD clinical trials of budesonide/formoterol, formoterol, or placebo in patients with moderate-to-very-severe COPD and a history of exacerbations in the previous year.	Budesonide	86-96	COPD	Homo sapiens	173-177
23625588-3	2014	In the present study, we investigated the potential additive or synergistic inhibitory effects on cancer cell proliferation by simultaneous application of fenofibrate and budesonide, agonists for PPARalpha and glucocorticoid receptor, respectively.	Budesonide	171-181	peroxisome proliferator activated receptor alpha	Homo sapiens	196-205
24182991-3	2014	We aimed to assess the association of the effect of fenoterol (beta2-AR agonist) on IL-4-driven and budesonide-induced IgE synthesis with genetic variants of beta2-AR.	Budesonide	100-110	immunoglobulin heavy constant epsilon	Homo sapiens	119-122
24182991-3	2014	We aimed to assess the association of the effect of fenoterol (beta2-AR agonist) on IL-4-driven and budesonide-induced IgE synthesis with genetic variants of beta2-AR.	Budesonide	100-110	adrenoceptor beta 2	Homo sapiens	158-166
24182991-8	2014	In contrast to fenoterol, budesonide-induced IgE synthesis was significantly increased in -47 T/T and -20 T/T patients as compared to -47 C/T, -47 C/C, -20 C/T and -47 C/C individuals.	Budesonide	26-36	immunoglobulin heavy constant epsilon	Homo sapiens	45-48
25313925-4	2014	Compared to the values obtained in rats exposed to cadmium, pretreatment of inhaled budesonide (0.5 mg/15 ml) elicited a significant decrease in total cell and neutrophil counts in bronchoalveolar lavage fluid (BALF) associated with a significant reduction of MMP-9 activity which was highly correlated with the number of inflammatory cells in BALF.	Budesonide	84-94	matrix metallopeptidase 9	Rattus norvegicus	260-265
25313925-6	2014	Though the low concentration of budesonide (0.25 mg/15 ml) exerted a very limited inhibitory effects in the present rat model, its combination with an inefficient concentration of formoterol (0.5 mg/30 ml) showed an enhanced inhibitory effect on neutrophil and total cell counts as well as on the histological lung injuries associated with a potentiation of inhibition on the MMP-9 activity.	Budesonide	32-42	matrix metallopeptidase 9	Rattus norvegicus	376-381
25313925-7	2014	In conclusion, high concentration of budesonide alone could partially protect the lungs against cadmium exposure induced-acute neutrophilic pulmonary inflammation via the inhibition of MMP-9 activity.	Budesonide	37-47	matrix metallopeptidase 9	Rattus norvegicus	185-190
25616301-12	2015	CONCLUSIONS: The action mechanism of budesonide in treating asthmatic mice may be related to the upregulation of GR expression and the inhibition of NF-kappaB activity.	Budesonide	37-47	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	149-158
24784698-12	2014	CONCLUSIONS: Both inhaled budesonide (200 mug, bid) and oral dexamethasone (4 mg, bid) were effective for the prevention of acute mountain sickness, especially its severe form, compared with placebo.	Budesonide	26-36	BH3 interacting domain death agonist	Homo sapiens	47-50
23625588-3	2014	In the present study, we investigated the potential additive or synergistic inhibitory effects on cancer cell proliferation by simultaneous application of fenofibrate and budesonide, agonists for PPARalpha and glucocorticoid receptor, respectively.	Budesonide	171-181	nuclear receptor subfamily 3 group C member 1	Homo sapiens	210-233
23625588-6	2014	The anti-proliferation effect of budesonide in TP53 wild type A549 cells was abolished in SK-MES-1 cells that do not have wild type TP53 protein.	Budesonide	33-43	tumor protein p53	Homo sapiens	47-51
23625588-6	2014	The anti-proliferation effect of budesonide in TP53 wild type A549 cells was abolished in SK-MES-1 cells that do not have wild type TP53 protein.	Budesonide	33-43	tumor protein p53	Homo sapiens	132-136
23625588-7	2014	An additive effect against cell proliferation by budesonide and fenofibrate combination was observed only in TP53 wild type A549 cancer cells.	Budesonide	49-59	tumor protein p53	Homo sapiens	109-113
24029379-7	2014	When the serum albumin level increased, the budesonide dose was tapered and stopped in 1 month.	Budesonide	44-54	albumin	Homo sapiens	15-22
24993070-5	2014	Inhaled budesonide, the classic therapeutic drug for chronic asthma, could inhibit asthma-induced microglial activation, down-regulate TNFalpha and IL-1beta but up-regulate TGFbeta and IL-10 of mouse brain, and thereby attenuate neuronal loss.	Budesonide	8-18	tumor necrosis factor	Mus musculus	135-143
24993070-5	2014	Inhaled budesonide, the classic therapeutic drug for chronic asthma, could inhibit asthma-induced microglial activation, down-regulate TNFalpha and IL-1beta but up-regulate TGFbeta and IL-10 of mouse brain, and thereby attenuate neuronal loss.	Budesonide	8-18	interleukin 1 beta	Mus musculus	148-156
24993070-5	2014	Inhaled budesonide, the classic therapeutic drug for chronic asthma, could inhibit asthma-induced microglial activation, down-regulate TNFalpha and IL-1beta but up-regulate TGFbeta and IL-10 of mouse brain, and thereby attenuate neuronal loss.	Budesonide	8-18	transforming growth factor, beta 1	Mus musculus	173-180
24993070-5	2014	Inhaled budesonide, the classic therapeutic drug for chronic asthma, could inhibit asthma-induced microglial activation, down-regulate TNFalpha and IL-1beta but up-regulate TGFbeta and IL-10 of mouse brain, and thereby attenuate neuronal loss.	Budesonide	8-18	interleukin 10	Mus musculus	185-190
24993070-6	2014	Further study showed that chronic asthma increased the expressions of TLR4 and p65/NFkappaB in the brain, which could be reversed by budesonide treatment.	Budesonide	133-143	toll-like receptor 4	Mus musculus	70-74
24993070-6	2014	Further study showed that chronic asthma increased the expressions of TLR4 and p65/NFkappaB in the brain, which could be reversed by budesonide treatment.	Budesonide	133-143	v-rel reticuloendotheliosis viral oncogene homolog A (avian)	Mus musculus	79-82
24993070-6	2014	Further study showed that chronic asthma increased the expressions of TLR4 and p65/NFkappaB in the brain, which could be reversed by budesonide treatment.	Budesonide	133-143	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	83-91
24880571-6	2014	RESULTS: Most of the compounds (hydrocortisone, betamethasone, flumethasone, triamcinolone, budesonide, fluticasone propionate, and fludrocortisone acetate) increased GR-positive cell growth, which was similar to or even stronger than the effect of dexamethasone.	Budesonide	92-102	nuclear receptor subfamily 3 group C member 1	Homo sapiens	167-169
24998372-4	2014	RESULTS: Treatment with formoterol and budesonide 72 h before and after RV14 infection reduced RV14 titers and cytokine concentrations, including interleukin (IL)-1beta, IL-6 and IL-8, in supernatants and viral RNA within cells.	Budesonide	39-49	interleukin 1 beta	Homo sapiens	146-168
24627531-3	2014	We studied CCL20 and CXCL8 sputum levels in asthmatic subjects using inhaled glucocorticoids or not, and the effect of budesonide on CCL20 and CXCL8 production in primary bronchial epithelial cells.	Budesonide	119-129	C-C motif chemokine ligand 20	Homo sapiens	133-138
24627531-4	2014	The mechanism behind the effect of budesonide-induced CCL20 production was studied in 16HBE14o- cells using inhibitors for the glucocorticoid receptor, intracellular pathways and metalloproteases.	Budesonide	35-45	C-C motif chemokine ligand 20	Homo sapiens	54-59
24627531-4	2014	The mechanism behind the effect of budesonide-induced CCL20 production was studied in 16HBE14o- cells using inhibitors for the glucocorticoid receptor, intracellular pathways and metalloproteases.	Budesonide	35-45	nuclear receptor subfamily 3 group C member 1	Homo sapiens	127-150
24627531-7	2014	Budesonide increased tumour necrosis factor (TNF)-alpha-induced CCL20 by primary bronchial epithelium, while CXCL8 was suppressed.	Budesonide	0-10	tumor necrosis factor	Homo sapiens	21-55
24627531-7	2014	Budesonide increased tumour necrosis factor (TNF)-alpha-induced CCL20 by primary bronchial epithelium, while CXCL8 was suppressed.	Budesonide	0-10	C-C motif chemokine ligand 20	Homo sapiens	64-69
24627531-10	2014	Inhibition of glucocorticoid receptor or ADAM17 abrogated the budesonide-induced increase in CCL20 levels.	Budesonide	62-72	nuclear receptor subfamily 3 group C member 1	Homo sapiens	14-37
24627531-10	2014	Inhibition of glucocorticoid receptor or ADAM17 abrogated the budesonide-induced increase in CCL20 levels.	Budesonide	62-72	ADAM metallopeptidase domain 17	Homo sapiens	41-47
24627531-10	2014	Inhibition of glucocorticoid receptor or ADAM17 abrogated the budesonide-induced increase in CCL20 levels.	Budesonide	62-72	C-C motif chemokine ligand 20	Homo sapiens	93-98
25330644-0	2014	[Prophylactic effect of budesonide on the expression of IL-4, IL-5 in model of allergic rhinitis rats].	Budesonide	24-34	interleukin 4	Rattus norvegicus	56-60
25330644-0	2014	[Prophylactic effect of budesonide on the expression of IL-4, IL-5 in model of allergic rhinitis rats].	Budesonide	24-34	interleukin 5	Rattus norvegicus	62-66
25330644-1	2014	OBJECTIVE: To explore the prophylactic effect of Budesonide on the expression of IL-4,IL-5 in nasal mucosa in model of minimal persistent inflammation of allergic rhinitis in rats.	Budesonide	49-59	interleukin 4	Rattus norvegicus	81-85
25330644-1	2014	OBJECTIVE: To explore the prophylactic effect of Budesonide on the expression of IL-4,IL-5 in nasal mucosa in model of minimal persistent inflammation of allergic rhinitis in rats.	Budesonide	49-59	interleukin 5	Rattus norvegicus	86-90
24998372-4	2014	RESULTS: Treatment with formoterol and budesonide 72 h before and after RV14 infection reduced RV14 titers and cytokine concentrations, including interleukin (IL)-1beta, IL-6 and IL-8, in supernatants and viral RNA within cells.	Budesonide	39-49	interleukin 6	Homo sapiens	170-174
24998372-4	2014	RESULTS: Treatment with formoterol and budesonide 72 h before and after RV14 infection reduced RV14 titers and cytokine concentrations, including interleukin (IL)-1beta, IL-6 and IL-8, in supernatants and viral RNA within cells.	Budesonide	39-49	C-X-C motif chemokine ligand 8	Homo sapiens	179-183
24998372-5	2014	Formoterol and budesonide reduced mRNA expression and protein concentration of intercellular adhesion molecule-1 (ICAM-1), the receptor for RV14.	Budesonide	15-25	intercellular adhesion molecule 1	Homo sapiens	79-112
24998372-5	2014	Formoterol and budesonide reduced mRNA expression and protein concentration of intercellular adhesion molecule-1 (ICAM-1), the receptor for RV14.	Budesonide	15-25	intercellular adhesion molecule 1	Homo sapiens	114-120
24998372-7	2014	Formoterol and budesonide reduced the activation of the nuclear factor kappa-B protein p65 in nuclear extracts.	Budesonide	15-25	RELA proto-oncogene, NF-kB subunit	Homo sapiens	87-90
24998372-8	2014	The effects of formoterol plus budesonide were additive with respect to RV14 replication, cytokine production, ICAM-1 expression, acidic endosome fluorescence intensity, and p65 activation.	Budesonide	31-41	intercellular adhesion molecule 1	Homo sapiens	111-117
24998372-8	2014	The effects of formoterol plus budesonide were additive with respect to RV14 replication, cytokine production, ICAM-1 expression, acidic endosome fluorescence intensity, and p65 activation.	Budesonide	31-41	RELA proto-oncogene, NF-kB subunit	Homo sapiens	174-177
24998372-10	2014	CONCLUSIONS: Formoterol and budesonide may inhibit RV infection by reducing the ICAM-1 levels and/or acidic endosomes and modulate airway inflammation associated with RV infections.	Budesonide	28-38	intercellular adhesion molecule 1	Homo sapiens	80-86
24940053-6	2014	In the base case, the treatment of a patient for 1 year with budesonide/formoterol led to a saving of $499.90 ($195.10 for drugs, $193.10 for COPD hospitalizations, and $111.70 for pneumonia hospitalizations) corresponding to a -27.6% difference compared with fluticasone/salmeterol treatment.	Budesonide	61-71	COPD	Homo sapiens	142-146
24940053-5	2014	RESULTS: The PATHOS study demonstrated a significant reduction in COPD hospitalizations and pneumonia-related hospitalizations in patients treated with budesonide/formoterol versus fluticasone/salmeterol (-29.1% and -42%, respectively).	Budesonide	152-162	COPD	Homo sapiens	66-70
24940053-7	2014	CONCLUSION: Treatment of COPD with budesonide/formoterol compared with fluticasone/salmeterol could lead to a reduction in direct health care costs, with relevant improvement in clinical outcomes.	Budesonide	35-45	COPD	Homo sapiens	25-29
24788354-8	2014	BET analysis determined an increase in surface area of eight times for budesonide NanoClusters and 10-15 times for danazol NanoClusters compared with the micronized stock.	Budesonide	71-81	delta/notch like EGF repeat containing	Homo sapiens	0-3
24717973-4	2014	Treatment of MSCs with glucocorticoids, budesonide or dexamethasone, enhanced IDO expression following IFN-gamma stimulation in multiple donors and was able to restore IDO expression in over-passaged MSCs.	Budesonide	40-50	indoleamine 2,3-dioxygenase 1	Homo sapiens	78-81
24717973-4	2014	Treatment of MSCs with glucocorticoids, budesonide or dexamethasone, enhanced IDO expression following IFN-gamma stimulation in multiple donors and was able to restore IDO expression in over-passaged MSCs.	Budesonide	40-50	interferon gamma	Homo sapiens	103-112
24717973-4	2014	Treatment of MSCs with glucocorticoids, budesonide or dexamethasone, enhanced IDO expression following IFN-gamma stimulation in multiple donors and was able to restore IDO expression in over-passaged MSCs.	Budesonide	40-50	indoleamine 2,3-dioxygenase 1	Homo sapiens	168-171
24717973-5	2014	As IDO enhancement was most notable when cells were continuously exposed to budesonide, we engineered MSC with budesonide loaded PLGA microparticles.	Budesonide	76-86	indoleamine 2,3-dioxygenase 1	Homo sapiens	3-6
24717973-5	2014	As IDO enhancement was most notable when cells were continuously exposed to budesonide, we engineered MSC with budesonide loaded PLGA microparticles.	Budesonide	111-121	indoleamine 2,3-dioxygenase 1	Homo sapiens	3-6
24462857-3	2014	We used the human promyelocytic cell line THP-1 to investigate the effects of cortisol, prednisone, prednisolone, budesonide, betamethasone and methylprednisolone on RACK-1 expression and cytokine production.	Budesonide	114-124	receptor for activated C kinase 1	Homo sapiens	166-172
24347165-3	2014	Glucocorticoids, including dexamethasone, methylprednisolone, budesonide, and fluticasone, potentiated TGF-beta signaling by the Acvrl1/Smad1/5/8 signaling axis and blunted signaling by the Tgfbr1/Smad2/3 axis in NIH/3T3 cells, as well as primary lung fibroblasts, smooth muscle cells, and endothelial cells.	Budesonide	62-72	activin A receptor, type II-like 1	Mus musculus	129-135
24347165-3	2014	Glucocorticoids, including dexamethasone, methylprednisolone, budesonide, and fluticasone, potentiated TGF-beta signaling by the Acvrl1/Smad1/5/8 signaling axis and blunted signaling by the Tgfbr1/Smad2/3 axis in NIH/3T3 cells, as well as primary lung fibroblasts, smooth muscle cells, and endothelial cells.	Budesonide	62-72	SMAD family member 1	Mus musculus	136-143
24347165-3	2014	Glucocorticoids, including dexamethasone, methylprednisolone, budesonide, and fluticasone, potentiated TGF-beta signaling by the Acvrl1/Smad1/5/8 signaling axis and blunted signaling by the Tgfbr1/Smad2/3 axis in NIH/3T3 cells, as well as primary lung fibroblasts, smooth muscle cells, and endothelial cells.	Budesonide	62-72	transforming growth factor, beta receptor I	Mus musculus	190-196
24347165-3	2014	Glucocorticoids, including dexamethasone, methylprednisolone, budesonide, and fluticasone, potentiated TGF-beta signaling by the Acvrl1/Smad1/5/8 signaling axis and blunted signaling by the Tgfbr1/Smad2/3 axis in NIH/3T3 cells, as well as primary lung fibroblasts, smooth muscle cells, and endothelial cells.	Budesonide	62-72	SMAD family member 2	Mus musculus	197-204
24164087-7	2014	Budesonide also reduced the concentrations of tumour necrosis factor-alpha, interleukin-1beta, interleukin-6 and interleukin-8 in bronchoalveolar lavage fluid, but increased interleukin-10 30 min after re-expansion (p < 0.05 for all measures).	Budesonide	0-10	interleukin 1 beta	Homo sapiens	76-93
24382005-8	2014	Budesonide is a glucocorticoid receptor/pregnane X receptor (PXR) agonist also involved in BA synthesis, metabolism and transport.	Budesonide	0-10	nuclear receptor subfamily 1 group I member 2	Homo sapiens	61-64
24568918-0	2014	[Down-regulatory effects of budesonide on expression of STAT6 and ORMDL3 in lung tissues of asthmatic mice].	Budesonide	28-38	signal transducer and activator of transcription 6	Mus musculus	56-61
24568918-0	2014	[Down-regulatory effects of budesonide on expression of STAT6 and ORMDL3 in lung tissues of asthmatic mice].	Budesonide	28-38	ORM1-like 3 (S. cerevisiae)	Mus musculus	66-72
24164087-7	2014	Budesonide also reduced the concentrations of tumour necrosis factor-alpha, interleukin-1beta, interleukin-6 and interleukin-8 in bronchoalveolar lavage fluid, but increased interleukin-10 30 min after re-expansion (p < 0.05 for all measures).	Budesonide	0-10	interleukin 6	Homo sapiens	95-108
24164087-7	2014	Budesonide also reduced the concentrations of tumour necrosis factor-alpha, interleukin-1beta, interleukin-6 and interleukin-8 in bronchoalveolar lavage fluid, but increased interleukin-10 30 min after re-expansion (p < 0.05 for all measures).	Budesonide	0-10	C-X-C motif chemokine ligand 8	Homo sapiens	113-126
24164087-7	2014	Budesonide also reduced the concentrations of tumour necrosis factor-alpha, interleukin-1beta, interleukin-6 and interleukin-8 in bronchoalveolar lavage fluid, but increased interleukin-10 30 min after re-expansion (p < 0.05 for all measures).	Budesonide	0-10	interleukin 10	Homo sapiens	174-188
24341818-4	2014	This review found that administration of beta2-agonist bronchodilators via dry powder inhalers (formoterol, salbutamol, terbutaline and budesonide/formoterol) was effective during severe asthma worsening and acute asthma attacks, and was as effective as established therapies with a pressurized metered-dose inhaler with or without a spacer, or nebulization.	Budesonide	136-146	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	41-46
24176116-12	2014	Glucocorticosteroid insensitivity was selective for proinflammatory cytokines because budesonide inhibition of LPS-stimulated IL-10 release was similar for all macrophages.	Budesonide	86-96	interleukin 10	Homo sapiens	126-131
24163441-3	2014	In human bronchial epithelial BEAS-2B cells (bronchial epithelium + adenovirus 12-SV40 hybrid), regulator of G-protein signaling (RGS) 2 mRNA and protein were synergistically induced in response to combinations of long-acting beta2-adrenoceptor agonist (LABA) (salmeterol, formoterol) plus glucocorticoid (dexamethasone, fluticasone propionate, budesonide).	Budesonide	345-355	regulator of G protein signaling 2	Homo sapiens	96-136
24386300-12	2013	In COPD subjects, budesonide/formoterol significantly increased the BAL concentrations of pro-SFTPB by a median of 62.46 ng/ml (p=0.022) or 48.7% from baseline median value.	Budesonide	18-28	surfactant protein B	Homo sapiens	94-99
23980116-5	2014	Budesonide significantly counteracted this effect, likely by protection against epidermal growth factor receptor-dependent cell-cell contact disruption.	Budesonide	0-10	epidermal growth factor receptor	Homo sapiens	80-112
24188202-6	2013	RSV-infected 16-HBEC was incubated with gradient concentration of budesonide (BUD) to assess its effects on LTC4 S expression and CysLT secretion.	Budesonide	66-76	leukotriene C4 synthase	Homo sapiens	108-114
24062615-7	2013	RESULTS: We have demonstrated that budesonide concentration-dependently (10(-10)-10(-7) M) inhibited IL-6, IL-8, MMP-1, and MMP-3 release by HFL-1 cells in response to IL-1beta plus TNF-alpha.	Budesonide	35-45	interleukin 6	Homo sapiens	101-105
23800689-8	2013	Budesonide, but not mometasone, reduced the levels of the neutrophil attractant CXCL1 in lavage fluid 6h after exposure.	Budesonide	0-10	chemokine (C-X-C motif) ligand 1	Mus musculus	80-85
23759184-7	2013	IL-33 expression was quantified in endobronchial biopsy (EB) specimens from children with STRA and related to remodeling, and collagen production by airway fibroblasts from pediatric patients stimulated with IL-33 and budesonide was quantified.	Budesonide	218-228	interleukin 33	Homo sapiens	0-5
24062615-7	2013	RESULTS: We have demonstrated that budesonide concentration-dependently (10(-10)-10(-7) M) inhibited IL-6, IL-8, MMP-1, and MMP-3 release by HFL-1 cells in response to IL-1beta plus TNF-alpha.	Budesonide	35-45	C-X-C motif chemokine ligand 8	Homo sapiens	107-111
24062615-7	2013	RESULTS: We have demonstrated that budesonide concentration-dependently (10(-10)-10(-7) M) inhibited IL-6, IL-8, MMP-1, and MMP-3 release by HFL-1 cells in response to IL-1beta plus TNF-alpha.	Budesonide	35-45	matrix metallopeptidase 1	Homo sapiens	113-118
24062615-7	2013	RESULTS: We have demonstrated that budesonide concentration-dependently (10(-10)-10(-7) M) inhibited IL-6, IL-8, MMP-1, and MMP-3 release by HFL-1 cells in response to IL-1beta plus TNF-alpha.	Budesonide	35-45	matrix metallopeptidase 3	Homo sapiens	124-129
24062615-7	2013	RESULTS: We have demonstrated that budesonide concentration-dependently (10(-10)-10(-7) M) inhibited IL-6, IL-8, MMP-1, and MMP-3 release by HFL-1 cells in response to IL-1beta plus TNF-alpha.	Budesonide	35-45	interleukin 1 beta	Homo sapiens	168-176
24062615-7	2013	RESULTS: We have demonstrated that budesonide concentration-dependently (10(-10)-10(-7) M) inhibited IL-6, IL-8, MMP-1, and MMP-3 release by HFL-1 cells in response to IL-1beta plus TNF-alpha.	Budesonide	35-45	tumor necrosis factor	Homo sapiens	182-191
24062615-8	2013	While an HDAC inhibitor significantly blocked the inhibitory effect of budesonide on human bronchial epithelial cells (HBECs) and monocytes (THP-1 cells), it did not block the inhibitory effect of budesonide on release of cytokines and MMPs from HFL-1 cells.	Budesonide	71-81	histone deacetylase 9	Homo sapiens	9-13
24062615-9	2013	Similarly, an HDAC2-siRNA blocked budesonide inhibition of cytokine release in HBECs, but it did not block the inhibitory effect of budesonide on HFL-1 cytokine and MMP release.	Budesonide	34-44	histone deacetylase 2	Homo sapiens	14-19
24062615-10	2013	Furthermore, budesonide significantly blocked release of cytokines and MMPs to a similar degree in normal and COPD lung fibroblasts as well as in HFL-1 cells exposed or not exposed to cigarette smoke extract.	Budesonide	13-23	matrix metallopeptidase 1	Homo sapiens	71-75
24062615-12	2013	These results also suggest that budesonide has the potential to modulate fibroblast-mediated tissue remodeling following airway inflammation in COPD, which is mediated via an HDAC2 independent pathway.	Budesonide	32-42	histone deacetylase 2	Homo sapiens	175-180
23717481-7	2013	The levels of MDSCs and IL-10 in asthmatic mice were significantly higher than those in the normal control mice (both p<0.05) and were reduced after budesonide treatment (both p<0.05).	Budesonide	152-162	interleukin 10	Mus musculus	24-29
23617551-10	2013	Inhaled budesonide significantly reduced LPS-induced IL-1beta, IL-6, IL-8 and TNF-alpha secretion, while inhaled formoterol had no such effect; however when combined, the inhibitory effect of budesonide was significantly increased by formoterol.	Budesonide	8-18	interleukin 1 beta	Homo sapiens	53-61
23617551-10	2013	Inhaled budesonide significantly reduced LPS-induced IL-1beta, IL-6, IL-8 and TNF-alpha secretion, while inhaled formoterol had no such effect; however when combined, the inhibitory effect of budesonide was significantly increased by formoterol.	Budesonide	8-18	interleukin 6	Homo sapiens	63-67
23617551-10	2013	Inhaled budesonide significantly reduced LPS-induced IL-1beta, IL-6, IL-8 and TNF-alpha secretion, while inhaled formoterol had no such effect; however when combined, the inhibitory effect of budesonide was significantly increased by formoterol.	Budesonide	8-18	C-X-C motif chemokine ligand 8	Homo sapiens	69-73
23617551-10	2013	Inhaled budesonide significantly reduced LPS-induced IL-1beta, IL-6, IL-8 and TNF-alpha secretion, while inhaled formoterol had no such effect; however when combined, the inhibitory effect of budesonide was significantly increased by formoterol.	Budesonide	8-18	tumor necrosis factor	Homo sapiens	78-87
23387852-0	2013	Budesonide suppresses pulmonary antibacterial host defense by down-regulating cathelicidin-related antimicrobial peptide in allergic inflammation mice and in lung epithelial cells.	Budesonide	0-10	cathelicidin antimicrobial peptide	Mus musculus	78-120
23633340-2	2013	The combination of formoterol and budesonide in one inhaler has made possible a single inhaler for both prevention and relief of symptoms (single inhaler therapy or SiT).	Budesonide	34-44	signaling threshold regulating transmembrane adaptor 1	Homo sapiens	165-168
23633340-6	2013	Studies had to assess the combination of formoterol and budesonide as SiT, against a control group that received inhaled steroids and a separate reliever inhaler.	Budesonide	56-66	signaling threshold regulating transmembrane adaptor 1	Homo sapiens	70-73
23633340-16	2013	Withdrawals due to adverse events were more common in people treated with SiT (OR 2.85; 95% CI 1.89 to 4.30, moderate quality evidence due to risk of detection bias).Three studies including 4209 adults compared SiT with higher dose budesonide maintenance and terbutaline for symptom relief.	Budesonide	232-242	signaling threshold regulating transmembrane adaptor 1	Homo sapiens	74-77
23633340-22	2013	Withdrawals due to adverse events were more common in people treated with SiT (OR 0.57; 95% CI 0.35 to 0.93, high quality evidence).One study included children (N = 224), in which SiT was compared with higher dose budesonide.	Budesonide	214-224	signaling threshold regulating transmembrane adaptor 1	Homo sapiens	74-77
23671450-10	2013	Inhaled administration of budesonide achieved anti-angiogenic activity through inhibition of HIF-1alpha and VEGF expression.	Budesonide	26-36	hypoxia inducible factor 1, alpha subunit	Mus musculus	93-103
23671450-10	2013	Inhaled administration of budesonide achieved anti-angiogenic activity through inhibition of HIF-1alpha and VEGF expression.	Budesonide	26-36	vascular endothelial growth factor A	Mus musculus	108-112
23562201-0	2013	Effects of budesonide on the expression of the glucocorticoid receptor-alpha in nasal polyp epithelial cells.	Budesonide	11-21	nuclear receptor subfamily 3 group C member 1	Homo sapiens	47-70
23562201-1	2013	BACKGROUND: This study explores effects of budesonide on the proliferation of nasal polyp epithelial cells and expression of the glucocorticoid receptor (GR) alpha in nasal polyp epithelial cells.	Budesonide	43-53	nuclear receptor subfamily 3 group C member 1	Homo sapiens	4-6
23387852-11	2013	Budesonide decreased the expression of CRAMP, increased the number of internalized P. aeruginosa in OVA-challenged mice and in lung epithelial cell lines.	Budesonide	0-10	cathelicidin antimicrobial peptide	Mus musculus	39-44
23387852-12	2013	These data indicate that inhaled budesonide can suppress pulmonary antibacterial host defense by down-regulating CRAMP in allergic inflammation mice and in cells in vitro.	Budesonide	33-43	cathelicidin antimicrobial peptide	Mus musculus	113-118
23143891-5	2013	In this work, the metabolism of four frequently prescribed inhaled GCs, triamcinolone acetonide, flunisolide, budesonide, and fluticasone propionate, by the CYP3A family of enzymes was studied to identify differences in their rates of clearance and to identify their metabolites.	Budesonide	110-120	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	157-162
23143891-8	2013	CYP3A5, which is particularly relevant to GC metabolism in the lungs, was also shown to efficiently metabolize triamcinolone acetonide, budesonide, and fluticasone propionate.	Budesonide	136-146	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	0-6
22948082-5	2013	We investigated the effects of corticosteroids plus long-acting beta(2)-agonists (LABAs; fluticasone/salmeterol or budesonide/formoterol) on the expression of B7-H1.	Budesonide	115-125	CD274 antigen	Mus musculus	159-164
23364258-0	2013	Active eosinophilic esophagitis is associated with impaired elimination of budesonide by cytochrome P450 3A enzymes.	Budesonide	75-85	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	89-107
23364258-2	2013	Safety of budesonide is based on high elimination by cytochrome P450 3A (CYP3A) enzymes.	Budesonide	10-20	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	53-71
23364258-2	2013	Safety of budesonide is based on high elimination by cytochrome P450 3A (CYP3A) enzymes.	Budesonide	10-20	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	73-78
23364258-10	2013	CONCLUSION: Active EoE is associated with reduced elimination of budesonide via CYP3A, the major subfamily of drug-metabolizing enzymes in humans.	Budesonide	65-75	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	80-85
22948082-14	2013	CONCLUSIONS: Fluticasone/salmeterol or budesonide/formoterol attenuate the virus-associated upregulation of B7-H1 on airway epithelial cells via suppression of NF-kB activation.	Budesonide	39-49	CD274 antigen	Mus musculus	108-113
22798431-9	2012	Collectively, inhaled corticosteroids such as FP and budesonide stimulate CFTR-mediated anion transport through adenylate cyclase-mediated mechanisms in a nongenomic fashion, thus sharing elements of a common pathway with forskolin.	Budesonide	53-63	CF transmembrane conductance regulator	Homo sapiens	74-78
24351982-5	2013	Here we present the NMR solution structure of the Drosophila Smo CRD, and describe interactions between the glucocorticoid budesonide (Bud) and the Smo CRDs from both Drosophila and human.	Budesonide	123-133	smoothened	Drosophila melanogaster	61-64
24351982-5	2013	Here we present the NMR solution structure of the Drosophila Smo CRD, and describe interactions between the glucocorticoid budesonide (Bud) and the Smo CRDs from both Drosophila and human.	Budesonide	123-133	smoothened	Drosophila melanogaster	148-151
23573194-8	2013	Budesonide with Formoterol reduced IL-17A and RORgamma(t), while increased FOXP3 in cultured T-lymphocytes from mild-moderate asthma/persistent rhinitis, and reduced the IL-8 release mediated by IL-17A present in NW and Ss from mild-moderate asthma/persistent rhinitis in nasal and bronchial epithelial cells.	Budesonide	0-10	interleukin 17A	Homo sapiens	35-41
23573194-8	2013	Budesonide with Formoterol reduced IL-17A and RORgamma(t), while increased FOXP3 in cultured T-lymphocytes from mild-moderate asthma/persistent rhinitis, and reduced the IL-8 release mediated by IL-17A present in NW and Ss from mild-moderate asthma/persistent rhinitis in nasal and bronchial epithelial cells.	Budesonide	0-10	C-X-C motif chemokine ligand 8	Homo sapiens	170-174
23573194-8	2013	Budesonide with Formoterol reduced IL-17A and RORgamma(t), while increased FOXP3 in cultured T-lymphocytes from mild-moderate asthma/persistent rhinitis, and reduced the IL-8 release mediated by IL-17A present in NW and Ss from mild-moderate asthma/persistent rhinitis in nasal and bronchial epithelial cells.	Budesonide	0-10	interleukin 17A	Homo sapiens	195-201
23573194-9	2013	Finally, Budesonide with Formoterol reduced IL-17A levels in P and Ss, CD4(+)IL-17A(+)T-cells, in naive children with mild-moderate asthma/persistent rhinitis after 12 weeks of treatment.	Budesonide	9-19	interleukin 17A	Homo sapiens	44-50
23573194-9	2013	Finally, Budesonide with Formoterol reduced IL-17A levels in P and Ss, CD4(+)IL-17A(+)T-cells, in naive children with mild-moderate asthma/persistent rhinitis after 12 weeks of treatment.	Budesonide	9-19	CD4 molecule	Homo sapiens	71-74
23573194-9	2013	Finally, Budesonide with Formoterol reduced IL-17A levels in P and Ss, CD4(+)IL-17A(+)T-cells, in naive children with mild-moderate asthma/persistent rhinitis after 12 weeks of treatment.	Budesonide	9-19	interleukin 17A	Homo sapiens	77-83
23244548-7	2012	RESULTS: NK-1R mRNA and protein expression in the budesonide treatment group rat"s lung and ASMCs were less than that in the asthmatic group but greater than that in the control group.	Budesonide	50-60	tachykinin receptor 1	Rattus norvegicus	9-14
23244548-8	2012	CONCLUSIONS: NK-1R is involved in the pathogenesis of asthma and that budesonide may downregulate the expression of NK-1R in the ASMCs and airways of asthmatic rats, which may alleviate neurogenic airway inflammation.	Budesonide	70-80	tachykinin receptor 1	Rattus norvegicus	116-121
22640563-7	2012	After the 4 week treatment period, a significant decrease was observed in the basal serum cortisol level of the prednisolone group (P<0.03), and a decrease was also seen in the ACTH-stimulated peak cortisol levels of both the prednisolone and fluticasone groups (P<0.001), compared with the budesonide group in which no suppression was detected.	Budesonide	297-307	proopiomelanocortin	Canis lupus familiaris	180-184
23148608-9	2012	Treatment with BIRB-796 and Budesonide together gave an additive decrease in TNFa release.	Budesonide	28-38	tumor necrosis factor	Homo sapiens	77-81
23146737-15	2012	Vitamin D can be used together with budesonide to further decrease the mRNA and protein expression of RANTES.	Budesonide	36-46	C-C motif chemokine ligand 5	Rattus norvegicus	102-108
23092234-6	2012	Among the different drugs evaluated, mesalazine, antibiotics (metronidazole and ornidazole), thiopurines and anti-TNFalpha antibodies have been shown to be effective whereas budesonide, probiotics and interleukin 10 are not effective.	Budesonide	174-184	tumor necrosis factor	Homo sapiens	114-122
23146737-10	2012	The budesonide+vitamin D intervention group showed less protein expression of RANTES in the lung tissue and BALF than both the budesonide intervention and vitamin D intervention groups (P<0.05).	Budesonide	4-14	C-C motif chemokine ligand 5	Rattus norvegicus	78-84
23189102-14	2012	Withdrawal of budesonide for 4 weeks in the COPD phenotype resulted in FEV(1) + 1.33% (SD +- 5.71) and FVC + 1.24% (SD +- 5.32); a change of <12% in all patients.	Budesonide	14-24	COPD	Homo sapiens	44-48
23146737-12	2012	The budesonide+vitamin D intervention group showed the lowest level of RANTES mRNA, with no significant difference from the normal control group.	Budesonide	4-14	C-C motif chemokine ligand 5	Rattus norvegicus	71-77
22766315-3	2012	Aims of our study were to investigate if real life COPD treatment affects peripheral blood NK cells total count and their receptors expression and to assess if different doses of formoterol and budesonide, administered alone or in combination, are able to modulate the surface expression of activating (NKp30, NKp44, NKp46 and NKG2D) and inhibitory (KIR2DL2/L3, KIR3DL1 and NKG2A) receptors on peripheral blood NK cells of COPD patients.	Budesonide	194-204	natural cytotoxicity triggering receptor 3	Homo sapiens	303-308
22766315-3	2012	Aims of our study were to investigate if real life COPD treatment affects peripheral blood NK cells total count and their receptors expression and to assess if different doses of formoterol and budesonide, administered alone or in combination, are able to modulate the surface expression of activating (NKp30, NKp44, NKp46 and NKG2D) and inhibitory (KIR2DL2/L3, KIR3DL1 and NKG2A) receptors on peripheral blood NK cells of COPD patients.	Budesonide	194-204	natural cytotoxicity triggering receptor 2	Homo sapiens	310-315
22766315-3	2012	Aims of our study were to investigate if real life COPD treatment affects peripheral blood NK cells total count and their receptors expression and to assess if different doses of formoterol and budesonide, administered alone or in combination, are able to modulate the surface expression of activating (NKp30, NKp44, NKp46 and NKG2D) and inhibitory (KIR2DL2/L3, KIR3DL1 and NKG2A) receptors on peripheral blood NK cells of COPD patients.	Budesonide	194-204	natural cytotoxicity triggering receptor 1	Homo sapiens	317-322
22766315-3	2012	Aims of our study were to investigate if real life COPD treatment affects peripheral blood NK cells total count and their receptors expression and to assess if different doses of formoterol and budesonide, administered alone or in combination, are able to modulate the surface expression of activating (NKp30, NKp44, NKp46 and NKG2D) and inhibitory (KIR2DL2/L3, KIR3DL1 and NKG2A) receptors on peripheral blood NK cells of COPD patients.	Budesonide	194-204	killer cell lectin like receptor K1	Homo sapiens	327-332
22766315-3	2012	Aims of our study were to investigate if real life COPD treatment affects peripheral blood NK cells total count and their receptors expression and to assess if different doses of formoterol and budesonide, administered alone or in combination, are able to modulate the surface expression of activating (NKp30, NKp44, NKp46 and NKG2D) and inhibitory (KIR2DL2/L3, KIR3DL1 and NKG2A) receptors on peripheral blood NK cells of COPD patients.	Budesonide	194-204	killer cell immunoglobulin like receptor, two Ig domains and long cytoplasmic tail 2	Homo sapiens	350-357
22766315-3	2012	Aims of our study were to investigate if real life COPD treatment affects peripheral blood NK cells total count and their receptors expression and to assess if different doses of formoterol and budesonide, administered alone or in combination, are able to modulate the surface expression of activating (NKp30, NKp44, NKp46 and NKG2D) and inhibitory (KIR2DL2/L3, KIR3DL1 and NKG2A) receptors on peripheral blood NK cells of COPD patients.	Budesonide	194-204	killer cell immunoglobulin like receptor, three Ig domains and long cytoplasmic tail 1	Homo sapiens	362-369
22766315-3	2012	Aims of our study were to investigate if real life COPD treatment affects peripheral blood NK cells total count and their receptors expression and to assess if different doses of formoterol and budesonide, administered alone or in combination, are able to modulate the surface expression of activating (NKp30, NKp44, NKp46 and NKG2D) and inhibitory (KIR2DL2/L3, KIR3DL1 and NKG2A) receptors on peripheral blood NK cells of COPD patients.	Budesonide	194-204	killer cell lectin like receptor C1	Homo sapiens	374-379
22766315-4	2012	Moreover, we evaluated the potential effect of treatment with budesonide and/or formoterol on IFN-gamma secretion in vitro.	Budesonide	62-72	interferon gamma	Homo sapiens	94-103
22766315-13	2012	Even if in vitro experiments with budesonide, alone or in combination with formoterol, showed a modulation of NKG2D receptor expression and IFN-gamma production, our ex vivo results show that real life LABA and ICS treatment does not influence peripheral NK cells count and their receptors phenotype.	Budesonide	34-44	killer cell lectin like receptor K1	Homo sapiens	110-124
22766315-13	2012	Even if in vitro experiments with budesonide, alone or in combination with formoterol, showed a modulation of NKG2D receptor expression and IFN-gamma production, our ex vivo results show that real life LABA and ICS treatment does not influence peripheral NK cells count and their receptors phenotype.	Budesonide	34-44	interferon gamma	Homo sapiens	140-149
22383665-2	2012	We aimed to investigate the effects of the ADRB2 Gly16Arg polymorphism on response to formoterol alone or in combination with the inhaled corticosteroid budesonide in patients with COPD.	Budesonide	153-163	adrenoceptor beta 2	Homo sapiens	43-48
22824974-4	2012	METHODS: We determined if GCs such as dexamethasone (DEX), budesonide (BUD), and fluticasone (FP) could suppress MUC5AC production induced by a combination of TGF-alpha and double-strand RNA, polyinosinic-polycytidylic acid (polyI:C).	Budesonide	59-69	mucin 5AC, oligomeric mucus/gel-forming	Homo sapiens	113-119
22824974-4	2012	METHODS: We determined if GCs such as dexamethasone (DEX), budesonide (BUD), and fluticasone (FP) could suppress MUC5AC production induced by a combination of TGF-alpha and double-strand RNA, polyinosinic-polycytidylic acid (polyI:C).	Budesonide	59-69	transforming growth factor alpha	Homo sapiens	159-168
22824974-4	2012	METHODS: We determined if GCs such as dexamethasone (DEX), budesonide (BUD), and fluticasone (FP) could suppress MUC5AC production induced by a combination of TGF-alpha and double-strand RNA, polyinosinic-polycytidylic acid (polyI:C).	Budesonide	71-74	mucin 5AC, oligomeric mucus/gel-forming	Homo sapiens	113-119
22824974-4	2012	METHODS: We determined if GCs such as dexamethasone (DEX), budesonide (BUD), and fluticasone (FP) could suppress MUC5AC production induced by a combination of TGF-alpha and double-strand RNA, polyinosinic-polycytidylic acid (polyI:C).	Budesonide	71-74	transforming growth factor alpha	Homo sapiens	159-168
23158492-12	2012	Saussurea and inhaled budesonide synergistically inhibited the expression of MUC5AC, IL-8 and TNF-alpha.	Budesonide	22-32	mucin 5AC, oligomeric mucus/gel-forming	Rattus norvegicus	77-83
23158492-12	2012	Saussurea and inhaled budesonide synergistically inhibited the expression of MUC5AC, IL-8 and TNF-alpha.	Budesonide	22-32	tumor necrosis factor	Rattus norvegicus	94-103
22101762-4	2012	In this study we investigated the expression of PDE4D in asthmatic and nonasthmatic ASM cells and its regulation by formoterol and budesonide.	Budesonide	131-141	phosphodiesterase 4D	Homo sapiens	48-53
22546485-7	2012	RESULTS: Both long-acting beta(2) agonists, salmeterol and formoterol, and corticosteroids, fluticasone and budesonide, showed anti-inflammatory effects to a certain extent on H(2)O(2)-induced IL-8 and MMP-9 release in alveolar macrophages.	Budesonide	108-118	C-X-C motif chemokine ligand 8	Homo sapiens	193-197
22546485-7	2012	RESULTS: Both long-acting beta(2) agonists, salmeterol and formoterol, and corticosteroids, fluticasone and budesonide, showed anti-inflammatory effects to a certain extent on H(2)O(2)-induced IL-8 and MMP-9 release in alveolar macrophages.	Budesonide	108-118	matrix metallopeptidase 9	Homo sapiens	202-207
22898286-0	2012	[Effects of budesonide on HIF-1alpha and VEGF expression and airway remodeling in an asthmatic mouse model].	Budesonide	12-22	hypoxia inducible factor 1, alpha subunit	Mus musculus	26-36
22898286-0	2012	[Effects of budesonide on HIF-1alpha and VEGF expression and airway remodeling in an asthmatic mouse model].	Budesonide	12-22	vascular endothelial growth factor A	Mus musculus	41-45
22898286-1	2012	OBJECTIVE: To study the effects of budesonide on hypoxia inducible factor 1alpha(HIF-1alpha) and vascular endothelial growth factor (VEGF) expression, angiogenesis and airway remodeling in the chronic asthmatic mouse model.	Budesonide	35-45	hypoxia inducible factor 1, alpha subunit	Mus musculus	49-91
22898286-11	2012	Administration of budesonide significantly reduced angiogenesis, collagen deposition of lung tissues and airway wall thickening, as well as expression of HIF-1alpha and VEGF.	Budesonide	18-28	hypoxia inducible factor 1, alpha subunit	Mus musculus	154-164
22898286-11	2012	Administration of budesonide significantly reduced angiogenesis, collagen deposition of lung tissues and airway wall thickening, as well as expression of HIF-1alpha and VEGF.	Budesonide	18-28	vascular endothelial growth factor A	Mus musculus	169-173
22898286-14	2012	CONCLUSIONS: Budesonide can decease angiogenesis and airway remodeling by inhibiting  HIF-1alpha and VEGF expression in asthmatic mice.	Budesonide	13-23	hypoxia inducible factor 1, alpha subunit	Mus musculus	86-96
22898286-14	2012	CONCLUSIONS: Budesonide can decease angiogenesis and airway remodeling by inhibiting  HIF-1alpha and VEGF expression in asthmatic mice.	Budesonide	13-23	vascular endothelial growth factor A	Mus musculus	101-105
22558986-1	2012	AIM: To observe the effect of Budesonide (BUD) on TGF-beta1,  PDGF-A,  Smad4 and PAI-1 in lung tissue in pulmonary fibrosis rats.	Budesonide	30-40	transforming growth factor, beta 1	Rattus norvegicus	50-59
22931800-0	2012	[The effect of budesonide on thymic stromal lymphopoietin receptor and cytokine profile of dendritic cells in OVA-induced asthma in mice].	Budesonide	15-25	cytokine receptor-like factor 2	Mus musculus	29-66
22931800-1	2012	OBJECTIVE: To investigate the effect of budesonide (BUD) on thymic stromal lymphopoietin receptor (TSLPR) of dendritic cells (DCs) in OVA-induced mouse asthma models and to explore the mechanisms by studying the effect of BUD on function of DCs from the model.	Budesonide	40-50	cytokine receptor-like factor 2	Mus musculus	60-97
22931800-1	2012	OBJECTIVE: To investigate the effect of budesonide (BUD) on thymic stromal lymphopoietin receptor (TSLPR) of dendritic cells (DCs) in OVA-induced mouse asthma models and to explore the mechanisms by studying the effect of BUD on function of DCs from the model.	Budesonide	40-50	cytokine receptor-like factor 2	Mus musculus	99-104
22200784-8	2012	Levels of lung TGF-beta1, TGF-beta1 mRNA and P-Smad2/3 were significantly reduced in mice treated with astragalus extract and budesonide.	Budesonide	126-136	transforming growth factor, beta 1	Mus musculus	15-24
22200784-8	2012	Levels of lung TGF-beta1, TGF-beta1 mRNA and P-Smad2/3 were significantly reduced in mice treated with astragalus extract and budesonide.	Budesonide	126-136	transforming growth factor, beta 1	Mus musculus	26-35
21827450-6	2012	KEY RESULTS: Compared with placebo, GILZ and FKBP51 mRNA expression was significantly elevated in budesonide-treated subjects.	Budesonide	98-108	TSC22 domain family member 3	Homo sapiens	36-40
21827450-7	2012	Budesonide also increased GILZ expression in human epithelial and smooth muscle cells in culture.	Budesonide	0-10	TSC22 domain family member 3	Homo sapiens	26-30
21827450-9	2012	CONCLUSIONS AND IMPLICATIONS: Expression of the corticosteroid-induced genes, GILZ and FKBP51, is up-regulated in the airways of allergen-challenged asthmatic subjects taking inhaled budesonide.	Budesonide	183-193	TSC22 domain family member 3	Homo sapiens	78-82
21778259-4	2012	RESULTS: The study group receiving a formoterol-budesonide combined treatment showed a significant improvement, both clinically and statistically, of symptoms (dyspnea, number of coughs, and rescue beta(2)-adrenergic agonist-free days).	Budesonide	48-58	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	198-204
21828034-3	2012	We investigated whether interleukin (IL)-17A induces GC insensitivity in airway epithelium by studying its effects on responsiveness of tumour necrosis factor (TNF)-alpha-induced IL-8 production to budesonide in human bronchial epithelial 16HBE cells.	Budesonide	198-208	tumor necrosis factor	Homo sapiens	136-170
21828034-3	2012	We investigated whether interleukin (IL)-17A induces GC insensitivity in airway epithelium by studying its effects on responsiveness of tumour necrosis factor (TNF)-alpha-induced IL-8 production to budesonide in human bronchial epithelial 16HBE cells.	Budesonide	198-208	C-X-C motif chemokine ligand 8	Homo sapiens	179-183
21828034-5	2012	We demonstrated that IL-17A-induced IL-8 production is normally sensitive to GCs, while IL-17A pre-treatment significantly reduced the sensitivity of TNF-alpha-induced IL-8 production to budesonide.	Budesonide	187-197	interleukin 17A	Homo sapiens	88-94
21828034-5	2012	We demonstrated that IL-17A-induced IL-8 production is normally sensitive to GCs, while IL-17A pre-treatment significantly reduced the sensitivity of TNF-alpha-induced IL-8 production to budesonide.	Budesonide	187-197	tumor necrosis factor	Homo sapiens	150-159
21828034-5	2012	We demonstrated that IL-17A-induced IL-8 production is normally sensitive to GCs, while IL-17A pre-treatment significantly reduced the sensitivity of TNF-alpha-induced IL-8 production to budesonide.	Budesonide	187-197	C-X-C motif chemokine ligand 8	Homo sapiens	168-172
23251336-0	2012	Multiple in vitro and in vivo regulatory effects of budesonide in CD4+ T lymphocyte subpopulations of allergic asthmatics.	Budesonide	52-62	CD4 molecule	Homo sapiens	66-69
22035853-7	2012	A combination of an inhaled corticosteroid and a long-acting beta-2 agonist was the reported therapy by 56.0% of patients, with the rate of controlled asthma and improved quality of life being higher in patients on extrafine beclomethasone/formoterol compared to budesonide/formoterol (p<0.05) and fluticasone/salmeterol (p<0.05 for quality of life).	Budesonide	263-273	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	61-67
23183768-7	2012	Budesonide and calcitriol administered in 1:3 ratio and budesonide and tacalcitol in 1:1 and 1:3 reduced RANTES concentration significantly better than each of the drug used in monotherapy (p<0.05).	Budesonide	56-66	C-C motif chemokine ligand 5	Homo sapiens	105-111
23183768-8	2012	Budesonide and tacalcitol in 1:1 and 1:3 ratios suppressed RANTES production to the lowest level (171.8+-97.6pg/ml and 178.7+-105.22pg/ml, respectively).	Budesonide	0-10	C-C motif chemokine ligand 5	Homo sapiens	59-65
22500185-8	2012	Budesonide stimulated fibronectin deposition, in the presence or absence of TGFbeta1, and this was partially reversed by formoterol (10(-8) M) in both asthmatic and nonasthmatic cells.	Budesonide	0-10	fibronectin 1	Homo sapiens	22-33
23251336-6	2012	In asthmatics, in vitro, budesonide was able to: 1) increase annexin V binding and to reduce ICOS in total lymphocytes; 2) increase annexin V binding and Foxp3 and to reduce ICOS in CD4+/CD25- cells; 3) reduce annexin V binding and to increase IL-10 and ICOS in CD4+/CD25+ cells; 4) reduce cell allergen induced proliferation.	Budesonide	25-35	annexin A5	Homo sapiens	61-70
23251336-6	2012	In asthmatics, in vitro, budesonide was able to: 1) increase annexin V binding and to reduce ICOS in total lymphocytes; 2) increase annexin V binding and Foxp3 and to reduce ICOS in CD4+/CD25- cells; 3) reduce annexin V binding and to increase IL-10 and ICOS in CD4+/CD25+ cells; 4) reduce cell allergen induced proliferation.	Budesonide	25-35	inducible T cell costimulator	Homo sapiens	93-97
23251336-6	2012	In asthmatics, in vitro, budesonide was able to: 1) increase annexin V binding and to reduce ICOS in total lymphocytes; 2) increase annexin V binding and Foxp3 and to reduce ICOS in CD4+/CD25- cells; 3) reduce annexin V binding and to increase IL-10 and ICOS in CD4+/CD25+ cells; 4) reduce cell allergen induced proliferation.	Budesonide	25-35	annexin A5	Homo sapiens	132-141
23251336-6	2012	In asthmatics, in vitro, budesonide was able to: 1) increase annexin V binding and to reduce ICOS in total lymphocytes; 2) increase annexin V binding and Foxp3 and to reduce ICOS in CD4+/CD25- cells; 3) reduce annexin V binding and to increase IL-10 and ICOS in CD4+/CD25+ cells; 4) reduce cell allergen induced proliferation.	Budesonide	25-35	forkhead box P3	Homo sapiens	154-159
23251336-6	2012	In asthmatics, in vitro, budesonide was able to: 1) increase annexin V binding and to reduce ICOS in total lymphocytes; 2) increase annexin V binding and Foxp3 and to reduce ICOS in CD4+/CD25- cells; 3) reduce annexin V binding and to increase IL-10 and ICOS in CD4+/CD25+ cells; 4) reduce cell allergen induced proliferation.	Budesonide	25-35	inducible T cell costimulator	Homo sapiens	174-178
23251336-6	2012	In asthmatics, in vitro, budesonide was able to: 1) increase annexin V binding and to reduce ICOS in total lymphocytes; 2) increase annexin V binding and Foxp3 and to reduce ICOS in CD4+/CD25- cells; 3) reduce annexin V binding and to increase IL-10 and ICOS in CD4+/CD25+ cells; 4) reduce cell allergen induced proliferation.	Budesonide	25-35	CD4 molecule	Homo sapiens	182-185
23251336-6	2012	In asthmatics, in vitro, budesonide was able to: 1) increase annexin V binding and to reduce ICOS in total lymphocytes; 2) increase annexin V binding and Foxp3 and to reduce ICOS in CD4+/CD25- cells; 3) reduce annexin V binding and to increase IL-10 and ICOS in CD4+/CD25+ cells; 4) reduce cell allergen induced proliferation.	Budesonide	25-35	interleukin 2 receptor subunit alpha	Homo sapiens	187-191
23251336-6	2012	In asthmatics, in vitro, budesonide was able to: 1) increase annexin V binding and to reduce ICOS in total lymphocytes; 2) increase annexin V binding and Foxp3 and to reduce ICOS in CD4+/CD25- cells; 3) reduce annexin V binding and to increase IL-10 and ICOS in CD4+/CD25+ cells; 4) reduce cell allergen induced proliferation.	Budesonide	25-35	annexin A5	Homo sapiens	132-141
23251336-6	2012	In asthmatics, in vitro, budesonide was able to: 1) increase annexin V binding and to reduce ICOS in total lymphocytes; 2) increase annexin V binding and Foxp3 and to reduce ICOS in CD4+/CD25- cells; 3) reduce annexin V binding and to increase IL-10 and ICOS in CD4+/CD25+ cells; 4) reduce cell allergen induced proliferation.	Budesonide	25-35	interleukin 10	Homo sapiens	244-249
23251336-6	2012	In asthmatics, in vitro, budesonide was able to: 1) increase annexin V binding and to reduce ICOS in total lymphocytes; 2) increase annexin V binding and Foxp3 and to reduce ICOS in CD4+/CD25- cells; 3) reduce annexin V binding and to increase IL-10 and ICOS in CD4+/CD25+ cells; 4) reduce cell allergen induced proliferation.	Budesonide	25-35	inducible T cell costimulator	Homo sapiens	174-178
23251336-6	2012	In asthmatics, in vitro, budesonide was able to: 1) increase annexin V binding and to reduce ICOS in total lymphocytes; 2) increase annexin V binding and Foxp3 and to reduce ICOS in CD4+/CD25- cells; 3) reduce annexin V binding and to increase IL-10 and ICOS in CD4+/CD25+ cells; 4) reduce cell allergen induced proliferation.	Budesonide	25-35	CD4 molecule	Homo sapiens	262-265
23251336-6	2012	In asthmatics, in vitro, budesonide was able to: 1) increase annexin V binding and to reduce ICOS in total lymphocytes; 2) increase annexin V binding and Foxp3 and to reduce ICOS in CD4+/CD25- cells; 3) reduce annexin V binding and to increase IL-10 and ICOS in CD4+/CD25+ cells; 4) reduce cell allergen induced proliferation.	Budesonide	25-35	interleukin 2 receptor subunit alpha	Homo sapiens	267-271
23251336-7	2012	In vivo, budesonide increased ICOS in CD4+/CD25+ while it increased Foxp3 and IL-10 in CD4+/CD25+ and in CD4+/CD25- cells.	Budesonide	9-19	inducible T cell costimulator	Homo sapiens	30-34
23251336-7	2012	In vivo, budesonide increased ICOS in CD4+/CD25+ while it increased Foxp3 and IL-10 in CD4+/CD25+ and in CD4+/CD25- cells.	Budesonide	9-19	CD4 molecule	Homo sapiens	38-41
23251336-7	2012	In vivo, budesonide increased ICOS in CD4+/CD25+ while it increased Foxp3 and IL-10 in CD4+/CD25+ and in CD4+/CD25- cells.	Budesonide	9-19	interleukin 2 receptor subunit alpha	Homo sapiens	43-47
23251336-7	2012	In vivo, budesonide increased ICOS in CD4+/CD25+ while it increased Foxp3 and IL-10 in CD4+/CD25+ and in CD4+/CD25- cells.	Budesonide	9-19	forkhead box P3	Homo sapiens	68-73
23251336-7	2012	In vivo, budesonide increased ICOS in CD4+/CD25+ while it increased Foxp3 and IL-10 in CD4+/CD25+ and in CD4+/CD25- cells.	Budesonide	9-19	interleukin 10	Homo sapiens	78-83
23251336-7	2012	In vivo, budesonide increased ICOS in CD4+/CD25+ while it increased Foxp3 and IL-10 in CD4+/CD25+ and in CD4+/CD25- cells.	Budesonide	9-19	CD4 molecule	Homo sapiens	87-90
23251336-7	2012	In vivo, budesonide increased ICOS in CD4+/CD25+ while it increased Foxp3 and IL-10 in CD4+/CD25+ and in CD4+/CD25- cells.	Budesonide	9-19	interleukin 2 receptor subunit alpha	Homo sapiens	92-96
23251336-7	2012	In vivo, budesonide increased ICOS in CD4+/CD25+ while it increased Foxp3 and IL-10 in CD4+/CD25+ and in CD4+/CD25- cells.	Budesonide	9-19	CD4 molecule	Homo sapiens	87-90
23251336-7	2012	In vivo, budesonide increased ICOS in CD4+/CD25+ while it increased Foxp3 and IL-10 in CD4+/CD25+ and in CD4+/CD25- cells.	Budesonide	9-19	interleukin 2 receptor subunit alpha	Homo sapiens	92-96
23251336-8	2012	CONCLUSIONS: Budesonide modulates T cell survival, ICOS, Foxp3 and IL-10 molecules differently in T lymphocyte sub-populations.	Budesonide	13-23	inducible T cell costimulator	Homo sapiens	51-55
23251336-8	2012	CONCLUSIONS: Budesonide modulates T cell survival, ICOS, Foxp3 and IL-10 molecules differently in T lymphocyte sub-populations.	Budesonide	13-23	forkhead box P3	Homo sapiens	57-62
23251336-8	2012	CONCLUSIONS: Budesonide modulates T cell survival, ICOS, Foxp3 and IL-10 molecules differently in T lymphocyte sub-populations.	Budesonide	13-23	interleukin 10	Homo sapiens	67-72
22340658-13	2011	The protein levels of TGF-beta1 and TSLP in the asthma group (0.89 +- 0.11, 0.74 +- 0.10) were markedly elevated versus the control (0.39 +- 0.04, 0.44 +- 0.05), the astragaloside (0.51 +- 0.08, 0.59 +- 0.12) and the budesonide groups (0.55 +- 0.08, 0.60 +- 0.08) (all P < 0.05).	Budesonide	217-227	transforming growth factor, beta 1	Mus musculus	22-31
22340658-13	2011	The protein levels of TGF-beta1 and TSLP in the asthma group (0.89 +- 0.11, 0.74 +- 0.10) were markedly elevated versus the control (0.39 +- 0.04, 0.44 +- 0.05), the astragaloside (0.51 +- 0.08, 0.59 +- 0.12) and the budesonide groups (0.55 +- 0.08, 0.60 +- 0.08) (all P < 0.05).	Budesonide	217-227	thymic stromal lymphopoietin	Mus musculus	36-40
21306583-10	2011	Budesonide inhibited the formoterol-induced reduction in plasma membrane beta(2)-adrenoceptor fluorescence.	Budesonide	0-10	adrenoceptor beta 2	Homo sapiens	73-93
22409907-6	2011	RESULTS: Mometasone and budesonide attenuate both EAR and LAR to allergen to a similar degree.	Budesonide	24-34	protein tyrosine phosphatase receptor type F	Homo sapiens	58-61
21378156-0	2011	New treatment for IgA nephropathy: enteric budesonide targeted to the ileocecal region ameliorates proteinuria.	Budesonide	43-53	CD79a molecule	Homo sapiens	18-21
21378156-4	2011	METHODS: Budesonide 8 mg/day was given to 16 patients with IgAN for 6 months, followed by a 3-month follow-up period.	Budesonide	9-19	IGAN1	Homo sapiens	59-63
21378156-10	2011	CONCLUSIONS: In the present pilot study, enteric budesonide targeted to the ileocecal region had a significant effect on urine albumin excretion, accompanied by a minor reduction of serum creatinine and a modest increase of eGFR calculated by the MDRD equation, while eGFR calculated from Cockcroft-Gault equation and cystatin C was not changed.	Budesonide	49-59	cystatin C	Homo sapiens	318-328
21378156-11	2011	Enteric budesonide may represent a new treatment of IgAN warranting further investigation.	Budesonide	8-18	IGAN1	Homo sapiens	52-56
21621192-1	2011	OBJECTIVE: To evaluate the effect of different concentrations of inhaled budesonide on secretion of tumoral necrosis factor-alpha (TNF-alpha) and on ligature-induced alveolar bone loss in Wistar rats.	Budesonide	73-83	tumor necrosis factor	Rattus norvegicus	131-140
21660539-7	2011	Serum albumin levels increased after initiation of budesonide for 90% of the patients, and clinical evidence of fluid overload improved for 60% of them.	Budesonide	51-61	albumin	Homo sapiens	6-13
21660539-10	2011	In this series of PLE patients, oral budesonide therapy was associated with significant symptomatic improvement and sustained increases in serum albumin.	Budesonide	37-47	albumin	Homo sapiens	145-152
21169556-12	2011	IL-6 contributes to the cardiovascular dysfunction related to LPS, and pretreatment with budesonide/formoterol reduces the systemic expression of IL-6 and improves cardiovascular dysfunction.	Budesonide	89-99	interleukin 6	Mus musculus	146-150
21875545-3	2011	OBJECTIVE: We aimed to compare the effect of GCS (budesonide) on interleukin (IL)-4-driven IgE production in vitro in allergic and non allergic subjects and assess the engagement of intracellular mechanisms.	Budesonide	50-60	interleukin 4	Homo sapiens	65-83
21875545-7	2011	RESULTS: Budesonide enhanced IgE synthesis to higher extent in healthy donors than in allergic patients (mean increase of 16.5 vs 6.3 kU/L, P< .05 respectively) acting through glucocorticoid receptor.	Budesonide	9-19	nuclear receptor subfamily 3 group C member 1	Homo sapiens	179-202
21875545-8	2011	Budesonide significantly increased lymhoplasmocytoid cells percentage in both media-controlled (2.5-fold increase) and IL-4-stimulated PBMCs (2-fold increase).	Budesonide	0-10	interleukin 4	Homo sapiens	119-123
21875545-9	2011	Added to IL-4 budesonide decreased the percentage of both T cells and CD40L(+) T cells, but strongly increased the percentage of B cells.	Budesonide	14-24	interleukin 4	Homo sapiens	9-13
21875545-9	2011	Added to IL-4 budesonide decreased the percentage of both T cells and CD40L(+) T cells, but strongly increased the percentage of B cells.	Budesonide	14-24	CD40 ligand	Homo sapiens	70-75
21878659-8	2011	Budesonide is an orally administered synthetic corticosteroid with high affinity for the glucocorticoid receptor that undergoes extensive first-pass metabolism.	Budesonide	0-10	nuclear receptor subfamily 3 group C member 1	Homo sapiens	89-112
21514131-0	2011	TGFbeta-induced matrix production by bronchial fibroblasts in asthma: budesonide and formoterol effects.	Budesonide	70-80	transforming growth factor beta 1	Homo sapiens	0-7
21924027-8	2011	The IFN-gamma level increased and the IL-17 level decreased more significantly in the budesonide+huai qi huang-treated asthma group when compared with the budesonide and huai qi huang alone treatment groups.	Budesonide	86-96	interferon gamma	Rattus norvegicus	4-13
21924027-8	2011	The IFN-gamma level increased and the IL-17 level decreased more significantly in the budesonide+huai qi huang-treated asthma group when compared with the budesonide and huai qi huang alone treatment groups.	Budesonide	86-96	interleukin 17A	Rattus norvegicus	38-43
21306583-12	2011	Budesonide protection against beta(2)-adrenoceptor tolerance was correlated with the retention of receptor fluorescence on the plasma membrane, thereby suggesting a mechanism by which steroids alter beta(2)-adrenoceptor function.	Budesonide	0-10	adrenoceptor beta 2	Homo sapiens	30-50
21306583-12	2011	Budesonide protection against beta(2)-adrenoceptor tolerance was correlated with the retention of receptor fluorescence on the plasma membrane, thereby suggesting a mechanism by which steroids alter beta(2)-adrenoceptor function.	Budesonide	0-10	adrenoceptor beta 2	Homo sapiens	199-219
21430235-5	2011	Finally, budesonide, cyclosporine, and rifampin were identified as inhibitors of OATP1B1-, OATP1B3-, and OATP2B1-meditated mesalazine uptake.	Budesonide	9-19	solute carrier organic anion transporter family member 1B1	Homo sapiens	81-88
21430235-5	2011	Finally, budesonide, cyclosporine, and rifampin were identified as inhibitors of OATP1B1-, OATP1B3-, and OATP2B1-meditated mesalazine uptake.	Budesonide	9-19	solute carrier organic anion transporter family member 1B3	Homo sapiens	91-98
21430235-5	2011	Finally, budesonide, cyclosporine, and rifampin were identified as inhibitors of OATP1B1-, OATP1B3-, and OATP2B1-meditated mesalazine uptake.	Budesonide	9-19	solute carrier organic anion transporter family member 2B1	Homo sapiens	105-112
21074892-5	2011	OVA induced asthma groups were either treated by intranasal instillation of normal saline, intranasal instillation of GC or inhaled budesonide.	Budesonide	132-142	serine (or cysteine) peptidase inhibitor, clade B, member 1, pseudogene	Mus musculus	0-3
21372631-4	2011	Furthermore, knockdown of IL-23 expression significantly decreased the levels of serum IgE, IL-23, IL-17, and IL-4, but not IFNgamma, and its anti-inflammatory effects were similar to or better than that of treatment with budesonide in asthmatic mice.	Budesonide	222-232	interleukin 23, alpha subunit p19	Mus musculus	26-31
21300705-6	2011	Corticosteroid sensitivity was evaluated by the inhibition of tumor necrosis factor alpha (TNFalpha)-induced interleukin 8 (IL-8) production by budesonide.	Budesonide	144-154	tumor necrosis factor	Homo sapiens	62-89
21300705-6	2011	Corticosteroid sensitivity was evaluated by the inhibition of tumor necrosis factor alpha (TNFalpha)-induced interleukin 8 (IL-8) production by budesonide.	Budesonide	144-154	tumor necrosis factor	Homo sapiens	91-99
21300705-6	2011	Corticosteroid sensitivity was evaluated by the inhibition of tumor necrosis factor alpha (TNFalpha)-induced interleukin 8 (IL-8) production by budesonide.	Budesonide	144-154	C-X-C motif chemokine ligand 8	Homo sapiens	109-122
21300705-6	2011	Corticosteroid sensitivity was evaluated by the inhibition of tumor necrosis factor alpha (TNFalpha)-induced interleukin 8 (IL-8) production by budesonide.	Budesonide	144-154	C-X-C motif chemokine ligand 8	Homo sapiens	124-128
21097795-3	2011	PATIENTS AND DESIGN: In an 18-month study, children aged 5-10 years with asthma received twice daily budesonide via a TBH.	Budesonide	101-111	PIF1 5'-to-3' DNA helicase	Homo sapiens	118-121
21395877-6	2011	RESULTS: Budesonide and dexamethasone produced a concentration-dependent inhibition of the LPS-induced IL-8 and TNF-alpha secretion with an E(max) about 90% of inhibition, which was reduced by approximately 30% in the presence of H(2)O(2) or CSE.	Budesonide	9-19	C-X-C motif chemokine ligand 8	Homo sapiens	103-107
21395877-6	2011	RESULTS: Budesonide and dexamethasone produced a concentration-dependent inhibition of the LPS-induced IL-8 and TNF-alpha secretion with an E(max) about 90% of inhibition, which was reduced by approximately 30% in the presence of H(2)O(2) or CSE.	Budesonide	9-19	tumor necrosis factor	Homo sapiens	112-121
21097795-13	2011	CONCLUSIONS: True adherence with budesonide TBH treatment decreased significantly during the 18-month study due to a decrease in adherence.	Budesonide	33-43	PIF1 5'-to-3' DNA helicase	Homo sapiens	44-47
21097795-14	2011	Inhaler competence with the correct use of the budesonide TBH was high and unchanged over the study period.	Budesonide	47-57	PIF1 5'-to-3' DNA helicase	Homo sapiens	58-61
21148795-3	2011	Cell treatment with the potent GC budesonide accelerated the decay of CCL2 mRNA (t(1/2) = 8 +- 1 min versus 62 +- 17 min in DMSO-treated cells) and CCL7 mRNA (t(1/2) = 15 +- 4 min versus 114 +- 37 min), but not that of CCL5 mRNA (t(1/2)=231 +- 8 min versus 266 +- 5 min) in the BEAS-2B cell line.	Budesonide	34-44	C-C motif chemokine ligand 2	Homo sapiens	70-74
21148795-3	2011	Cell treatment with the potent GC budesonide accelerated the decay of CCL2 mRNA (t(1/2) = 8 +- 1 min versus 62 +- 17 min in DMSO-treated cells) and CCL7 mRNA (t(1/2) = 15 +- 4 min versus 114 +- 37 min), but not that of CCL5 mRNA (t(1/2)=231 +- 8 min versus 266 +- 5 min) in the BEAS-2B cell line.	Budesonide	34-44	C-C motif chemokine ligand 7	Homo sapiens	148-152
21148795-3	2011	Cell treatment with the potent GC budesonide accelerated the decay of CCL2 mRNA (t(1/2) = 8 +- 1 min versus 62 +- 17 min in DMSO-treated cells) and CCL7 mRNA (t(1/2) = 15 +- 4 min versus 114 +- 37 min), but not that of CCL5 mRNA (t(1/2)=231 +- 8 min versus 266 +- 5 min) in the BEAS-2B cell line.	Budesonide	34-44	C-C motif chemokine ligand 5	Homo sapiens	219-223
21170080-9	2011	The expression of MMP-9, TIMP-1, and TGF-beta(1) in induced sputum samples increased in patients with asthma and decreased dramatically after treatment with formoterol-budesonide.	Budesonide	168-178	matrix metallopeptidase 9	Homo sapiens	18-23
21170080-9	2011	The expression of MMP-9, TIMP-1, and TGF-beta(1) in induced sputum samples increased in patients with asthma and decreased dramatically after treatment with formoterol-budesonide.	Budesonide	168-178	TIMP metallopeptidase inhibitor 1	Homo sapiens	25-31
21170080-9	2011	The expression of MMP-9, TIMP-1, and TGF-beta(1) in induced sputum samples increased in patients with asthma and decreased dramatically after treatment with formoterol-budesonide.	Budesonide	168-178	transforming growth factor beta 1	Homo sapiens	37-48
21084452-7	2011	Of note, CpdA failed to induce osteogenic differentiation of BMSCs, whereas DEX and budesonide enhanced matrix mineralization an d increased runt-related transcription factor 2 and alkaline phosphatase mRNA levels up to 5-fold in a dose-dependent manner.	Budesonide	84-94	RUNX family transcription factor 2	Homo sapiens	141-176
21646801-3	2011	We investigated the effect of a beta(2)-agonist, i.e. procaterol, and a corticosteroid, i.e. budesonide, that are commonly used for viral-induced asthma, on TLR7 ligand-induced activation of eosinophils in vitro.	Budesonide	93-103	toll like receptor 7	Homo sapiens	157-161
21646801-10	2011	Budesonide significantly inhibited R-837-induced IL-8 production in a concentration-dependent manner, and procaterol potentiated inhibition by budesonide although single-agent procaterol had no effect.	Budesonide	0-10	C-X-C motif chemokine ligand 8	Homo sapiens	49-53
21646801-11	2011	CONCLUSION: A combination of procaterol and budesonide inhibits the TLR7-mediated effector function of eosinophils, indicating their possible anti-inflammatory effect for virus-induced asthma.	Budesonide	44-54	toll like receptor 7	Homo sapiens	68-72
21498933-5	2011	METHODS: Patients with ABPA-S were treated with a combination of formoterol/budesonide (24-1600 micrograms per day), and followed up with history, physical examination, chest radiograph and total IgE levels at 6, 12, 18 and 24 weeks.	Budesonide	76-86	filamin C	Homo sapiens	23-29
21942463-0	2011	Comparative effectiveness of budesonide/formoterol and fluticasone/salmeterol for COPD management.	Budesonide	29-39	COPD	Homo sapiens	82-86
22125636-6	2011	In PBMC from healthy donors, budesonide alone inhibited IP-10 and IL-6 production induced by imiquimod in a concentration-dependent manner and the degree of inhibition was amplified when budesonide and formoterol were used in combination.	Budesonide	29-39	C-X-C motif chemokine ligand 10	Homo sapiens	56-61
21434575-1	2011	Budesonide is a potent glucocorticoid with high affinity for the glucocorticoid receptor, which is used for the treatment of inflammatory bowel diseases.	Budesonide	0-10	nuclear receptor subfamily 3 group C member 1	Homo sapiens	65-88
22125636-6	2011	In PBMC from healthy donors, budesonide alone inhibited IP-10 and IL-6 production induced by imiquimod in a concentration-dependent manner and the degree of inhibition was amplified when budesonide and formoterol were used in combination.	Budesonide	29-39	interleukin 6	Homo sapiens	66-70
22125636-6	2011	In PBMC from healthy donors, budesonide alone inhibited IP-10 and IL-6 production induced by imiquimod in a concentration-dependent manner and the degree of inhibition was amplified when budesonide and formoterol were used in combination.	Budesonide	187-197	interleukin 6	Homo sapiens	66-70
22125636-8	2011	In RV16 stimulated PBMC, the combination of budesonide and formoterol inhibited IFNalpha and IP-10 production in asthmatic as well as healthy donors.	Budesonide	44-54	interferon alpha 1	Homo sapiens	80-88
22125636-8	2011	In RV16 stimulated PBMC, the combination of budesonide and formoterol inhibited IFNalpha and IP-10 production in asthmatic as well as healthy donors.	Budesonide	44-54	C-X-C motif chemokine ligand 10	Homo sapiens	93-98
21139721-11	2010	Nebulized budesonide may be an alternative to parental/oral prednisolone in the treatment of acute exacerbations of COPD but further studies should be done to evaluate its long-term impact on clinical outcomes after an initial episode of COPD exacerbation.	Budesonide	10-20	COPD	Homo sapiens	116-120
20729385-7	2010	Pretreatment with budesonide, a currently used inhaled corticosteroid, decreased LPS-induced expression of TNF-alpha, IL-6, and IL-8, and reduced LPS-induced neutrophilia by ~84%.	Budesonide	18-28	tumor necrosis factor	Homo sapiens	107-116
20729385-7	2010	Pretreatment with budesonide, a currently used inhaled corticosteroid, decreased LPS-induced expression of TNF-alpha, IL-6, and IL-8, and reduced LPS-induced neutrophilia by ~84%.	Budesonide	18-28	interleukin 6	Homo sapiens	118-122
20729385-7	2010	Pretreatment with budesonide, a currently used inhaled corticosteroid, decreased LPS-induced expression of TNF-alpha, IL-6, and IL-8, and reduced LPS-induced neutrophilia by ~84%.	Budesonide	18-28	C-X-C motif chemokine ligand 8	Homo sapiens	128-132
21128746-0	2010	Budesonide and formoterol in a single pressurized metered-dose inhaler for treatment of COPD.	Budesonide	0-10	COPD	Homo sapiens	88-92
20889339-6	2010	It was found that the aminoCPOs were able to reduce TNFalpha secretion to a level equivalent to the reduction caused by the steroid drug budesonide (BUD).	Budesonide	137-147	tumor necrosis factor	Mus musculus	52-60
20889339-6	2010	It was found that the aminoCPOs were able to reduce TNFalpha secretion to a level equivalent to the reduction caused by the steroid drug budesonide (BUD).	Budesonide	149-152	tumor necrosis factor	Mus musculus	52-60
21139721-11	2010	Nebulized budesonide may be an alternative to parental/oral prednisolone in the treatment of acute exacerbations of COPD but further studies should be done to evaluate its long-term impact on clinical outcomes after an initial episode of COPD exacerbation.	Budesonide	10-20	COPD	Homo sapiens	238-242
20943044-5	2010	Expression of CD4+ T cell activation markers was measured in induced sputum at baseline and after 1, 4, 8 and 12 weeks of treatment by flow cytometry, which showed a down-regulation of HLA-DR and CD25 surface proteins in the budesonide group, compared with the control group; these differences resulted as being statistically significant through weeks 4-12.	Budesonide	225-235	CD4 molecule	Homo sapiens	14-17
20307681-4	2010	Formoterol enhanced and budesonide inhibited IL-6, CXCL8 and CXCL1 release from LPS-stimulated neutrophils.	Budesonide	24-34	interleukin 6	Homo sapiens	45-49
20307681-4	2010	Formoterol enhanced and budesonide inhibited IL-6, CXCL8 and CXCL1 release from LPS-stimulated neutrophils.	Budesonide	24-34	C-X-C motif chemokine ligand 8	Homo sapiens	51-56
20307681-4	2010	Formoterol enhanced and budesonide inhibited IL-6, CXCL8 and CXCL1 release from LPS-stimulated neutrophils.	Budesonide	24-34	C-X-C motif chemokine ligand 1	Homo sapiens	61-66
20307681-5	2010	Formoterol up-regulated both CXCR1 and CXCR2 expression, whereas budesonide up-regulated the expression of CXCR2 only.	Budesonide	65-75	C-X-C motif chemokine receptor 2	Homo sapiens	107-112
20704802-0	2010	[Regulative mechanism of budesonide on endogenous hydrogen sulfide, cystathionine-gamma-lyase and cystathionine-beta-synthase system in asthmatic rats].	Budesonide	25-35	cystathionine gamma-lyase	Rattus norvegicus	68-93
20704802-0	2010	[Regulative mechanism of budesonide on endogenous hydrogen sulfide, cystathionine-gamma-lyase and cystathionine-beta-synthase system in asthmatic rats].	Budesonide	25-35	cystathionine beta synthase	Rattus norvegicus	98-125
20704802-10	2010	The budesonide treatment group had a decreased CSE mRNA expression and CBE mRNA expression compared with the control group, but had significantly increased CSE and CBE mRNA expression compared with the asthma group (P < 0.01).	Budesonide	4-14	cystathionine gamma-lyase	Rattus norvegicus	47-50
20704802-10	2010	The budesonide treatment group had a decreased CSE mRNA expression and CBE mRNA expression compared with the control group, but had significantly increased CSE and CBE mRNA expression compared with the asthma group (P < 0.01).	Budesonide	4-14	cystathionine gamma-lyase	Rattus norvegicus	156-159
20704802-13	2010	Budesonide may alleviate airway inflammation in asthmatic rats possibly through the system of endogenous H2S, CSE and CBS.	Budesonide	0-10	cystathionine gamma-lyase	Rattus norvegicus	110-113
20359293-0	2010	Effect of budesonide on TGF-beta1-enhanced VEGF production by lung fibroblasts.	Budesonide	10-20	transforming growth factor beta 1	Homo sapiens	24-33
20359293-0	2010	Effect of budesonide on TGF-beta1-enhanced VEGF production by lung fibroblasts.	Budesonide	10-20	vascular endothelial growth factor A	Homo sapiens	43-47
20359293-2	2010	Since the glucocorticoids have shown antifibrosis properties, we sought to investigate whether budesonide, a widely used glucocorticoid in clinical practice, could attenuate TGF-beta1 (transforming growth factor-beta1)-induced VEGF production by HFL-1 (human lung fibroblasts).	Budesonide	95-105	transforming growth factor beta 1	Homo sapiens	174-183
20359293-2	2010	Since the glucocorticoids have shown antifibrosis properties, we sought to investigate whether budesonide, a widely used glucocorticoid in clinical practice, could attenuate TGF-beta1 (transforming growth factor-beta1)-induced VEGF production by HFL-1 (human lung fibroblasts).	Budesonide	95-105	transforming growth factor beta 1	Homo sapiens	185-217
20359293-2	2010	Since the glucocorticoids have shown antifibrosis properties, we sought to investigate whether budesonide, a widely used glucocorticoid in clinical practice, could attenuate TGF-beta1 (transforming growth factor-beta1)-induced VEGF production by HFL-1 (human lung fibroblasts).	Budesonide	95-105	vascular endothelial growth factor A	Homo sapiens	227-231
20359293-2	2010	Since the glucocorticoids have shown antifibrosis properties, we sought to investigate whether budesonide, a widely used glucocorticoid in clinical practice, could attenuate TGF-beta1 (transforming growth factor-beta1)-induced VEGF production by HFL-1 (human lung fibroblasts).	Budesonide	95-105	complement factor H related 1	Homo sapiens	246-251
20359293-3	2010	HFL-1 fibroblasts were treated with various concentrations of budesonide (10(-11) M, 10(-9) M and 10(-7) M) in the absence or presence of TGF-beta1.	Budesonide	62-72	complement factor H related 1	Homo sapiens	0-5
20359293-6	2010	The results suggested that budesonide pretreatment reduced the significant increase of VEGF release induced by TGF-beta1 in HFL-1 fibroblasts in a dose-dependent manner, and suppressed the increase of phospho-Smad3 and phosphor-ERK (extracellular signal-regulated kinase) protein levels.	Budesonide	27-37	vascular endothelial growth factor A	Homo sapiens	87-91
20359293-6	2010	The results suggested that budesonide pretreatment reduced the significant increase of VEGF release induced by TGF-beta1 in HFL-1 fibroblasts in a dose-dependent manner, and suppressed the increase of phospho-Smad3 and phosphor-ERK (extracellular signal-regulated kinase) protein levels.	Budesonide	27-37	transforming growth factor beta 1	Homo sapiens	111-120
20359293-6	2010	The results suggested that budesonide pretreatment reduced the significant increase of VEGF release induced by TGF-beta1 in HFL-1 fibroblasts in a dose-dependent manner, and suppressed the increase of phospho-Smad3 and phosphor-ERK (extracellular signal-regulated kinase) protein levels.	Budesonide	27-37	complement factor H related 1	Homo sapiens	124-129
20359293-6	2010	The results suggested that budesonide pretreatment reduced the significant increase of VEGF release induced by TGF-beta1 in HFL-1 fibroblasts in a dose-dependent manner, and suppressed the increase of phospho-Smad3 and phosphor-ERK (extracellular signal-regulated kinase) protein levels.	Budesonide	27-37	mitogen-activated protein kinase 1	Homo sapiens	228-231
20359293-7	2010	In conclusion, budesonide may reduce TGF-beta1-induced VEGF production in the lung, probably through the Smad/ERK signalling pathway and, thus, may provide new sight into the molecular mechanism underlying glucocorticoid therapy for airway inflammatory diseases.	Budesonide	15-25	transforming growth factor beta 1	Homo sapiens	37-46
20359293-7	2010	In conclusion, budesonide may reduce TGF-beta1-induced VEGF production in the lung, probably through the Smad/ERK signalling pathway and, thus, may provide new sight into the molecular mechanism underlying glucocorticoid therapy for airway inflammatory diseases.	Budesonide	15-25	vascular endothelial growth factor A	Homo sapiens	55-59
20359293-7	2010	In conclusion, budesonide may reduce TGF-beta1-induced VEGF production in the lung, probably through the Smad/ERK signalling pathway and, thus, may provide new sight into the molecular mechanism underlying glucocorticoid therapy for airway inflammatory diseases.	Budesonide	15-25	mitogen-activated protein kinase 1	Homo sapiens	110-113
20959050-0	2010	[Effects of inhaled budesonide on the bronchial-pulmonary pathology and expression of thymic stromal lymphopoietin in lung tissues in asthmatic rats].	Budesonide	20-30	thymic stromal lymphopoietin	Rattus norvegicus	86-114
20959050-2	2010	This study was designed to examine the effects of inhaled budesonide on TSLP expression in the lung tissues and on the bronchial-pulmonary pathology in asthmatic rats.	Budesonide	58-68	thymic stromal lymphopoietin	Rattus norvegicus	72-76
20959050-9	2010	TSLP expression in the lung tissues was significantly lower in the budesonide treatment group than that in the asthma control group both 29 and 36 days after OVA challenge (P<0.05).	Budesonide	67-77	thymic stromal lymphopoietin	Rattus norvegicus	0-4
20959050-10	2010	CONCLUSIONS: Inhaled budesonide can inhibit the TSLP expression in the lung tissues and alleviate lung inflammatory reactions in asthmatic rats, but there is end-of-dose failure.	Budesonide	21-31	thymic stromal lymphopoietin	Rattus norvegicus	48-52
20639142-2	2010	This study evaluates in conscious guinea-pigs the bronchodilator effect, alone or combined with salbutamol, of TPI 1020, a novel anti-inflammatory corticosteroid and nitric oxide (NO) donor derived from budesonide.	Budesonide	203-213	triosephosphate isomerase 1	Homo sapiens	111-114
20637110-7	2010	Budesonide alone protected mSin3a protein expression with no additional effect seen with abrogation of PI3Kgamma/delta activity, however Mi-2alpha, but not Mi-2beta, expression was protected in both PI3KdeltaD910/A910 and PI3Kgamma-/- budesonide-treated smoke-exposed mice.	Budesonide	0-10	transcriptional regulator, SIN3A (yeast)	Mus musculus	27-33
19926732-7	2010	Budesonide inhibited release of all three cytokines (EC(50) TNF-alpha: 1.2+/-0.4 nM; GM-CSF: 0.4+/-0.2 nM; CXCL8: 0.4+/-0.1 nM; n = 3-4).	Budesonide	0-10	tumor necrosis factor	Homo sapiens	60-69
19926732-7	2010	Budesonide inhibited release of all three cytokines (EC(50) TNF-alpha: 1.2+/-0.4 nM; GM-CSF: 0.4+/-0.2 nM; CXCL8: 0.4+/-0.1 nM; n = 3-4).	Budesonide	0-10	colony stimulating factor 2	Homo sapiens	85-91
19926732-7	2010	Budesonide inhibited release of all three cytokines (EC(50) TNF-alpha: 1.2+/-0.4 nM; GM-CSF: 0.4+/-0.2 nM; CXCL8: 0.4+/-0.1 nM; n = 3-4).	Budesonide	0-10	C-X-C motif chemokine ligand 8	Homo sapiens	107-112
19926732-11	2010	Combining budesonide (0.3 nM) with formoterol, inhibited TNF-alpha release additively.	Budesonide	10-20	tumor necrosis factor	Homo sapiens	57-66
20943044-5	2010	Expression of CD4+ T cell activation markers was measured in induced sputum at baseline and after 1, 4, 8 and 12 weeks of treatment by flow cytometry, which showed a down-regulation of HLA-DR and CD25 surface proteins in the budesonide group, compared with the control group; these differences resulted as being statistically significant through weeks 4-12.	Budesonide	225-235	interleukin 2 receptor subunit alpha	Homo sapiens	196-200
19786805-4	2010	Inhaled budesonide increased TIMP-1 levels in both groups of asthmatic children and normalized the MMP-8/TIMP-1 ratio, and this paralleled the improvement in forced expiratory volume in 1 s in children with mild symptoms.	Budesonide	8-18	TIMP metallopeptidase inhibitor 1	Homo sapiens	29-35
20646342-0	2010	Effects of budesonide on P38 MAPK activation, apoptosis and IL-8 secretion, induced by TNF-alpha and Haemophilus influenzae in human bronchial epithelial cells.	Budesonide	11-21	mitogen-activated protein kinase 14	Homo sapiens	25-28
20646342-0	2010	Effects of budesonide on P38 MAPK activation, apoptosis and IL-8 secretion, induced by TNF-alpha and Haemophilus influenzae in human bronchial epithelial cells.	Budesonide	11-21	tumor necrosis factor	Homo sapiens	87-96
20646342-12	2010	Furthermore, budesonide can be very effective in preventing, through inhibition of p38 MAPK phosphorylation, both structural and proinflammatory changes elicited in bronchial epithelium by TNF-alpha and NTHi.	Budesonide	13-23	mitogen-activated protein kinase 14	Homo sapiens	83-86
20646342-12	2010	Furthermore, budesonide can be very effective in preventing, through inhibition of p38 MAPK phosphorylation, both structural and proinflammatory changes elicited in bronchial epithelium by TNF-alpha and NTHi.	Budesonide	13-23	tumor necrosis factor	Homo sapiens	189-198
20061444-9	2010	In tracheal smooth muscle, beta(2)AR mRNA was not affected by the cytokines but increased with budesonide.	Budesonide	95-105	adrenergic receptor, beta 2	Mus musculus	27-36
20061444-11	2010	It is noteworthy that the cytokine-induced increase of COX-2 was blocked by concomitant budesonide suggesting that heterologous desensitization of beta(2)AR by the cytokines may be prevented by budesonide treatment.	Budesonide	88-98	cytochrome c oxidase II, mitochondrial	Mus musculus	55-60
20061444-11	2010	It is noteworthy that the cytokine-induced increase of COX-2 was blocked by concomitant budesonide suggesting that heterologous desensitization of beta(2)AR by the cytokines may be prevented by budesonide treatment.	Budesonide	88-98	adrenergic receptor, beta 2	Mus musculus	147-156
20061444-11	2010	It is noteworthy that the cytokine-induced increase of COX-2 was blocked by concomitant budesonide suggesting that heterologous desensitization of beta(2)AR by the cytokines may be prevented by budesonide treatment.	Budesonide	194-204	cytochrome c oxidase II, mitochondrial	Mus musculus	55-60
20061444-11	2010	It is noteworthy that the cytokine-induced increase of COX-2 was blocked by concomitant budesonide suggesting that heterologous desensitization of beta(2)AR by the cytokines may be prevented by budesonide treatment.	Budesonide	194-204	adrenergic receptor, beta 2	Mus musculus	147-156
20061444-12	2010	Budesonide prevented cytokine-induced impairment of the tracheal relaxation and beta(2)AR/cAMP signaling for formoterol but not for salmeterol.	Budesonide	0-10	adrenergic receptor, beta 2	Mus musculus	80-89
20423862-10	2010	The percentage of pulmonary perivascular VEGF-positive cells in the bicuculline group was significantly greater in the control and budesonide groups (P<0.01 and P<0.05), but comparable to that in the asthmatic model group (P>0.05).	Budesonide	131-141	vascular endothelial growth factor A	Mus musculus	41-45
20172140-9	2010	Serum albumin level improved in all patients within 6 months of starting budesonide (mean 2.9 g/dL; range, 2.2 to 3.8 g/dL).	Budesonide	73-83	albumin	Homo sapiens	6-13
19875223-4	2010	Both groups were treated with budesonide (200 mcg bid delivered by MDI and spacer) for three months.	Budesonide	30-40	BH3 interacting domain death agonist	Homo sapiens	50-53
20482961-8	2010	In summary, budesonide/formoterol pMDI is an effective, well-tolerated treatment option for patients with persistent asthma for whom ICS/long-acting beta2-adrenergic agonist combination therapy is appropriate.	Budesonide	12-22	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	149-154
20388003-0	2010	Budesonide enhances Toll-like receptor 2 expression in activated bronchial epithelial cells.	Budesonide	0-10	toll like receptor 2	Homo sapiens	20-40
20388003-8	2010	Budesonide significantly attenuated the release and expression of IL-6 and IL-8 after exposure.	Budesonide	0-10	interleukin 6	Homo sapiens	66-70
20388003-8	2010	Budesonide significantly attenuated the release and expression of IL-6 and IL-8 after exposure.	Budesonide	0-10	C-X-C motif chemokine ligand 8	Homo sapiens	75-79
20388003-9	2010	Budesonide did not influence TLR expression, but costimulation with LPS, TNF, or dust together with budesonide increased TLR2 expression synergistically.	Budesonide	100-110	toll like receptor 2	Homo sapiens	121-125
20388003-11	2010	Budesonide reduced IL-6 and IL-8 production and enhanced expression of TLR2 in PBECs only in the presence of a proinflammatory stimulus.	Budesonide	0-10	interleukin 6	Homo sapiens	19-23
20388003-11	2010	Budesonide reduced IL-6 and IL-8 production and enhanced expression of TLR2 in PBECs only in the presence of a proinflammatory stimulus.	Budesonide	0-10	C-X-C motif chemokine ligand 8	Homo sapiens	28-32
20388003-11	2010	Budesonide reduced IL-6 and IL-8 production and enhanced expression of TLR2 in PBECs only in the presence of a proinflammatory stimulus.	Budesonide	0-10	toll like receptor 2	Homo sapiens	71-75
20138301-8	2010	Infants in the group treated with budesonide tended to have higher PDI and MDI scores than infants in the control group (79 +/- 20 vs 74 +/- 18 and 80 +/- 19 vs 75 +/- 20), but these differences were not statistically significant.	Budesonide	34-44	peptidyl arginine deiminase 1	Homo sapiens	67-70
20850023-0	2010	[Budesonide/formoterol in the treatment of COPD].	Budesonide	1-11	COPD	Homo sapiens	43-47
20850023-1	2010	Two large, 12-month clinical trials have been performed with budesonide-formoterol in patients with stable COPD and have shown clear data on the efficacy of this combination in improving pulmonary function, symptoms and health-related quality of life and in reducing the number of exacerbations.	Budesonide	61-71	COPD	Homo sapiens	107-111
20850023-2	2010	Before these trials, information was already available on the efficacy of both monocomponents in this disease, although the main clinical data obtained with formoterol and budesonide separately in the treatment of COPD come from the respective branches of these drugs in the two large clinical trials described in the present article.	Budesonide	172-182	COPD	Homo sapiens	214-218
20850023-8	2010	The present review discusses the main findings on the efficacy of the combination of budesonide-formoterol in stable COPD.	Budesonide	85-95	COPD	Homo sapiens	117-121
19786805-4	2010	Inhaled budesonide increased TIMP-1 levels in both groups of asthmatic children and normalized the MMP-8/TIMP-1 ratio, and this paralleled the improvement in forced expiratory volume in 1 s in children with mild symptoms.	Budesonide	8-18	matrix metallopeptidase 8	Homo sapiens	99-104
19786805-4	2010	Inhaled budesonide increased TIMP-1 levels in both groups of asthmatic children and normalized the MMP-8/TIMP-1 ratio, and this paralleled the improvement in forced expiratory volume in 1 s in children with mild symptoms.	Budesonide	8-18	TIMP metallopeptidase inhibitor 1	Homo sapiens	105-111
19786805-6	2010	Budesonide decreased the percentage of MMP-8-positive macrophages and increased that of TIMP-1-positive macrophages; these changes were significant in asthmatic children with mild symptoms.	Budesonide	0-10	matrix metallopeptidase 8	Homo sapiens	39-44
19786805-6	2010	Budesonide decreased the percentage of MMP-8-positive macrophages and increased that of TIMP-1-positive macrophages; these changes were significant in asthmatic children with mild symptoms.	Budesonide	0-10	TIMP metallopeptidase inhibitor 1	Homo sapiens	88-94
19786805-7	2010	CONCLUSIONS: Inhaled budesonide normalized the MMP-8/TIMP-1 ratio in asthmatic children by upregulation of TIMP-1 production and downregulation of MMP-8 production by airway macrophages.	Budesonide	21-31	matrix metallopeptidase 8	Homo sapiens	47-52
19786805-7	2010	CONCLUSIONS: Inhaled budesonide normalized the MMP-8/TIMP-1 ratio in asthmatic children by upregulation of TIMP-1 production and downregulation of MMP-8 production by airway macrophages.	Budesonide	21-31	TIMP metallopeptidase inhibitor 1	Homo sapiens	53-59
19786805-7	2010	CONCLUSIONS: Inhaled budesonide normalized the MMP-8/TIMP-1 ratio in asthmatic children by upregulation of TIMP-1 production and downregulation of MMP-8 production by airway macrophages.	Budesonide	21-31	TIMP metallopeptidase inhibitor 1	Homo sapiens	107-113
19786805-7	2010	CONCLUSIONS: Inhaled budesonide normalized the MMP-8/TIMP-1 ratio in asthmatic children by upregulation of TIMP-1 production and downregulation of MMP-8 production by airway macrophages.	Budesonide	21-31	matrix metallopeptidase 8	Homo sapiens	147-152
19375904-0	2009	Budesonide/formoterol effects on metalloproteolytic balance in TGFbeta-activated human lung fibroblasts.	Budesonide	0-10	transforming growth factor beta 1	Homo sapiens	63-70
19473192-14	2009	In addition, the expression of cyclo-oxygenase (COX)-2 and intercellular adhesion molecule (ICAM)-1 in the lamina propria was reduced in patients treated with both gliadin and budesonide compared with patients treated with gliadin alone.	Budesonide	176-186	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	31-54
19473192-14	2009	In addition, the expression of cyclo-oxygenase (COX)-2 and intercellular adhesion molecule (ICAM)-1 in the lamina propria was reduced in patients treated with both gliadin and budesonide compared with patients treated with gliadin alone.	Budesonide	176-186	intercellular adhesion molecule 1	Homo sapiens	59-99
19375904-6	2009	Concurrent budesonide/formoterol combination counteracted the enhanced: PG and TIMP-1 production, MMP-9 activity and MMP-9/TIMP-1 ratio, whereas MMP-2 and MMP-3 were not affected and so their ratios to TIMP-1 were significantly increased.	Budesonide	11-21	TIMP metallopeptidase inhibitor 1	Homo sapiens	79-85
19375904-6	2009	Concurrent budesonide/formoterol combination counteracted the enhanced: PG and TIMP-1 production, MMP-9 activity and MMP-9/TIMP-1 ratio, whereas MMP-2 and MMP-3 were not affected and so their ratios to TIMP-1 were significantly increased.	Budesonide	11-21	matrix metallopeptidase 9	Homo sapiens	98-103
19375904-6	2009	Concurrent budesonide/formoterol combination counteracted the enhanced: PG and TIMP-1 production, MMP-9 activity and MMP-9/TIMP-1 ratio, whereas MMP-2 and MMP-3 were not affected and so their ratios to TIMP-1 were significantly increased.	Budesonide	11-21	matrix metallopeptidase 9	Homo sapiens	117-122
19375904-6	2009	Concurrent budesonide/formoterol combination counteracted the enhanced: PG and TIMP-1 production, MMP-9 activity and MMP-9/TIMP-1 ratio, whereas MMP-2 and MMP-3 were not affected and so their ratios to TIMP-1 were significantly increased.	Budesonide	11-21	TIMP metallopeptidase inhibitor 1	Homo sapiens	123-129
19644045-3	2009	OBJECTIVES: To assess the efficacy and tolerability of budesonide/formoterol added to tiotropium in patients eligible for inhaled corticosteroid/long-acting beta(2)-agonist combination therapy.	Budesonide	55-65	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	157-163
19430548-12	2009	CONCLUSION: Asthmatic patients with the Arg/Arg genotype at codon 16 of ADRB2 achieve better asthma control with long-term regular use of combined budesonide and formoterol treatment, suggesting that the ADRB2 genotype may dictate choice of treatment strategy.	Budesonide	147-157	adrenoceptor beta 2	Homo sapiens	72-77
19375904-6	2009	Concurrent budesonide/formoterol combination counteracted the enhanced: PG and TIMP-1 production, MMP-9 activity and MMP-9/TIMP-1 ratio, whereas MMP-2 and MMP-3 were not affected and so their ratios to TIMP-1 were significantly increased.	Budesonide	11-21	TIMP metallopeptidase inhibitor 1	Homo sapiens	123-129
19375904-7	2009	Budesonide or formoterol alone achieved equal effects as budesonide/formoterol on MMP-9 and MMP-9/TIMP-1 ratio but had no effects on TIMP-1, MMP-2 or MMP-3.	Budesonide	0-10	matrix metallopeptidase 9	Homo sapiens	92-97
19375904-7	2009	Budesonide or formoterol alone achieved equal effects as budesonide/formoterol on MMP-9 and MMP-9/TIMP-1 ratio but had no effects on TIMP-1, MMP-2 or MMP-3.	Budesonide	0-10	TIMP metallopeptidase inhibitor 1	Homo sapiens	98-104
19375904-7	2009	Budesonide or formoterol alone achieved equal effects as budesonide/formoterol on MMP-9 and MMP-9/TIMP-1 ratio but had no effects on TIMP-1, MMP-2 or MMP-3.	Budesonide	57-67	matrix metallopeptidase 9	Homo sapiens	82-87
19375904-7	2009	Budesonide or formoterol alone achieved equal effects as budesonide/formoterol on MMP-9 and MMP-9/TIMP-1 ratio but had no effects on TIMP-1, MMP-2 or MMP-3.	Budesonide	57-67	matrix metallopeptidase 9	Homo sapiens	92-97
19375904-9	2009	These results suggest that the budesonide/formoterol combination enhanced metalloproteolytic activity of human lung fibroblasts via a synergistic decrease of TIMP-1, and that this mechanism may be involved in the synergistic inhibition of the TGFbeta1-induced PG production.	Budesonide	31-41	TIMP metallopeptidase inhibitor 1	Homo sapiens	158-164
19375904-9	2009	These results suggest that the budesonide/formoterol combination enhanced metalloproteolytic activity of human lung fibroblasts via a synergistic decrease of TIMP-1, and that this mechanism may be involved in the synergistic inhibition of the TGFbeta1-induced PG production.	Budesonide	31-41	transforming growth factor beta 1	Homo sapiens	243-251
19953024-5	2009	METHODS: The present prospective multi-centered, randomised double-blind trial is designed to evaluate the efficacy of the combination of budesonide/formoterol (400/12 microg 2 inhalations bid) versus placebo in patients with moderate to severe obstructive airway disease, not requiring initiation or intensification of systemic immunosuppressive therapy for extra thoracic graft versus host disease.	Budesonide	138-148	BH3 interacting domain death agonist	Homo sapiens	189-192
19286361-8	2009	Sputum neutrophils (%) tended to decrease more with TPI 1020 (32.6% decrease versus 3.7% increase for budesonide); the decrease occurring only in patients with high neutrophils at baseline.	Budesonide	102-112	triosephosphate isomerase 1	Homo sapiens	52-55
19286361-10	2009	Budesonide caused a statistically significant decrease in 24h urinary free cortisol over 22days (median of 4.4-2.8mcg/ml, p=0.01) whereas TPI 1020 had no such effect (4.4-5.8mcg/ml), suggesting lower systemic corticosteroid exposure following TPI 1020 treatment.	Budesonide	0-10	triosephosphate isomerase 1	Homo sapiens	243-246
19470266-8	2009	The budesonide-treated asthma group demonstrated significantly decreased b-FGF (111.61+/- 5.52 vs 126.21+/- 6.46; P< 0.05) and NF-kappaB expression (110.65+/- 8.71 vs 134.15+/- 9.42; P< 0.05) in the airway as compared with the untreated asthma group.	Budesonide	4-14	fibroblast growth factor 2	Rattus norvegicus	73-78
19470266-9	2009	B-FGF expression was positively correlated to NF-kappaB expression in the budesonide-treated group.	Budesonide	74-84	fibroblast growth factor 2	Rattus norvegicus	0-5
19470266-11	2009	Budesonide can improve airway remodeling, possibly by decreasing the expression of b-FGF and NF-kappaB.	Budesonide	0-10	fibroblast growth factor 2	Rattus norvegicus	83-88
19430548-12	2009	CONCLUSION: Asthmatic patients with the Arg/Arg genotype at codon 16 of ADRB2 achieve better asthma control with long-term regular use of combined budesonide and formoterol treatment, suggesting that the ADRB2 genotype may dictate choice of treatment strategy.	Budesonide	147-157	adrenoceptor beta 2	Homo sapiens	204-209
19138736-6	2009	Induction experiments in human LS180 colon carcinoma cells showed an increased expression of CYP3A4 mRNA after budesonide treatment.	Budesonide	111-121	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	93-99
19138736-7	2009	Transactivation assays revealed that budesonide activates the CYP3A4 promoter via the pregnane X receptor (PXR).	Budesonide	37-47	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	62-68
19138736-7	2009	Transactivation assays revealed that budesonide activates the CYP3A4 promoter via the pregnane X receptor (PXR).	Budesonide	37-47	nuclear receptor subfamily 1, group I, member 2	Mus musculus	86-105
19138736-7	2009	Transactivation assays revealed that budesonide activates the CYP3A4 promoter via the pregnane X receptor (PXR).	Budesonide	37-47	nuclear receptor subfamily 1, group I, member 2	Mus musculus	107-110
19138736-8	2009	In mice, oral budesonide administration (25mg/kg) for 4 days induced the murine homolog Cyp3a11 in the intestine 3-fold, whereas liver expression was notably less influenced.	Budesonide	14-24	cytochrome P450, family 3, subfamily a, polypeptide 11	Mus musculus	88-95
19138736-9	2009	In knockout mice devoid of PXR, budesonide-mediated inductions were reduced compared to wild-type mice.	Budesonide	32-42	nuclear receptor subfamily 1, group I, member 2	Mus musculus	27-30
19138736-10	2009	In conclusion, we could demonstrate that budesonide is not an efficient inhibitor but rather an inducer of CYP3A via a PXR-mediated mechanism.	Budesonide	41-51	cytochrome P450, family 3, subfamily a, polypeptide 11	Mus musculus	107-112
19138736-10	2009	In conclusion, we could demonstrate that budesonide is not an efficient inhibitor but rather an inducer of CYP3A via a PXR-mediated mechanism.	Budesonide	41-51	nuclear receptor subfamily 1, group I, member 2	Mus musculus	119-122
19068102-2	2009	OBJECTIVES: The objectives of this study were to observe the effect of budesonide on the expression of IL-1beta, TNF-alpha, granulocyte macrophage-colony stimulating factor, intercellular adhesion molecule (ICAM)-1, basic fibroblast growth factor, eotaxin-2, glucocorticoid receptor (GR)-alpha, GR-beta, c-Fos and p65 in nasal polyps and to correlate their expression to clinical response.	Budesonide	71-81	interleukin 1 beta	Homo sapiens	103-111
19138736-0	2009	PXR-mediated induction of human CYP3A4 and mouse Cyp3a11 by the glucocorticoid budesonide.	Budesonide	79-89	nuclear receptor subfamily 1 group I member 2	Homo sapiens	0-3
19138736-0	2009	PXR-mediated induction of human CYP3A4 and mouse Cyp3a11 by the glucocorticoid budesonide.	Budesonide	79-89	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	32-38
19203724-2	2009	Safety of approved oral budesonide is based on high intestinal and hepatic extraction by cytochrome P450 3A (CYP3A) enzymes.	Budesonide	24-34	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	89-107
19203724-2	2009	Safety of approved oral budesonide is based on high intestinal and hepatic extraction by cytochrome P450 3A (CYP3A) enzymes.	Budesonide	24-34	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	109-114
19203724-6	2009	We assessed CYP3A-dependent metabolites in both healthy subjects and patients after buccal budesonide.	Budesonide	91-101	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	12-17
19203724-8	2009	Reduced buccal CYP3A activity (lower inactivation of budesonide) in patients contributed to this remarkable difference.	Budesonide	53-63	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	15-20
19203724-10	2009	We are the first to report the biotransformation of budesonide via CYP3A enzymes after buccal drug administration.	Budesonide	52-62	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	67-72
19228428-0	2009	Budesonide/formoterol as effective as prednisolone plus formoterol in acute exacerbations of COPD.	Budesonide	0-10	COPD	Homo sapiens	93-97
19228428-12	2009	CONCLUSION: High dose budesonide/formoterol was as effective as prednisolone plus formoterol for the ambulatory treatment of acute exacerbations in non-hospitalized COPD patients.	Budesonide	22-32	COPD	Homo sapiens	165-169
18804521-1	2009	Budesonide is a potent glucocorticoid with high affinity for the glucocorticoid receptor, which is now used for the treatment of inflammatory bowel diseases.	Budesonide	0-10	nuclear receptor subfamily 3, group C, member 1	Rattus norvegicus	65-88
19138736-0	2009	PXR-mediated induction of human CYP3A4 and mouse Cyp3a11 by the glucocorticoid budesonide.	Budesonide	79-89	cytochrome P450, family 3, subfamily a, polypeptide 11	Mus musculus	49-56
19138736-2	2009	Cytochrome P450 3A4 (CYP3A4) is an enzyme involved in the metabolism of numerous drugs, including budesonide.	Budesonide	98-108	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	21-27
19068102-2	2009	OBJECTIVES: The objectives of this study were to observe the effect of budesonide on the expression of IL-1beta, TNF-alpha, granulocyte macrophage-colony stimulating factor, intercellular adhesion molecule (ICAM)-1, basic fibroblast growth factor, eotaxin-2, glucocorticoid receptor (GR)-alpha, GR-beta, c-Fos and p65 in nasal polyps and to correlate their expression to clinical response.	Budesonide	71-81	tumor necrosis factor	Homo sapiens	113-122
19138736-3	2009	Since inhibition or induction of CYP3A4 is often the cause of drug-drug interactions we analyzed how budesonide affects the activity and expression of this enzyme.	Budesonide	101-111	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	33-39
19068102-9	2009	CONCLUSION: Topical budesonide reduced the expression of TNF-alpha, eotaxin-2 and p65.	Budesonide	20-30	tumor necrosis factor	Homo sapiens	57-66
19068102-9	2009	CONCLUSION: Topical budesonide reduced the expression of TNF-alpha, eotaxin-2 and p65.	Budesonide	20-30	C-C motif chemokine ligand 24	Homo sapiens	68-77
18669576-5	2009	INTERVENTIONS: Patients in clinical remission after 6 weeks" open-label therapy with oral budesonide (Entocort CIR capsules, 9 mg/day) received 24 weeks" double-blind maintenance therapy with budesonide 6 mg/day or placebo.	Budesonide	90-100	corepressor interacting with RBPJ, CIR1	Homo sapiens	111-114
19439980-4	2009	The aim of this study was to evaluate the effect of the inhaled glucocorticoid budesonide on sPLA(2)-induced activation of primary human macrophages.	Budesonide	79-89	phospholipase A2 group X	Homo sapiens	93-100
19439980-9	2009	RESULTS: Budesonide inhibited the release of TNF-alpha, IL-6 and IL-8 from sPLA(2)-stimulated macrophages in a concentration-dependent manner.	Budesonide	9-19	tumor necrosis factor	Homo sapiens	45-54
19439980-9	2009	RESULTS: Budesonide inhibited the release of TNF-alpha, IL-6 and IL-8 from sPLA(2)-stimulated macrophages in a concentration-dependent manner.	Budesonide	9-19	interleukin 6	Homo sapiens	56-60
19571567-6	2009	METHODS: Following pretreatment of NHLF with tumor necrosis factor-alpha (TNF-alpha) in the presence of various concentrations of procaterol and/or budesonide, the eotaxin-stimulated eosinophil adhesion was determined using the peroxidase activity of eosinophils.	Budesonide	148-158	tumor necrosis factor	Homo sapiens	74-83
19439980-9	2009	RESULTS: Budesonide inhibited the release of TNF-alpha, IL-6 and IL-8 from sPLA(2)-stimulated macrophages in a concentration-dependent manner.	Budesonide	9-19	C-X-C motif chemokine ligand 8	Homo sapiens	65-69
19571567-6	2009	METHODS: Following pretreatment of NHLF with tumor necrosis factor-alpha (TNF-alpha) in the presence of various concentrations of procaterol and/or budesonide, the eotaxin-stimulated eosinophil adhesion was determined using the peroxidase activity of eosinophils.	Budesonide	148-158	C-C motif chemokine ligand 11	Homo sapiens	164-171
19439980-9	2009	RESULTS: Budesonide inhibited the release of TNF-alpha, IL-6 and IL-8 from sPLA(2)-stimulated macrophages in a concentration-dependent manner.	Budesonide	9-19	phospholipase A2 group X	Homo sapiens	75-81
19571567-9	2009	Both procaterol and budesonide resulted in concentration-dependent inhibition of expression of ICAM-1 and VCAM-1 in NHLF, and an additive inhibitory effect was found when the agents were combined.	Budesonide	20-30	intercellular adhesion molecule 1	Homo sapiens	95-101
19439980-12	2009	Suppression of cytokine/chemokine production by budesonide was associated with inhibition of sPLA(2)-induced ERK 1/2 and p38 activation.	Budesonide	48-58	phospholipase A2 group X	Homo sapiens	93-99
19571567-9	2009	Both procaterol and budesonide resulted in concentration-dependent inhibition of expression of ICAM-1 and VCAM-1 in NHLF, and an additive inhibitory effect was found when the agents were combined.	Budesonide	20-30	vascular cell adhesion molecule 1	Homo sapiens	106-112
19439980-12	2009	Suppression of cytokine/chemokine production by budesonide was associated with inhibition of sPLA(2)-induced ERK 1/2 and p38 activation.	Budesonide	48-58	mitogen-activated protein kinase 3	Homo sapiens	109-116
19439980-12	2009	Suppression of cytokine/chemokine production by budesonide was associated with inhibition of sPLA(2)-induced ERK 1/2 and p38 activation.	Budesonide	48-58	mitogen-activated protein kinase 1	Homo sapiens	121-124
19439980-13	2009	CONCLUSIONS: Budesonide inhibits the production of proinflammatory cytokines/chemokines from human lung macrophages activated by sPLA(2).	Budesonide	13-23	phospholipase A2 group X	Homo sapiens	129-136
19439980-14	2009	Budesonide represents the first example of a drug able to block the nonenzymatic effects of sPLA(2) on human inflammatory cells and, therefore, may provide a useful therapeutic options for diseases associated with enhanced release of sPLA(2)s in vivo.	Budesonide	0-10	phospholipase A2 group X	Homo sapiens	92-99
19439980-14	2009	Budesonide represents the first example of a drug able to block the nonenzymatic effects of sPLA(2) on human inflammatory cells and, therefore, may provide a useful therapeutic options for diseases associated with enhanced release of sPLA(2)s in vivo.	Budesonide	0-10	phospholipase A2 group IID	Homo sapiens	234-242
18618676-8	2008	All 3 were treated with oral budesonide in lieu of systemic corticosteroids.	Budesonide	29-39	paired box 5	Homo sapiens	0-5
19075593-2	2008	We evaluated the ability of the glucocorticoid budesonide and of the natural agent phenethyl isothiocyanate (PEITC) to affect DNA damage in bronchoalveolar lavage (BAL) cells of CD-1 mice exposed to ECS, starting within 12 h after birth and continuing until the end of the experiment.	Budesonide	47-57	CD1 antigen complex	Mus musculus	178-182
18618676-10	2008	RESULTS: All 3 cases of de novo post transplant IBD went into clinical remission with oral budesonide.	Budesonide	91-101	paired box 5	Homo sapiens	9-14
20477290-1	2008	Budesonide/formoterol is a combination of an inhaled corticosteroid plus a long-acting beta(2)-agonist available as a dry-powder inhaler for the indication of asthma and chronic obstructive pulmonary disease in various countries outside of the USA and as a pressurized metered-dose inhaler in the USA for the indication of asthma.	Budesonide	0-10	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	87-93
18829252-5	2008	Most of the drugs available for long-term management of COPD have significant effects on the frequency of exacerbations: tiotropium and salmeterol, each used alone, as well as fixed combinations of salmeterol/fluticasone or formoterol/budesonide.	Budesonide	235-245	COPD	Homo sapiens	56-60
18972276-9	2008	In conclusion, budesonide/formoterol reduces sputum eosinophils and improves symptoms in the treatment of out-patient COPD exacerbations.	Budesonide	15-25	COPD	Homo sapiens	118-122
19068102-9	2009	CONCLUSION: Topical budesonide reduced the expression of TNF-alpha, eotaxin-2 and p65.	Budesonide	20-30	RELA proto-oncogene, NF-kB subunit	Homo sapiens	82-85
19068102-10	2009	Poor responders to topical budesonide exhibit higher levels of IL-1beta, ICAM-1 and nuclear factor (NF)-kappaB at diagnosis and higher expression of both IL-1beta and GR-beta after treatment.	Budesonide	27-37	interleukin 1 beta	Homo sapiens	63-71
19068102-10	2009	Poor responders to topical budesonide exhibit higher levels of IL-1beta, ICAM-1 and nuclear factor (NF)-kappaB at diagnosis and higher expression of both IL-1beta and GR-beta after treatment.	Budesonide	27-37	intercellular adhesion molecule 1	Homo sapiens	73-79
19068102-10	2009	Poor responders to topical budesonide exhibit higher levels of IL-1beta, ICAM-1 and nuclear factor (NF)-kappaB at diagnosis and higher expression of both IL-1beta and GR-beta after treatment.	Budesonide	27-37	nuclear factor kappa B subunit 1	Homo sapiens	84-110
19068102-10	2009	Poor responders to topical budesonide exhibit higher levels of IL-1beta, ICAM-1 and nuclear factor (NF)-kappaB at diagnosis and higher expression of both IL-1beta and GR-beta after treatment.	Budesonide	27-37	interleukin 1 beta	Homo sapiens	154-162
19134256-19	2008	CONCLUSION: The conditioned immune response models established by both noise and SAC as CS and budesonide and salbutamol as UCS can downregulate nAChRalpha7 on CD4(+)T lymphocytes, regulate the function of CD4(+)T lymphocytes, and achieve the same therapeutic efficacy in treatment of asthma.	Budesonide	95-105	CD4 antigen	Mus musculus	160-163
19134256-19	2008	CONCLUSION: The conditioned immune response models established by both noise and SAC as CS and budesonide and salbutamol as UCS can downregulate nAChRalpha7 on CD4(+)T lymphocytes, regulate the function of CD4(+)T lymphocytes, and achieve the same therapeutic efficacy in treatment of asthma.	Budesonide	95-105	CD4 antigen	Mus musculus	206-209
18706998-1	2008	The CYP3A4 substrate budesonide was used to investigate gut wall first-pass metabolism in jejunum, ileum and colon of eight healthy men.	Budesonide	21-31	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	4-10
18706998-9	2008	The data are in accordance with the well-known CYP3A activity in the small intestine, evidently capable of metabolising at least half the absorbed dose of budesonide.	Budesonide	155-165	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	47-52
18926826-2	2008	METHODS: This randomized, double-blind, placebo-controlled, multicenter study evaluated the efficacy and safety of long-term therapy with oral budesonide (Entocort CIR capsules) for maintenance of clinical remission of collagenous colitis.	Budesonide	143-153	corepressor interacting with RBPJ, CIR1	Homo sapiens	164-167
18647595-3	2008	Treatment with anti-TNF-alpha antibodies or budesonide suppressed in increase in TNF-alpha production and IL-8 mRNA expression.	Budesonide	44-54	tumor necrosis factor	Mus musculus	81-90
18647595-3	2008	Treatment with anti-TNF-alpha antibodies or budesonide suppressed in increase in TNF-alpha production and IL-8 mRNA expression.	Budesonide	44-54	chemokine (C-X-C motif) ligand 15	Mus musculus	106-110
18155275-6	2008	Budesonide at greater than 1 nmol/L reversed the augmenting effects of beta-agonists on IL-13+ T-cell accumulation, and budesonide at greater than 10 nmol/L inhibited increases in IL-13+ T cells stimulated by IL-2.	Budesonide	0-10	interleukin 13	Homo sapiens	88-93
18972276-0	2008	Anti-inflammatory effects of combined budesonide/formoterol in COPD exacerbations.	Budesonide	38-48	COPD	Homo sapiens	63-67
18646064-17	2008	Budesonide was significantly less effective than conventional steroids for induction of remission (RR 0.86, 95% CI 0.76 to 0.98), particularly among patients with severe disease (CDAI > 300) (RR 0.52, 95% CI 0.28 to 0.95).	Budesonide	0-10	codanin 1	Homo sapiens	179-183
18421428-0	2008	Budesonide/formoterol decreases expression of vascular endothelial growth factor (VEGF) and VEGF receptor 1 within airway remodelling in asthma.	Budesonide	0-10	vascular endothelial growth factor A	Homo sapiens	46-80
18421428-0	2008	Budesonide/formoterol decreases expression of vascular endothelial growth factor (VEGF) and VEGF receptor 1 within airway remodelling in asthma.	Budesonide	0-10	vascular endothelial growth factor A	Homo sapiens	82-86
18421428-0	2008	Budesonide/formoterol decreases expression of vascular endothelial growth factor (VEGF) and VEGF receptor 1 within airway remodelling in asthma.	Budesonide	0-10	vascular endothelial growth factor A	Homo sapiens	92-96
18421428-5	2008	We also investigated the effect of treatment with budesonide/formoterol (Symbicort; AstraZeneca, Lund, Sweden) in the relationship between VEGF and airway remodelling.	Budesonide	50-60	vascular endothelial growth factor A	Homo sapiens	139-143
18421428-13	2008	After treatment with budesonide/formoterol for 6 months, the expression of VEGF and VEGFR1 was decreased, with correlatory decreased airway remodelling in patients with asthma.	Budesonide	21-31	vascular endothelial growth factor A	Homo sapiens	75-79
18421428-13	2008	After treatment with budesonide/formoterol for 6 months, the expression of VEGF and VEGFR1 was decreased, with correlatory decreased airway remodelling in patients with asthma.	Budesonide	21-31	fms related receptor tyrosine kinase 1	Homo sapiens	84-90
18421428-15	2008	Budesonide/formoterol therapy for 6 months can decrease the expression of VEGF and VEGFR(1) alongside airway remodelling in asthma.	Budesonide	0-10	vascular endothelial growth factor A	Homo sapiens	74-78
18421428-15	2008	Budesonide/formoterol therapy for 6 months can decrease the expression of VEGF and VEGFR(1) alongside airway remodelling in asthma.	Budesonide	0-10	fms related receptor tyrosine kinase 1	Homo sapiens	83-91
18414714-3	2008	Budesonide, a synthetic glucocorticoid, undergoes a high degree of first-pass metabolism, reducing its systemic bioavailability, and has a 15-fold greater affinity for the glucocorticoid receptor than prednisolone.	Budesonide	0-10	nuclear receptor subfamily 3 group C member 1	Homo sapiens	172-195
18926058-10	2008	A dramatic increase in the expressions of SP-A and SP-B was observed after budesonide treatment.	Budesonide	75-85	surfactant associated protein A1	Mus musculus	42-46
18926058-10	2008	A dramatic increase in the expressions of SP-A and SP-B was observed after budesonide treatment.	Budesonide	75-85	surfactant associated protein B	Mus musculus	51-55
18926058-12	2008	A possible explanation for the result is that an early budesonide inhaled treatment inhibits TGF-beta-induced reduction of SP-A and SP-B expression through inhibition of active TGF-beta/Smad signal transduction pathway in asthmatic mice.	Budesonide	55-65	transforming growth factor, beta 1	Mus musculus	93-101
18926058-12	2008	A possible explanation for the result is that an early budesonide inhaled treatment inhibits TGF-beta-induced reduction of SP-A and SP-B expression through inhibition of active TGF-beta/Smad signal transduction pathway in asthmatic mice.	Budesonide	55-65	surfactant associated protein A1	Mus musculus	123-127
18926058-12	2008	A possible explanation for the result is that an early budesonide inhaled treatment inhibits TGF-beta-induced reduction of SP-A and SP-B expression through inhibition of active TGF-beta/Smad signal transduction pathway in asthmatic mice.	Budesonide	55-65	surfactant associated protein B	Mus musculus	132-136
18926058-12	2008	A possible explanation for the result is that an early budesonide inhaled treatment inhibits TGF-beta-induced reduction of SP-A and SP-B expression through inhibition of active TGF-beta/Smad signal transduction pathway in asthmatic mice.	Budesonide	55-65	transforming growth factor, beta 1	Mus musculus	177-185
18926058-12	2008	A possible explanation for the result is that an early budesonide inhaled treatment inhibits TGF-beta-induced reduction of SP-A and SP-B expression through inhibition of active TGF-beta/Smad signal transduction pathway in asthmatic mice.	Budesonide	55-65	SMAD family member 4	Mus musculus	186-190
18761816-5	2008	The results showed that additional inhalation of budesonide and terbutaline could upregulate serum IL-2 levels, the percentages of CD3+ T and CD4+ T cells, and CD4/CD8 ratio, and decrease eosinophils and serum CRP level more efficiently than conventional treatment in patients with AECOPD.	Budesonide	49-59	interleukin 2	Homo sapiens	99-103
18761816-5	2008	The results showed that additional inhalation of budesonide and terbutaline could upregulate serum IL-2 levels, the percentages of CD3+ T and CD4+ T cells, and CD4/CD8 ratio, and decrease eosinophils and serum CRP level more efficiently than conventional treatment in patients with AECOPD.	Budesonide	49-59	CD4 molecule	Homo sapiens	142-145
18761816-5	2008	The results showed that additional inhalation of budesonide and terbutaline could upregulate serum IL-2 levels, the percentages of CD3+ T and CD4+ T cells, and CD4/CD8 ratio, and decrease eosinophils and serum CRP level more efficiently than conventional treatment in patients with AECOPD.	Budesonide	49-59	CD4 molecule	Homo sapiens	160-163
18761816-5	2008	The results showed that additional inhalation of budesonide and terbutaline could upregulate serum IL-2 levels, the percentages of CD3+ T and CD4+ T cells, and CD4/CD8 ratio, and decrease eosinophils and serum CRP level more efficiently than conventional treatment in patients with AECOPD.	Budesonide	49-59	CD8a molecule	Homo sapiens	164-167
18761816-5	2008	The results showed that additional inhalation of budesonide and terbutaline could upregulate serum IL-2 levels, the percentages of CD3+ T and CD4+ T cells, and CD4/CD8 ratio, and decrease eosinophils and serum CRP level more efficiently than conventional treatment in patients with AECOPD.	Budesonide	49-59	C-reactive protein	Homo sapiens	210-213
18270839-7	2008	Animals fed SFA and given budesonide had a reduction in jejunal ODC mRNA compared with those fed PUFA or chow.	Budesonide	26-36	ornithine decarboxylase 1	Rattus norvegicus	64-67
18322448-0	2008	Influence of CYP3A4, CYP3A5, and ABCB1 genotype and expression on budesonide pharmacokinetics: a possible role of intestinal CYP3A4 expression.	Budesonide	66-76	ATP binding cassette subfamily B member 1	Homo sapiens	33-38
18322448-1	2008	Budesonide treatment of chronic inflammatory bowel disease commonly leads to non-response or adverse reactions, possibly because of alterations in efflux transport mediated by the ABCB1 gene product P-glycoprotein or metabolism by CYP3A isoenzymes.	Budesonide	0-10	ATP binding cassette subfamily B member 1	Homo sapiens	180-185
18322448-1	2008	Budesonide treatment of chronic inflammatory bowel disease commonly leads to non-response or adverse reactions, possibly because of alterations in efflux transport mediated by the ABCB1 gene product P-glycoprotein or metabolism by CYP3A isoenzymes.	Budesonide	0-10	ATP binding cassette subfamily B member 1	Homo sapiens	199-213
18322448-1	2008	Budesonide treatment of chronic inflammatory bowel disease commonly leads to non-response or adverse reactions, possibly because of alterations in efflux transport mediated by the ABCB1 gene product P-glycoprotein or metabolism by CYP3A isoenzymes.	Budesonide	0-10	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	231-236
18322448-6	2008	However, intestinal CYP3A4 expression was shown to correlate directly with partial metabolic clearances of 16-hydroxy-prednisolone (r(2) = 0.30; P = 0.010) and 6-hydroxy-budesonide (r(2) = 0.25; P = 0.016), but inversely with budesonide AUC(0-24 h) (r(2) = 0.18; P = 0.040).	Budesonide	170-180	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	20-26
18322448-8	2008	This study suggests that intestinal CYP3A4 expression has an impact on budesonide pharmacokinetics.	Budesonide	71-81	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	36-42
18256057-8	2008	Formoterol- and LPS-induced MDC expression was inhibited by budesonide.	Budesonide	60-70	C-C motif chemokine ligand 22	Homo sapiens	28-31
18554472-0	2008	[Effect of budesonide on the heme oxygenase-1 expression in lung tissues of rats with asthma].	Budesonide	11-21	heme oxygenase 1	Rattus norvegicus	29-45
18554472-1	2008	OBJECTIVE: To study the expression of heme oxygenase-1 (HO-1) gene and protein and the effect of budesonide (BUD) on the HO-1 expression in lung tissues in rats with asthma.	Budesonide	97-107	heme oxygenase 1	Rattus norvegicus	121-125
18415826-5	2008	Budesonide attenuated the IL-6 and IL-8 release, an inhibiting effect that was sustained, but not reinforced, by formoterol.	Budesonide	0-10	interleukin 6	Homo sapiens	26-30
18415826-5	2008	Budesonide attenuated the IL-6 and IL-8 release, an inhibiting effect that was sustained, but not reinforced, by formoterol.	Budesonide	0-10	C-X-C motif chemokine ligand 8	Homo sapiens	35-39
18155275-6	2008	Budesonide at greater than 1 nmol/L reversed the augmenting effects of beta-agonists on IL-13+ T-cell accumulation, and budesonide at greater than 10 nmol/L inhibited increases in IL-13+ T cells stimulated by IL-2.	Budesonide	120-130	interleukin 13	Homo sapiens	180-185
18155275-6	2008	Budesonide at greater than 1 nmol/L reversed the augmenting effects of beta-agonists on IL-13+ T-cell accumulation, and budesonide at greater than 10 nmol/L inhibited increases in IL-13+ T cells stimulated by IL-2.	Budesonide	120-130	interleukin 2	Homo sapiens	209-213
18155275-7	2008	Budesonide decreased, whereas beta-agonist did not affect, numbers of total and IFN-gamma+ T cells in IL-2-stimulated cultures.	Budesonide	0-10	interleukin 2	Homo sapiens	102-106
17901197-4	2008	In contrast, simple glucocorticoid response element (GRE)-dependent transcription induced by dexamethasone, budesonide, and fluticasone was synergistically enhanced by beta(2)-adrenoceptor agonists, including salmeterol and formoterol, to a level that could not be achieved by glucocorticoid alone.	Budesonide	108-118	adrenoceptor beta 2	Homo sapiens	168-188
18990976-6	2008	RESULTS: Formoterol had a minor effect, whereas budesonide concentration-dependently decreased CF transport by MRP1.	Budesonide	48-58	ATP binding cassette subfamily C member 1	Homo sapiens	111-115
18990976-10	2008	CONCLUSIONS: Our data suggest that, besides their positive effects on respiratory symptoms, budesonide, formoterol, ipratropium bromide, and NAC modulate MRP1 activity in bronchial epithelial cells.	Budesonide	92-102	ATP binding cassette subfamily C member 1	Homo sapiens	154-158
18422165-0	2008	[Effects of intranasal budesonide on the expression of c-fos and c-myc in nasal polyps].	Budesonide	23-33	Fos proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	55-60
18422165-0	2008	[Effects of intranasal budesonide on the expression of c-fos and c-myc in nasal polyps].	Budesonide	23-33	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	65-70
18504402-0	2008	Inhibitory effect of budesonide alone and in combination with formoterol on IL-5 and RANTES production from mononuclear cells.	Budesonide	21-31	interleukin 5	Homo sapiens	76-80
18504402-0	2008	Inhibitory effect of budesonide alone and in combination with formoterol on IL-5 and RANTES production from mononuclear cells.	Budesonide	21-31	C-C motif chemokine ligand 5	Homo sapiens	85-91
19343093-7	2008	RESULTS: i) up-regulation of eosinophil/basophil colony-forming units is due to the direct effects of budesonide on IL-5-stimulated progenitors; ii) GATA-1 is likely involved in the early amplification of eosinophil/basophil progenitor commitment leading to increased differentiation.	Budesonide	102-112	interleukin 5	Homo sapiens	116-120
19343093-7	2008	RESULTS: i) up-regulation of eosinophil/basophil colony-forming units is due to the direct effects of budesonide on IL-5-stimulated progenitors; ii) GATA-1 is likely involved in the early amplification of eosinophil/basophil progenitor commitment leading to increased differentiation.	Budesonide	102-112	GATA binding protein 1	Homo sapiens	149-155
18048573-4	2007	The CYP3A-dependent metabolic profile of an oral dose of budesonide (3 mg) and that of endogenous cortisol were compared intraindividually before and after administration of metronidazole.	Budesonide	57-67	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	4-9
17596271-3	2007	The present study investigates the effects of formoterol (FORM), salmeterol (SALM) and budesonide (BUD) on GR activation in bronchial epithelial cells via tumour necrosis factor-alpha-stimulated granulocyte-macrophage colony-stimulating factor (GM-CSF) release, GR nuclear translocation and GR-regulated reporter gene activity.	Budesonide	87-97	nuclear receptor subfamily 3 group C member 1	Homo sapiens	107-109
17596271-3	2007	The present study investigates the effects of formoterol (FORM), salmeterol (SALM) and budesonide (BUD) on GR activation in bronchial epithelial cells via tumour necrosis factor-alpha-stimulated granulocyte-macrophage colony-stimulating factor (GM-CSF) release, GR nuclear translocation and GR-regulated reporter gene activity.	Budesonide	99-102	nuclear receptor subfamily 3 group C member 1	Homo sapiens	107-109
17335542-0	2007	An integrated model for the effect of budesonide on ACTH and cortisol in healthy volunteers.	Budesonide	38-48	proopiomelanocortin	Homo sapiens	52-56
17537779-8	2007	Treatment with budesonide also prevented airway smooth muscle thickening, contractile protein expression, tracheal hypercontractility and mucous gland hypertrophy, and partially reduced MUC5AC-positive goblet cell numbers and eosinophilia.	Budesonide	15-25	mucin-5AC	Cavia porcellus	186-192
17335542-2	2007	The aim of the study was to develop a PK/PD model for the effect of budesonide on ACTH and cortisol.	Budesonide	68-78	proopiomelanocortin	Homo sapiens	82-86
17335542-12	2007	CONCLUSIONS: The present PK/PD model of the effect of budesonide on ACTH and cortisol can serve as a tool for further understanding of the hypothalamic-pituitary-adrenal (HPA) axis and be useful in the development of drugs interacting with the axis.	Budesonide	54-64	proopiomelanocortin	Homo sapiens	68-72
17988555-0	2007	[Effects of beclomethasone dipropionate and budesonide on interleukin-13 induced cytokine release, proliferation and differentiation of the human lung fibroblasts].	Budesonide	44-54	interleukin 13	Homo sapiens	58-72
17215115-12	2007	Tryptase, ECP, and alpha(2)-macroglobulin were significantly reduced by budesonide.	Budesonide	72-82	ribonuclease A family member 3	Homo sapiens	10-13
17803855-1	2007	OBJECTIVE: To investigate the effects of budesonide (BUD) on the airway remodeling and the expression of Janus protein tyrosine kinases 1 (JAK1) and signal transducer and activator of transcription 6 (STAT6) in asthma.	Budesonide	41-51	Janus kinase 1	Mus musculus	139-143
17215115-12	2007	Tryptase, ECP, and alpha(2)-macroglobulin were significantly reduced by budesonide.	Budesonide	72-82	alpha-2-macroglobulin	Homo sapiens	19-41
17653314-7	2007	Both Singulair and budesonide aerosol could correct the imbalance of Th1 and Th2 cytokines.	Budesonide	19-29	negative elongation factor complex member C/D	Homo sapiens	69-72
17660164-0	2007	Effects of inhaled budesonide on insulin sensitivity in nondiabetic patients with asthma and chronic obstructive pulmonary disease.	Budesonide	19-29	insulin	Homo sapiens	33-40
17251232-0	2007	The role of nebulised budesonide in the treatment of exacerbations of COPD.	Budesonide	22-32	COPD	Homo sapiens	70-74
17329493-1	2007	Clinical trials have recently demonstrated that using a budesonide/formoterol combination inhaler as regular maintenance treatment twice daily but also as a rescue therapy for breakthrough symptoms can provide more effective control of asthma, particularly in reducing exacerbations, than using a short-acting beta2-agonist or formoterol as rescue therapy.	Budesonide	56-66	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	310-315
17179942-0	2007	Effects of budesonide on P-glycoprotein expression in intestinal cell lines.	Budesonide	11-21	ATP binding cassette subfamily B member 1	Homo sapiens	25-39
17983258-1	2007	The use of combination budesonide/formoterol dry powder inhaler (Symbicort Turbuhaler) for both daily maintenance therapy and as-needed relief of breakthrough symptoms using a single inhaler is a new approach to asthma management that is indicated in patients with persistent asthma not adequately controlled by conventional regimens using reliever therapy with a short-acting beta(2)-adrenoceptor agonist alone.	Budesonide	23-33	adrenoceptor beta 2	Homo sapiens	377-397
17179942-2	2007	Since glucocorticoids, such as budesonide, are frequently used during inflammatory bowel disease we investigated how budesonide influences P-gp expression in different intestinal cell lines.	Budesonide	117-127	ATP binding cassette subfamily B member 1	Homo sapiens	139-143
17179942-6	2007	KEY RESULTS: Budesonide showed an induction of P-gp in LS180 cells and a down-regulation in Caco-2 cells.	Budesonide	13-23	ATP binding cassette subfamily B member 1	Homo sapiens	47-51
17179942-9	2007	In PXR-transfected Caco-2 cells the budesonide-mediated down-regulation of P-gp was abolished.	Budesonide	36-46	nuclear receptor subfamily 1 group I member 2	Homo sapiens	3-6
17179942-9	2007	In PXR-transfected Caco-2 cells the budesonide-mediated down-regulation of P-gp was abolished.	Budesonide	36-46	ATP binding cassette subfamily B member 1	Homo sapiens	75-79
17179942-10	2007	Furthermore the expression of cytochrome P450 3A4 (CYP3A4), another PXR target gene, was induced in PXR-transfected Caco-2 cells after budesonide treatment.	Budesonide	135-145	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	30-49
17179942-10	2007	Furthermore the expression of cytochrome P450 3A4 (CYP3A4), another PXR target gene, was induced in PXR-transfected Caco-2 cells after budesonide treatment.	Budesonide	135-145	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	51-57
17179942-10	2007	Furthermore the expression of cytochrome P450 3A4 (CYP3A4), another PXR target gene, was induced in PXR-transfected Caco-2 cells after budesonide treatment.	Budesonide	135-145	nuclear receptor subfamily 1 group I member 2	Homo sapiens	68-71
17179942-10	2007	Furthermore the expression of cytochrome P450 3A4 (CYP3A4), another PXR target gene, was induced in PXR-transfected Caco-2 cells after budesonide treatment.	Budesonide	135-145	nuclear receptor subfamily 1 group I member 2	Homo sapiens	100-103
17179942-11	2007	CONCLUSIONS AND IMPLICATIONS: Budesonide has the potential to influence MDR1 expression in vitro.	Budesonide	30-40	ATP binding cassette subfamily B member 1	Homo sapiens	72-76
17179942-12	2007	In LS180 cells, the induction of MDR1 by budesonide probably is mediated via PXR.	Budesonide	41-51	ATP binding cassette subfamily B member 1	Homo sapiens	33-37
17179942-12	2007	In LS180 cells, the induction of MDR1 by budesonide probably is mediated via PXR.	Budesonide	41-51	nuclear receptor subfamily 1 group I member 2	Homo sapiens	77-80
17179942-14	2007	Further studies are required to evaluate how budesonide alters P-gp expression in vivo.	Budesonide	45-55	ATP binding cassette subfamily B member 1	Homo sapiens	63-67
17983258-2	2007	The administration of additional corticosteroid with each reliever inhalation in response to symptoms is expected to provide improved control of airway inflammation.Budesonide/formoterol maintenance and reliever therapy reduced the risk of severe asthma exacerbations compared with conventional regimens using a short-acting beta(2)-adrenoceptor agonist alone as reliever therapy in the majority of trials, while providing similar or better daily asthma control than higher fixed maintenance doses of budesonide or inhaled corticosteroid/long-acting beta(2)-adrenoceptor agonist combination therapy in patients with generally moderate to severe, uncontrolled, persistent asthma.	Budesonide	165-175	adrenoceptor beta 2	Homo sapiens	325-345
17983258-2	2007	The administration of additional corticosteroid with each reliever inhalation in response to symptoms is expected to provide improved control of airway inflammation.Budesonide/formoterol maintenance and reliever therapy reduced the risk of severe asthma exacerbations compared with conventional regimens using a short-acting beta(2)-adrenoceptor agonist alone as reliever therapy in the majority of trials, while providing similar or better daily asthma control than higher fixed maintenance doses of budesonide or inhaled corticosteroid/long-acting beta(2)-adrenoceptor agonist combination therapy in patients with generally moderate to severe, uncontrolled, persistent asthma.	Budesonide	165-175	adrenoceptor beta 2	Homo sapiens	550-570
17208590-5	2007	Budesonide completely inhibited C/EBPalpha and beta expression; formoterol increased C/EBPalpha expression (2-fold).	Budesonide	0-10	CCAAT enhancer binding protein alpha	Homo sapiens	32-42
17208590-9	2007	Budesonide and formoterol increased C/EBPbeta levels (3.4-fold and 2.5-fold, respectively), leaving C/EBPalpha, delta, and epsilon levels unaffected.	Budesonide	0-10	CCAAT enhancer binding protein beta	Homo sapiens	36-45
17208590-12	2007	Budesonide inhibited C/EBPalpha and beta expression, upregulated C/EBPdelta (3.2-fold), and had no effect on C/EBPepsilon.	Budesonide	0-10	CCAAT enhancer binding protein alpha	Homo sapiens	21-31
17208590-12	2007	Budesonide inhibited C/EBPalpha and beta expression, upregulated C/EBPdelta (3.2-fold), and had no effect on C/EBPepsilon.	Budesonide	0-10	CCAAT enhancer binding protein delta	Homo sapiens	65-75
17208590-16	2007	Budesonide and formoterol modulate C/EBP expression in a drug- and disease-specific pattern.	Budesonide	0-10	CCAAT enhancer binding protein alpha	Homo sapiens	35-40
16549198-3	2007	Whether 11beta-HSD2 inactivates the synthetic glucocorticoids used for asthma treatment during pregnancy (budesonide, beclomethasone dipropionate and fluticasone propionate) remains unknown.	Budesonide	106-116	hydroxysteroid 11-beta dehydrogenase 2	Homo sapiens	8-19
16549198-7	2007	Placental 11beta-HSD2 activity was determined using beclomethasone dipropionate, budesonide, fluticasone propionate, prednisolone, dexamethasone and betamethasone as steroid substrates.	Budesonide	81-91	hydroxysteroid 11-beta dehydrogenase 2	Homo sapiens	10-21
16630150-7	2006	RESULTS: Low-dose RWJ-58643 (100 microg) and budesonide (200 microg) significantly reduced symptoms, eosinophils and levels of IL-5 following NAC.	Budesonide	45-55	interleukin 5	Homo sapiens	127-131
16996482-14	2006	The corticosteroid budesonide inhibited the TNF-alpha release dose dependently with an IC(50) of 0.55+/-0.13 nM.	Budesonide	19-29	tumor necrosis factor	Homo sapiens	44-53
16996482-16	2006	Finally, R,R-glycopyrrolate was most effective in the triple combination with budesonide and rolipram in the reduction of TNF-alpha release.	Budesonide	78-88	tumor necrosis factor	Homo sapiens	122-131
16751221-9	2006	The proportion of apoptotic epithelial cells as measured by terminal deoxynucleotidyltransferase-mediated dUTP biotin nick end labeling both at and away from the wound edge was higher in monolayers treated with budesonide compared with controls.	Budesonide	211-221	DNA nucleotidylexotransferase	Homo sapiens	60-96
16573703-8	2006	Children receiving budesonide also needed significantly less intervention with other inhaled corticosteroids (12.3% vs. 22.5% over 3 yrs; p < 0.01), with trends towards decreased usage of oral/systemic corticosteroids and inhaled short-acting beta2-agonists.	Budesonide	19-29	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	246-251
16448811-7	2006	The stimulatory effect of pyocyanin on the IL-1beta- or PDBu-stimulated IL-8 release was reduced in the presence of dexamethasone, budesonide, and fluticasone.	Budesonide	131-141	interleukin 1 beta	Homo sapiens	43-51
16448811-7	2006	The stimulatory effect of pyocyanin on the IL-1beta- or PDBu-stimulated IL-8 release was reduced in the presence of dexamethasone, budesonide, and fluticasone.	Budesonide	131-141	C-X-C motif chemokine ligand 8	Homo sapiens	72-76
16433920-10	2006	CONCLUSION: Budesonide/formoterol and formoterol provided similarly rapid relief of acute bronchoconstriction in patients with asthma who showed evidence of refractoriness to a short-acting beta2-agonist.	Budesonide	12-22	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	190-195
16428071-5	2006	Budesonide had a suppressive effect on both constitutive and LPS-induced IL-8 gene expression.	Budesonide	0-10	C-X-C motif chemokine ligand 8	Homo sapiens	73-77
16428071-6	2006	The amount of TNF-alpha mRNA was diminished in unstimulated keratinocytes, while TLR2 mRNA expression was markedly enhanced both in unstimulated and LPS-treated cells after incubation with budesonide.	Budesonide	189-199	toll like receptor 2	Homo sapiens	81-85
16428071-9	2006	Budesonide, but not tacrolimus, significantly inhibited the NF-kappaB-dependent luciferase reporter activity in HaCaT cells after induction with LPS or TNF-alpha.	Budesonide	0-10	tumor necrosis factor	Homo sapiens	152-161
16638036-7	2006	RESULTS: The use of inhaled budesonide was associated with significantly increased placental 11beta-HSD-2 activity relative to the control group.	Budesonide	28-38	hydroxysteroid 11-beta dehydrogenase 2	Homo sapiens	93-105
16584389-0	2006	Multidrug resistance 1 genotype and disposition of budesonide in early primary biliary cirrhosis.	Budesonide	51-61	ATP binding cassette subfamily B member 1	Homo sapiens	0-22
16584389-1	2006	BACKGROUND: Budesonide, which is a dual substrate of P-glycoprotein, the product of the multidrug resistance 1 (MDR1) gene, and cytochrome P450 3A (CYP3A) has been proposed for treatment of early primary biliary cirrhosis (PBC).	Budesonide	12-22	ATP binding cassette subfamily B member 1	Homo sapiens	53-67
16584389-1	2006	BACKGROUND: Budesonide, which is a dual substrate of P-glycoprotein, the product of the multidrug resistance 1 (MDR1) gene, and cytochrome P450 3A (CYP3A) has been proposed for treatment of early primary biliary cirrhosis (PBC).	Budesonide	12-22	ATP binding cassette subfamily B member 1	Homo sapiens	88-110
16584389-1	2006	BACKGROUND: Budesonide, which is a dual substrate of P-glycoprotein, the product of the multidrug resistance 1 (MDR1) gene, and cytochrome P450 3A (CYP3A) has been proposed for treatment of early primary biliary cirrhosis (PBC).	Budesonide	12-22	ATP binding cassette subfamily B member 1	Homo sapiens	112-116
16584389-3	2006	We tested the hypothesis that MDR1 gene polymorphisms affect absorption of oral budesonide.	Budesonide	80-90	ATP binding cassette subfamily B member 1	Homo sapiens	30-34
16584389-6	2006	RESULTS: In MDR1 2,677 GG and 3,435 CC genotypes, absorption and elimination of budesonide were not significantly different from those in corresponding homozygous variants.	Budesonide	80-90	ATP binding cassette subfamily B member 1	Homo sapiens	12-16
16442095-5	2006	Budesonide also stimulated ATPase activity.	Budesonide	0-10	dynein axonemal heavy chain 8	Homo sapiens	27-33
16291871-3	2006	We found that CD38 expression induced by TNFalpha alone was completely abrogated by fluticasone (100 nM), dexamethasone (1 microM), or budesonide (100 nM).	Budesonide	135-145	CD38 molecule	Homo sapiens	14-18
16291871-3	2006	We found that CD38 expression induced by TNFalpha alone was completely abrogated by fluticasone (100 nM), dexamethasone (1 microM), or budesonide (100 nM).	Budesonide	135-145	tumor necrosis factor	Homo sapiens	41-49
15936184-0	2006	Effect of formoterol/budesonide combination on arterial blood gases in patients with acute exacerbation of COPD.	Budesonide	21-31	COPD	Homo sapiens	107-111
16336831-0	2005	Investigation of the measurement of murine airway hyperresponsiveness and the therapeutic effects of budesonide on ovalbumin sensitized and challenged mice.	Budesonide	101-111	serine (or cysteine) peptidase inhibitor, clade B, member 1, pseudogene	Mus musculus	115-124
18044091-6	2006	However, when patients with more severe COPD were studied using a combination of budesonide and formoterol, a clear improvement was seen in the overall exacerbation rates compared with the use of a long-acting beta2-agonist alone.	Budesonide	81-91	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	210-215
18046888-7	2006	Improving lung function and decreasing symptoms significantly, budesonide-formoterol combination therapy provides significant clinical improvements in COPD, despite the limited reversibility of impaired lung function in the disease.	Budesonide	63-73	COPD	Homo sapiens	151-155
16266385-6	2005	A single dose of nasal budesonide caused a decrease in symptoms (P < 0.05) and nasal eosinophils (P < 0.05) with selective abrogation of IL-5 and IL-13 responses (P < 0.05), but a lack of effect on levels of eotaxin, RANTES, IL-8 and MCP-1.	Budesonide	23-33	interleukin 5	Homo sapiens	143-147
16266385-6	2005	A single dose of nasal budesonide caused a decrease in symptoms (P < 0.05) and nasal eosinophils (P < 0.05) with selective abrogation of IL-5 and IL-13 responses (P < 0.05), but a lack of effect on levels of eotaxin, RANTES, IL-8 and MCP-1.	Budesonide	23-33	interleukin 13	Homo sapiens	152-157
16266385-6	2005	A single dose of nasal budesonide caused a decrease in symptoms (P < 0.05) and nasal eosinophils (P < 0.05) with selective abrogation of IL-5 and IL-13 responses (P < 0.05), but a lack of effect on levels of eotaxin, RANTES, IL-8 and MCP-1.	Budesonide	23-33	C-C motif chemokine ligand 11	Homo sapiens	217-224
16266385-6	2005	A single dose of nasal budesonide caused a decrease in symptoms (P < 0.05) and nasal eosinophils (P < 0.05) with selective abrogation of IL-5 and IL-13 responses (P < 0.05), but a lack of effect on levels of eotaxin, RANTES, IL-8 and MCP-1.	Budesonide	23-33	C-C motif chemokine ligand 5	Homo sapiens	226-232
16266385-6	2005	A single dose of nasal budesonide caused a decrease in symptoms (P < 0.05) and nasal eosinophils (P < 0.05) with selective abrogation of IL-5 and IL-13 responses (P < 0.05), but a lack of effect on levels of eotaxin, RANTES, IL-8 and MCP-1.	Budesonide	23-33	C-X-C motif chemokine ligand 8	Homo sapiens	234-238
16266385-6	2005	A single dose of nasal budesonide caused a decrease in symptoms (P < 0.05) and nasal eosinophils (P < 0.05) with selective abrogation of IL-5 and IL-13 responses (P < 0.05), but a lack of effect on levels of eotaxin, RANTES, IL-8 and MCP-1.	Budesonide	23-33	C-C motif chemokine ligand 2	Homo sapiens	243-248
16136557-0	2005	SCF-engineered powders for delivery of budesonide from passive DPI devices.	Budesonide	39-49	KIT ligand	Homo sapiens	0-3
16192748-4	2005	In absence of L-arginine, budesonide (5 x 10(-7) to 4 x 10(-6) mol/l) dose-dependently reduced both fMLP- and PMA-induced LACL (18.3-50.6%).	Budesonide	26-36	formyl peptide receptor 1	Homo sapiens	100-104
15946834-5	2005	The budesonide-treated subjects had significant reductions in IL-8 levels in the BAL after therapy (mean+/-sem, 1.53+/-0.72 at baseline vs. 0.70+/-0.48 ng/ml at 6 months, P=0.004) and a reduction in the mean percentages of neutrophils (17.16+/-2.67% vs. 13.25+/-2.28% P=0.002).	Budesonide	4-14	C-X-C motif chemokine ligand 8	Homo sapiens	62-66
15946834-7	2005	In stable patients with COPD, treatment with inhaled budesonide for a period of 6 months has a positive effect on markers of lung inflammation, as assessed by reduction in percentage neutrophils and IL-8 concentration in BAL.	Budesonide	53-63	C-X-C motif chemokine ligand 8	Homo sapiens	199-203
16002568-8	2005	In addition, in an in vivo antigen-driven model of airway inflammation, the IKK-2 inhibitor blocked NF-kappaB nuclear translocation, which was associated with a reduction in inflammatory cytokine gene and protein expression, airway eosinophilia, and late asthmatic reaction, similar in magnitude to that obtained with budesonide.	Budesonide	318-328	inhibitor of nuclear factor kappa B kinase subunit beta	Homo sapiens	76-81
16118056-4	2005	Addition of budesonide to the apical side of Caco-2 cells, decreased both IL-8 and ENA-78 mRNA levels in a dose dependent manner.	Budesonide	12-22	C-X-C motif chemokine ligand 8	Homo sapiens	74-78
16118056-4	2005	Addition of budesonide to the apical side of Caco-2 cells, decreased both IL-8 and ENA-78 mRNA levels in a dose dependent manner.	Budesonide	12-22	C-X-C motif chemokine ligand 5	Homo sapiens	83-89
16160912-0	2005	The combined effects of zafirlukast, prednisone, and inhaled budesonide on IL-13 and IFN-gamma secretion.	Budesonide	61-71	interleukin 13	Homo sapiens	75-80
16160912-0	2005	The combined effects of zafirlukast, prednisone, and inhaled budesonide on IL-13 and IFN-gamma secretion.	Budesonide	61-71	interferon gamma	Homo sapiens	85-94
15854773-0	2005	Budesonide epimer R, LAU-8080 and phenyl butyl nitrone synergistically repress cyclooxygenase-2 induction in [IL-1beta+Abeta42]-stressed human neural cells.	Budesonide	0-10	prostaglandin-endoperoxide synthase 2	Homo sapiens	79-95
15967733-5	2005	Pretreatment with NAC partially prevented tumor necrosis factor alpha (TNFalpha) production induced by the low concentration of LPS, while pretreatment with budesonide totally prevented the increased production of TNFalpha, interleukin (IL)-1beta, IL-6, and monocyte chemoattractive protein (MCP)-1 after LPS challenge at both low and high concentrations.	Budesonide	157-167	tumor necrosis factor	Rattus norvegicus	214-222
15967733-5	2005	Pretreatment with NAC partially prevented tumor necrosis factor alpha (TNFalpha) production induced by the low concentration of LPS, while pretreatment with budesonide totally prevented the increased production of TNFalpha, interleukin (IL)-1beta, IL-6, and monocyte chemoattractive protein (MCP)-1 after LPS challenge at both low and high concentrations.	Budesonide	157-167	interleukin 1 beta	Rattus norvegicus	224-246
15967733-5	2005	Pretreatment with NAC partially prevented tumor necrosis factor alpha (TNFalpha) production induced by the low concentration of LPS, while pretreatment with budesonide totally prevented the increased production of TNFalpha, interleukin (IL)-1beta, IL-6, and monocyte chemoattractive protein (MCP)-1 after LPS challenge at both low and high concentrations.	Budesonide	157-167	interleukin 6	Rattus norvegicus	248-252
15967733-5	2005	Pretreatment with NAC partially prevented tumor necrosis factor alpha (TNFalpha) production induced by the low concentration of LPS, while pretreatment with budesonide totally prevented the increased production of TNFalpha, interleukin (IL)-1beta, IL-6, and monocyte chemoattractive protein (MCP)-1 after LPS challenge at both low and high concentrations.	Budesonide	157-167	C-C motif chemokine ligand 2	Rattus norvegicus	258-298
15817714-9	2005	At -50 mV, ACh efflux by human OCT2 was trans-inhibited by micromolar concentrations of the inhalational glucocorticoid budesonide, which is used in treatment of asthma (K(i) approximately 2.7 microM).	Budesonide	120-130	POU class 2 homeobox 2	Homo sapiens	31-35
15817714-10	2005	The data show that OCT1 and OCT2 mediate luminal ACh release in human airways and suggest that ACh release is blocked after inhalation of budesonide.	Budesonide	138-148	solute carrier family 22 member 1	Homo sapiens	19-23
15817714-10	2005	The data show that OCT1 and OCT2 mediate luminal ACh release in human airways and suggest that ACh release is blocked after inhalation of budesonide.	Budesonide	138-148	POU class 2 homeobox 2	Homo sapiens	28-32
15969944-0	2005	Intratracheal budesonide-poly(lactide-co-glycolide) microparticles reduce oxidative stress, VEGF expression, and vascular leakage in a benzo(a)pyrene-fed mouse model.	Budesonide	14-24	vascular endothelial growth factor A	Mus musculus	92-96
15969944-11	2005	Thus, biodegradable budesonide microparticles sustained budesonide release and reduced MDA accumulation, GSH depletion, vascular leakage, and VEGF and c-myc expression in B[a]P-fed mice, indicating the potential of locally delivered sustained-release particles for inhibiting angiogenic factors in lung cancer.	Budesonide	20-30	vascular endothelial growth factor A	Mus musculus	142-146
15990626-6	2005	Physicians uninformed about their CARD15 status prescribed significantly more budesonide and prednisolone intermittently and more alimentary supplementation to these patients.	Budesonide	78-88	nucleotide binding oligomerization domain containing 2	Homo sapiens	34-40
15879435-7	2005	The hypothesis that Met772-AC9 is associated with an improved albuterol bronchodilator response in asthmatics was investigated in 436 asthmatic children who were followed for 4 years and randomized to receive placebo or the inhaled corticosteroid budesonide.	Budesonide	247-257	adenylate cyclase 9	Homo sapiens	27-30
15879435-9	2005	Moreover, a highly significant interaction (P=0.002) was found for budesonide treatment and the AC9 polymorphism.	Budesonide	67-77	adenylate cyclase 9	Homo sapiens	96-99
15854773-0	2005	Budesonide epimer R, LAU-8080 and phenyl butyl nitrone synergistically repress cyclooxygenase-2 induction in [IL-1beta+Abeta42]-stressed human neural cells.	Budesonide	0-10	interleukin 1 beta	Homo sapiens	110-118
15679716-4	2005	OBJECTIVE: We examined the effects of inhaled budesonide (BUD) on the expression of TARC and the number of inflammatory cells in bronchial biopsy specimens taken from asthma patients.	Budesonide	46-56	C-C motif chemokine ligand 17	Homo sapiens	84-88
16429733-2	2005	In the present study, we aimed at observing whether IL-4 could be released from human mast cell line (HMC-1) after the stimulation of PMA + A23187, and the effects of systemic glucocorticosteroid, dexamethasone, topical glucocorticosteroid, budesonide and H1 antagonist, desloratadine on IL-4 release and mRNA expression.	Budesonide	241-251	interleukin 4	Homo sapiens	52-56
16429733-11	2005	Dexamethasone, budesonide and desloratadine all had inhibitory effects on IL-4 release from HMC-1.	Budesonide	15-25	interleukin 4	Homo sapiens	74-78
15784120-5	2005	RESULTS: Budesonide administration reduced airway hyper-reactivity and leukocyte infiltration in association with a decrease in production of the Th2 mediators, IL-4, IL-13 and eotaxin-1.	Budesonide	9-19	interleukin 4	Mus musculus	161-165
15784120-5	2005	RESULTS: Budesonide administration reduced airway hyper-reactivity and leukocyte infiltration in association with a decrease in production of the Th2 mediators, IL-4, IL-13 and eotaxin-1.	Budesonide	9-19	interleukin 13	Mus musculus	167-172
15784120-7	2005	Moreover, our data show for the first time that, Budesonide treatment regulated active transforming growth factor (TGF)-beta signalling with a reduction in the expression of pSmad 2 and the concomitant up-regulation of Smad 7 in lung tissue sections.	Budesonide	49-59	SMAD family member 7	Mus musculus	219-225
15824018-7	2005	Budesonide administered for only 7 days prior to sacrifice caused a dose-dependent (0.6 to 2.4 mg/kg diet) reversal in tumors of DNA hypomethylation and hypomethylation of the insulin-like growth factor (IGF)-II gene in the differentially methylated region (DMR) 2 region of exons 4 to 5.	Budesonide	0-10	insulin-like growth factor 2	Mus musculus	176-211
15726657-3	2005	Therefore, we compared the induction potential of UDCA with that of the prototypical inducer rifampicin in a human model study with the CYP3A substrates budesonide and cortisol.	Budesonide	153-163	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	136-141
15726657-9	2005	In contrast, administration of rifampicin markedly induced CYP3A metabolism, resulting in abolished budesonide plasma levels and high urinary excretion of 6beta-hydroxycortisol.	Budesonide	100-110	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	59-64
16429733-7	2005	Dexamethasone, budesonide and desloratadine had potent inhibitory effect on IL-4 release at any concentrations and time points, with significant deference (P < 0.05) compared to the control cells.	Budesonide	15-25	interleukin 4	Homo sapiens	76-80
15502112-3	2005	We hypothesized that in patients receiving low maintenance dose budesonide/formoterol (bud/form), replacing short-acting beta2-agonist (SABA) reliever with as-needed bud/form would provide rapid symptom relief and simultaneous adjustment in antiinflammatory therapy, thereby reducing exacerbations.	Budesonide	64-74	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	121-126
15654514-1	2004	OBJECTIVE: To determine the inhibitory potency of budesonide on interleukin (IL)-4, 6 and 8, GM-CSF and TNF-alpha release from the human mast cell line (HMC-1) in comparison with the systemic glucocorticosteroid, dexamethasone, and H(1) antagonist, desloratadine.	Budesonide	50-60	interleukin 4	Homo sapiens	64-91
16255498-0	2005	Regulation of expression of galectin-7 in human nasal polyps by budesonide.	Budesonide	64-74	galectin 7	Homo sapiens	28-38
16255498-6	2005	Treatment of polyps from allergic and non-allergic patients with 50 ng/ml budesonide increased the extent of galectin-7 expression in the connective tissue (p = 0.01).	Budesonide	74-84	galectin 7	Homo sapiens	109-119
16255498-8	2005	In the surface epithelium of nasal polyps from non-allergic patients, the percentage of galectin-7-immunopositive cells was decreased (p = 0.03) by treatment with 250 ng/ml budesonide.	Budesonide	173-183	galectin 7	Homo sapiens	88-98
16255498-11	2005	Galectin-7 expression coincides with the degree of epithelial stratification, and is subject to upregulation in the connective tissue in response to treatment with 50 ng/ml budesonide.	Budesonide	173-183	galectin 7	Homo sapiens	0-10
16255498-12	2005	Budesonide modulates galectin-7 expression differently in the surface epithelia of polyps from allergic and non-allergic patients.	Budesonide	0-10	galectin 7	Homo sapiens	21-31
15939317-0	2005	The effect of montelukast and different doses of budesonide on IgE serum levels and clinical parameters in children with newly diagnosed asthma.	Budesonide	49-59	immunoglobulin heavy constant epsilon	Homo sapiens	63-66
15569474-13	2004	After treatment with budesonide, IL-4 and MMP-12 decreased and IFN-gamma increased.	Budesonide	21-31	interleukin 4	Rattus norvegicus	33-37
15569474-13	2004	After treatment with budesonide, IL-4 and MMP-12 decreased and IFN-gamma increased.	Budesonide	21-31	matrix metallopeptidase 12	Rattus norvegicus	42-48
15569474-13	2004	After treatment with budesonide, IL-4 and MMP-12 decreased and IFN-gamma increased.	Budesonide	21-31	interferon gamma	Rattus norvegicus	63-72
15569474-25	2004	Budesonide can mitigate the changes in IL-4 and IFN-gamma levels induced by smoke exposure.	Budesonide	0-10	interleukin 4	Rattus norvegicus	39-43
15569474-25	2004	Budesonide can mitigate the changes in IL-4 and IFN-gamma levels induced by smoke exposure.	Budesonide	0-10	interferon gamma	Rattus norvegicus	48-57
15654514-1	2004	OBJECTIVE: To determine the inhibitory potency of budesonide on interleukin (IL)-4, 6 and 8, GM-CSF and TNF-alpha release from the human mast cell line (HMC-1) in comparison with the systemic glucocorticosteroid, dexamethasone, and H(1) antagonist, desloratadine.	Budesonide	50-60	colony stimulating factor 2	Homo sapiens	93-99
15654514-1	2004	OBJECTIVE: To determine the inhibitory potency of budesonide on interleukin (IL)-4, 6 and 8, GM-CSF and TNF-alpha release from the human mast cell line (HMC-1) in comparison with the systemic glucocorticosteroid, dexamethasone, and H(1) antagonist, desloratadine.	Budesonide	50-60	tumor necrosis factor	Homo sapiens	104-113
15361829-8	2004	Our results suggest that budesonide exerts its effects of chemoprevention through growth arrest via Mad2/3 and through apoptosis via Bim/Blk and, by inference, caspase-8/9.	Budesonide	25-35	MAD2 mitotic arrest deficient-like 1	Mus musculus	100-106
15612964-9	2004	Although sputum ECP levels decreased significantly in the groups treated with zafirlukast and budesonide (zafirlukast group, 580-135 microg/L, P < 0.01; budesonide group, 683-268 microg/L, P < 0.01), the decrease was not statistically significant in the theophylline-treated group (498-361 microg/L, P > 0.05).	Budesonide	94-104	ribonuclease A family member 3	Homo sapiens	16-19
15612964-11	2004	CONCLUSIONS: All three treatments resulted in significant decreases in sputum total cell counts and eosinophil percentage, but the decrease in sputum ECP level was only seen in the groups treated with budesonide and zafirlukast.	Budesonide	201-211	ribonuclease A family member 3	Homo sapiens	150-153
15361829-8	2004	Our results suggest that budesonide exerts its effects of chemoprevention through growth arrest via Mad2/3 and through apoptosis via Bim/Blk and, by inference, caspase-8/9.	Budesonide	25-35	B lymphoid kinase	Mus musculus	137-140
15361829-8	2004	Our results suggest that budesonide exerts its effects of chemoprevention through growth arrest via Mad2/3 and through apoptosis via Bim/Blk and, by inference, caspase-8/9.	Budesonide	25-35	caspase 8	Mus musculus	160-171
15478389-7	2004	There was a significant correlation between serum leptin levels before and after budesonide treatment (r = 0.68; P = .007).	Budesonide	81-91	leptin	Homo sapiens	50-56
15475437-9	2004	Budesonide treatment resulted in a modest decrease in p53 and BclII protein expression in bronchial biopsies and a slightly higher rate of resolution of computed tomography-detected lung nodules.	Budesonide	0-10	tumor protein p53	Homo sapiens	54-57
15479233-1	2004	In A549 pulmonary cells, the dexamethasone- and budesonide-dependent repression of interleukin-1beta-induced prostaglandin E2 release was mimicked by the steroid antagonist, RU486.	Budesonide	48-58	interleukin 1 beta	Homo sapiens	83-100
15479233-2	2004	Conversely, whereas dexamethasone and budesonide were highly effective inhibitors of interleukin-1beta-induced cyclooxygenase (COX)/prostaglandin E synthase (PGES) activity and COX-2 expression, RU486 (<1 microm) was a poor inhibitor, but was able to efficiently antagonize the effects of dexamethasone and budesonide.	Budesonide	38-48	interleukin 1 beta	Homo sapiens	85-102
15479233-2	2004	Conversely, whereas dexamethasone and budesonide were highly effective inhibitors of interleukin-1beta-induced cyclooxygenase (COX)/prostaglandin E synthase (PGES) activity and COX-2 expression, RU486 (<1 microm) was a poor inhibitor, but was able to efficiently antagonize the effects of dexamethasone and budesonide.	Budesonide	38-48	prostaglandin E synthase	Homo sapiens	132-156
15479233-2	2004	Conversely, whereas dexamethasone and budesonide were highly effective inhibitors of interleukin-1beta-induced cyclooxygenase (COX)/prostaglandin E synthase (PGES) activity and COX-2 expression, RU486 (<1 microm) was a poor inhibitor, but was able to efficiently antagonize the effects of dexamethasone and budesonide.	Budesonide	38-48	prostaglandin E synthase	Homo sapiens	158-162
15479233-2	2004	Conversely, whereas dexamethasone and budesonide were highly effective inhibitors of interleukin-1beta-induced cyclooxygenase (COX)/prostaglandin E synthase (PGES) activity and COX-2 expression, RU486 (<1 microm) was a poor inhibitor, but was able to efficiently antagonize the effects of dexamethasone and budesonide.	Budesonide	38-48	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	177-182
15479233-2	2004	Conversely, whereas dexamethasone and budesonide were highly effective inhibitors of interleukin-1beta-induced cyclooxygenase (COX)/prostaglandin E synthase (PGES) activity and COX-2 expression, RU486 (<1 microm) was a poor inhibitor, but was able to efficiently antagonize the effects of dexamethasone and budesonide.	Budesonide	310-320	interleukin 1 beta	Homo sapiens	85-102
15472518-0	2004	Identification of budesonide and prednisone as substrates of the intestinal drug efflux pump P-glycoprotein.	Budesonide	18-28	ATP binding cassette subfamily B member 1	Homo sapiens	93-107
15472518-4	2004	We tested the hypothesis that budesonide and prednisone are substrates of P-glycoprotein thereby possibly contributing to variable therapeutic effects.	Budesonide	30-40	ATP binding cassette subfamily B member 1	Homo sapiens	74-88
15472518-9	2004	The net transport rate from the basolateral to the apical side was significantly higher in L-MDR1 than in LLC-PK1 cells for both budesonide and prednisone.	Budesonide	129-139	ATP-binding cassette, sub-family B (MDR/TAP), member 1	Sus scrofa	93-97
15472518-12	2004	In conclusion, budesonide and prednisone were identified as substrates of the intestinal drug efflux pump, P-glycoprotein.	Budesonide	15-25	ATP binding cassette subfamily B member 1	Homo sapiens	107-121
15274414-0	2004	Budesonide-dependent modulation of expression of macrophage migration inhibitory factor in a polyposis model: evidence for differential regulation in surface and glandular epithelia.	Budesonide	0-10	macrophage migration inhibitory factor	Homo sapiens	49-87
15476327-11	2004	TGF-beta1 may play an important role during the process of airway remodeling, and could be influenced by early drugs intervention such as budesonide and erythromycin, which may imply their potency in the treatment of COPD.	Budesonide	138-148	transforming growth factor, beta 1	Rattus norvegicus	0-9
15288343-1	2004	The objective of this study was to assess the performance of SCF-engineered budesonide and albuterol sulfate powder blends in passive dry powder inhalers (DPI) relative to micronized drug blends.	Budesonide	76-86	KIT ligand	Homo sapiens	61-64
15274414-2	2004	To provide further insights into the way expression of pleiotropically acting MIF is modulated by glucocorticoids, we investigated the influence of the glucocorticoid budesonide on the level of expression of MIF in a model of human nasal polyposis by quantitative immunohistochemical analysis.	Budesonide	167-177	macrophage migration inhibitory factor	Homo sapiens	208-211
15257469-0	2004	[Effect of two doses of budesonide on exhaled nitric oxide and urinary EPX excretion in asthmatic children].	Budesonide	24-34	eosinophil peroxidase	Homo sapiens	71-74
15136485-0	2004	Effects of budesonide on overall 5-methylcytosine levels and specific methylation and messenger RNA expression of the insulin-like growth factor II gene in mouse lung tumors.	Budesonide	11-21	insulin-like growth factor 2	Mus musculus	118-147
15132725-11	2004	CONCLUSIONS: Inhaled budesonide decreased serum DHEA-S concentrations, which may indicate adrenocortical suppression.	Budesonide	21-31	sulfotransferase family 2A member 1	Homo sapiens	48-54
15007718-6	2004	Serum levels of ICTP increased, while levels of osteocalcin decreased after budesonide therapy in the asthmatic group ( P=0.001, P=0.005).	Budesonide	76-86	bone gamma-carboxyglutamate protein	Homo sapiens	48-59
15086961-7	2004	Female mice were slightly less sensitive to budesonide"s inhibitory action on interleukin-5 production and the development of airway hyperreactivity.	Budesonide	44-54	interleukin 5	Mus musculus	78-91
15028972-4	2004	Therefore, we investigated the expression of vascular endothelial growth factor in the colonic mucosa of patients with collagenous colitis before and after long-term treatment with oral budesonide.	Budesonide	186-196	vascular endothelial growth factor A	Homo sapiens	45-79
15028972-8	2004	After long-term treatment with oral budesonide, the amount of immunostaining for leucocyte-derived vascular endothelial growth factor within the lamina propria decreased significantly to normal levels.	Budesonide	36-46	vascular endothelial growth factor A	Homo sapiens	99-133
14718604-8	2004	In vivo, ciclesonide (intratracheal administration), des-CIC, and budesonide inhibited antigen-induced accumulation of eosinophils, protein, and tumor necrosis factor-alpha into the bronchoalveolar lavage fluid of ovalbumin-sensitized and -challenged Brown Norway rats with an ED(50) value ranging from 0.4 to 1.3 mg/kg, indicating similar potency, which suggests in vivo activation of the parent compound.	Budesonide	66-76	tumor necrosis factor	Rattus norvegicus	145-172
14742792-6	2004	DISCUSSION: Budesonide is a potent glucocorticoid that is metabolized in the liver by the CYP3A4 isoenzyme to inactive metabolites.	Budesonide	12-22	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	90-96
15008976-7	2004	Pretreatment of AM with PCT-233 and budesonide before LPS stimulation reduced TNF production at both protein and mRNA levels, whereas IL-10 production was increased.	Budesonide	36-46	tumor necrosis factor	Homo sapiens	78-81
15008976-8	2004	Moreover, TNF/IL-10 ratio was reduced further with the combination PCT-233/budesonide.	Budesonide	75-85	tumor necrosis factor	Homo sapiens	10-13
15008976-8	2004	Moreover, TNF/IL-10 ratio was reduced further with the combination PCT-233/budesonide.	Budesonide	75-85	interleukin 10	Homo sapiens	14-19
15008976-9	2004	Interestingly, AM treatment with PCT-233 and budesonide 18 h after LPS stimulation did not modulate TNF release significantly but it did increase IL-10 production, and a synergistic effect was observed with the combination PCT-233/budesonide.	Budesonide	45-55	interleukin 10	Homo sapiens	146-151
15355126-12	2004	Strong CYP3A4 inhibitors, such as ketoconazole, will inhibit the metabolism of budesonide, resulting in several-fold increases in the area under the concentration-time curve of budesonide.	Budesonide	79-89	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	7-13
14662725-7	2004	We here evaluated the early kinetic of SCF expression regulated by interleukin (IL)-1beta, budesonide and the combination of both in human lung fibroblasts in culture.	Budesonide	91-101	KIT ligand	Homo sapiens	39-42
14662725-9	2004	Budesonide potentiated the IL-1beta-enhanced expression of SCF mRNA (+103%) and protein (+98%) very shortly after treatment (at 30 min and 1 h, respectively).	Budesonide	0-10	interleukin 1 beta	Homo sapiens	27-35
14662725-9	2004	Budesonide potentiated the IL-1beta-enhanced expression of SCF mRNA (+103%) and protein (+98%) very shortly after treatment (at 30 min and 1 h, respectively).	Budesonide	0-10	KIT ligand	Homo sapiens	59-62
14662725-11	2004	This potentiating effect of budesonide was related to increased SCF mRNA stability and SCF gene transcription.	Budesonide	28-38	KIT ligand	Homo sapiens	64-67
14662725-11	2004	This potentiating effect of budesonide was related to increased SCF mRNA stability and SCF gene transcription.	Budesonide	28-38	KIT ligand	Homo sapiens	87-90
14662725-13	2004	Deletion of a kappaB-like site that we identified in the first intron of the SCF gene, in a luciferase reporter system, abolished the potentiation by budesonide, as well as the effect of IL-1beta alone, as compared to the wild-type construction activity.	Budesonide	150-160	KIT ligand	Homo sapiens	77-80
15355126-12	2004	Strong CYP3A4 inhibitors, such as ketoconazole, will inhibit the metabolism of budesonide, resulting in several-fold increases in the area under the concentration-time curve of budesonide.	Budesonide	177-187	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	7-13
15355126-13	2004	Also, grapefruit juice intake may increase systemic availability of budesonide, probably by inhibition of intestinal CYP3A4 activity.	Budesonide	68-78	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	117-123
14684580-8	2004	In 10 healthy male volunteers, ASBT protein expression was increased 1.34 (0.11)-fold (mean (SEM); p<0.05) after 21 days" intake of budesonide (9 mg/day) whereas expression of the peptide transporter 1 was unaffected.	Budesonide	135-145	solute carrier family 10 member 2	Homo sapiens	31-35
14969576-1	2004	Budesonide/formoterol is a fixed-dose combination of the corticosteroid budesonide and the long-acting beta2-agonist formoterol, and is inhaled via the Turbuhaler device.	Budesonide	0-10	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	103-108
14684580-8	2004	In 10 healthy male volunteers, ASBT protein expression was increased 1.34 (0.11)-fold (mean (SEM); p<0.05) after 21 days" intake of budesonide (9 mg/day) whereas expression of the peptide transporter 1 was unaffected.	Budesonide	135-145	solute carrier family 15 member 1	Homo sapiens	183-204
14684580-9	2004	Reporter constructs of the human ASBT promoter were activated 15-20-fold by coexpression of the glucocorticoid receptor (GR) and exposure to the GR ligands dexamethasone or budesonide.	Budesonide	173-183	solute carrier family 10 member 2	Homo sapiens	33-37
14684580-9	2004	Reporter constructs of the human ASBT promoter were activated 15-20-fold by coexpression of the glucocorticoid receptor (GR) and exposure to the GR ligands dexamethasone or budesonide.	Budesonide	173-183	nuclear receptor subfamily 3 group C member 1	Homo sapiens	145-147
14692430-10	2003	Budesonide aqueous nasal spray treatment showed a significant decrease of IL-4 (P = .007), IL-5 (P = .04), and IL-6 levels (P = .009).	Budesonide	0-10	interleukin 4	Homo sapiens	74-78
14643170-2	2004	This study was performed to investigate the effectiveness of the commonly used steroids beclomethasone, budesonide and fluticasone in downregulating HASMC production of RANTES and IL-8.	Budesonide	104-114	C-C motif chemokine ligand 5	Homo sapiens	169-175
14643170-2	2004	This study was performed to investigate the effectiveness of the commonly used steroids beclomethasone, budesonide and fluticasone in downregulating HASMC production of RANTES and IL-8.	Budesonide	104-114	C-X-C motif chemokine ligand 8	Homo sapiens	180-184
14643170-5	2004	Pre-treatment with beclomethasone, budesonide or fluticasone reduced TNFalpha- and IL-1beta-stimulated IL-8 and RANTES release from HASMC in a dose dependent manner.	Budesonide	35-45	tumor necrosis factor	Homo sapiens	69-77
14643170-5	2004	Pre-treatment with beclomethasone, budesonide or fluticasone reduced TNFalpha- and IL-1beta-stimulated IL-8 and RANTES release from HASMC in a dose dependent manner.	Budesonide	35-45	interleukin 1 beta	Homo sapiens	83-91
14643170-5	2004	Pre-treatment with beclomethasone, budesonide or fluticasone reduced TNFalpha- and IL-1beta-stimulated IL-8 and RANTES release from HASMC in a dose dependent manner.	Budesonide	35-45	C-X-C motif chemokine ligand 8	Homo sapiens	103-107
14643170-5	2004	Pre-treatment with beclomethasone, budesonide or fluticasone reduced TNFalpha- and IL-1beta-stimulated IL-8 and RANTES release from HASMC in a dose dependent manner.	Budesonide	35-45	C-C motif chemokine ligand 5	Homo sapiens	112-118
14643170-7	2004	TNFalpha- and IL-1beta-induced RANTES and IL-8 expression was reduced on the transcriptional level by pre-treatment with fluticasone and budesonide.	Budesonide	137-147	tumor necrosis factor	Homo sapiens	0-8
14643170-7	2004	TNFalpha- and IL-1beta-induced RANTES and IL-8 expression was reduced on the transcriptional level by pre-treatment with fluticasone and budesonide.	Budesonide	137-147	interleukin 1 beta	Homo sapiens	14-22
14643170-7	2004	TNFalpha- and IL-1beta-induced RANTES and IL-8 expression was reduced on the transcriptional level by pre-treatment with fluticasone and budesonide.	Budesonide	137-147	C-C motif chemokine ligand 5	Homo sapiens	31-37
14643170-7	2004	TNFalpha- and IL-1beta-induced RANTES and IL-8 expression was reduced on the transcriptional level by pre-treatment with fluticasone and budesonide.	Budesonide	137-147	C-X-C motif chemokine ligand 8	Homo sapiens	42-46
14643170-8	2004	The results suggest that the topical steroids fluticasone, budesonide and to a lesser extent beclomethasone may have beneficial effects on airway inflammation in asthma by reducing RANTES and IL-8-induced leukocyte infiltration into the airway wall.	Budesonide	59-69	C-C motif chemokine ligand 5	Homo sapiens	181-187
14643170-8	2004	The results suggest that the topical steroids fluticasone, budesonide and to a lesser extent beclomethasone may have beneficial effects on airway inflammation in asthma by reducing RANTES and IL-8-induced leukocyte infiltration into the airway wall.	Budesonide	59-69	C-X-C motif chemokine ligand 8	Homo sapiens	192-196
15219267-4	2004	Budesonide (0.7 mM) and a molar equivalent concentration of the NO-donating budesonide derivative, NCX 1020, were inhaled (15 min) at 24 h and 45 min before LPS.	Budesonide	76-86	T cell leukemia homeobox 2	Homo sapiens	99-102
15219267-7	2004	The combined inhalation before LPS of the NO donor, SNAP (1.4 mM), with budesonide (0.7 mM) blocked the AHR to histamine and significantly reduced neutrophils (1 and 24 h) and MPO (1 and 24 h), while NO levels were raised at 1 h after LPS.	Budesonide	72-82	myeloperoxidase	Homo sapiens	176-179
14563684-4	2003	Chromatin immunoprecipitation showed that co-treatment with IL-1beta and the glucocorticoid budesonide increased the SCF promoter occupancy by NF-kappaB and GR, as compared with IL-1beta and budesonide alone.	Budesonide	92-102	KIT ligand	Homo sapiens	117-120
14563684-4	2003	Chromatin immunoprecipitation showed that co-treatment with IL-1beta and the glucocorticoid budesonide increased the SCF promoter occupancy by NF-kappaB and GR, as compared with IL-1beta and budesonide alone.	Budesonide	92-102	nuclear factor kappa B subunit 1	Homo sapiens	143-152
14563684-4	2003	Chromatin immunoprecipitation showed that co-treatment with IL-1beta and the glucocorticoid budesonide increased the SCF promoter occupancy by NF-kappaB and GR, as compared with IL-1beta and budesonide alone.	Budesonide	92-102	interleukin 1 beta	Homo sapiens	178-186
14563684-4	2003	Chromatin immunoprecipitation showed that co-treatment with IL-1beta and the glucocorticoid budesonide increased the SCF promoter occupancy by NF-kappaB and GR, as compared with IL-1beta and budesonide alone.	Budesonide	191-201	interleukin 1 beta	Homo sapiens	60-68
14563684-4	2003	Chromatin immunoprecipitation showed that co-treatment with IL-1beta and the glucocorticoid budesonide increased the SCF promoter occupancy by NF-kappaB and GR, as compared with IL-1beta and budesonide alone.	Budesonide	191-201	KIT ligand	Homo sapiens	117-120
12920235-0	2003	Identification of a novel glucocorticoid receptor mutation in budesonide-resistant human bronchial epithelial cells.	Budesonide	62-72	nuclear receptor subfamily 3 group C member 1	Homo sapiens	26-49
12920235-1	2003	We developed a molecular genetic model to investigate glucocorticoid receptor (GR) signaling in human bronchial epithelial cells in response to the therapeutic steroid budesonide.	Budesonide	168-178	nuclear receptor subfamily 3 group C member 1	Homo sapiens	54-77
12920235-1	2003	We developed a molecular genetic model to investigate glucocorticoid receptor (GR) signaling in human bronchial epithelial cells in response to the therapeutic steroid budesonide.	Budesonide	168-178	nuclear receptor subfamily 3 group C member 1	Homo sapiens	79-81
12920235-3	2003	Three spontaneous budesonide-resistant subclones were found to express low levels of GR, whereas two mutants isolated from ethylmethane sulfonate-treated cultures contained normal levels of GR protein.	Budesonide	18-28	nuclear receptor subfamily 3 group C member 1	Homo sapiens	85-87
12920235-4	2003	Analysis of the GR coding sequence in the budesonide-resistant subclone Ch-BdE5 identified a novel Val to Met mutation at amino acid position 575 (GRV575M) which caused an 80% decrease in transcriptional regulatory functions with only a minimal effect on ligand binding activity.	Budesonide	42-52	nuclear receptor subfamily 3 group C member 1	Homo sapiens	16-18
14692430-10	2003	Budesonide aqueous nasal spray treatment showed a significant decrease of IL-4 (P = .007), IL-5 (P = .04), and IL-6 levels (P = .009).	Budesonide	0-10	interleukin 5	Homo sapiens	91-95
14692430-10	2003	Budesonide aqueous nasal spray treatment showed a significant decrease of IL-4 (P = .007), IL-5 (P = .04), and IL-6 levels (P = .009).	Budesonide	0-10	interleukin 6	Homo sapiens	111-115
14519149-5	2003	RESULTS: Following RV16-infection, a significant increase in IL-8 was observed in the placebo- and budesonide-treated asthmatics (P=0.033 and 0.037, respectively), whereas IL-1beta only increased in the two asthma groups combined (P=0.035).	Budesonide	99-109	C-X-C motif chemokine ligand 8	Homo sapiens	61-65
14519035-5	2003	DATA SYNTHESIS: Budesonide"s high potency at the glucocorticoid receptor and extensive first-pass hepatic metabolism result in a topical antiinflammatory effect on intestinal tissue, with minimal systemic glucocorticoid adverse effects.	Budesonide	16-26	nuclear receptor subfamily 3 group C member 1	Homo sapiens	49-72
14519149-6	2003	A small, but significant, increase in IL-1ra was only observed in the budesonide-treated asthmatics (P=0.047).	Budesonide	70-80	interleukin 1 receptor antagonist	Homo sapiens	38-44
14519149-10	2003	In addition, the observation that budesonide-treatment may result in higher nasal IL-1ra levels supports the hypothesis that steroids act in part by increasing the endogenous anti-inflammatory screen.	Budesonide	34-44	interleukin 1 receptor antagonist	Homo sapiens	82-88
12693793-4	2003	Compared with budesonide alone, change in mean morning and evening peak expiratory flow was greater in the once-daily budesonide/formoterol group (27 and 171 min(-1), respectively; P < 0.001) and twice-daily budesonide/formoterol group (23 and 24 l min(-1), respectively; P < 0.001).	Budesonide	118-128	CD59 molecule (CD59 blood group)	Homo sapiens	158-164
12907609-0	2003	Mice with alterations in both p53 and Ink4a/Arf display a striking increase in lung tumor multiplicity and progression: differential chemopreventive effect of budesonide in wild-type and mutant A/J mice.	Budesonide	159-169	transformation related protein 53, pseudogene	Mus musculus	30-33
12907609-0	2003	Mice with alterations in both p53 and Ink4a/Arf display a striking increase in lung tumor multiplicity and progression: differential chemopreventive effect of budesonide in wild-type and mutant A/J mice.	Budesonide	159-169	cyclin dependent kinase inhibitor 2A	Mus musculus	38-47
12907609-10	2003	However, the efficacy of budesonide against lung tumor progression decreased from 94 to 77% (P = 0.07) in mice with alterations in both p53 and Ink4A/Arf in a 40-week chemoprevention assay.	Budesonide	25-35	transformation related protein 53, pseudogene	Mus musculus	136-139
12907609-10	2003	However, the efficacy of budesonide against lung tumor progression decreased from 94 to 77% (P = 0.07) in mice with alterations in both p53 and Ink4A/Arf in a 40-week chemoprevention assay.	Budesonide	25-35	cyclin dependent kinase inhibitor 2A	Mus musculus	144-153
12907609-11	2003	Similarly, when mice bearing established lung adenomas were treated with budesonide, genotype-dependent differential effects of budesonide in wild-type and mutant mice were clearly revealed with a 82, 64, 45, and 33% decrease in tumor volume in wild-type mice, p53(+/+)Ink4a/Arf(+/-) mice, p53(+/-)Ink4a/Arf(+/+) mice, and p53(+/-)Ink4a/Arf(+/-), respectively.	Budesonide	73-83	transformation related protein 53, pseudogene	Mus musculus	261-264
12907609-11	2003	Similarly, when mice bearing established lung adenomas were treated with budesonide, genotype-dependent differential effects of budesonide in wild-type and mutant mice were clearly revealed with a 82, 64, 45, and 33% decrease in tumor volume in wild-type mice, p53(+/+)Ink4a/Arf(+/-) mice, p53(+/-)Ink4a/Arf(+/+) mice, and p53(+/-)Ink4a/Arf(+/-), respectively.	Budesonide	73-83	cyclin dependent kinase inhibitor 2A	Mus musculus	269-274
12907609-11	2003	Similarly, when mice bearing established lung adenomas were treated with budesonide, genotype-dependent differential effects of budesonide in wild-type and mutant mice were clearly revealed with a 82, 64, 45, and 33% decrease in tumor volume in wild-type mice, p53(+/+)Ink4a/Arf(+/-) mice, p53(+/-)Ink4a/Arf(+/+) mice, and p53(+/-)Ink4a/Arf(+/-), respectively.	Budesonide	73-83	transformation related protein 53, pseudogene	Mus musculus	290-293
12907609-11	2003	Similarly, when mice bearing established lung adenomas were treated with budesonide, genotype-dependent differential effects of budesonide in wild-type and mutant mice were clearly revealed with a 82, 64, 45, and 33% decrease in tumor volume in wild-type mice, p53(+/+)Ink4a/Arf(+/-) mice, p53(+/-)Ink4a/Arf(+/+) mice, and p53(+/-)Ink4a/Arf(+/-), respectively.	Budesonide	73-83	cyclin dependent kinase inhibitor 2A	Mus musculus	298-303
12907609-11	2003	Similarly, when mice bearing established lung adenomas were treated with budesonide, genotype-dependent differential effects of budesonide in wild-type and mutant mice were clearly revealed with a 82, 64, 45, and 33% decrease in tumor volume in wild-type mice, p53(+/+)Ink4a/Arf(+/-) mice, p53(+/-)Ink4a/Arf(+/+) mice, and p53(+/-)Ink4a/Arf(+/-), respectively.	Budesonide	73-83	transformation related protein 53, pseudogene	Mus musculus	290-293
12907609-11	2003	Similarly, when mice bearing established lung adenomas were treated with budesonide, genotype-dependent differential effects of budesonide in wild-type and mutant mice were clearly revealed with a 82, 64, 45, and 33% decrease in tumor volume in wild-type mice, p53(+/+)Ink4a/Arf(+/-) mice, p53(+/-)Ink4a/Arf(+/+) mice, and p53(+/-)Ink4a/Arf(+/-), respectively.	Budesonide	73-83	cyclin dependent kinase inhibitor 2A	Mus musculus	298-303
12907609-11	2003	Similarly, when mice bearing established lung adenomas were treated with budesonide, genotype-dependent differential effects of budesonide in wild-type and mutant mice were clearly revealed with a 82, 64, 45, and 33% decrease in tumor volume in wild-type mice, p53(+/+)Ink4a/Arf(+/-) mice, p53(+/-)Ink4a/Arf(+/+) mice, and p53(+/-)Ink4a/Arf(+/-), respectively.	Budesonide	128-138	transformation related protein 53, pseudogene	Mus musculus	261-264
12907609-11	2003	Similarly, when mice bearing established lung adenomas were treated with budesonide, genotype-dependent differential effects of budesonide in wild-type and mutant mice were clearly revealed with a 82, 64, 45, and 33% decrease in tumor volume in wild-type mice, p53(+/+)Ink4a/Arf(+/-) mice, p53(+/-)Ink4a/Arf(+/+) mice, and p53(+/-)Ink4a/Arf(+/-), respectively.	Budesonide	128-138	cyclin dependent kinase inhibitor 2A	Mus musculus	269-274
12907609-11	2003	Similarly, when mice bearing established lung adenomas were treated with budesonide, genotype-dependent differential effects of budesonide in wild-type and mutant mice were clearly revealed with a 82, 64, 45, and 33% decrease in tumor volume in wild-type mice, p53(+/+)Ink4a/Arf(+/-) mice, p53(+/-)Ink4a/Arf(+/+) mice, and p53(+/-)Ink4a/Arf(+/-), respectively.	Budesonide	128-138	transformation related protein 53, pseudogene	Mus musculus	290-293
12907609-11	2003	Similarly, when mice bearing established lung adenomas were treated with budesonide, genotype-dependent differential effects of budesonide in wild-type and mutant mice were clearly revealed with a 82, 64, 45, and 33% decrease in tumor volume in wild-type mice, p53(+/+)Ink4a/Arf(+/-) mice, p53(+/-)Ink4a/Arf(+/+) mice, and p53(+/-)Ink4a/Arf(+/-), respectively.	Budesonide	128-138	cyclin dependent kinase inhibitor 2A	Mus musculus	298-303
12907609-11	2003	Similarly, when mice bearing established lung adenomas were treated with budesonide, genotype-dependent differential effects of budesonide in wild-type and mutant mice were clearly revealed with a 82, 64, 45, and 33% decrease in tumor volume in wild-type mice, p53(+/+)Ink4a/Arf(+/-) mice, p53(+/-)Ink4a/Arf(+/+) mice, and p53(+/-)Ink4a/Arf(+/-), respectively.	Budesonide	128-138	transformation related protein 53, pseudogene	Mus musculus	290-293
12907609-11	2003	Similarly, when mice bearing established lung adenomas were treated with budesonide, genotype-dependent differential effects of budesonide in wild-type and mutant mice were clearly revealed with a 82, 64, 45, and 33% decrease in tumor volume in wild-type mice, p53(+/+)Ink4a/Arf(+/-) mice, p53(+/-)Ink4a/Arf(+/+) mice, and p53(+/-)Ink4a/Arf(+/-), respectively.	Budesonide	128-138	cyclin dependent kinase inhibitor 2A	Mus musculus	298-303
12907609-12	2003	Thus, mutant mice with alterations in p53 and/or Ink4A/Arf exhibited a significant resistance to chemoprevention by budesonide.	Budesonide	116-126	transformation related protein 53, pseudogene	Mus musculus	38-41
12907609-12	2003	Thus, mutant mice with alterations in p53 and/or Ink4A/Arf exhibited a significant resistance to chemoprevention by budesonide.	Budesonide	116-126	cyclin dependent kinase inhibitor 2A	Mus musculus	49-58
12756375-3	2003	RESULTS: Budesonide-treated patients had significantly lower median (1st, 3rd quartile) FE(NO) (21.5 [13.2, 84.4] vs 62.5 [26.2, 115.0] ppb, P <.01) and eosinophil cationic protein levels (17.4 [10.1, 24.3] vs 24.0 [15.4, 33.9] mg/dL, P =.05) compared with placebo, whereas no differences were noted between nedocromil and placebo groups.	Budesonide	9-19	ribonuclease A family member 3	Homo sapiens	156-183
12877646-1	2003	Budesonide/formoterol (Symbicort), AstraZeneca plc) is a novel treatment for asthma, combining an inhaled corticosteroid - budesonide, and a long-acting beta(2)-agonist - formoterol, in a single inhaler, the Turbuhaler.	Budesonide	0-10	heparan sulfate proteoglycan 2	Homo sapiens	47-50
12847477-5	2003	RESULTS: First, the density of CD8(+) cells was markedly increased in NP tissues after intranasal budesonide treatment from 16.1 +/- 8.4 (M +/- SEM) per mm(2) to 39.9 +/- 24.1.	Budesonide	98-108	CD8a molecule	Homo sapiens	31-34
12847477-7	2003	The density of IL-4(+) and IL-5(+) cells in NP tissues significantly decreased after budesonide treatment from 40 +/- 12 to 17.8 +/- 8 and from 19.3 +/- 11 to 10.4 +/- 7, respectively.	Budesonide	85-95	interleukin 4	Homo sapiens	15-19
12847477-7	2003	The density of IL-4(+) and IL-5(+) cells in NP tissues significantly decreased after budesonide treatment from 40 +/- 12 to 17.8 +/- 8 and from 19.3 +/- 11 to 10.4 +/- 7, respectively.	Budesonide	85-95	interleukin 5	Homo sapiens	27-31
12847477-9	2003	In addition, we found that the density of TGF-beta(+) cells significantly increased after intranasal budesonide from 18 +/- 5 to 41 +/- 9.	Budesonide	101-111	transforming growth factor beta 1	Homo sapiens	42-50
12847477-12	2003	CONCLUSIONS: These findings demonstrate that intranasal budesonide induced an increase in CD8 population and a selective regulatory effect on tissue cytokine expression.	Budesonide	56-66	CD8a molecule	Homo sapiens	90-93
12789234-11	2003	Production of VEGF stimulated by all cytokines was inhibited by budesonide.	Budesonide	64-74	vascular endothelial growth factor A	Homo sapiens	14-18
12693793-4	2003	Compared with budesonide alone, change in mean morning and evening peak expiratory flow was greater in the once-daily budesonide/formoterol group (27 and 171 min(-1), respectively; P < 0.001) and twice-daily budesonide/formoterol group (23 and 24 l min(-1), respectively; P < 0.001).	Budesonide	118-128	CD59 molecule (CD59 blood group)	Homo sapiens	252-258
12693793-4	2003	Compared with budesonide alone, change in mean morning and evening peak expiratory flow was greater in the once-daily budesonide/formoterol group (27 and 171 min(-1), respectively; P < 0.001) and twice-daily budesonide/formoterol group (23 and 24 l min(-1), respectively; P < 0.001).	Budesonide	118-128	CD59 molecule (CD59 blood group)	Homo sapiens	158-164
12693793-4	2003	Compared with budesonide alone, change in mean morning and evening peak expiratory flow was greater in the once-daily budesonide/formoterol group (27 and 171 min(-1), respectively; P < 0.001) and twice-daily budesonide/formoterol group (23 and 24 l min(-1), respectively; P < 0.001).	Budesonide	118-128	CD59 molecule (CD59 blood group)	Homo sapiens	252-258
12589352-8	2003	RESULTS: Weekly therapy with budesonide encapsulated in stealth liposomes was as effective as daily budesonide therapy in decreasing lung inflammation and lowering eosinophil peroxidase activity, peripheral blood eosinophils, and total serum IgE levels.	Budesonide	29-39	eosinophil peroxidase	Mus musculus	164-185
12601049-0	2003	Subconjunctival nano- and microparticles sustain retinal delivery of budesonide, a corticosteroid capable of inhibiting VEGF expression.	Budesonide	69-79	vascular endothelial growth factor A	Homo sapiens	120-124
12601049-1	2003	PURPOSE: The purpose of this study was to determine whether budesonide inhibits expression of vascular endothelial growth factor (VEGF) in a retinal pigment epithelial cell line (ARPE-19) and to determine whether subconjunctivally administered budesonide nano- and microparticles sustain retinal drug levels.	Budesonide	60-70	vascular endothelial growth factor A	Homo sapiens	94-128
12601049-1	2003	PURPOSE: The purpose of this study was to determine whether budesonide inhibits expression of vascular endothelial growth factor (VEGF) in a retinal pigment epithelial cell line (ARPE-19) and to determine whether subconjunctivally administered budesonide nano- and microparticles sustain retinal drug levels.	Budesonide	60-70	vascular endothelial growth factor A	Homo sapiens	130-134
12601049-6	2003	RESULTS: At concentrations devoid of cytotoxicity, budesonide inhibited VEGF secretion as well as mRNA expression in ARPE-19 cells in a dose-dependent manner.	Budesonide	51-61	vascular endothelial growth factor A	Homo sapiens	72-76
12601049-7	2003	RU486 treatment prevented budesonide-mediated inhibition of VEGF secretion and VEGF mRNA expression.	Budesonide	26-36	vascular endothelial growth factor A	Homo sapiens	60-64
12601049-7	2003	RU486 treatment prevented budesonide-mediated inhibition of VEGF secretion and VEGF mRNA expression.	Budesonide	26-36	vascular endothelial growth factor A	Homo sapiens	79-83
12601049-10	2003	CONCLUSIONS: Budesonide is capable of inhibiting VEGF expression through glucocorticoid receptor activity.	Budesonide	13-23	vascular endothelial growth factor A	Homo sapiens	49-53
12601049-10	2003	CONCLUSIONS: Budesonide is capable of inhibiting VEGF expression through glucocorticoid receptor activity.	Budesonide	13-23	nuclear receptor subfamily 3 group C member 1	Homo sapiens	73-96
12603713-7	2003	Budesonide significantly inhibited the seasonal increase in alpha2-macroglobulin as well as the exudative hyperresponsiveness to histamine.	Budesonide	0-10	alpha-2-macroglobulin	Homo sapiens	60-80
12570112-8	2003	Budesonide/formoterol decreased all symptom scores and use of reliever beta2-agonists significantly versus placebo and budesonide, and improved HRQL versus placebo.	Budesonide	0-10	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	71-76
12949438-7	2003	In addition, 1 case is reported who presented the highest trough levels of the CYP3A substrate budesonide in serum ever measured.	Budesonide	95-105	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	79-84
14520851-4	2003	Budesonide reduced frequency of acute asthma episodes and the need in inhalations of short-acting beta 2-agonists.	Budesonide	0-10	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	98-104
12423562-0	2002	[Effect of budesonide on Clara cell secretory protein and its mRNA expression in a rat model of asthma].	Budesonide	11-21	secretoglobin family 1A member 1	Rattus norvegicus	25-53
12452208-3	2002	AIMS AND METHODS: Our aim was to confirm that sputum and serum ECP measurements would provide a more sensitive indicator of responses to asthma treatment than eosinophil counts per se, in a randomized, placebo-controlled, crossover study of terbutaline, budesonide, and their combination in patients with chronic persistent asthma.	Budesonide	254-264	ribonuclease A family member 3	Homo sapiens	63-66
12452208-10	2002	Correlations between sputum eosinophils and ECP, and between blood eosinophils and serum ECP were greatest during treatment with placebo or terbutaline alone: budesonide weakened or abolished these relationships.	Budesonide	159-169	ribonuclease A family member 3	Homo sapiens	89-92
12394202-1	2002	OBJECTIVE: To assess change in symptoms, quality of life (QOL), and performance ability before, during, and after treatment with budesonide in a group of Olympic and Paralympic athletes with seasonal allergic rhinoconjunctivitis (SAR/C).	Budesonide	129-139	sarcosine dehydrogenase	Homo sapiens	230-233
12394202-2	2002	DESIGN: Because budesonide has already been proven to be an effective and well-tolerated treatment of SAR/C(1), an open-label treatment format was used.	Budesonide	16-26	sarcosine dehydrogenase	Homo sapiens	102-105
12498371-3	2002	Intercellular adhesion molecule 1 (ICAM-1) and vascular cell adhesion molecule 1 (VCAM-1) were chosen as methodological controls, because data already published in the literature clearly indicated budesonide-mediated effects on ICAM-1 and VCAM-1 levels of expression.	Budesonide	197-207	intercellular adhesion molecule 1	Homo sapiens	228-234
12498371-3	2002	Intercellular adhesion molecule 1 (ICAM-1) and vascular cell adhesion molecule 1 (VCAM-1) were chosen as methodological controls, because data already published in the literature clearly indicated budesonide-mediated effects on ICAM-1 and VCAM-1 levels of expression.	Budesonide	197-207	vascular cell adhesion molecule 1	Homo sapiens	239-245
12498371-4	2002	The present data show that budesonide significantly modified the levels of expression of ICAM-1 and VCAM-1, and to a lesser extent that of P-selectin, in the surface and glandular epithelia.	Budesonide	27-37	intercellular adhesion molecule 1	Homo sapiens	89-95
12498371-4	2002	The present data show that budesonide significantly modified the levels of expression of ICAM-1 and VCAM-1, and to a lesser extent that of P-selectin, in the surface and glandular epithelia.	Budesonide	27-37	vascular cell adhesion molecule 1	Homo sapiens	100-106
12498371-4	2002	The present data show that budesonide significantly modified the levels of expression of ICAM-1 and VCAM-1, and to a lesser extent that of P-selectin, in the surface and glandular epithelia.	Budesonide	27-37	selectin P	Homo sapiens	139-149
12418591-8	2002	A concentration of 1 nM budesonide inhibited GM-CSF production by more than 50% at all time points.	Budesonide	24-34	colony stimulating factor 2	Homo sapiens	45-51
12270249-0	2002	Deposition and pharmacokinetics of budesonide from the Miat Monodose inhaler, a simple dry powder device.	Budesonide	35-45	myocardial infarction associated transcript	Homo sapiens	55-59
12325039-0	2002	Effect of budesonide on the methylation and mRNA expression of the insulin-like growth factor 2 and c-myc genes in mouse lung tumors.	Budesonide	10-20	insulin-like growth factor 2	Mus musculus	67-95
12325039-2	2002	To define potential surrogate end-point biomarkers, the ability of budesonide to decrease mRNA expression of the insulin-like growth factor-2 (Igf-II) and c-myc genes and to cause the remethylation of the genes was investigated in lung tumors.	Budesonide	67-77	insulin-like growth factor 2	Mus musculus	113-141
12325039-2	2002	To define potential surrogate end-point biomarkers, the ability of budesonide to decrease mRNA expression of the insulin-like growth factor-2 (Igf-II) and c-myc genes and to cause the remethylation of the genes was investigated in lung tumors.	Budesonide	67-77	insulin-like growth factor 2	Mus musculus	143-149
12325039-15	2002	The results support the possibility of using decreased mRNA expression and remethylation of the Igf-II and c-myc genes as biomarkers for the efficacy of budesonide.	Budesonide	153-163	insulin-like growth factor 2	Mus musculus	96-102
12153960-9	2002	In the budesonide group, the changes in PC(20), sputum ECP, and exhaled NO were significantly different as compared with the placebo group (p < 0.03).	Budesonide	7-17	ribonuclease A family member 3	Homo sapiens	55-58
12119225-0	2002	The effects of intranasal budesonide on allergen-induced production of interleukin-5 and eotaxin, airways, blood, and bone marrow eosinophilia, and eosinophil progenitor expansion in sensitized mice.	Budesonide	26-36	chemokine (C-C motif) ligand 11	Mus musculus	89-96
12119225-3	2002	Budesonide treatment attenuated allergen-induced eosinophilia in bone marrow, peripheral blood, and airways as well as allergen-induced increases in bone marrow eosinophil progenitors but not allergen-induced increases in IL-5 or eotaxin 12 h following the second of two daily exposures to allergen; at later time points treatment was associated with attenuation of IL-5, eosinophilia, Eo-CFU, and airway hyperresponsiveness.	Budesonide	0-10	interleukin 5	Mus musculus	222-226
12119225-3	2002	Budesonide treatment attenuated allergen-induced eosinophilia in bone marrow, peripheral blood, and airways as well as allergen-induced increases in bone marrow eosinophil progenitors but not allergen-induced increases in IL-5 or eotaxin 12 h following the second of two daily exposures to allergen; at later time points treatment was associated with attenuation of IL-5, eosinophilia, Eo-CFU, and airway hyperresponsiveness.	Budesonide	0-10	chemokine (C-C motif) ligand 11	Mus musculus	230-237
12119225-3	2002	Budesonide treatment attenuated allergen-induced eosinophilia in bone marrow, peripheral blood, and airways as well as allergen-induced increases in bone marrow eosinophil progenitors but not allergen-induced increases in IL-5 or eotaxin 12 h following the second of two daily exposures to allergen; at later time points treatment was associated with attenuation of IL-5, eosinophilia, Eo-CFU, and airway hyperresponsiveness.	Budesonide	0-10	interleukin 5	Mus musculus	366-370
12166560-2	2002	Itraconazole can inhibit CYP3A, thus interfering with synthesis of gluco- and mineralocorticoids, androgens and oestradiol as well as the metabolism of budesonide.	Budesonide	152-162	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	25-30
12194641-0	2002	Effects of 4-week treatment with low-dose budesonide (100 micrograms BID) from a novel inhaler Airmax and from a conventional inhaler on bronchial hyper-responsiveness, lung function and symptoms in patients with mild asthma.	Budesonide	42-52	BH3 interacting domain death agonist	Homo sapiens	69-72
12194641-11	2002	In conclusion, 100 micrograms budesonide bid during 4 weeks from Airmax effectively attenuates the response to AMP in mild asthmatics.	Budesonide	30-40	BH3 interacting domain death agonist	Homo sapiens	41-44
12108857-8	2002	Budesonide treatment was associated with a slight but statistically significant decrease in the area under the concentration-time curve for serum osteocalcin.	Budesonide	0-10	bone gamma-carboxyglutamate protein	Homo sapiens	146-157
12117777-12	2002	Budesonide treatment also increased the protein level of the p21 and p27 genes and increased the mRNA level of p21.	Budesonide	0-10	cyclin-dependent kinase inhibitor 1A (P21)	Mus musculus	61-64
12117777-12	2002	Budesonide treatment also increased the protein level of the p21 and p27 genes and increased the mRNA level of p21.	Budesonide	0-10	dynactin 6	Mus musculus	69-72
12117777-12	2002	Budesonide treatment also increased the protein level of the p21 and p27 genes and increased the mRNA level of p21.	Budesonide	0-10	cyclin-dependent kinase inhibitor 1A (P21)	Mus musculus	111-114
11950791-0	2002	Sulfation of budesonide by human cytosolic sulfotransferase, dehydroepiandrosterone-sulfotransferase (DHEA-ST).	Budesonide	13-23	sulfotransferase family 2A member 1	Homo sapiens	102-109
11950791-7	2002	Only dehydroepiandrosterone-sulfotransferase (DHEA-ST, SULT2A1) was capable of forming a sulfated budesonide product.	Budesonide	98-108	sulfotransferase family 2A member 1	Homo sapiens	46-53
11950791-7	2002	Only dehydroepiandrosterone-sulfotransferase (DHEA-ST, SULT2A1) was capable of forming a sulfated budesonide product.	Budesonide	98-108	sulfotransferase family 2A member 1	Homo sapiens	55-62
11950791-11	2002	Although sulfation of budesonide by DHEA-ST may not be an important factor in its use as an antiasthmatic, intestinal and hepatic sulfation will be important for its proposed systemic use as an anti-inflammatory agent.	Budesonide	22-32	sulfotransferase family 2A member 1	Homo sapiens	36-43
12150618-5	2002	RESULTS: We found an improvement in the symptom scores in 11 of the 13 patients who received budesonide; we also found a decrease in CD-3 (P = .02) and eosinophils (P = .002), and a decrease in the density of cells expressing interleukin4 (P = .0001) and interleukin-5 messenger RNA (P = .006) after treatment.	Budesonide	93-103	interleukin 4	Homo sapiens	226-238
12150618-5	2002	RESULTS: We found an improvement in the symptom scores in 11 of the 13 patients who received budesonide; we also found a decrease in CD-3 (P = .02) and eosinophils (P = .002), and a decrease in the density of cells expressing interleukin4 (P = .0001) and interleukin-5 messenger RNA (P = .006) after treatment.	Budesonide	93-103	interleukin 5	Homo sapiens	255-268
11906363-0	2002	Down-regulated IL-5 receptor expression on peripheral blood eosinophils from budesonide-treated children with asthma.	Budesonide	77-87	interleukin 5	Homo sapiens	15-19
11874817-1	2002	Nebulized budesonide has been used successfully to treat acute asthma exacerbation, and we hypothesized that it could also be effective for exacerbations of chronic obstructive pulmonary disease (COPD).	Budesonide	10-20	COPD	Homo sapiens	196-200
11874817-9	2002	Both budesonide and prednisolone improved airflow in COPD patients with acute exacerbations when compared with placebo.	Budesonide	5-15	COPD	Homo sapiens	53-57
11874817-10	2002	Nebulized budesonide may be an alternative to oral prednisolone in the treatment of nonacidotic exacerbations of COPD but further studies should be done to evaluate its long-term impact on clinical outcomes after an initial episode of COPD exacerbation.	Budesonide	10-20	COPD	Homo sapiens	113-117
11874817-10	2002	Nebulized budesonide may be an alternative to oral prednisolone in the treatment of nonacidotic exacerbations of COPD but further studies should be done to evaluate its long-term impact on clinical outcomes after an initial episode of COPD exacerbation.	Budesonide	10-20	COPD	Homo sapiens	235-239
11906363-5	2002	The IL-5R expression on PBE, as well as the in vitro responsiveness of PBE to recombinant IL-5, was reduced (P < 0.05), in budesonide-treated asthmatic children compared to nonsteroid-treated asthmatic children and healthy children.	Budesonide	126-136	interleukin 5	Homo sapiens	4-8
11906363-8	2002	CONCLUSIONS: Budesonide-treatment of asthmatic children induces a selectively reduced IL-5R expression on PBE, concomitant with a reduced in vitro responsiveness of PBE to IL-5.	Budesonide	13-23	interleukin 5 receptor subunit alpha	Homo sapiens	86-91
11906363-8	2002	CONCLUSIONS: Budesonide-treatment of asthmatic children induces a selectively reduced IL-5R expression on PBE, concomitant with a reduced in vitro responsiveness of PBE to IL-5.	Budesonide	13-23	interleukin 5	Homo sapiens	86-90
11906363-9	2002	We suggest that this budesonide-related down-regulation of the IL-5R might be a mechanism by which steroid treatment inhibits the action of IL-5 on eosinophil accumulation and activation in vivo.	Budesonide	21-31	interleukin 5 receptor subunit alpha	Homo sapiens	63-68
11906363-9	2002	We suggest that this budesonide-related down-regulation of the IL-5R might be a mechanism by which steroid treatment inhibits the action of IL-5 on eosinophil accumulation and activation in vivo.	Budesonide	21-31	interleukin 5	Homo sapiens	63-67
11934803-12	2002	Budesonide inhibited IL-1beta-induced SCF mRNA expression (-68%) at 2.5 h and even more so at 10 h (-192%) (P<0.001).	Budesonide	0-10	interleukin 1 beta	Homo sapiens	21-29
11934803-12	2002	Budesonide inhibited IL-1beta-induced SCF mRNA expression (-68%) at 2.5 h and even more so at 10 h (-192%) (P<0.001).	Budesonide	0-10	KIT ligand	Homo sapiens	38-41
11934803-17	2002	Budesonide decreased this IL-1beta-enhanced stability by about 1.5-fold (P<0.001).	Budesonide	0-10	interleukin 1 beta	Homo sapiens	26-34
11910357-5	2002	Although acute administration of corticosteroids showed no effect, treatment for 2 days with dexamethasone or budesonide increased (P < 0.05) biliary bicarbonate concentration and secretion, which were blocked by the specific GcR antagonist, RU-486.	Budesonide	110-120	nuclear receptor subfamily 3, group C, member 1	Rattus norvegicus	229-232
11910357-6	2002	IBDUs isolated from rats treated with dexamethasone or budesonide showed an increased (P < 0.05) activity of the Na+/H+ exchanger (NHE1 isoform) and Cl-/HCO3- exchanger (AE2 member), which was blocked by RU-486.	Budesonide	55-65	solute carrier family 9 member A1	Rattus norvegicus	134-138
11910357-6	2002	IBDUs isolated from rats treated with dexamethasone or budesonide showed an increased (P < 0.05) activity of the Na+/H+ exchanger (NHE1 isoform) and Cl-/HCO3- exchanger (AE2 member), which was blocked by RU-486.	Budesonide	55-65	solute carrier family 4 member 2	Rattus norvegicus	173-176
11909610-10	2002	The striking similarity to budesonide, a clinically used anti-inflammatory agent, suggests that adenosine A2A receptor agonists may be useful alternatives to glucocorticosteroids in the treatment of asthma.	Budesonide	27-37	adenosine A2a receptor	Rattus norvegicus	96-118
11867828-6	2002	RESULTS: Formoterol exerted an additive effect on the inhibition of IL-1beta stimulated ICAM-1 and VCAM-1 upregulation and GM-CSF production by budesonide in concentrations of 10(-9) M and above (p<0.05).	Budesonide	144-154	interleukin 1 beta	Homo sapiens	68-76
11867828-6	2002	RESULTS: Formoterol exerted an additive effect on the inhibition of IL-1beta stimulated ICAM-1 and VCAM-1 upregulation and GM-CSF production by budesonide in concentrations of 10(-9) M and above (p<0.05).	Budesonide	144-154	colony stimulating factor 2	Homo sapiens	123-129
11890908-5	2002	Budesonide abolished airway inflammation, suppressed the mRNA expression for interleukin-2, interleukin-4, and interleukin-5 (P<0.03), and bronchial hyperresponsiveness (P<0.05).	Budesonide	0-10	interleukin 2	Rattus norvegicus	77-90
11890908-5	2002	Budesonide abolished airway inflammation, suppressed the mRNA expression for interleukin-2, interleukin-4, and interleukin-5 (P<0.03), and bronchial hyperresponsiveness (P<0.05).	Budesonide	0-10	interleukin 4	Rattus norvegicus	92-105
11890908-5	2002	Budesonide abolished airway inflammation, suppressed the mRNA expression for interleukin-2, interleukin-4, and interleukin-5 (P<0.03), and bronchial hyperresponsiveness (P<0.05).	Budesonide	0-10	interleukin 5	Rattus norvegicus	111-124
11864633-7	2002	Thus, budesonide inhibits MRP1 expression and may be useful as a chemosensitizer in tumor chemotherapy.	Budesonide	6-16	ATP binding cassette subfamily C member 1	Homo sapiens	26-30
11850528-0	2002	Galectin-1 is overexpressed in nasal polyps under budesonide and inhibits eosinophil migration.	Budesonide	50-60	galectin 1	Homo sapiens	0-10
11850528-1	2002	Because of the importance of galectins for various cellular activities, the influence of the glucocorticoid budesonide on the level of expression of galectins-1 and -3 was investigated in human nasal polyposis.	Budesonide	108-118	galectin 1	Homo sapiens	149-167
11906363-5	2002	The IL-5R expression on PBE, as well as the in vitro responsiveness of PBE to recombinant IL-5, was reduced (P < 0.05), in budesonide-treated asthmatic children compared to nonsteroid-treated asthmatic children and healthy children.	Budesonide	126-136	interleukin 5 receptor subunit alpha	Homo sapiens	4-9
12412882-8	2002	CONCLUSION: This observation suggests that the metabolic clearance of buDesonide was compromised by itraconazole"s inhibition of cytochrome P450 enzymes, especially the CYP3A isoforms, causing an elevation in systemic budesonide concentration.	Budesonide	70-80	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	169-174
14720060-4	2002	Concomitant administration of montelukast (5 mg/day) and inhaled budesonide (200 microg twice daily) resulted in a trend towards an increase in FEV1 (p=0.06, primary endpoint) and a statistically significant reduction in both as-needed beta2-agonist usage and the percentage of days with asthma exacerbations compared with budesonide plus placebo.	Budesonide	65-75	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	236-241
12884561-9	2002	In following 2 weeks of budesonide treatment sputum ECP concentration was statistically negligible in relation to previous treatment in spite of increasing tendency (50 +/- 61.3 mcg/L (p = 0.2394).	Budesonide	24-34	ribonuclease A family member 3	Homo sapiens	52-55
11751182-5	2001	Budesonide treatment did not inhibit the functional response to ozone exposure, as determined by reduction in FEV(1) and increase in total symptom score, but it significantly blunted the increase in the percentage of sputum neutrophils and interleukin-8 concentrations in the supernatant (p < 0.05).	Budesonide	0-10	C-X-C motif chemokine ligand 8	Homo sapiens	240-253
11864633-4	2002	Following 14-day budesonide treatment, fluorescein accumulation increased and fluorescein efflux decreased, consistent with the inhibition of MRP1 activity by budesonide.	Budesonide	17-27	ATP binding cassette subfamily C member 1	Homo sapiens	142-146
11864633-4	2002	Following 14-day budesonide treatment, fluorescein accumulation increased and fluorescein efflux decreased, consistent with the inhibition of MRP1 activity by budesonide.	Budesonide	159-169	ATP binding cassette subfamily C member 1	Homo sapiens	142-146
11864633-5	2002	At a concentration (10 microM) devoid of cytotoxicity, budesonide treatment decreased MRP1 mRNA and MRP1 protein expression in Calu-1 cells by 38% and 42%, respectively.	Budesonide	55-65	ATP binding cassette subfamily C member 1	Homo sapiens	86-90
11864633-5	2002	At a concentration (10 microM) devoid of cytotoxicity, budesonide treatment decreased MRP1 mRNA and MRP1 protein expression in Calu-1 cells by 38% and 42%, respectively.	Budesonide	55-65	ATP binding cassette subfamily C member 1	Homo sapiens	100-104
11864633-6	2002	In addition, budesonide (10 microM) enhanced the sensitivity of the MRP1 overexpressing COR-L23R cells to vincristine, suggesting the chemosensitizing effect of budesonide.	Budesonide	13-23	ATP binding cassette subfamily C member 1	Homo sapiens	68-72
11864633-6	2002	In addition, budesonide (10 microM) enhanced the sensitivity of the MRP1 overexpressing COR-L23R cells to vincristine, suggesting the chemosensitizing effect of budesonide.	Budesonide	161-171	ATP binding cassette subfamily C member 1	Homo sapiens	68-72
11758896-6	2001	Inhaled budesonide therapy was accompanied by a significant decrease in serum interleukin (IL)-5 levels (p < 0.0005) and blood, sputum, and nasal eosinophil counts (p < 0.005).	Budesonide	8-18	interleukin 5	Homo sapiens	78-96
11742191-0	2001	Association of HLA-DR genotypes and IL-1ra gene polymorphism with treatment failure of budesonide and disease patterns in Crohn"s disease.	Budesonide	87-97	major histocompatibility complex, class II, DR beta 1	Homo sapiens	15-18
11742191-0	2001	Association of HLA-DR genotypes and IL-1ra gene polymorphism with treatment failure of budesonide and disease patterns in Crohn"s disease.	Budesonide	87-97	interleukin 1 receptor antagonist	Homo sapiens	36-42
11742191-5	2001	MAIN OUTCOME MEASURES: The HLA-DRB1 genotypes 1-16 and the IL-1ra gene polymorphism were examined for an association with budesonide treatment failure.	Budesonide	122-132	major histocompatibility complex, class II, DR beta 1	Homo sapiens	27-35
11742191-5	2001	MAIN OUTCOME MEASURES: The HLA-DRB1 genotypes 1-16 and the IL-1ra gene polymorphism were examined for an association with budesonide treatment failure.	Budesonide	122-132	interleukin 1 receptor antagonist	Homo sapiens	59-65
11742191-6	2001	RESULTS: Only HLA-DR 8 was associated with treatment failure of budesonide.	Budesonide	64-74	major histocompatibility complex, class II, DR beta 1	Homo sapiens	14-17
11730731-3	2001	Beclomethasone, budesonide, dexamethasone, fluticasone propionate, hydrocortisone and prednisolone inhibited apoptosis in a concentration-dependent manner as assessed by flow cytometric analysis, annexin-V binding and morphological analysis.	Budesonide	16-26	annexin A5	Homo sapiens	196-205
11730731-8	2001	The present data suggests that budesonide and fluticasone propionate prolong human neutrophil survival by inhibiting apoptosis at clinically relevant drug concentrations via an effect on glucocorticoid receptor.	Budesonide	31-41	nuclear receptor subfamily 3 group C member 1	Homo sapiens	187-210
11529904-10	2001	Budesonide reduced eotaxin levels during repeat allergen challenge (P <0.05).	Budesonide	0-10	C-C motif chemokine ligand 11	Homo sapiens	19-26
11502275-0	2001	Budesonide reduces vascular endothelial growth factor secretion and expression in airway (Calu-1) and alveolar (A549) epithelial cells.	Budesonide	0-10	vascular endothelial growth factor A	Homo sapiens	19-53
11502275-1	2001	Vascular endothelial growth factor (VEGF), a cytokine expressed in the respiratory epithelial cells, induces vascular hyperpermeability and edema, symptoms that are alleviated by budesonide, an anti-asthma corticosteroid.	Budesonide	179-189	vascular endothelial growth factor A	Homo sapiens	0-34
11502275-1	2001	Vascular endothelial growth factor (VEGF), a cytokine expressed in the respiratory epithelial cells, induces vascular hyperpermeability and edema, symptoms that are alleviated by budesonide, an anti-asthma corticosteroid.	Budesonide	179-189	vascular endothelial growth factor A	Homo sapiens	36-40
11502275-2	2001	However, modulation of VEGF levels by budesonide in the respiratory epithelium has not been studied.	Budesonide	38-48	vascular endothelial growth factor A	Homo sapiens	23-27
11502275-5	2001	At concentrations devoid of cytotoxicity, budesonide reduced VEGF secretion and VEGF mRNA expression in both cell types and these effects were inhibited by mifepristone (RU 486), a glucocorticoid receptor antagonist, suggesting that budesonide reduces VEGF secretion and expression through its glucocorticoid receptor-mediated action.	Budesonide	42-52	vascular endothelial growth factor A	Homo sapiens	61-65
11502275-5	2001	At concentrations devoid of cytotoxicity, budesonide reduced VEGF secretion and VEGF mRNA expression in both cell types and these effects were inhibited by mifepristone (RU 486), a glucocorticoid receptor antagonist, suggesting that budesonide reduces VEGF secretion and expression through its glucocorticoid receptor-mediated action.	Budesonide	42-52	vascular endothelial growth factor A	Homo sapiens	80-84
11502275-5	2001	At concentrations devoid of cytotoxicity, budesonide reduced VEGF secretion and VEGF mRNA expression in both cell types and these effects were inhibited by mifepristone (RU 486), a glucocorticoid receptor antagonist, suggesting that budesonide reduces VEGF secretion and expression through its glucocorticoid receptor-mediated action.	Budesonide	42-52	nuclear receptor subfamily 3 group C member 1	Homo sapiens	181-204
11502275-5	2001	At concentrations devoid of cytotoxicity, budesonide reduced VEGF secretion and VEGF mRNA expression in both cell types and these effects were inhibited by mifepristone (RU 486), a glucocorticoid receptor antagonist, suggesting that budesonide reduces VEGF secretion and expression through its glucocorticoid receptor-mediated action.	Budesonide	42-52	vascular endothelial growth factor A	Homo sapiens	80-84
11502275-5	2001	At concentrations devoid of cytotoxicity, budesonide reduced VEGF secretion and VEGF mRNA expression in both cell types and these effects were inhibited by mifepristone (RU 486), a glucocorticoid receptor antagonist, suggesting that budesonide reduces VEGF secretion and expression through its glucocorticoid receptor-mediated action.	Budesonide	42-52	nuclear receptor subfamily 3 group C member 1	Homo sapiens	294-317
11502275-6	2001	Also, budesonide-mediated inhibition of VEGF mRNA was time- and protein synthesis-dependent.	Budesonide	6-16	vascular endothelial growth factor A	Homo sapiens	40-44
11502275-7	2001	Thus, budesonide may be of potential value in treating disorders of the respiratory tract that are associated with VEGF elevation.	Budesonide	6-16	vascular endothelial growth factor A	Homo sapiens	115-119
11509812-5	2001	Our results showed that dexamethasone, budesonide and rIL-10 significantly inhibited both IL-6 and TNF-alpha production in the THP-1 cell line stimulated by lipopolysaccharide and Ureaplasma urealyticum antigen.	Budesonide	39-49	interleukin 6	Homo sapiens	90-94
11509812-5	2001	Our results showed that dexamethasone, budesonide and rIL-10 significantly inhibited both IL-6 and TNF-alpha production in the THP-1 cell line stimulated by lipopolysaccharide and Ureaplasma urealyticum antigen.	Budesonide	39-49	tumor necrosis factor	Homo sapiens	99-108
11587995-5	2001	After budesonide treatment there was a significant decrease in the number of submucosal cells staining for total NF-kappaB, granulocyte macrophage colony-stimulating factor (GM-CSF) and tumor necrosis factor-alpha (TNF-alpha), accompanied by a significant decrease in mucosal eosinophils and expression of vascular cell adhesion molecule-1 (VCAM-1) in the endothelium and interleukin-8 (IL-8) in the epithelium.	Budesonide	6-16	nuclear factor kappa B subunit 1	Homo sapiens	113-122
11587995-5	2001	After budesonide treatment there was a significant decrease in the number of submucosal cells staining for total NF-kappaB, granulocyte macrophage colony-stimulating factor (GM-CSF) and tumor necrosis factor-alpha (TNF-alpha), accompanied by a significant decrease in mucosal eosinophils and expression of vascular cell adhesion molecule-1 (VCAM-1) in the endothelium and interleukin-8 (IL-8) in the epithelium.	Budesonide	6-16	colony stimulating factor 2	Homo sapiens	124-172
11587995-5	2001	After budesonide treatment there was a significant decrease in the number of submucosal cells staining for total NF-kappaB, granulocyte macrophage colony-stimulating factor (GM-CSF) and tumor necrosis factor-alpha (TNF-alpha), accompanied by a significant decrease in mucosal eosinophils and expression of vascular cell adhesion molecule-1 (VCAM-1) in the endothelium and interleukin-8 (IL-8) in the epithelium.	Budesonide	6-16	colony stimulating factor 2	Homo sapiens	174-180
11587995-5	2001	After budesonide treatment there was a significant decrease in the number of submucosal cells staining for total NF-kappaB, granulocyte macrophage colony-stimulating factor (GM-CSF) and tumor necrosis factor-alpha (TNF-alpha), accompanied by a significant decrease in mucosal eosinophils and expression of vascular cell adhesion molecule-1 (VCAM-1) in the endothelium and interleukin-8 (IL-8) in the epithelium.	Budesonide	6-16	tumor necrosis factor	Homo sapiens	186-213
11587995-5	2001	After budesonide treatment there was a significant decrease in the number of submucosal cells staining for total NF-kappaB, granulocyte macrophage colony-stimulating factor (GM-CSF) and tumor necrosis factor-alpha (TNF-alpha), accompanied by a significant decrease in mucosal eosinophils and expression of vascular cell adhesion molecule-1 (VCAM-1) in the endothelium and interleukin-8 (IL-8) in the epithelium.	Budesonide	6-16	tumor necrosis factor	Homo sapiens	215-224
11587995-5	2001	After budesonide treatment there was a significant decrease in the number of submucosal cells staining for total NF-kappaB, granulocyte macrophage colony-stimulating factor (GM-CSF) and tumor necrosis factor-alpha (TNF-alpha), accompanied by a significant decrease in mucosal eosinophils and expression of vascular cell adhesion molecule-1 (VCAM-1) in the endothelium and interleukin-8 (IL-8) in the epithelium.	Budesonide	6-16	vascular cell adhesion molecule 1	Homo sapiens	306-339
11587995-5	2001	After budesonide treatment there was a significant decrease in the number of submucosal cells staining for total NF-kappaB, granulocyte macrophage colony-stimulating factor (GM-CSF) and tumor necrosis factor-alpha (TNF-alpha), accompanied by a significant decrease in mucosal eosinophils and expression of vascular cell adhesion molecule-1 (VCAM-1) in the endothelium and interleukin-8 (IL-8) in the epithelium.	Budesonide	6-16	vascular cell adhesion molecule 1	Homo sapiens	341-347
11587995-5	2001	After budesonide treatment there was a significant decrease in the number of submucosal cells staining for total NF-kappaB, granulocyte macrophage colony-stimulating factor (GM-CSF) and tumor necrosis factor-alpha (TNF-alpha), accompanied by a significant decrease in mucosal eosinophils and expression of vascular cell adhesion molecule-1 (VCAM-1) in the endothelium and interleukin-8 (IL-8) in the epithelium.	Budesonide	6-16	C-X-C motif chemokine ligand 8	Homo sapiens	372-385
11587995-5	2001	After budesonide treatment there was a significant decrease in the number of submucosal cells staining for total NF-kappaB, granulocyte macrophage colony-stimulating factor (GM-CSF) and tumor necrosis factor-alpha (TNF-alpha), accompanied by a significant decrease in mucosal eosinophils and expression of vascular cell adhesion molecule-1 (VCAM-1) in the endothelium and interleukin-8 (IL-8) in the epithelium.	Budesonide	6-16	C-X-C motif chemokine ligand 8	Homo sapiens	387-391
11723527-8	2001	RESULTS: Budesonide 400 microg (bid) was significantly more effective than placebo in improving morning peak expiratory flow (mean difference: 67.9 l/min; P < 0.005) and FEV1 (mean difference: 0.60 l; P < 0.005) over the 8-week treatment period.	Budesonide	9-19	BH3 interacting domain death agonist	Homo sapiens	32-35
11447387-10	2001	Budesonide caused a dose-related inhibition of lactoferrin secretion induced by IL-1beta (down to -76%) and TNF-alpha (down to -70%), whereas IL-10 had no effect.	Budesonide	0-10	interleukin 1 beta	Homo sapiens	80-88
11447387-10	2001	Budesonide caused a dose-related inhibition of lactoferrin secretion induced by IL-1beta (down to -76%) and TNF-alpha (down to -70%), whereas IL-10 had no effect.	Budesonide	0-10	tumor necrosis factor	Homo sapiens	108-117
11529904-12	2001	Topical budesonide attenuates this effect, suggesting the possibility that inhibitory effects on mucosal eotaxin may contribute to anti-eosinophilic actions of topical glucocorticosteroids.	Budesonide	8-18	C-C motif chemokine ligand 11	Homo sapiens	105-112
11415942-3	2001	We found that IL-13 upregulated eotaxin messenger RNA and protein synthesis in the airway epithelial cell line BEAS-2B; this effect showed synergy with tumor necrosis factor (TNF)-alpha and also was inhibited by the glucocorticoid budesonide.	Budesonide	231-241	interleukin 13	Homo sapiens	14-19
11415942-3	2001	We found that IL-13 upregulated eotaxin messenger RNA and protein synthesis in the airway epithelial cell line BEAS-2B; this effect showed synergy with tumor necrosis factor (TNF)-alpha and also was inhibited by the glucocorticoid budesonide.	Budesonide	231-241	C-C motif chemokine ligand 11	Homo sapiens	32-39
11491146-0	2001	Effects of formoterol and budesonide on GM-CSF and IL-8 secretion by triggered human bronchial epithelial cells.	Budesonide	26-36	colony stimulating factor 2	Homo sapiens	40-46
11491146-0	2001	Effects of formoterol and budesonide on GM-CSF and IL-8 secretion by triggered human bronchial epithelial cells.	Budesonide	26-36	C-X-C motif chemokine ligand 8	Homo sapiens	51-55
11491146-4	2001	Budesonide (10(-8) M) reduced the amounts of both cytokines (GM-CSF and IL-8) by 40%.	Budesonide	0-10	colony stimulating factor 2	Homo sapiens	61-67
11491146-4	2001	Budesonide (10(-8) M) reduced the amounts of both cytokines (GM-CSF and IL-8) by 40%.	Budesonide	0-10	C-X-C motif chemokine ligand 8	Homo sapiens	72-76
11491146-5	2001	Simultaneous addition of formoterol and budesonide reduced GM-CSF levels approximately 75%, while IL-8 levels were decreased approximately 40%, similar to the reduction obtained with budesonide alone.	Budesonide	40-50	colony stimulating factor 2	Homo sapiens	59-65
11491146-9	2001	In conclusion, the combination of budesonide and formoterol reduces the secretion of granulocyte macrophage-colony stimulating factor to basal levels and counteracts the capacity of formoterol alone to induce interleukin-8 production, modulations which may facilitate improved asthma control.	Budesonide	34-44	colony stimulating factor 2	Homo sapiens	85-133
11491146-9	2001	In conclusion, the combination of budesonide and formoterol reduces the secretion of granulocyte macrophage-colony stimulating factor to basal levels and counteracts the capacity of formoterol alone to induce interleukin-8 production, modulations which may facilitate improved asthma control.	Budesonide	34-44	C-X-C motif chemokine ligand 8	Homo sapiens	209-222
11421509-10	2001	In conclusion, adding the inhaled, long-acting beta2-agonist formoterol to low-moderate doses of the inhaled corticosteroid budesonide generated significant gains in all outcome measures with partial or complete offset of costs.	Budesonide	124-134	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	47-52
11549547-4	2001	Using a vector expressing murine interleukin-6 (mIL-6) as a marker cytokine for gene expression, we show that budesonide given around exposure to adenovirus to the lung significantly maintained high levels of expressed transgene protein in bronchoalveolar lavage fluid (BALF) after as many as four consecutive injections of virus at two weekly intervals (p = 0.02 versus saline).	Budesonide	110-120	interleukin 6	Mus musculus	33-46
11549547-4	2001	Using a vector expressing murine interleukin-6 (mIL-6) as a marker cytokine for gene expression, we show that budesonide given around exposure to adenovirus to the lung significantly maintained high levels of expressed transgene protein in bronchoalveolar lavage fluid (BALF) after as many as four consecutive injections of virus at two weekly intervals (p = 0.02 versus saline).	Budesonide	110-120	interleukin 6	Mus musculus	48-53
11549547-6	2001	In Week 4, transgene mIL-6 concentration was 2,327 +/- 955 pg/ml in budesonide compared with 336 +/- 246 pg/ml in saline-treated mice (p = 0.001).	Budesonide	68-78	interleukin 6	Mus musculus	21-26
11392584-1	2001	We investigated the effect of budesonide and nedocromil sodium on the secretion of IL-6 and IL-8 by cultured epithelial cells from healthy nasal mucosa and nasal polyps.	Budesonide	30-40	interleukin 6	Homo sapiens	83-87
11392584-3	2001	Budesonide inhibited FCS-induced IL-6 and IL-8 release in a dose-dependent manner.	Budesonide	0-10	interleukin 6	Homo sapiens	33-37
11392584-3	2001	Budesonide inhibited FCS-induced IL-6 and IL-8 release in a dose-dependent manner.	Budesonide	0-10	C-X-C motif chemokine ligand 8	Homo sapiens	42-46
11392584-4	2001	The IC25 (25% inhibitory concentration) of budesonide on IL-6 release was higher in nasal polyp than in nasal mucosa epithelial cells (34 nM vs. 200 pM).	Budesonide	43-53	interleukin 6	Homo sapiens	57-61
11392584-5	2001	The IC25 of budesonide on IL-8 release was higher in nasal mucosa than in nasal polyps (145 pM vs. 4 pM).	Budesonide	12-22	C-X-C motif chemokine ligand 8	Homo sapiens	26-30
11392584-8	2001	Budesonide and nedocromil sodium may exert their anti-inflammatory action in the respiratory mucosa by modulating the secretion of IL-6 and IL-8.	Budesonide	0-10	interleukin 6	Homo sapiens	131-135
11392584-8	2001	Budesonide and nedocromil sodium may exert their anti-inflammatory action in the respiratory mucosa by modulating the secretion of IL-6 and IL-8.	Budesonide	0-10	C-X-C motif chemokine ligand 8	Homo sapiens	140-144
11392584-9	2001	The different effect of budesonide and nedocromil sodium on IL-6 and IL-8 release may be explained by differences in the mechanisms which regulate the upregulation of these cytokines in inflammatory responses.	Budesonide	24-34	interleukin 6	Homo sapiens	60-64
11392584-9	2001	The different effect of budesonide and nedocromil sodium on IL-6 and IL-8 release may be explained by differences in the mechanisms which regulate the upregulation of these cytokines in inflammatory responses.	Budesonide	24-34	C-X-C motif chemokine ligand 8	Homo sapiens	69-73
11295658-14	2001	Budesonide inhibited this PAR-2 effect.	Budesonide	0-10	F2R like trypsin receptor 1	Homo sapiens	26-31
11289332-10	2001	CONCLUSIONS: Short-term high-dose budesonide therapy can be considered an alternative for children who are experiencing an acute asthma attack that is unresponsive to home management with regular use of an inhaled beta2 mimetic, yet who are not severe enough to hospitalize.	Budesonide	34-44	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	214-219
11258648-0	2001	Effects of topical budesonide treatment on glucocorticoid receptor mRNA down-regulation and cytokine patterns in nasal polyps.	Budesonide	19-29	nuclear receptor subfamily 3 group C member 1	Homo sapiens	43-66
11182010-11	2001	Only budesonide reduced the serum level of osteocalcin.	Budesonide	5-15	bone gamma-carboxyglutamate protein	Homo sapiens	43-54
11258648-1	2001	UNLABELLED: The effects of a topically applied corticosteroid, budesonide, on the expression of glucocorticoid receptor (GR) mRNA and regulation of pro-inflammatory cytokine patterns in patients with nasal polyps were evaluated.	Budesonide	63-73	nuclear receptor subfamily 3 group C member 1	Homo sapiens	96-119
11258648-1	2001	UNLABELLED: The effects of a topically applied corticosteroid, budesonide, on the expression of glucocorticoid receptor (GR) mRNA and regulation of pro-inflammatory cytokine patterns in patients with nasal polyps were evaluated.	Budesonide	63-73	nuclear receptor subfamily 3 group C member 1	Homo sapiens	121-123
11217872-1	2001	Current evidence suggests that the addition of the long acting inhaled beta2-agonist formoterol to low or moderate doses of the inhaled corticosteroid budesonide is effective in improving lung function and reducing the incidence of asthma exacerbations.	Budesonide	151-161	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	71-76
11146490-4	2001	Rats treated with budesonide did not develop edema following challenge with ovalbumin, and these animals showed a significant decrease in BAL fluid inflammatory cell numbers and eosinophil peroxidase and myeloperoxidase activities.	Budesonide	18-28	myeloperoxidase	Rattus norvegicus	204-219
11007238-1	2000	OBJECTIVE: This study was designed to evaluate the safety and estimate the efficacy of oral budesonide in patients with primary sclerosing cholangitis (PSC).	Budesonide	92-102	PSC	Homo sapiens	152-155
11112128-6	2000	Budesonide attenuated the allergen-induced increase in circulating eosinophils (4.0 +/- 0.4 x 10(5)/ml versus 6.5 +/- 0.7 x 10(5)/ml, p = 0.0001), circulating Eo/B CFU (12.4 +/- 2.3/10(6) NAMC versus 18.8 +/- 4.6/10(6) NAMC, p = 0.05), and immunolocalization of GM-CSF in Eo/B colony cells (11.8 +/- 1.9% positive versus 18.0 +/- 2.2%, p = 0.01) but not immunolocalization of IL-5 (7.9 +/- 1.4% versus 4.5 +/- 0.6%, p > 0.05).	Budesonide	0-10	colony stimulating factor 2	Homo sapiens	262-268
11112128-6	2000	Budesonide attenuated the allergen-induced increase in circulating eosinophils (4.0 +/- 0.4 x 10(5)/ml versus 6.5 +/- 0.7 x 10(5)/ml, p = 0.0001), circulating Eo/B CFU (12.4 +/- 2.3/10(6) NAMC versus 18.8 +/- 4.6/10(6) NAMC, p = 0.05), and immunolocalization of GM-CSF in Eo/B colony cells (11.8 +/- 1.9% positive versus 18.0 +/- 2.2%, p = 0.01) but not immunolocalization of IL-5 (7.9 +/- 1.4% versus 4.5 +/- 0.6%, p > 0.05).	Budesonide	0-10	interleukin 5	Homo sapiens	376-380
11112128-7	2000	Inhaled budesonide attenuated the number of allergen-induced circulating eosinophils and their progenitors grown in the presence of GM-CSF, which may partially be a result of regulating eosinophil progenitor expression of the autocrine growth factor GM-CSF.	Budesonide	8-18	colony stimulating factor 2	Homo sapiens	132-138
11112128-7	2000	Inhaled budesonide attenuated the number of allergen-induced circulating eosinophils and their progenitors grown in the presence of GM-CSF, which may partially be a result of regulating eosinophil progenitor expression of the autocrine growth factor GM-CSF.	Budesonide	8-18	colony stimulating factor 2	Homo sapiens	250-256
11129126-2	2000	In infants and young children with persistent asthma, day- and night-time symptom scores, and the number of days in which beta2-agonist bronchodilators were required, were significantly lower during randomised, double-blind treatment with budesonide inhalation suspension 0.5 to 2 mg/day than placebo in 3 multicentre trials.	Budesonide	239-249	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	122-127
11040338-7	2000	The results suggest that fluticasone and budesonide induce eosinophil apoptosis at clinically achievable drug concentrations via an effect on glucocorticoid receptor.	Budesonide	41-51	nuclear receptor subfamily 3 group C member 1	Homo sapiens	142-165
11029322-4	2000	We measured the modulation of expression of clonal designator (CD)11b and L-selectin with flow cytometry after 4 h or 16 h of culture of eosinophils when budesonide or formoterol was applied either directly to the eosinophils while they were stimulated with FCM (direct method) or when each drug was applied to lung fibroblasts from which conditioned medium was then administered to eosinophils (indirect method).	Budesonide	154-164	integrin subunit alpha M	Homo sapiens	63-69
11029322-5	2000	In the direct method, budesonide (10(-)(8) M) inhibited the modulation of CD11b (44 [25th to 75th percentiles: 26 to 66]% of control) and L-selectin (30 [-13 to 48]% of control) only after 16 h, and not after 4 h. Formoterol did not directly inhibit the modulation of eosinophil CD11b and L-selectin expression.	Budesonide	22-32	integrin subunit alpha M	Homo sapiens	74-79
11029322-5	2000	In the direct method, budesonide (10(-)(8) M) inhibited the modulation of CD11b (44 [25th to 75th percentiles: 26 to 66]% of control) and L-selectin (30 [-13 to 48]% of control) only after 16 h, and not after 4 h. Formoterol did not directly inhibit the modulation of eosinophil CD11b and L-selectin expression.	Budesonide	22-32	selectin L	Homo sapiens	138-148
11029322-5	2000	In the direct method, budesonide (10(-)(8) M) inhibited the modulation of CD11b (44 [25th to 75th percentiles: 26 to 66]% of control) and L-selectin (30 [-13 to 48]% of control) only after 16 h, and not after 4 h. Formoterol did not directly inhibit the modulation of eosinophil CD11b and L-selectin expression.	Budesonide	22-32	integrin subunit alpha M	Homo sapiens	279-284
11029322-5	2000	In the direct method, budesonide (10(-)(8) M) inhibited the modulation of CD11b (44 [25th to 75th percentiles: 26 to 66]% of control) and L-selectin (30 [-13 to 48]% of control) only after 16 h, and not after 4 h. Formoterol did not directly inhibit the modulation of eosinophil CD11b and L-selectin expression.	Budesonide	22-32	selectin L	Homo sapiens	289-299
11029322-6	2000	In the indirect method, both budesonide and formoterol inhibited lung fibroblast activation, resulting in diminished eosinophil activation after 4 h. Budesonide or formoterol at 10(-)(8) M inhibited upregulation of CD11b to 26 [15 to 40]% and 38 [23 to 46]%, respectively, and inhibited L-selectin shedding to 14 [-3 to 50]% and 27 [2 to 62]%, respectively, of control values.	Budesonide	29-39	integrin subunit alpha M	Homo sapiens	215-220
11029322-6	2000	In the indirect method, both budesonide and formoterol inhibited lung fibroblast activation, resulting in diminished eosinophil activation after 4 h. Budesonide or formoterol at 10(-)(8) M inhibited upregulation of CD11b to 26 [15 to 40]% and 38 [23 to 46]%, respectively, and inhibited L-selectin shedding to 14 [-3 to 50]% and 27 [2 to 62]%, respectively, of control values.	Budesonide	29-39	selectin L	Homo sapiens	287-297
11029322-6	2000	In the indirect method, both budesonide and formoterol inhibited lung fibroblast activation, resulting in diminished eosinophil activation after 4 h. Budesonide or formoterol at 10(-)(8) M inhibited upregulation of CD11b to 26 [15 to 40]% and 38 [23 to 46]%, respectively, and inhibited L-selectin shedding to 14 [-3 to 50]% and 27 [2 to 62]%, respectively, of control values.	Budesonide	150-160	integrin subunit alpha M	Homo sapiens	215-220
11029322-6	2000	In the indirect method, both budesonide and formoterol inhibited lung fibroblast activation, resulting in diminished eosinophil activation after 4 h. Budesonide or formoterol at 10(-)(8) M inhibited upregulation of CD11b to 26 [15 to 40]% and 38 [23 to 46]%, respectively, and inhibited L-selectin shedding to 14 [-3 to 50]% and 27 [2 to 62]%, respectively, of control values.	Budesonide	150-160	selectin L	Homo sapiens	287-297
11029322-7	2000	These results show that budesonide inhibits eosinophil activation primarily through effects on lung fibroblasts, presumably by inhibiting production of granulocyte-macrophage colony-stimulating factor.	Budesonide	24-34	colony stimulating factor 2	Homo sapiens	152-200
10988100-7	2000	Budesonide decreased ex vivo generation of IL-5 and IFN-gamma by BAL cells.	Budesonide	0-10	interleukin 5	Homo sapiens	43-47
11007238-2	2000	METHODS: Twenty-one patients with PSC were treated with 9 mg daily of oral budesonide for 1 yr.	Budesonide	75-85	PSC	Homo sapiens	34-37
10988100-7	2000	Budesonide decreased ex vivo generation of IL-5 and IFN-gamma by BAL cells.	Budesonide	0-10	interferon gamma	Homo sapiens	52-61
10988100-10	2000	Budesonide decreased circulating eosinophils and serum levels of IL-5, but did not reduce IL-5 generation by peripheral blood mononuclear cells.	Budesonide	0-10	interleukin 5	Homo sapiens	65-69
11007238-8	2000	CONCLUSIONS: Oral budesonide appears to be of minimal, if any, benefit and it is associated with a significant worsening of osteoporosis in patients with PSC.	Budesonide	18-28	PSC	Homo sapiens	154-157
10988100-12	2000	These findings suggest that long-term treatment with inhaled budesonide reduces airway cell generation of cytokines, specifically IL-5, which then decreases circulating eosinophils and their availability for recruitment to the airway after allergen exposure.	Budesonide	61-71	interleukin 5	Homo sapiens	130-134
10903904-5	2000	Both RT-PCR and FACS analysis showed that budesonide concomitantly attenuated IL-1beta mediated MUC2 gene as well as protein production levels.	Budesonide	42-52	interleukin 1 beta	Homo sapiens	78-86
10984373-11	2000	At the season peak, the budesonide-treated group had significantly lower nasal fluid eosinophil-derived neurotoxin, IL-5, and soluble intracellular adhesion molecule-1 levels.	Budesonide	24-34	interleukin 5	Homo sapiens	116-120
10984375-8	2000	Dexamethasone and budesonide (10(-6) to 10(-10) mmol) inhibited PAR-2-mediated MMP-9 release.	Budesonide	18-28	F2R like trypsin receptor 1	Homo sapiens	64-69
10984375-8	2000	Dexamethasone and budesonide (10(-6) to 10(-10) mmol) inhibited PAR-2-mediated MMP-9 release.	Budesonide	18-28	matrix metallopeptidase 9	Homo sapiens	79-84
10903904-5	2000	Both RT-PCR and FACS analysis showed that budesonide concomitantly attenuated IL-1beta mediated MUC2 gene as well as protein production levels.	Budesonide	42-52	mucin 2, oligomeric mucus/gel-forming	Homo sapiens	96-100
10903904-6	2000	Use of the glucocorticoid receptor antagonist, RU-486, restored the inhibitory effect of budesonide on the IL-1beta-mediated MUC2 protein as well as gene.	Budesonide	89-99	interleukin 1 beta	Homo sapiens	107-115
10903904-6	2000	Use of the glucocorticoid receptor antagonist, RU-486, restored the inhibitory effect of budesonide on the IL-1beta-mediated MUC2 protein as well as gene.	Budesonide	89-99	mucin 2, oligomeric mucus/gel-forming	Homo sapiens	125-129
10903904-7	2000	The data suggest that IL-1beta up-regulates MUC2 gene by transcriptional regulation and that budesonide suppresses the IL-1beta-medicated MUC2 expression via decreased transcriptional activation.	Budesonide	93-103	interleukin 1 beta	Homo sapiens	119-127
10903904-7	2000	The data suggest that IL-1beta up-regulates MUC2 gene by transcriptional regulation and that budesonide suppresses the IL-1beta-medicated MUC2 expression via decreased transcriptional activation.	Budesonide	93-103	mucin 2, oligomeric mucus/gel-forming	Homo sapiens	138-142
10903220-7	2000	The rank order of trans-repression potencies in A549 lung cells transiently transfected with an AP-1- or NF-kappaB-dependent luciferase gene was fluticasone propionate > budesonide > beclomethasone dipropionate, triamcinolone acetonide, and flunisolide.	Budesonide	173-183	JunB proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	96-100
10903220-7	2000	The rank order of trans-repression potencies in A549 lung cells transiently transfected with an AP-1- or NF-kappaB-dependent luciferase gene was fluticasone propionate > budesonide > beclomethasone dipropionate, triamcinolone acetonide, and flunisolide.	Budesonide	173-183	nuclear factor kappa B subunit 1	Homo sapiens	105-114
10837366-4	2000	Budesonide, hydrocortisone, and prednisolone, but not the sex steroids testosterone and progesterone, reduced CD11b and CD49d cell-surface expression to a similar extent.	Budesonide	0-10	integrin subunit alpha M	Homo sapiens	110-115
10837366-4	2000	Budesonide, hydrocortisone, and prednisolone, but not the sex steroids testosterone and progesterone, reduced CD11b and CD49d cell-surface expression to a similar extent.	Budesonide	0-10	integrin subunit alpha 4	Homo sapiens	120-125
10945311-2	2000	Ketoconazole is a potent inhibitor of the cytochrome P450 3A (CYP3A) activities and known to inhibit the elimination of drugs metabolized by CYP3A, including budesonide.	Budesonide	158-168	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	62-67
10945311-2	2000	Ketoconazole is a potent inhibitor of the cytochrome P450 3A (CYP3A) activities and known to inhibit the elimination of drugs metabolized by CYP3A, including budesonide.	Budesonide	158-168	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	141-146
10926339-12	2000	The change was even more marked with regard to serum EPX (P=0.005; high vs. low dose budesonide).	Budesonide	85-95	eosinophil peroxidase	Homo sapiens	53-56
10553092-2	1999	We investigated whether cytokines and the topical glucocorticoid budesonide differentially regulate RANTES, monocyte chemoattractant protein-4 (MCP-4), and eotaxin mRNA and protein expression in the human bronchial epithelial cell line BEAS-2B and in primary human bronchial epithelial cells by Northern blot analysis and ELISAs.	Budesonide	65-75	C-C motif chemokine ligand 5	Homo sapiens	100-106
10940797-6	2000	Within the budesonide group, there was a decrease in IL2 receptor-activated T-helper lymphocytes and an improvement in FEV(1).	Budesonide	11-21	interleukin 2	Homo sapiens	53-56
10805216-5	2000	IFN-gamma as well as the GCs, Dexamethasone and Budesonide, inhibited TNF-alpha induced IL-8 secretion in a dose-dependent manner.	Budesonide	48-58	tumor necrosis factor	Homo sapiens	70-79
10805216-5	2000	IFN-gamma as well as the GCs, Dexamethasone and Budesonide, inhibited TNF-alpha induced IL-8 secretion in a dose-dependent manner.	Budesonide	48-58	C-X-C motif chemokine ligand 8	Homo sapiens	88-92
10678623-0	2000	Budesonide and formoterol inhibit ICAM-1 and VCAM-1 expression of human lung fibroblasts.	Budesonide	0-10	intercellular adhesion molecule 1	Homo sapiens	34-40
10678623-0	2000	Budesonide and formoterol inhibit ICAM-1 and VCAM-1 expression of human lung fibroblasts.	Budesonide	0-10	vascular cell adhesion molecule 1	Homo sapiens	45-51
10718988-3	2000	In the presence of different concentrations of budesonide (0.1-100 nM), we tested: a) eosinophil migration induced by C5a through HBEC monolayers; b) ICAM-1 expression on HBECs, stimulated with C5a and c) LFA-1 and Mac-1 expression on eosinophils, stimulated with C5a or with ah-CD23 mabs plus GM-CSF.	Budesonide	47-57	complement C5a receptor 1	Homo sapiens	118-121
10718988-3	2000	In the presence of different concentrations of budesonide (0.1-100 nM), we tested: a) eosinophil migration induced by C5a through HBEC monolayers; b) ICAM-1 expression on HBECs, stimulated with C5a and c) LFA-1 and Mac-1 expression on eosinophils, stimulated with C5a or with ah-CD23 mabs plus GM-CSF.	Budesonide	47-57	intercellular adhesion molecule 1	Homo sapiens	150-156
10718988-4	2000	Eosinophils showed a remarkable chemotactic response to C5a (P<0.001), that was effectively down-regulated by the presence in the chemotactic chambers of budesonide at all the concentrations tested (P<0.05).	Budesonide	157-167	complement C5a receptor 1	Homo sapiens	56-59
10718988-6	2000	Preincubation of the cells with different concentrations of budesonide was also effective in down-regulating the C5a-induced ICAM-1 expression on HBECs and the ah-CD23 and GM-CSF-induced LFA-1 and Mac-1 expression on eosinophils.	Budesonide	60-70	complement C5a receptor 1	Homo sapiens	113-116
10718988-6	2000	Preincubation of the cells with different concentrations of budesonide was also effective in down-regulating the C5a-induced ICAM-1 expression on HBECs and the ah-CD23 and GM-CSF-induced LFA-1 and Mac-1 expression on eosinophils.	Budesonide	60-70	intercellular adhesion molecule 1	Homo sapiens	125-131
10718988-6	2000	Preincubation of the cells with different concentrations of budesonide was also effective in down-regulating the C5a-induced ICAM-1 expression on HBECs and the ah-CD23 and GM-CSF-induced LFA-1 and Mac-1 expression on eosinophils.	Budesonide	60-70	Fc epsilon receptor II	Homo sapiens	163-167
10718988-6	2000	Preincubation of the cells with different concentrations of budesonide was also effective in down-regulating the C5a-induced ICAM-1 expression on HBECs and the ah-CD23 and GM-CSF-induced LFA-1 and Mac-1 expression on eosinophils.	Budesonide	60-70	colony stimulating factor 2	Homo sapiens	172-178
10718988-6	2000	Preincubation of the cells with different concentrations of budesonide was also effective in down-regulating the C5a-induced ICAM-1 expression on HBECs and the ah-CD23 and GM-CSF-induced LFA-1 and Mac-1 expression on eosinophils.	Budesonide	60-70	integrin subunit alpha L	Homo sapiens	187-192
10718988-6	2000	Preincubation of the cells with different concentrations of budesonide was also effective in down-regulating the C5a-induced ICAM-1 expression on HBECs and the ah-CD23 and GM-CSF-induced LFA-1 and Mac-1 expression on eosinophils.	Budesonide	60-70	integrin subunit alpha M	Homo sapiens	197-202
10553092-2	1999	We investigated whether cytokines and the topical glucocorticoid budesonide differentially regulate RANTES, monocyte chemoattractant protein-4 (MCP-4), and eotaxin mRNA and protein expression in the human bronchial epithelial cell line BEAS-2B and in primary human bronchial epithelial cells by Northern blot analysis and ELISAs.	Budesonide	65-75	C-C motif chemokine ligand 13	Homo sapiens	108-142
10553092-2	1999	We investigated whether cytokines and the topical glucocorticoid budesonide differentially regulate RANTES, monocyte chemoattractant protein-4 (MCP-4), and eotaxin mRNA and protein expression in the human bronchial epithelial cell line BEAS-2B and in primary human bronchial epithelial cells by Northern blot analysis and ELISAs.	Budesonide	65-75	C-C motif chemokine ligand 13	Homo sapiens	144-149
10553092-2	1999	We investigated whether cytokines and the topical glucocorticoid budesonide differentially regulate RANTES, monocyte chemoattractant protein-4 (MCP-4), and eotaxin mRNA and protein expression in the human bronchial epithelial cell line BEAS-2B and in primary human bronchial epithelial cells by Northern blot analysis and ELISAs.	Budesonide	65-75	C-C motif chemokine ligand 11	Homo sapiens	156-163
10553092-7	1999	Although budesonide inhibited the expression of chemokine mRNA to a variable extent, it effectively inhibited production of eotaxin and RANTES protein.	Budesonide	9-19	C-C motif chemokine ligand 11	Homo sapiens	124-131
10553092-7	1999	Although budesonide inhibited the expression of chemokine mRNA to a variable extent, it effectively inhibited production of eotaxin and RANTES protein.	Budesonide	9-19	C-C motif chemokine ligand 5	Homo sapiens	136-142
10553092-8	1999	Budesonide inhibited both RANTES- and eotaxin promoter-driven reporter gene activity.	Budesonide	0-10	C-C motif chemokine ligand 5	Homo sapiens	26-32
10553092-8	1999	Budesonide inhibited both RANTES- and eotaxin promoter-driven reporter gene activity.	Budesonide	0-10	C-C motif chemokine ligand 11	Homo sapiens	38-45
10553092-9	1999	Budesonide also selectively accelerated the decay of eotaxin and MCP-4 mRNA.	Budesonide	0-10	C-C motif chemokine ligand 11	Homo sapiens	53-60
10553092-9	1999	Budesonide also selectively accelerated the decay of eotaxin and MCP-4 mRNA.	Budesonide	0-10	C-C motif chemokine ligand 13	Homo sapiens	65-70
10442524-10	1999	In conclusion, budesonide and fluticasone propionate, in concentrations that probably occur in the airway lining fluid during inhalational therapy, inhibited cytokine release from human lung epithelial cells (IL-6, IL-8) and alveolar macrophages (TNF-alpha, IL-6, IL-8).	Budesonide	15-25	interleukin 6	Homo sapiens	209-213
10495335-5	1999	Budesonide suspension, 0.5 mg mL-1, 2 mL, was used.	Budesonide	0-10	L1 cell adhesion molecule	Mus musculus	30-40
10565558-3	1999	IL-5 levels and relative eosinophil counts in nasal lavage fluid increased significantly in patients with allergic rhinitis during the pollen season, compared with values obtained before the start of the season, and decreased significantly after treatment with budesonide.	Budesonide	261-271	interleukin 5	Homo sapiens	0-4
10565558-6	1999	After budesonide treatment, the correlation between IL-8 and neutrophils remained, and a correlation between IL-8 and eosinophils emerged.	Budesonide	6-16	C-X-C motif chemokine ligand 8	Homo sapiens	52-56
10565558-6	1999	After budesonide treatment, the correlation between IL-8 and neutrophils remained, and a correlation between IL-8 and eosinophils emerged.	Budesonide	6-16	C-X-C motif chemokine ligand 8	Homo sapiens	109-113
10442524-10	1999	In conclusion, budesonide and fluticasone propionate, in concentrations that probably occur in the airway lining fluid during inhalational therapy, inhibited cytokine release from human lung epithelial cells (IL-6, IL-8) and alveolar macrophages (TNF-alpha, IL-6, IL-8).	Budesonide	15-25	C-X-C motif chemokine ligand 8	Homo sapiens	215-219
10442524-10	1999	In conclusion, budesonide and fluticasone propionate, in concentrations that probably occur in the airway lining fluid during inhalational therapy, inhibited cytokine release from human lung epithelial cells (IL-6, IL-8) and alveolar macrophages (TNF-alpha, IL-6, IL-8).	Budesonide	15-25	tumor necrosis factor	Homo sapiens	247-256
10442524-10	1999	In conclusion, budesonide and fluticasone propionate, in concentrations that probably occur in the airway lining fluid during inhalational therapy, inhibited cytokine release from human lung epithelial cells (IL-6, IL-8) and alveolar macrophages (TNF-alpha, IL-6, IL-8).	Budesonide	15-25	interleukin 6	Homo sapiens	258-262
10442524-10	1999	In conclusion, budesonide and fluticasone propionate, in concentrations that probably occur in the airway lining fluid during inhalational therapy, inhibited cytokine release from human lung epithelial cells (IL-6, IL-8) and alveolar macrophages (TNF-alpha, IL-6, IL-8).	Budesonide	15-25	C-X-C motif chemokine ligand 8	Homo sapiens	264-268
10367823-13	1999	Fewer beta2-agonist activations were used at the end of the trial by patients receiving budesonide (2.4/d vs 4.2/d; P=.01).	Budesonide	88-98	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	6-11
10433506-0	1999	IL-2 and IL-4 counteract budesonide inhibition of GM-CSF and IL-10, but not of IL-8, IL-12 or TNF-alpha production by human mononuclear blood cells.	Budesonide	25-35	interleukin 4	Homo sapiens	9-13
10433506-0	1999	IL-2 and IL-4 counteract budesonide inhibition of GM-CSF and IL-10, but not of IL-8, IL-12 or TNF-alpha production by human mononuclear blood cells.	Budesonide	25-35	interleukin 2	Homo sapiens	0-4
10335001-8	1999	RESULTS: Budesonide increased GR activity (p<0.05) and decreased NFkappaB activity (p<0.05).	Budesonide	9-19	nuclear factor kappa B subunit 1	Homo sapiens	68-76
10228111-5	1999	Budesonide inhalation significantly attenuated the allergen-induced early and late asthmatic responses, degree of increase in sputum and blood eosinophils, as well as the baseline numbers of total bone marrow CD34(+) cells (p < 0.05), CD34(+)IL-3Ralpha+ cells (p < 0.01) and IL-5-responsive Eo/B-CFU (p < 0.05).	Budesonide	0-10	CD34 molecule	Homo sapiens	209-213
10228111-5	1999	Budesonide inhalation significantly attenuated the allergen-induced early and late asthmatic responses, degree of increase in sputum and blood eosinophils, as well as the baseline numbers of total bone marrow CD34(+) cells (p < 0.05), CD34(+)IL-3Ralpha+ cells (p < 0.01) and IL-5-responsive Eo/B-CFU (p < 0.05).	Budesonide	0-10	CD34 molecule	Homo sapiens	238-242
10228111-5	1999	Budesonide inhalation significantly attenuated the allergen-induced early and late asthmatic responses, degree of increase in sputum and blood eosinophils, as well as the baseline numbers of total bone marrow CD34(+) cells (p < 0.05), CD34(+)IL-3Ralpha+ cells (p < 0.01) and IL-5-responsive Eo/B-CFU (p < 0.05).	Budesonide	0-10	interleukin 3 receptor subunit alpha	Homo sapiens	245-255
10228111-5	1999	Budesonide inhalation significantly attenuated the allergen-induced early and late asthmatic responses, degree of increase in sputum and blood eosinophils, as well as the baseline numbers of total bone marrow CD34(+) cells (p < 0.05), CD34(+)IL-3Ralpha+ cells (p < 0.01) and IL-5-responsive Eo/B-CFU (p < 0.05).	Budesonide	0-10	interleukin 5	Homo sapiens	281-285
10344474-1	1999	OBJECTIVE: The potency of budesonide, beclomethasone dipropionate (BDP), dexamethasone, hydrocortisone and tixocortol pivalate as inhibitors of interleukin-5 (IL-5) and interferon-gamma (IFNgamma) release from human bronchoalveolar lavage cells in vitro were compared.	Budesonide	26-36	interleukin 5	Homo sapiens	144-157
10464891-0	1999	Serum leptin in children with asthma treated with inhaled budesonide.	Budesonide	58-68	leptin	Homo sapiens	6-12
10464891-3	1999	In this study, we aimed to assess serum leptin in children with asthma treated with inhaled budesonide 800 micrograms day-1.	Budesonide	92-102	leptin	Homo sapiens	40-46
10085100-2	1999	Utilizing Northern dot blot analysis and a quantitative reverse transcription-polymerase chain reaction protocol for IL-1R1 and IL-1R2, dexamethasone and, in particular, the budesonide epimer R were shown to effectively and rapidly induce transcription from the IL-IR2 gene when compared with IL-1R1 or beta-actin RNA message levels in the same sample.	Budesonide	174-184	interleukin 1 receptor type 1	Homo sapiens	117-123
10085100-2	1999	Utilizing Northern dot blot analysis and a quantitative reverse transcription-polymerase chain reaction protocol for IL-1R1 and IL-1R2, dexamethasone and, in particular, the budesonide epimer R were shown to effectively and rapidly induce transcription from the IL-IR2 gene when compared with IL-1R1 or beta-actin RNA message levels in the same sample.	Budesonide	174-184	interleukin 1 receptor type 2	Homo sapiens	128-134
10085100-2	1999	Utilizing Northern dot blot analysis and a quantitative reverse transcription-polymerase chain reaction protocol for IL-1R1 and IL-1R2, dexamethasone and, in particular, the budesonide epimer R were shown to effectively and rapidly induce transcription from the IL-IR2 gene when compared with IL-1R1 or beta-actin RNA message levels in the same sample.	Budesonide	174-184	interleukin 1 receptor type 1	Homo sapiens	293-299
10085100-2	1999	Utilizing Northern dot blot analysis and a quantitative reverse transcription-polymerase chain reaction protocol for IL-1R1 and IL-1R2, dexamethasone and, in particular, the budesonide epimer R were shown to effectively and rapidly induce transcription from the IL-IR2 gene when compared with IL-1R1 or beta-actin RNA message levels in the same sample.	Budesonide	174-184	POTE ankyrin domain family member F	Homo sapiens	303-313
10085100-5	1999	Parallel time course kinetic analysis of IL-1R2 RNA message levels with Western immunoblotting revealed tight coupling of de novo IL-IR2 gene transcription with translation of the IL-1R2 RNA message; a newly synthesized ( approximately 46-kDa) IL-1R2 protein was detected in the HEK growth medium as early as 1 h after budesonide epimer R treatment.	Budesonide	319-329	interleukin 1 receptor type 2	Homo sapiens	180-186
10085100-5	1999	Parallel time course kinetic analysis of IL-1R2 RNA message levels with Western immunoblotting revealed tight coupling of de novo IL-IR2 gene transcription with translation of the IL-1R2 RNA message; a newly synthesized ( approximately 46-kDa) IL-1R2 protein was detected in the HEK growth medium as early as 1 h after budesonide epimer R treatment.	Budesonide	319-329	interleukin 1 receptor type 2	Homo sapiens	180-186
10030836-5	1999	We also investigated the effect of the topical corticosteroid budesonide on the numbers of CD34(+) cells and vessels in nasal polyps.	Budesonide	62-72	CD34 molecule	Homo sapiens	91-95
10084466-0	1999	A bolus of inhaled budesonide rapidly reverses airway subsensitivity and beta2-adrenoceptor down-regulation after regular inhaled formoterol.	Budesonide	19-29	adrenoceptor beta 2	Homo sapiens	73-91
10084466-14	1999	CONCLUSION: We have shown that a bolus dose of inhaled budesonide rapidly reverses subsensitivity to AMP bronchoprotection and associated beta2-adrenoceptor down-regulation in asthmatics taking regular formoterol.	Budesonide	55-65	adrenoceptor beta 2	Homo sapiens	138-156
10433506-0	1999	IL-2 and IL-4 counteract budesonide inhibition of GM-CSF and IL-10, but not of IL-8, IL-12 or TNF-alpha production by human mononuclear blood cells.	Budesonide	25-35	colony stimulating factor 2	Homo sapiens	50-56
10433506-0	1999	IL-2 and IL-4 counteract budesonide inhibition of GM-CSF and IL-10, but not of IL-8, IL-12 or TNF-alpha production by human mononuclear blood cells.	Budesonide	25-35	interleukin 10	Homo sapiens	61-66
10433506-9	1999	GM-CSF production was totally inhibited by budesonide at 10(-8) M in vehicle treated cultures, while IL-10 was inhibited to 33.4+/-4.3% of control.	Budesonide	43-53	colony stimulating factor 2	Homo sapiens	0-6
10433506-10	1999	IL-2, IL-4, or IL-2 + IL-4 reduced the inhibitory effects of budesonide on GM-CSF to similar levels (23.7 6.7, 31.6+/-8.5 and 35.1+/-4.3% of control, respectively).	Budesonide	61-71	interleukin 2	Homo sapiens	0-4
10433506-10	1999	IL-2, IL-4, or IL-2 + IL-4 reduced the inhibitory effects of budesonide on GM-CSF to similar levels (23.7 6.7, 31.6+/-8.5 and 35.1+/-4.3% of control, respectively).	Budesonide	61-71	interleukin 4	Homo sapiens	6-10
10433506-10	1999	IL-2, IL-4, or IL-2 + IL-4 reduced the inhibitory effects of budesonide on GM-CSF to similar levels (23.7 6.7, 31.6+/-8.5 and 35.1+/-4.3% of control, respectively).	Budesonide	61-71	interleukin 2	Homo sapiens	15-19
10433506-10	1999	IL-2, IL-4, or IL-2 + IL-4 reduced the inhibitory effects of budesonide on GM-CSF to similar levels (23.7 6.7, 31.6+/-8.5 and 35.1+/-4.3% of control, respectively).	Budesonide	61-71	interleukin 4	Homo sapiens	22-26
10433506-10	1999	IL-2, IL-4, or IL-2 + IL-4 reduced the inhibitory effects of budesonide on GM-CSF to similar levels (23.7 6.7, 31.6+/-8.5 and 35.1+/-4.3% of control, respectively).	Budesonide	61-71	colony stimulating factor 2	Homo sapiens	75-81
10433506-11	1999	IL-2, IL-4, or IL-2 + IL-4 also reduced the inhibitory effects of budesonide on IL-10 production (46.5+/-6.6, 55.9+/-7.3%, and 68.3+/-9.9% of control, respectively).	Budesonide	66-76	interleukin 2	Homo sapiens	0-4
10433506-11	1999	IL-2, IL-4, or IL-2 + IL-4 also reduced the inhibitory effects of budesonide on IL-10 production (46.5+/-6.6, 55.9+/-7.3%, and 68.3+/-9.9% of control, respectively).	Budesonide	66-76	interleukin 4	Homo sapiens	6-10
10433506-11	1999	IL-2, IL-4, or IL-2 + IL-4 also reduced the inhibitory effects of budesonide on IL-10 production (46.5+/-6.6, 55.9+/-7.3%, and 68.3+/-9.9% of control, respectively).	Budesonide	66-76	interleukin 2	Homo sapiens	15-19
10433506-11	1999	IL-2, IL-4, or IL-2 + IL-4 also reduced the inhibitory effects of budesonide on IL-10 production (46.5+/-6.6, 55.9+/-7.3%, and 68.3+/-9.9% of control, respectively).	Budesonide	66-76	interleukin 4	Homo sapiens	22-26
10433506-11	1999	IL-2, IL-4, or IL-2 + IL-4 also reduced the inhibitory effects of budesonide on IL-10 production (46.5+/-6.6, 55.9+/-7.3%, and 68.3+/-9.9% of control, respectively).	Budesonide	66-76	interleukin 10	Homo sapiens	80-85
10433509-6	1999	The topically active steroids fluticasone propionate (EC50= 1.8 x 10(-11) M) and budesonide (EC50=5.0 x 10(-11) M) were more potent in inhibiting GM-CSF release from A549 cells than tipredane (EC50 = 8.3 x 10(-10)) M), butixicort (EC50 = 3.7 x 10(-8) M) and dexamethasone (EC50 = 2.2 x 10(-9) M).	Budesonide	81-91	colony stimulating factor 2	Homo sapiens	146-152
10380744-0	1999	Topical budesonide treatment reduces endothelial expression of intercellular adhesion molecules (vascular cell adhesion molecule-1 and P-selectin) and eosinophil infiltration in nasal polyps.	Budesonide	8-18	vascular cell adhesion molecule 1	Homo sapiens	97-130
10380744-0	1999	Topical budesonide treatment reduces endothelial expression of intercellular adhesion molecules (vascular cell adhesion molecule-1 and P-selectin) and eosinophil infiltration in nasal polyps.	Budesonide	8-18	selectin P	Homo sapiens	135-145
9855636-3	1998	In this study, we evaluated the effect of the glucocorticoid budesonide on the constitutive expression of SCF by human lung fibroblasts in primary culture.	Budesonide	61-71	KIT ligand	Homo sapiens	106-109
11424740-3	1999	We speculated that the relatively small inhibitory effect of budesonide on the survival of NP-EOS could be the result of these EOS being exposed to substantial amounts of GM-CSF, IL-5 or IL-3.	Budesonide	61-71	colony stimulating factor 2	Homo sapiens	171-177
11424740-3	1999	We speculated that the relatively small inhibitory effect of budesonide on the survival of NP-EOS could be the result of these EOS being exposed to substantial amounts of GM-CSF, IL-5 or IL-3.	Budesonide	61-71	interleukin 5	Homo sapiens	179-183
11424740-3	1999	We speculated that the relatively small inhibitory effect of budesonide on the survival of NP-EOS could be the result of these EOS being exposed to substantial amounts of GM-CSF, IL-5 or IL-3.	Budesonide	61-71	interleukin 3	Homo sapiens	187-191
10095821-8	1999	RESULTS: Following administration of 800 micrograms day-1 of inhaled budesonide, there was an increase in the mean FEV1 from 1.40 +/- 0.20 to 1.92 +/- 0.22 L (P < 0.001) and a significant decrease in inhaled beta 2 agonist consumption in group A.	Budesonide	69-79	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	211-217
10384060-3	1999	The aim of our study was to evaluate in vitro the activity of budesonide on blood eosinophils by measuring their chemotactic response, eosinophil cationic protein (ECP) release, and hydrogen peroxide (H2O2) production in the presence of different drug concentrations similar to those obtained at airway level (10(-8) and 10(-7) M) and at blood level (10(-10) and 10(-9) M).	Budesonide	62-72	ribonuclease A family member 3	Homo sapiens	135-162
10384060-4	1999	Partially purified blood eosinophils, isolated from 23 asthmatic subjects, were used to evaluate the activity of budesonide on: (1) chemotaxis toward the activated fifth component of complement (C5a, 0.1 microg/ml) or recombinant human (rh) interleukin (IL)-5 (200 pg/ml), (2) ECP release by cells stimulated with tetradecanoylphorbol acetate (TPA) and (3) H2O2 production by TPA-activated cells.	Budesonide	113-123	complement C5a receptor 1	Homo sapiens	195-198
10384060-5	1999	The chemotactic response to C5a was down-regulated significantly by budesonide only by the highest concentrations tested (10(-8) and 10(-7) M); differently, budesonide was effective in inhibiting eosinophil migration toward rhIL-5, at all concentrations tested (p < 0.01, each comparison).	Budesonide	68-78	complement C5a receptor 1	Homo sapiens	28-31
10384060-5	1999	The chemotactic response to C5a was down-regulated significantly by budesonide only by the highest concentrations tested (10(-8) and 10(-7) M); differently, budesonide was effective in inhibiting eosinophil migration toward rhIL-5, at all concentrations tested (p < 0.01, each comparison).	Budesonide	157-167	complement C5a receptor 1	Homo sapiens	28-31
9855636-4	1998	Budesonide (0.1 microM) induced a time-dependent biphasic effect on SCF mRNA and protein production.	Budesonide	0-10	KIT ligand	Homo sapiens	68-71
9754979-11	1998	CONCLUSION: Concomitant therapy with inhaled budesonide resensitised the cardiac beta2-adrenoceptor response to salbutamol in subjects who were receiving regular twice-daily eformoterol.	Budesonide	45-55	adrenoceptor beta 2	Homo sapiens	81-99
9811532-10	1998	The maximal inhibitory effect of budesonide was seen at 10(-8) M. The inhibition of IL-12 production was significantly higher than the inhibition of GM-CSF (P<0.01) or IL-1beta (P<0.001).	Budesonide	33-43	colony stimulating factor 2	Homo sapiens	149-155
9811532-10	1998	The maximal inhibitory effect of budesonide was seen at 10(-8) M. The inhibition of IL-12 production was significantly higher than the inhibition of GM-CSF (P<0.01) or IL-1beta (P<0.001).	Budesonide	33-43	interleukin 1 beta	Homo sapiens	171-179
9836146-4	1998	In the gastrocnemius muscle, both the alpha and beta glucocorticoid receptor mRNA forms were detected and found to be downregulated four hours after the budesonide instillation.	Budesonide	153-163	nuclear receptor subfamily 3, group C, member 1	Rattus norvegicus	53-76
9836146-8	1998	In conclusion, after intra-tracheal instillation of budesonide, both alpha and beta glucocorticoid receptor forms were downregulated in muscle tissue.	Budesonide	52-62	nuclear receptor subfamily 3, group C, member 1	Rattus norvegicus	84-107
9721148-9	1998	More than 90% of all budesonide patients had a normal adrenocorticotropin (ACTH)-stimulated cortisol response at the last visit.	Budesonide	21-31	proopiomelanocortin	Homo sapiens	75-79
9814730-8	1998	In the adolescent group reduced levels of osteocalcin were seen during budesonide treatment.	Budesonide	71-81	bone gamma-carboxyglutamate protein	Homo sapiens	42-53
9726641-1	1998	We studied the effect of the glucocorticoids, dexamethasone and budesonide, on the interleukin-1beta-induced increase of bradykinin B2 receptors in cultured human bronchial smooth muscle cells, a cellular model of bronchial hyperreactivity.	Budesonide	64-74	interleukin 1 beta	Homo sapiens	83-100
9726641-1	1998	We studied the effect of the glucocorticoids, dexamethasone and budesonide, on the interleukin-1beta-induced increase of bradykinin B2 receptors in cultured human bronchial smooth muscle cells, a cellular model of bronchial hyperreactivity.	Budesonide	64-74	kininogen 1	Homo sapiens	121-131
9701427-1	1998	We assessed the effect of long-term treatment with inhaled budesonide (BUD) on the occurrence of posterior subcapsular cataracts (PSC), bruises and hoarseness in children with asthma.	Budesonide	59-69	PSC	Homo sapiens	130-133
9701427-1	1998	We assessed the effect of long-term treatment with inhaled budesonide (BUD) on the occurrence of posterior subcapsular cataracts (PSC), bruises and hoarseness in children with asthma.	Budesonide	71-74	PSC	Homo sapiens	130-133
9795066-1	1998	Glucocorticoid receptor-ligand binding kinetics of budesonide, a glucocorticoid used for inhalation therapy, were determined and compared with dexamethasone and fluticasone propionate using glucocorticoid receptors from human lung tissue.	Budesonide	51-61	nuclear receptor subfamily 3 group C member 1	Homo sapiens	0-23
9864001-9	1998	In conclusion inhaled budesonide can lead to improvements in noninvasive markers of airway inflammation, in association with a small improvement in lung function, even in mildly asthmatic patients who require an inhaled beta2-agonist less than once daily.	Budesonide	22-32	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	220-225
9795066-0	1998	Binding kinetics of budesonide to the human glucocorticoid receptor.	Budesonide	20-30	nuclear receptor subfamily 3 group C member 1	Homo sapiens	44-67
9627589-4	1998	RESULTS: Patients in each of the three budesonide treatment groups showed significant dose-related improvements in lung function (morning peak expiratory flow and FEV1), in asthma symptoms, and with a significant decrease in inhaled beta 2-agonist use in comparison with placebo.	Budesonide	39-49	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	233-239
9655217-8	1998	In conclusion, topical budesonide treatment seems to downregulate ICAM-1 expression on the vascular endothelium in nasal polyps.	Budesonide	23-33	intercellular adhesion molecule 1	Homo sapiens	66-72
9657565-8	1998	Nasal brush eosinophils and nasal lavage fluid levels of eosinophil cationic protein as well as blood eosinophils were increased during the season (p<0.05), but these increases were prevented by the inhaled budesonide.	Budesonide	210-220	ribonuclease A family member 3	Homo sapiens	57-84
9520467-0	1998	Budesonide epimer R or dexamethasone selectively inhibit platelet-activating factor-induced or interleukin 1beta-induced DNA binding activity of cis-acting transcription factors and cyclooxygenase-2 gene expression in human epidermal keratinocytes.	Budesonide	0-10	interleukin 1 beta	Homo sapiens	95-112
9814730-0	1998	Differential effects of inhaled budesonide on serum osteocalcin in children and adolescents with asthma.	Budesonide	32-42	bone gamma-carboxyglutamate protein	Homo sapiens	52-63
9574878-14	1998	Only budesonide reduced allergen-challenge-induced increments of albumin levels in postchallenge nasal lavage fluids (P<0.05, in comparison with placebo).	Budesonide	5-15	albumin	Homo sapiens	65-72
9520467-0	1998	Budesonide epimer R or dexamethasone selectively inhibit platelet-activating factor-induced or interleukin 1beta-induced DNA binding activity of cis-acting transcription factors and cyclooxygenase-2 gene expression in human epidermal keratinocytes.	Budesonide	0-10	prostaglandin-endoperoxide synthase 2	Homo sapiens	182-198
9777883-0	1998	Effects of beta2-agonists and budesonide on interleukin-1beta and leukotriene B4 secretion: studies of human monocytes and alveolar macrophages.	Budesonide	30-40	interleukin 1 beta	Homo sapiens	44-61
9517606-9	1998	Budesonide decreased serum IL-8 from 9.2 +/- 3.7 to 6.2 +/- 2.1 pg/ml (p < 0.001).	Budesonide	0-10	C-X-C motif chemokine ligand 8	Homo sapiens	27-31
9777883-1	1998	The aims of the present study were to determine whether beta2-agonists (short- and long-acting) and a glucocorticoid (budesonide) influence the secretion of a pro-inflammatory cytokine (interleukin-1, [IL-1]) and a granulocyte attractant (leukotriene B4 [LTB4]) and to compare these effects on blood monocyte and alveolar macrophages.	Budesonide	118-128	interleukin 1 alpha	Homo sapiens	186-207
9777883-3	1998	The influence of four beta2-agonists (salbutamol, terbutaline, formoterol, and salmeterol) and a corticosteroid (budesonide) on the release of interleukin-1beta (IL-1beta) and LTB4 was studied in a dose-response manner (10(-8)-10(-5) mol/L for beta2-agonists and 10(-10)-10(-6) mol/ L for budesonide).	Budesonide	113-123	interleukin 1 beta	Homo sapiens	143-160
9777883-5	1998	Budesonide significantly inhibited the release of IL-1beta from blood monocytes (p < 0.001), but no such effect was observed in alveolar macrophages.	Budesonide	0-10	interleukin 1 beta	Homo sapiens	50-58
9777883-8	1998	In conclusion, beta2-agonists exhibited only minor effects on IL-1beta secretion from blood monocytes and no effect on LTB4-secretion from either cell type, and budesonide effectively inhibited the IL-1beta release in blood monocytes, but not in alveolar macrophages.	Budesonide	161-171	interleukin 1 beta	Homo sapiens	198-206
8886853-5	1996	The percentage of CD56+ NK cells tended to increase after pre-incubation with a high inhibiting concentration of budesonide, prednisolone, and cortisol.	Budesonide	113-123	neural cell adhesion molecule 1	Homo sapiens	18-22
9367464-9	1997	ACTH (ng/L, means and 95% CI for difference) demonstrated a similar nonsignificant trend to cortisol, with suppression in both basal and stimulated forms: 8 AM ACTH, budesonide (36.6) vs placebo (42.2) (95% CI, -2.6 to 13.8); CRF peak response, budesonide (49.9) vs placebo (62.8) (95% CI, -3.6 to 29.5).	Budesonide	166-176	proopiomelanocortin	Homo sapiens	0-4
9387942-6	1997	The mean increase in morning peak expiratory flow (PEF) was 28 L x min(-1) after budesonide treatment compared with no increase in the placebo group (p=0.011).	Budesonide	81-91	CD59 molecule (CD59 blood group)	Homo sapiens	67-73
9387942-9	1997	During the 6 month follow-up, the PEF values of the patients who had previously been treated with budesonide decreased by 18 L x min(-1) while the PD20 decreased by approximately one doubling dose step.	Budesonide	98-108	CD59 molecule (CD59 blood group)	Homo sapiens	129-135
9310019-7	1997	In patients with birch-pollen-sensitive asthma during the birch-pollen season, inhaled corticosteroid treatment, budesonide 400 micrograms twice daily, decreased tenascin immunoreactivity, in comparison with effects of placebo (p = 0.01).	Budesonide	113-123	tenascin C	Homo sapiens	162-170
9314353-9	1997	In vitro treatment with budesonide of SCF-producing fibroblasts demonstrated inhibition of unstimulated, primary Np fibroblasts but not of IL-1-stimulated fibroblasts or transformed cell lines.	Budesonide	24-34	KIT ligand	Homo sapiens	38-41
9314353-9	1997	In vitro treatment with budesonide of SCF-producing fibroblasts demonstrated inhibition of unstimulated, primary Np fibroblasts but not of IL-1-stimulated fibroblasts or transformed cell lines.	Budesonide	24-34	interleukin 1 alpha	Homo sapiens	139-143
9532255-7	1997	Following treatment with a topical steroid (budesonide) there was a statistically significant increase of the levels of soluble IL-4 receptor.	Budesonide	44-54	interleukin 4 receptor	Homo sapiens	128-141
9062350-9	1997	Pretreatment of BEAS-2B epithelial cells with the glucocorticoid budesonide inhibited MCP-4 mRNA expression.	Budesonide	65-75	C-C motif chemokine ligand 13	Homo sapiens	86-91
9298179-5	1997	Budesonide was added at concentrations corresponding to 10(-8), 10(-7), and 10(-6) mol/l in cultured epithelial cells, either in the absence of any stimulus or in the presence of interferon-gamma (IFN-gamma) at 500 U/ml.	Budesonide	0-10	interferon gamma	Homo sapiens	179-195
9298179-5	1997	Budesonide was added at concentrations corresponding to 10(-8), 10(-7), and 10(-6) mol/l in cultured epithelial cells, either in the absence of any stimulus or in the presence of interferon-gamma (IFN-gamma) at 500 U/ml.	Budesonide	0-10	interferon gamma	Homo sapiens	197-206
9298179-8	1997	The results showed that budesonide inhibits ICAM-1 and CD29 basal expression on the cells studied (P < 0.05): budesonide was effective in a dose-dependent manner.	Budesonide	24-34	intercellular adhesion molecule 1	Homo sapiens	44-50
9298179-8	1997	The results showed that budesonide inhibits ICAM-1 and CD29 basal expression on the cells studied (P < 0.05): budesonide was effective in a dose-dependent manner.	Budesonide	24-34	integrin subunit beta 1	Homo sapiens	55-59
9298179-8	1997	The results showed that budesonide inhibits ICAM-1 and CD29 basal expression on the cells studied (P < 0.05): budesonide was effective in a dose-dependent manner.	Budesonide	113-123	intercellular adhesion molecule 1	Homo sapiens	44-50
9298179-9	1997	In addition, budesonide reduced surface ICAM-1 upregulation induced by IFN-gamma at 500 U/ml (P < 0.05).	Budesonide	13-23	intercellular adhesion molecule 1	Homo sapiens	40-46
9298179-9	1997	In addition, budesonide reduced surface ICAM-1 upregulation induced by IFN-gamma at 500 U/ml (P < 0.05).	Budesonide	13-23	interferon gamma	Homo sapiens	71-80
9298179-10	1997	Finally, cell cultures with budesonide showed decreased levels of soluble ICAM-1 in basal condition, but not after IFN-gamma stimulation.	Budesonide	28-38	intercellular adhesion molecule 1	Homo sapiens	74-80
9292183-3	1997	Furthermore, nasal polyps from 5 of 17 patients treated with clinical doses of a topical nasal steroid, budesonide, appear to show a stronger staining intensity for P-gp than polyps from 13 untreated patients.	Budesonide	104-114	phosphoglycolate phosphatase	Homo sapiens	165-169
9261851-7	1997	Children with high concentrations of respiratory tract ECP seemed to benefit from anti-inflammatory therapy with nebulized cromolyn sodium or budesonide; both drugs significantly decreased the number of subsequent physician-diagnosed bronchial obstruction (P = 0.0006), and they tended to decrease the number of hospital admissions for wheezing (P = 0.08).	Budesonide	142-152	ribonuclease A family member 3	Homo sapiens	55-58
8977508-4	1996	Peripheral blood mononuclear cell GCR binding affinities for dexamethasone and budesonide were also determined for both patient groups by using a radioligand binding assay and Scatchard analysis.	Budesonide	79-89	nuclear receptor subfamily 3 group C member 1	Homo sapiens	34-37
8977508-9	1996	The GCR binding affinity for budesonide was significantly higher in both groups (i.e., lower dissociation constant) than that obtained for dexamethasone.	Budesonide	29-39	nuclear receptor subfamily 3 group C member 1	Homo sapiens	4-7
8977508-10	1996	CONCLUSION: These data suggest that glucocorticoids such as budesonide, by virtue of their high GCR binding affinities and greater ability to suppress lymphocyte proliferation, may therefore be beneficial in the management of difficult-to-control asthma.	Budesonide	60-70	nuclear receptor subfamily 3 group C member 1	Homo sapiens	96-99
8886853-7	1996	The increase of the budesonide- or prednisolone-suppressed NK cell activity after in vivo administration of ACTH to the CD patients is therefore probably not a direct effect of cortisol or ACTH.	Budesonide	20-30	proopiomelanocortin	Homo sapiens	108-112
8641833-8	1996	The addition of budesonide (10(-7) M) or prednisolone (10(-6) M) significantly inhibited LPS-induced TNF alpha release, whereas cyclosporin A (10(-7) - 10(-5) M) had no marked effect.	Budesonide	16-26	tumor necrosis factor	Mus musculus	101-110
8809423-0	1996	Eosinophil locomotion and the release of IL-3 and IL-5 by allergen-stimulated mononuclear cells are effectively downregulated in vitro by budesonide.	Budesonide	138-148	interleukin 3	Homo sapiens	41-45
8809423-0	1996	Eosinophil locomotion and the release of IL-3 and IL-5 by allergen-stimulated mononuclear cells are effectively downregulated in vitro by budesonide.	Budesonide	138-148	interleukin 5	Homo sapiens	50-54
8809423-9	1996	Similarly, "systemic concentrations" of BDN (10(-10) M and 10(-9) M) totally inhibited the chemotactic response of blood eosinophils toward recombinant human IL-3 and IL-5 (P < 0.005).	Budesonide	40-43	interleukin 3	Homo sapiens	158-162
8809423-9	1996	Similarly, "systemic concentrations" of BDN (10(-10) M and 10(-9) M) totally inhibited the chemotactic response of blood eosinophils toward recombinant human IL-3 and IL-5 (P < 0.005).	Budesonide	40-43	interleukin 5	Homo sapiens	167-171
8648010-9	1996	In the asthma group urinary EPX, as well as serum ECP, decreased significantly after 3 months of treatment with budesonide (116.4 to 68.4 micrograms/mmol creatinine [p = 0.005] and 37.0 to 24.0 micrograms/L [p = 0.04]).	Budesonide	112-122	eosinophil peroxidase	Homo sapiens	28-31
8648010-9	1996	In the asthma group urinary EPX, as well as serum ECP, decreased significantly after 3 months of treatment with budesonide (116.4 to 68.4 micrograms/mmol creatinine [p = 0.005] and 37.0 to 24.0 micrograms/L [p = 0.04]).	Budesonide	112-122	ribonuclease A family member 3	Homo sapiens	50-53
8641833-11	1996	Budesonide markedly decreased mRNA expression and abolished immunostaining of TNF alpha stimulated by LPS.	Budesonide	0-10	tumor necrosis factor	Mus musculus	78-87
8641833-13	1996	Contrary to cyclosporin A, corticosteroids such as prednisolone and budesonide potently inhibit TNF alpha production.	Budesonide	68-78	tumor necrosis factor	Mus musculus	96-105
7497762-6	1995	In six of eight "responders to beta 2-agonist," there was a significant improvement in the FEV1 (defined as > or = 20%) following inhaled budesonide, as compared with placebo.	Budesonide	141-151	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	31-37
8630596-4	1996	Lung functions (FEV1% predicted, and histamine PC20) and the eosinophil markers ECP and EPX/EDN were improved and reduced, respectively, by budesonide in a dose-dependent and temporally parallel fashion.	Budesonide	140-150	ribonuclease A family member 3	Homo sapiens	80-83
8630596-4	1996	Lung functions (FEV1% predicted, and histamine PC20) and the eosinophil markers ECP and EPX/EDN were improved and reduced, respectively, by budesonide in a dose-dependent and temporally parallel fashion.	Budesonide	140-150	eosinophil peroxidase	Homo sapiens	88-91
8630596-4	1996	Lung functions (FEV1% predicted, and histamine PC20) and the eosinophil markers ECP and EPX/EDN were improved and reduced, respectively, by budesonide in a dose-dependent and temporally parallel fashion.	Budesonide	140-150	ribonuclease A family member 2	Homo sapiens	92-95
8966364-0	1996	Release of endothelin-1 into rat airways following Sephadex-induced inflammation; modulation by enzyme inhibitors and budesonide.	Budesonide	118-128	endothelin 1	Rattus norvegicus	11-23
8713673-4	1996	Variation at the glucocorticoid receptor locus can be identified as a biallelic restriction fragment length polymorphism (Bcl1); subjects with contrasting genotypes show altered skin vasoconstrictor responses to topically applied budesonide without any significant change in leucocyte receptor binding characteristics.	Budesonide	230-240	nuclear receptor subfamily 3 group C member 1	Homo sapiens	17-40
8713673-4	1996	Variation at the glucocorticoid receptor locus can be identified as a biallelic restriction fragment length polymorphism (Bcl1); subjects with contrasting genotypes show altered skin vasoconstrictor responses to topically applied budesonide without any significant change in leucocyte receptor binding characteristics.	Budesonide	230-240	cyclin D1	Homo sapiens	122-126
8601642-3	1996	We also show that constitutive CD40 mRNA expression in eosinophils could be upregulated by exposure to IgA immune complexes and downregulated by IL-10 and the synthetic steroid budesonide.	Budesonide	177-187	CD40 molecule	Homo sapiens	31-35
8613948-6	1996	Budesonide (10(-7) M) dramatically reduced A-PBM proliferation (measured by 3H-thymidine incorporation) and cytokine (IL-1beta, IL-2, IL-6, IFN-gamma, TNF-alpha) production, but was not cytotoxic to immune cells.	Budesonide	0-10	interleukin 1 beta	Homo sapiens	118-126
8613948-6	1996	Budesonide (10(-7) M) dramatically reduced A-PBM proliferation (measured by 3H-thymidine incorporation) and cytokine (IL-1beta, IL-2, IL-6, IFN-gamma, TNF-alpha) production, but was not cytotoxic to immune cells.	Budesonide	0-10	interleukin 2	Homo sapiens	128-132
8613948-6	1996	Budesonide (10(-7) M) dramatically reduced A-PBM proliferation (measured by 3H-thymidine incorporation) and cytokine (IL-1beta, IL-2, IL-6, IFN-gamma, TNF-alpha) production, but was not cytotoxic to immune cells.	Budesonide	0-10	interleukin 6	Homo sapiens	134-138
8613948-6	1996	Budesonide (10(-7) M) dramatically reduced A-PBM proliferation (measured by 3H-thymidine incorporation) and cytokine (IL-1beta, IL-2, IL-6, IFN-gamma, TNF-alpha) production, but was not cytotoxic to immune cells.	Budesonide	0-10	interferon gamma	Homo sapiens	140-149
8613948-6	1996	Budesonide (10(-7) M) dramatically reduced A-PBM proliferation (measured by 3H-thymidine incorporation) and cytokine (IL-1beta, IL-2, IL-6, IFN-gamma, TNF-alpha) production, but was not cytotoxic to immune cells.	Budesonide	0-10	tumor necrosis factor	Homo sapiens	151-160
8621851-0	1996	Regulation of glucocorticoid receptor mRNA in nasal mucosa by local administration of fluticasone and budesonide.	Budesonide	102-112	nuclear receptor subfamily 3 group C member 1	Homo sapiens	14-37
7488811-8	1995	Budesonide/placebo was given by Turbuhaler at 0.2 mg qid for 3 days, tid for 3 and bid for the last 3 days.	Budesonide	0-10	BH3 interacting domain death agonist	Homo sapiens	83-86
7605858-9	1995	CONCLUSION: Both budesonide and prednisolone treatment suppress peripheral blood natural killer cell activity of patients with active ileocaecal Crohn"s disease by decreasing the numbers of CD16+ NK cells in the circulation.	Budesonide	17-27	Fc gamma receptor IIIa	Homo sapiens	190-194
8846393-2	1995	The effects of systemic treatment with the corticosteroid budesonide on basal CGRP expression and on changes under inflammatory conditions were examined.	Budesonide	58-68	calcitonin-related polypeptide alpha	Rattus norvegicus	78-82
8846393-4	1995	Budesonide reduced the constitutive CGRP mRNA levels in DRG, compared with untreated control rats, and reversed the CIA-induced increase.	Budesonide	0-10	calcitonin-related polypeptide alpha	Rattus norvegicus	36-40
8846393-6	1995	Budesonide had no effect on constitutive CGRP mRNA levels in motoneurons and attenuated the decrease in CGRP mRNA levels in motoneurons of rats subjected to CIA.	Budesonide	0-10	calcitonin-related polypeptide alpha	Rattus norvegicus	104-108
7541423-6	1995	Pretreatment of cells with the glucocorticoid budesonide (10(-10)-10(-7) M) for 24 h inhibited expression of RANTES mRNA and protein stimulated by either TNF-alpha or TNF-alpha plus IFN-gamma in a concentration- and time-dependent manner.	Budesonide	46-56	C-C motif chemokine ligand 5	Homo sapiens	109-115
7541423-6	1995	Pretreatment of cells with the glucocorticoid budesonide (10(-10)-10(-7) M) for 24 h inhibited expression of RANTES mRNA and protein stimulated by either TNF-alpha or TNF-alpha plus IFN-gamma in a concentration- and time-dependent manner.	Budesonide	46-56	tumor necrosis factor	Homo sapiens	154-163
7541423-6	1995	Pretreatment of cells with the glucocorticoid budesonide (10(-10)-10(-7) M) for 24 h inhibited expression of RANTES mRNA and protein stimulated by either TNF-alpha or TNF-alpha plus IFN-gamma in a concentration- and time-dependent manner.	Budesonide	46-56	tumor necrosis factor	Homo sapiens	167-176
7541423-6	1995	Pretreatment of cells with the glucocorticoid budesonide (10(-10)-10(-7) M) for 24 h inhibited expression of RANTES mRNA and protein stimulated by either TNF-alpha or TNF-alpha plus IFN-gamma in a concentration- and time-dependent manner.	Budesonide	46-56	interferon gamma	Homo sapiens	182-191
7604948-3	1995	It has an absolute affinity (KD) of 0.5 nM for the glucocorticoid receptor and a relative receptor affinity 1.5- and 3.0-times greater than that of beclomethasone-17-monopropionate (17-BMP) and budesonide, respectively.	Budesonide	194-204	nuclear receptor subfamily 3 group C member 1	Homo sapiens	51-74
7697252-3	1995	In this study we evaluated whether prophylactic budesonide would prevent relapse of asthma in children re-exposed to offending allergens at sea level, after a period of antigen avoidance at high altitude.	Budesonide	48-58	S13 erythroblastosis (avian) oncogene homolog	Homo sapiens	140-143
7741186-5	1995	Significantly fewer sleep disturbances and fewer nighttime inhalations of beta 2-agonists were required during budesonide and combination therapy than theophylline treatment.	Budesonide	111-121	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	74-80
7716352-0	1995	Regulatory effects of aerosolized budesonide and adrenalectomy on the lung content of endothelin-1 in the rat.	Budesonide	34-44	endothelin 1	Rattus norvegicus	86-98
7720517-0	1995	Budesonide is metabolized by cytochrome P450 3A (CYP3A) enzymes in human liver.	Budesonide	0-10	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	29-47
7720517-0	1995	Budesonide is metabolized by cytochrome P450 3A (CYP3A) enzymes in human liver.	Budesonide	0-10	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	49-54
7720517-6	1995	When budesonide (10 microM) was incubated with human liver microsomes in the presence of compounds known to interact with different isoforms or subfamilies of CYP, ketoconazole was found to be the strongest inhibitor of budesonide metabolism (IC50: approximately 0.1 microM) followed by troleandomycin (IC50: approximately 1 microM), erythromycin, and cyclosporin, all substances known to interact with CYP3A isoenzymes.	Budesonide	5-15	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	403-408
7720517-8	1995	In addition, formation of the budesonide metabolites (16 alpha-hydroxyprednisolone and 6 beta-hydroxybudesonide) was inhibited by antibodies against the CYP3A subfamily, but not by antibodies against the CYP1A subfamily or control immunoglobulin G. We conclude that the formation of 16 alpha-hydroxyprednisolone and 6 beta-hydroxybudesonide from budesonide is catalyzed by isoenzymes within the CYP3A subfamily.	Budesonide	30-40	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	153-158
7720517-8	1995	In addition, formation of the budesonide metabolites (16 alpha-hydroxyprednisolone and 6 beta-hydroxybudesonide) was inhibited by antibodies against the CYP3A subfamily, but not by antibodies against the CYP1A subfamily or control immunoglobulin G. We conclude that the formation of 16 alpha-hydroxyprednisolone and 6 beta-hydroxybudesonide from budesonide is catalyzed by isoenzymes within the CYP3A subfamily.	Budesonide	30-40	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	395-400
7720517-8	1995	In addition, formation of the budesonide metabolites (16 alpha-hydroxyprednisolone and 6 beta-hydroxybudesonide) was inhibited by antibodies against the CYP3A subfamily, but not by antibodies against the CYP1A subfamily or control immunoglobulin G. We conclude that the formation of 16 alpha-hydroxyprednisolone and 6 beta-hydroxybudesonide from budesonide is catalyzed by isoenzymes within the CYP3A subfamily.	Budesonide	101-111	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	153-158
7822661-5	1995	RESULTS: One hundred micrograms of budesonide per day markedly improved symptoms, morning and evening peak expiratory flow rates, and use of rescue beta 2-agonists (p < 0.01).	Budesonide	35-45	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	148-154
8198250-9	1994	In spite of the low pollen exposure, treatment with budesonide reduced the lavage fluid levels of both bradykinins and fibrinogen.	Budesonide	52-62	fibrinogen beta chain	Homo sapiens	119-129
7524716-8	1994	Only the steroid budesonide appeared to reduce both spontaneous and IL-1 beta induced cytokine release.	Budesonide	17-27	interleukin 1 beta	Homo sapiens	68-77
8003851-9	1994	In contrast, GM-CSF release in these cultures was almost totally inhibited by budesonide (> or = 10(-8) M).	Budesonide	78-88	colony stimulating factor 2	Homo sapiens	13-19
8003851-8	1994	When added to the BM cultures concomitantly with LPS, budesonide suppressed IL-1 beta and IL-6 only partially (to 30% of the control level).	Budesonide	54-64	interleukin 1 beta	Homo sapiens	76-85
8003851-8	1994	When added to the BM cultures concomitantly with LPS, budesonide suppressed IL-1 beta and IL-6 only partially (to 30% of the control level).	Budesonide	54-64	interleukin 6	Homo sapiens	90-94
8143834-4	1994	Budesonide was inhaled at a normal flow of 58 l.min-1 and at a slow flow of 36 l-min-1.	Budesonide	0-10	CD59 molecule (CD59 blood group)	Homo sapiens	48-53
8143834-4	1994	Budesonide was inhaled at a normal flow of 58 l.min-1 and at a slow flow of 36 l-min-1.	Budesonide	0-10	CD59 molecule (CD59 blood group)	Homo sapiens	81-86
8003851-10	1994	The IC50 for inhibition of the GM-CSF secretion was as low as 2 x 10(-10) M. In the AM cultures, budesonide had very little effect on IL-1 beta and IL-6 secretion (inhibition to 80% and 60% of control levels, respectively), while GM-CSF secretion was suppressed to 20% of control by budesonide concentrations > or = 10(-7) M.(ABSTRACT TRUNCATED AT 250 WORDS)	Budesonide	97-107	colony stimulating factor 2	Homo sapiens	31-37
8317785-0	1993	Effects of short-term inhaled budesonide and beclomethasone dipropionate on serum osteocalcin in premenopausal women.	Budesonide	30-40	bone gamma-carboxyglutamate protein	Homo sapiens	82-93
8256243-20	1993	CONCLUSIONS: In patients stressed by uncontrolled asthma, the antiasthmatic effect of high dose beclomethasone dipropionate and budesonide was accompanied by a significant initial decrease in insulin resistance with a parallel improvement in glucose tolerance.	Budesonide	128-138	insulin	Homo sapiens	192-199
8218754-4	1993	Maximal plasma concentration (Cmax) of budesonide was 2.1 nmol/L 1.3 h after the first dose and 2.5 nmol/L 1.2 h after the last dose; the difference was not significant.	Budesonide	39-49	immunoglobulin kappa variable 2-4 (pseudogene)	Homo sapiens	63-68
8335852-2	1993	We measured serum ECP levels before and 1 and 5 months after treatment with inhaled budesonide (n = 10) or sodium cromoglycate (SCG) (n = 7) in children with asthma.	Budesonide	84-94	ribonuclease A family member 3	Homo sapiens	18-21
8335852-5	1993	RESULTS: ECP decreased during the 5 months of treatment (p = 0.020 for treatment groups combined; p = 0.049 for the budesonide group; p = NS for the SCG group).	Budesonide	116-126	ribonuclease A family member 3	Homo sapiens	9-12
8335852-6	1993	The higher the serum ECP level at entry, the more it decreased during treatment, both in the budesonide group (r = -0.697, p < 0.05) and in the SCG group (r = -0.893, p < 0.05).	Budesonide	93-103	ribonuclease A family member 3	Homo sapiens	21-24
1280129-3	1992	Budesonide given s.c. abolished these effects and even reduced basal endothelin-1 content by 72%.	Budesonide	0-10	endothelin 1	Rattus norvegicus	69-81
8436777-7	1993	RESULTS: Budesonide treatment resulted in a fall in mean eosinophil count from 0.37 +/- 0.05 x 10(9) L-1 after placebo to 0.16 +/- 0.03 x 10(9) L-1 (p < 0.01).	Budesonide	9-19	immunoglobulin kappa variable 1-16	Homo sapiens	101-104
8436777-7	1993	RESULTS: Budesonide treatment resulted in a fall in mean eosinophil count from 0.37 +/- 0.05 x 10(9) L-1 after placebo to 0.16 +/- 0.03 x 10(9) L-1 (p < 0.01).	Budesonide	9-19	immunoglobulin kappa variable 1-16	Homo sapiens	144-147
1280129-6	1992	If it is so, the ability of budesonide to reduce endothelin-1 content could thus be added to the list of beneficial effects of glucocorticosteroids in these conditions.	Budesonide	28-38	endothelin 1	Rattus norvegicus	49-61
1997509-0	1991	Differential effects of inhaled budesonide and oral prednisolone on serum osteocalcin.	Budesonide	32-42	bone gamma-carboxyglutamate protein	Homo sapiens	74-85
1430701-7	1992	Budesonide reduced both eosinophil numbers and ECP levels, especially at night; bambuterol had no effect on both variables.	Budesonide	0-10	ribonuclease A family member 3	Homo sapiens	47-50
1430706-9	1992	Only during budesonide use did osteocalcin and PICP decrease, the median osteocalcin by 8% at 1 month (p < 0.05) and by 6% at 5 months (n = 15), and PICP by 5% at 1 month (p < 0.05) and by 28% at 5 months (n = 7, p < 0.01).	Budesonide	12-22	bone gamma-carboxyglutamate protein	Homo sapiens	31-42
1430706-9	1992	Only during budesonide use did osteocalcin and PICP decrease, the median osteocalcin by 8% at 1 month (p < 0.05) and by 6% at 5 months (n = 15), and PICP by 5% at 1 month (p < 0.05) and by 28% at 5 months (n = 7, p < 0.01).	Budesonide	12-22	bone gamma-carboxyglutamate protein	Homo sapiens	73-84
1955630-7	1991	The preexercise serum ECP levels correlated significantly to the maximal fall in peak expiratory flow in the untreated group (r = 0.91; p less than 0.001) and in the group receiving one dose of budesonide (r = 0.62; p less than 0.05).	Budesonide	194-204	ribonuclease A family member 3	Homo sapiens	22-25
2062329-8	1991	Budesonide was also more effective in reducing the symptoms of asthma (P less than 0.01) and the use of supplemental beta 2-agonist medication (P less than 0.01).	Budesonide	0-10	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	117-123
2054193-9	1991	Budesonide inhibited both spontaneous and interleukin-1 (IL-1)-induced GM-CSF production by cultured HBEC.	Budesonide	0-10	interleukin 1 alpha	Homo sapiens	42-61
2054193-9	1991	Budesonide inhibited both spontaneous and interleukin-1 (IL-1)-induced GM-CSF production by cultured HBEC.	Budesonide	0-10	colony stimulating factor 2	Homo sapiens	71-77
2054193-10	1991	In addition, preincubation of eosinophils with budesonide caused marked abrogation of the survival induced subsequently with either HBEC-CM or recombinant human GM-CSF.	Budesonide	47-57	colony stimulating factor 2	Homo sapiens	161-167
1997509-10	1991	Osteocalcin levels increased by 56% and 50% in the low dose budesonide and prednisolone groups and by 106% in the high dose budesonide group, but did not change in the high dose prednisolone group.	Budesonide	60-70	bone gamma-carboxyglutamate protein	Homo sapiens	0-11
1997509-10	1991	Osteocalcin levels increased by 56% and 50% in the low dose budesonide and prednisolone groups and by 106% in the high dose budesonide group, but did not change in the high dose prednisolone group.	Budesonide	124-134	bone gamma-carboxyglutamate protein	Homo sapiens	0-11
1997509-11	1991	The osteocalcin response to calcitriol was significantly higher in the budesonide groups (P = 0.03, by analysis of variance).	Budesonide	71-81	bone gamma-carboxyglutamate protein	Homo sapiens	4-15
1847594-6	1991	In both confluent and nonconfluent cultures, the glucocorticoid budesonide increased neutral endopeptidase activity in time- and concentration-dependent fashions.	Budesonide	64-74	membrane metalloendopeptidase	Homo sapiens	85-106
1889254-4	1991	After treatment with budesonide, the response to both inhaled histamine and bradykinin was decreased when compared with placebo.	Budesonide	21-31	kininogen 1	Homo sapiens	76-86
1889254-8	1991	Inhaled budesonide therefore inhibits to the same extent the exaggerated response to both directly acting histamine and bradykinin which acts through airway nerves.	Budesonide	8-18	kininogen 1	Homo sapiens	120-130
34342835-1	2021	Budesonide/glycopyrronium/formoterol (BREZTRI AEROSPHERE ; TRIXEO AEROSPHERE ) is an inhaled fixed-dose combination of the inhaled corticosteroid (ICS) budesonide, the long-acting muscarinic antagonist (LAMA) glycopyrronium bromide and the long-acting beta2-agonist (LABA) formoterol fumarate approved for the maintenance treatment of chronic obstructive pulmonary disease (COPD).	Budesonide	0-10	ATPase H+ transporting V0 subunit a2	Homo sapiens	252-257
2186673-11	1990	Intranasal budesonide, 200 micrograms bid, thus appears to be efficacious, highly acceptable, and safe for the treatment of perennial rhinitis.	Budesonide	11-21	BH3 interacting domain death agonist	Homo sapiens	38-41
2105990-10	1990	The generation of HS NCA was more or less inhibited by all three drugs with 4 weeks of treatment with budesonide as the most potent regimen.	Budesonide	102-112	CEA cell adhesion molecule 6	Homo sapiens	21-24
34414506-11	2021	CONCLUSION: NGAL/LCN2 is upregulated in the epithelium of active CC and reduced during budesonide-induced clinical remission to the level of HC and IBD-S.	Budesonide	87-97	lipocalin 2	Homo sapiens	12-16
34414506-11	2021	CONCLUSION: NGAL/LCN2 is upregulated in the epithelium of active CC and reduced during budesonide-induced clinical remission to the level of HC and IBD-S.	Budesonide	87-97	lipocalin 2	Homo sapiens	17-21
2195937-10	1990	However, BAL-ECP levels were decreased by budesonide treatment (p less than 0.05).	Budesonide	42-52	ribonuclease A family member 3	Homo sapiens	13-16
34262692-11	2021	Interleukin (IL)-8, IL-10, IL-1alpha, and tissue inhibitor of metalloproteinase (TIMP)-1 concentrations were significantly increased in the culture medium of cells exposed to PM2.5, and budesonide significantly reduced the changes in IL-8, IL-1alpha, and TIMP-1.	Budesonide	186-196	C-X-C motif chemokine ligand 8	Homo sapiens	0-18
34262692-11	2021	Interleukin (IL)-8, IL-10, IL-1alpha, and tissue inhibitor of metalloproteinase (TIMP)-1 concentrations were significantly increased in the culture medium of cells exposed to PM2.5, and budesonide significantly reduced the changes in IL-8, IL-1alpha, and TIMP-1.	Budesonide	186-196	interleukin 10	Homo sapiens	20-25
34262692-11	2021	Interleukin (IL)-8, IL-10, IL-1alpha, and tissue inhibitor of metalloproteinase (TIMP)-1 concentrations were significantly increased in the culture medium of cells exposed to PM2.5, and budesonide significantly reduced the changes in IL-8, IL-1alpha, and TIMP-1.	Budesonide	186-196	interleukin 1 alpha	Homo sapiens	27-36
34262692-11	2021	Interleukin (IL)-8, IL-10, IL-1alpha, and tissue inhibitor of metalloproteinase (TIMP)-1 concentrations were significantly increased in the culture medium of cells exposed to PM2.5, and budesonide significantly reduced the changes in IL-8, IL-1alpha, and TIMP-1.	Budesonide	186-196	TIMP metallopeptidase inhibitor 1	Homo sapiens	42-88
34262692-11	2021	Interleukin (IL)-8, IL-10, IL-1alpha, and tissue inhibitor of metalloproteinase (TIMP)-1 concentrations were significantly increased in the culture medium of cells exposed to PM2.5, and budesonide significantly reduced the changes in IL-8, IL-1alpha, and TIMP-1.	Budesonide	186-196	C-X-C motif chemokine ligand 8	Homo sapiens	234-238
34262692-11	2021	Interleukin (IL)-8, IL-10, IL-1alpha, and tissue inhibitor of metalloproteinase (TIMP)-1 concentrations were significantly increased in the culture medium of cells exposed to PM2.5, and budesonide significantly reduced the changes in IL-8, IL-1alpha, and TIMP-1.	Budesonide	186-196	interleukin 1 alpha	Homo sapiens	240-249
34262692-11	2021	Interleukin (IL)-8, IL-10, IL-1alpha, and tissue inhibitor of metalloproteinase (TIMP)-1 concentrations were significantly increased in the culture medium of cells exposed to PM2.5, and budesonide significantly reduced the changes in IL-8, IL-1alpha, and TIMP-1.	Budesonide	186-196	TIMP metallopeptidase inhibitor 1	Homo sapiens	255-261
34414894-8	2021	The combination of azithromycin and budesonide had a more pronounced inhibitory effect on the production of IL-4 and CXCL8 by NK and NKT-like cells than the effect of these drugs alone.	Budesonide	36-46	interleukin 4	Homo sapiens	108-112
34414894-8	2021	The combination of azithromycin and budesonide had a more pronounced inhibitory effect on the production of IL-4 and CXCL8 by NK and NKT-like cells than the effect of these drugs alone.	Budesonide	36-46	C-X-C motif chemokine ligand 8	Homo sapiens	117-122
34414894-9	2021	The combination of theophylline and budesonide suppressed synthesis of IL-4 and CXCL8 by NK and NKT-like cells, as well as the production of TNFalpha and IFNgamma by NK cells stronger than budesonide alone.	Budesonide	36-46	interleukin 4	Homo sapiens	71-75
34414894-9	2021	The combination of theophylline and budesonide suppressed synthesis of IL-4 and CXCL8 by NK and NKT-like cells, as well as the production of TNFalpha and IFNgamma by NK cells stronger than budesonide alone.	Budesonide	36-46	C-X-C motif chemokine ligand 8	Homo sapiens	80-85
34414894-9	2021	The combination of theophylline and budesonide suppressed synthesis of IL-4 and CXCL8 by NK and NKT-like cells, as well as the production of TNFalpha and IFNgamma by NK cells stronger than budesonide alone.	Budesonide	36-46	tumor necrosis factor	Homo sapiens	141-149
34414894-9	2021	The combination of theophylline and budesonide suppressed synthesis of IL-4 and CXCL8 by NK and NKT-like cells, as well as the production of TNFalpha and IFNgamma by NK cells stronger than budesonide alone.	Budesonide	36-46	interferon gamma	Homo sapiens	154-162
34414894-9	2021	The combination of theophylline and budesonide suppressed synthesis of IL-4 and CXCL8 by NK and NKT-like cells, as well as the production of TNFalpha and IFNgamma by NK cells stronger than budesonide alone.	Budesonide	189-199	tumor necrosis factor	Homo sapiens	141-149
34414894-9	2021	The combination of theophylline and budesonide suppressed synthesis of IL-4 and CXCL8 by NK and NKT-like cells, as well as the production of TNFalpha and IFNgamma by NK cells stronger than budesonide alone.	Budesonide	189-199	interferon gamma	Homo sapiens	154-162
35584388-7	2022	Smoking (P = 0.02), single daily dose of AZA (P < 0.001), and concomitant budesonide (P = 0.001) were risk factors for AIP.	Budesonide	74-84	aryl hydrocarbon receptor interacting protein	Homo sapiens	119-122
34414894-6	2021	Budesonide reduced synthesis of interleukin 4 (IL-4), CXCL8, tumor necrosis factor alpha (TNFalpha) by NK and NKT-like cells, as well as production of interferon gamma (IFNgamma) by NK cells.	Budesonide	0-10	interleukin 4	Homo sapiens	32-45
34414894-6	2021	Budesonide reduced synthesis of interleukin 4 (IL-4), CXCL8, tumor necrosis factor alpha (TNFalpha) by NK and NKT-like cells, as well as production of interferon gamma (IFNgamma) by NK cells.	Budesonide	0-10	interleukin 4	Homo sapiens	47-51
34414894-6	2021	Budesonide reduced synthesis of interleukin 4 (IL-4), CXCL8, tumor necrosis factor alpha (TNFalpha) by NK and NKT-like cells, as well as production of interferon gamma (IFNgamma) by NK cells.	Budesonide	0-10	C-X-C motif chemokine ligand 8	Homo sapiens	54-59
34414894-6	2021	Budesonide reduced synthesis of interleukin 4 (IL-4), CXCL8, tumor necrosis factor alpha (TNFalpha) by NK and NKT-like cells, as well as production of interferon gamma (IFNgamma) by NK cells.	Budesonide	0-10	tumor necrosis factor	Homo sapiens	61-88
34414894-6	2021	Budesonide reduced synthesis of interleukin 4 (IL-4), CXCL8, tumor necrosis factor alpha (TNFalpha) by NK and NKT-like cells, as well as production of interferon gamma (IFNgamma) by NK cells.	Budesonide	0-10	tumor necrosis factor	Homo sapiens	90-98
34414894-6	2021	Budesonide reduced synthesis of interleukin 4 (IL-4), CXCL8, tumor necrosis factor alpha (TNFalpha) by NK and NKT-like cells, as well as production of interferon gamma (IFNgamma) by NK cells.	Budesonide	0-10	interferon gamma	Homo sapiens	151-167
34414894-6	2021	Budesonide reduced synthesis of interleukin 4 (IL-4), CXCL8, tumor necrosis factor alpha (TNFalpha) by NK and NKT-like cells, as well as production of interferon gamma (IFNgamma) by NK cells.	Budesonide	0-10	interferon gamma	Homo sapiens	169-177
35397798-17	2022	Budesonide treatment modulated inflammation in the nose and blood and was shown to decrease IL-33 and increase CCL17.	Budesonide	0-10	interleukin 33	Homo sapiens	92-97
35397798-17	2022	Budesonide treatment modulated inflammation in the nose and blood and was shown to decrease IL-33 and increase CCL17.	Budesonide	0-10	C-C motif chemokine ligand 17	Homo sapiens	111-116
35538539-8	2022	RESULTS: Our results show that both tanimilast and budesonide reduced the production of the immunostimulatory cytokine IFN-gamma by CD4+ T cells.	Budesonide	51-61	interferon gamma	Homo sapiens	119-128
35538539-8	2022	RESULTS: Our results show that both tanimilast and budesonide reduced the production of the immunostimulatory cytokine IFN-gamma by CD4+ T cells.	Budesonide	51-61	CD4 molecule	Homo sapiens	132-135
35468610-2	2022	The study was aimed to assess the influence of budesonide nasal spray on CD8+CD25+Foxp3+ Tregs and to evaluate their cellular functions in neutrophilic chronic rhinosinusitis with nasal polyps (CRSwNPs).	Budesonide	47-57	CD8a molecule	Homo sapiens	73-76
35468610-2	2022	The study was aimed to assess the influence of budesonide nasal spray on CD8+CD25+Foxp3+ Tregs and to evaluate their cellular functions in neutrophilic chronic rhinosinusitis with nasal polyps (CRSwNPs).	Budesonide	47-57	interleukin 2 receptor subunit alpha	Homo sapiens	77-81
35468610-2	2022	The study was aimed to assess the influence of budesonide nasal spray on CD8+CD25+Foxp3+ Tregs and to evaluate their cellular functions in neutrophilic chronic rhinosinusitis with nasal polyps (CRSwNPs).	Budesonide	47-57	forkhead box P3	Homo sapiens	82-87
35080786-7	2022	As a result, while budesonide had the highest inhibitory potency on hydratase activity of hCA-I with the IC50 of 0.08 mM, levofloxacin showed the highest inhibition effect on hCA-II with the IC50 of 0.886 mM.	Budesonide	19-29	carbonic anhydrase 1	Homo sapiens	90-95
35189144-2	2022	Here, we explore the synergy that occurs between synthetic glucocorticoids (dexamethasone, budesonide) and pro-inflammatory cytokines (IL1B, TNF) on the expression of the toll-like receptor 2 (TLR2).	Budesonide	91-101	interleukin 1 beta	Homo sapiens	135-139
35189144-2	2022	Here, we explore the synergy that occurs between synthetic glucocorticoids (dexamethasone, budesonide) and pro-inflammatory cytokines (IL1B, TNF) on the expression of the toll-like receptor 2 (TLR2).	Budesonide	91-101	tumor necrosis factor	Homo sapiens	141-144
35189144-2	2022	Here, we explore the synergy that occurs between synthetic glucocorticoids (dexamethasone, budesonide) and pro-inflammatory cytokines (IL1B, TNF) on the expression of the toll-like receptor 2 (TLR2).	Budesonide	91-101	toll like receptor 2	Homo sapiens	171-191
35189144-2	2022	Here, we explore the synergy that occurs between synthetic glucocorticoids (dexamethasone, budesonide) and pro-inflammatory cytokines (IL1B, TNF) on the expression of the toll-like receptor 2 (TLR2).	Budesonide	91-101	toll like receptor 2	Homo sapiens	193-197
35348513-1	2022	Budesonide (Tarpeyo) has received accelerated approval to reduce proteinuria in adults with primary immunoglobulin A nephropathy, also known as Berger"s disease.Nurses should assess if any coprescribed drugs could induce a drug-drug interaction via the cytochrome P-450 isoenzyme system.	Budesonide	0-10	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	253-269
35584388-8	2022	In multivariate analysis, concomitant treatment with budesonide (odds ratio, 5.3; P = 0.002) and single daily dose of AZA (odds ratio, 3.8; P = 0.002) were the only predictors of AIP.	Budesonide	53-63	aryl hydrocarbon receptor interacting protein	Homo sapiens	179-182
35226290-3	2022	We have previously reported that bile ducts isolated from rats treated with dexamethasone or budesonide showed an enhanced activity of the Na+/H+ exchanger isoform 1 (NHE1) and Cl-/HCO3- exchanger protein 2 (AE2) .	Budesonide	93-103	solute carrier family 9 member A1	Rattus norvegicus	139-165
35226290-3	2022	We have previously reported that bile ducts isolated from rats treated with dexamethasone or budesonide showed an enhanced activity of the Na+/H+ exchanger isoform 1 (NHE1) and Cl-/HCO3- exchanger protein 2 (AE2) .	Budesonide	93-103	solute carrier family 9 member A1	Rattus norvegicus	167-171
35226290-3	2022	We have previously reported that bile ducts isolated from rats treated with dexamethasone or budesonide showed an enhanced activity of the Na+/H+ exchanger isoform 1 (NHE1) and Cl-/HCO3- exchanger protein 2 (AE2) .	Budesonide	93-103	solute carrier family 4 member 2	Rattus norvegicus	208-211
35072213-7	2022	The combination of azithromycin and budesonide suppressed inflammatory response by inhibition of IL-4, IL-5, IL-8, IL-13, IL-17A, IL-33, thymic stromal lymphopoietin (TSLP), macrophage migration inhibitory factor (MIF) release from PBMCs and by reduction of the percentage of IL-4-, IL-8-, interferon gamma- and tumor necrosis factor a-expressing CD4+ and CD8+ T cells.	Budesonide	36-46	interleukin 4	Homo sapiens	97-101
35072213-7	2022	The combination of azithromycin and budesonide suppressed inflammatory response by inhibition of IL-4, IL-5, IL-8, IL-13, IL-17A, IL-33, thymic stromal lymphopoietin (TSLP), macrophage migration inhibitory factor (MIF) release from PBMCs and by reduction of the percentage of IL-4-, IL-8-, interferon gamma- and tumor necrosis factor a-expressing CD4+ and CD8+ T cells.	Budesonide	36-46	interleukin 5	Homo sapiens	103-107
35072213-7	2022	The combination of azithromycin and budesonide suppressed inflammatory response by inhibition of IL-4, IL-5, IL-8, IL-13, IL-17A, IL-33, thymic stromal lymphopoietin (TSLP), macrophage migration inhibitory factor (MIF) release from PBMCs and by reduction of the percentage of IL-4-, IL-8-, interferon gamma- and tumor necrosis factor a-expressing CD4+ and CD8+ T cells.	Budesonide	36-46	C-X-C motif chemokine ligand 8	Homo sapiens	109-113
35072213-7	2022	The combination of azithromycin and budesonide suppressed inflammatory response by inhibition of IL-4, IL-5, IL-8, IL-13, IL-17A, IL-33, thymic stromal lymphopoietin (TSLP), macrophage migration inhibitory factor (MIF) release from PBMCs and by reduction of the percentage of IL-4-, IL-8-, interferon gamma- and tumor necrosis factor a-expressing CD4+ and CD8+ T cells.	Budesonide	36-46	interleukin 13	Homo sapiens	115-120
35072213-7	2022	The combination of azithromycin and budesonide suppressed inflammatory response by inhibition of IL-4, IL-5, IL-8, IL-13, IL-17A, IL-33, thymic stromal lymphopoietin (TSLP), macrophage migration inhibitory factor (MIF) release from PBMCs and by reduction of the percentage of IL-4-, IL-8-, interferon gamma- and tumor necrosis factor a-expressing CD4+ and CD8+ T cells.	Budesonide	36-46	interleukin 17A	Homo sapiens	122-128
35072213-7	2022	The combination of azithromycin and budesonide suppressed inflammatory response by inhibition of IL-4, IL-5, IL-8, IL-13, IL-17A, IL-33, thymic stromal lymphopoietin (TSLP), macrophage migration inhibitory factor (MIF) release from PBMCs and by reduction of the percentage of IL-4-, IL-8-, interferon gamma- and tumor necrosis factor a-expressing CD4+ and CD8+ T cells.	Budesonide	36-46	interleukin 33	Homo sapiens	130-135
35072213-7	2022	The combination of azithromycin and budesonide suppressed inflammatory response by inhibition of IL-4, IL-5, IL-8, IL-13, IL-17A, IL-33, thymic stromal lymphopoietin (TSLP), macrophage migration inhibitory factor (MIF) release from PBMCs and by reduction of the percentage of IL-4-, IL-8-, interferon gamma- and tumor necrosis factor a-expressing CD4+ and CD8+ T cells.	Budesonide	36-46	thymic stromal lymphopoietin	Homo sapiens	137-165
35072213-7	2022	The combination of azithromycin and budesonide suppressed inflammatory response by inhibition of IL-4, IL-5, IL-8, IL-13, IL-17A, IL-33, thymic stromal lymphopoietin (TSLP), macrophage migration inhibitory factor (MIF) release from PBMCs and by reduction of the percentage of IL-4-, IL-8-, interferon gamma- and tumor necrosis factor a-expressing CD4+ and CD8+ T cells.	Budesonide	36-46	thymic stromal lymphopoietin	Homo sapiens	167-171
35072213-7	2022	The combination of azithromycin and budesonide suppressed inflammatory response by inhibition of IL-4, IL-5, IL-8, IL-13, IL-17A, IL-33, thymic stromal lymphopoietin (TSLP), macrophage migration inhibitory factor (MIF) release from PBMCs and by reduction of the percentage of IL-4-, IL-8-, interferon gamma- and tumor necrosis factor a-expressing CD4+ and CD8+ T cells.	Budesonide	36-46	macrophage migration inhibitory factor	Homo sapiens	174-212
35072213-5	2022	Phytohaemagglutinin-induced release of pro-inflammatory mediators from PBMCs and production of intracellular cytokines by CD4+ and CD8+ T cells stimulated with phorbol 12-myristate 13-acetate and ionomycin in the presence or absence of 10 mug/mL azithromycin and 10 nM budesonide were determined using enzyme linked immunosorbent assay and flow cytometry.	Budesonide	269-279	CD4 molecule	Homo sapiens	122-125
35072213-7	2022	The combination of azithromycin and budesonide suppressed inflammatory response by inhibition of IL-4, IL-5, IL-8, IL-13, IL-17A, IL-33, thymic stromal lymphopoietin (TSLP), macrophage migration inhibitory factor (MIF) release from PBMCs and by reduction of the percentage of IL-4-, IL-8-, interferon gamma- and tumor necrosis factor a-expressing CD4+ and CD8+ T cells.	Budesonide	36-46	macrophage migration inhibitory factor	Homo sapiens	214-217
35072213-5	2022	Phytohaemagglutinin-induced release of pro-inflammatory mediators from PBMCs and production of intracellular cytokines by CD4+ and CD8+ T cells stimulated with phorbol 12-myristate 13-acetate and ionomycin in the presence or absence of 10 mug/mL azithromycin and 10 nM budesonide were determined using enzyme linked immunosorbent assay and flow cytometry.	Budesonide	269-279	CD8a molecule	Homo sapiens	131-134
35072213-7	2022	The combination of azithromycin and budesonide suppressed inflammatory response by inhibition of IL-4, IL-5, IL-8, IL-13, IL-17A, IL-33, thymic stromal lymphopoietin (TSLP), macrophage migration inhibitory factor (MIF) release from PBMCs and by reduction of the percentage of IL-4-, IL-8-, interferon gamma- and tumor necrosis factor a-expressing CD4+ and CD8+ T cells.	Budesonide	36-46	CD4 molecule	Homo sapiens	347-350
35072213-7	2022	The combination of azithromycin and budesonide suppressed inflammatory response by inhibition of IL-4, IL-5, IL-8, IL-13, IL-17A, IL-33, thymic stromal lymphopoietin (TSLP), macrophage migration inhibitory factor (MIF) release from PBMCs and by reduction of the percentage of IL-4-, IL-8-, interferon gamma- and tumor necrosis factor a-expressing CD4+ and CD8+ T cells.	Budesonide	36-46	CD8a molecule	Homo sapiens	356-359
35072213-8	2022	The inhibitory effect of azithromycin combined with budesonide on IL-4, IL-5, IL-8, IL-17A, TSLP production by PBMCs, as well as IL-4 and IL-8 production by T helper cells and cytotoxic T lymphocytes was significantly greater than the effect of budesonide alone.	Budesonide	52-62	interleukin 4	Homo sapiens	66-70
35072213-8	2022	The inhibitory effect of azithromycin combined with budesonide on IL-4, IL-5, IL-8, IL-17A, TSLP production by PBMCs, as well as IL-4 and IL-8 production by T helper cells and cytotoxic T lymphocytes was significantly greater than the effect of budesonide alone.	Budesonide	52-62	interleukin 5	Homo sapiens	72-76
35072213-8	2022	The inhibitory effect of azithromycin combined with budesonide on IL-4, IL-5, IL-8, IL-17A, TSLP production by PBMCs, as well as IL-4 and IL-8 production by T helper cells and cytotoxic T lymphocytes was significantly greater than the effect of budesonide alone.	Budesonide	52-62	C-X-C motif chemokine ligand 8	Homo sapiens	78-82
35072213-8	2022	The inhibitory effect of azithromycin combined with budesonide on IL-4, IL-5, IL-8, IL-17A, TSLP production by PBMCs, as well as IL-4 and IL-8 production by T helper cells and cytotoxic T lymphocytes was significantly greater than the effect of budesonide alone.	Budesonide	52-62	interleukin 17A	Homo sapiens	84-90
35072213-8	2022	The inhibitory effect of azithromycin combined with budesonide on IL-4, IL-5, IL-8, IL-17A, TSLP production by PBMCs, as well as IL-4 and IL-8 production by T helper cells and cytotoxic T lymphocytes was significantly greater than the effect of budesonide alone.	Budesonide	52-62	thymic stromal lymphopoietin	Homo sapiens	92-96
35110509-5	2022	PEPT2 function, estimated by measuring beta-alanyl-Nepsilon-(7-amino-4-methyl-2-oxo-2H-1-benzopyran-3-acetyl)-L-lysine (beta-Ala-Lys-AMCA) uptake in H441 cells, was suppressed by treatment with DEX and BUD in a concentration- and time-dependent manner.	Budesonide	202-205	solute carrier family 15 member 2	Homo sapiens	0-5
3811967-3	1986	The short elimination half-life (t1/2 beta = 1.55 hrs) and high blood clearance (Cl = 9.04 l/hr/kg) demonstrated a rapid elimination of budesonide from the body.	Budesonide	136-146	brachyury, T-box transcription factor T	Mus musculus	33-49
12412753-4	1989	Both prednisolone and budesonide inhibited TNF secretion induced by these four stimulating agents in a different degree.	Budesonide	22-32	tumor necrosis factor	Homo sapiens	43-46
2852389-7	1988	However, a decrease in serum ACE (p less than 0.1) and beta 2 M (p less than 0.05) as well as in BAL-hyaluronan (p less than 0.01) was found in the budesonide-treated patients as well as a decrease in the percentage of BAL T-lymphocytes (p less than 0.05) and the T4/T8 ratio (p less than 0.1).	Budesonide	148-158	angiotensin I converting enzyme	Homo sapiens	29-32
2520343-10	1989	During treatment with budesonide only a significant correlation of beta 2-agonist use with PC20 histamine remained.	Budesonide	22-32	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	67-73
3144513-4	1988	Pre-challenge levels of ECP were significantly reduced both after 4 weeks and after a one-dose treatment with budesonide whereas the EPX levels were reduced only after the former.	Budesonide	110-120	ribonuclease A family member 3	Homo sapiens	24-27
32960007-11	2021	CONCLUSIONS: The treatment of salbutamol combined with budesonide for pediatric BA has significant therapeutic effects; it can restore the pulmonary functions rapidly and improve the immunity of the lung, reduce the levels of eotaxin, ECP and EOS of the child patients and promote EOS apoptosis.	Budesonide	55-65	C-C motif chemokine ligand 11	Homo sapiens	226-233
32960007-11	2021	CONCLUSIONS: The treatment of salbutamol combined with budesonide for pediatric BA has significant therapeutic effects; it can restore the pulmonary functions rapidly and improve the immunity of the lung, reduce the levels of eotaxin, ECP and EOS of the child patients and promote EOS apoptosis.	Budesonide	55-65	ribonuclease A family member 3	Homo sapiens	235-238
33931866-9	2021	Nevertheless, budesonide needs to be maintained in the baseline series for its good ability to detect CS sensitization.	Budesonide	14-24	citrate synthase	Homo sapiens	102-104
33164838-5	2021	Differences in the physiology of CD patients were identified in literature and their impact on budesonide performance was investigated with a PBPK model, revealing the highest impact on the simulated bioavailability for the reduced hepatic CYP3A4 enzyme abundance and lower human serum albumin concentration.	Budesonide	95-105	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	240-246
33742420-10	2021	The budesonide-related AR suppression had to do with a decrease in proinflammatory cytokines and an increase in the anti-inflammatory IL-10, with negligible influence on growth factors synthesis and mucous glands activity.	Budesonide	4-14	interleukin-10	Cavia porcellus	134-139
33376135-12	2021	Significance Statement In human bronchial epithelial cells, formoterol, a long-acting beta2-adrenoceptor agonist enhanced the expression of inflammatory genes and many of these changes were reduced by the glucocorticoid, budesonide.	Budesonide	221-231	adrenoceptor beta 2	Homo sapiens	86-104
33278326-10	2021	This information is relevant for PBPK model development and could aid with dose adjustment decisions for oral CYP3A4 substrates administered during CD flare (e.g., budesonide).	Budesonide	164-174	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	110-116
33164838-5	2021	Differences in the physiology of CD patients were identified in literature and their impact on budesonide performance was investigated with a PBPK model, revealing the highest impact on the simulated bioavailability for the reduced hepatic CYP3A4 enzyme abundance and lower human serum albumin concentration.	Budesonide	95-105	albumin	Homo sapiens	286-293
33454440-3	2021	Budesonide quantification was performed with a RP-C18 column using methanol and water mixture (69:31, v/v) as mobile phase, pumped at 0.8 ml/min.	Budesonide	0-10	RNA polymerase II, I and III subunit H	Homo sapiens	47-53
32807688-2	2021	Lopinavir-interferon alpha2b boosted ribavirin following with lopinavir boosted budesonide might be a potent treatment for viral clearance.	Budesonide	80-90	interferon alpha 2	Homo sapiens	10-28
32950590-9	2021	The proportion of patients with ALP <1.67xULN, >=15% decrease and normal bilirubin, was higher in the budesonide group than in the placebo group at 12, 24, and 36 months (p<0.05, each).	Budesonide	102-112	alkaline phosphatase, placental	Homo sapiens	32-35
32950590-10	2021	In contrast to placebo, budesonide reduced mean ALP, and 35% of budesonide-treated patients had normalisation of ALP (Placebo: 9%; p=0.023).	Budesonide	24-34	alkaline phosphatase, placental	Homo sapiens	48-51
32950590-10	2021	In contrast to placebo, budesonide reduced mean ALP, and 35% of budesonide-treated patients had normalisation of ALP (Placebo: 9%; p=0.023).	Budesonide	64-74	alkaline phosphatase, placental	Homo sapiens	113-116
33423318-5	2021	RESULTS: In asthmatic patients inhaled budesonide inhibited airway macrophage autophagy (beclin-1, LC3) as well as autophagic flux (p62), which was enhanced by simvastatin and was correlated with increased sputum IL-10 and reduced IL-4 concentrations.	Budesonide	39-49	beclin 1	Homo sapiens	89-97
33466782-3	2021	In the present work, the level of 5-HT in serum and the number of enteroendocrine cells (EECs) as well as the expression of the 5-HT rate-limiting enzyme tryptophan hydroxylase 1 (TPH1) in colonic biopsies and urine 5-hydroxyindoeoacetic acid (5-HIAA) were determined in 36 LC patients that were treated with budesonide and 32 healthy controls.	Budesonide	309-319	tryptophan hydroxylase 1	Homo sapiens	154-178
33466782-3	2021	In the present work, the level of 5-HT in serum and the number of enteroendocrine cells (EECs) as well as the expression of the 5-HT rate-limiting enzyme tryptophan hydroxylase 1 (TPH1) in colonic biopsies and urine 5-hydroxyindoeoacetic acid (5-HIAA) were determined in 36 LC patients that were treated with budesonide and 32 healthy controls.	Budesonide	309-319	tryptophan hydroxylase 1	Homo sapiens	180-184
33466782-6	2021	Budesonide decreased the levels of 5-HT, 5-HIAA, and TPH1 expression and the number of EECs to values that did not differ from those for controls.	Budesonide	0-10	tryptophan hydroxylase 1	Homo sapiens	53-57
33423318-5	2021	RESULTS: In asthmatic patients inhaled budesonide inhibited airway macrophage autophagy (beclin-1, LC3) as well as autophagic flux (p62), which was enhanced by simvastatin and was correlated with increased sputum IL-10 and reduced IL-4 concentrations.	Budesonide	39-49	microtubule associated protein 1 light chain 3 alpha	Homo sapiens	99-102
33423318-5	2021	RESULTS: In asthmatic patients inhaled budesonide inhibited airway macrophage autophagy (beclin-1, LC3) as well as autophagic flux (p62), which was enhanced by simvastatin and was correlated with increased sputum IL-10 and reduced IL-4 concentrations.	Budesonide	39-49	nucleoporin 62	Homo sapiens	132-135
33423318-5	2021	RESULTS: In asthmatic patients inhaled budesonide inhibited airway macrophage autophagy (beclin-1, LC3) as well as autophagic flux (p62), which was enhanced by simvastatin and was correlated with increased sputum IL-10 and reduced IL-4 concentrations.	Budesonide	39-49	interleukin 10	Homo sapiens	213-218
33423318-5	2021	RESULTS: In asthmatic patients inhaled budesonide inhibited airway macrophage autophagy (beclin-1, LC3) as well as autophagic flux (p62), which was enhanced by simvastatin and was correlated with increased sputum IL-10 and reduced IL-4 concentrations.	Budesonide	39-49	interleukin 4	Homo sapiens	231-235
33423318-6	2021	In macrophages in-vitro, budesonide and simvastatin inhibited rapamycin-induced autophagy as well as autophagic flux, with reduced expression of beclin-1 and LC3, but enhanced the accumulation of p62 and increased expression of IL-10, which itself further inhibited autophagy in macrophages.	Budesonide	25-35	beclin 1	Homo sapiens	145-153
33423318-6	2021	In macrophages in-vitro, budesonide and simvastatin inhibited rapamycin-induced autophagy as well as autophagic flux, with reduced expression of beclin-1 and LC3, but enhanced the accumulation of p62 and increased expression of IL-10, which itself further inhibited autophagy in macrophages.	Budesonide	25-35	microtubule associated protein 1 light chain 3 alpha	Homo sapiens	158-161
33423318-6	2021	In macrophages in-vitro, budesonide and simvastatin inhibited rapamycin-induced autophagy as well as autophagic flux, with reduced expression of beclin-1 and LC3, but enhanced the accumulation of p62 and increased expression of IL-10, which itself further inhibited autophagy in macrophages.	Budesonide	25-35	nucleoporin 62	Homo sapiens	196-199
33423318-6	2021	In macrophages in-vitro, budesonide and simvastatin inhibited rapamycin-induced autophagy as well as autophagic flux, with reduced expression of beclin-1 and LC3, but enhanced the accumulation of p62 and increased expression of IL-10, which itself further inhibited autophagy in macrophages.	Budesonide	25-35	interleukin 10	Homo sapiens	228-233
33423318-8	2021	Neutralisation of IL-10 with recombinant specific blocking antibody and silencing IL-10 transcription reversed the inhibitory effects of budesonide and simvastatin on macrophage autophagy.	Budesonide	137-147	interleukin 10	Homo sapiens	18-23
33423318-8	2021	Neutralisation of IL-10 with recombinant specific blocking antibody and silencing IL-10 transcription reversed the inhibitory effects of budesonide and simvastatin on macrophage autophagy.	Budesonide	137-147	interleukin 10	Homo sapiens	82-87
32444401-7	2020	Participants randomised to as-needed budesonide-formoterol took higher equivalent doses of beta2-agonist both overall (median number of actuations 0.8 versus 0.3 per day respectively) and in response to worsening asthma (total number of "overuse days" of >8 or >16 actuations of budesonide-formoterol or terbutaline 33 versus 10 respectively).	Budesonide	37-47	ATPase H+ transporting V0 subunit a2	Homo sapiens	91-96
33506054-13	2021	Additionally, budesonide significantly increased the expression of SLPI and CLU in cultured nasal tissues.	Budesonide	14-24	secretory leukocyte peptidase inhibitor	Homo sapiens	67-71
33506054-13	2021	Additionally, budesonide significantly increased the expression of SLPI and CLU in cultured nasal tissues.	Budesonide	14-24	clusterin	Homo sapiens	76-79
33387985-7	2021	For patients with COPD using an ICS/LABA (n = 574), budesonide/formoterol fumarate dihydrate (160 mug/4.5 mug) pMDI had the highest PrCP (56.6%), and for those using a LAMA/LABA inhaler (n = 217), tiotropium/olodaterol (2.5 mug/2.5 mug) soft mist inhaler had the highest PrCP (42.3%).	Budesonide	52-62	prolylcarboxypeptidase	Homo sapiens	132-136
33387985-7	2021	For patients with COPD using an ICS/LABA (n = 574), budesonide/formoterol fumarate dihydrate (160 mug/4.5 mug) pMDI had the highest PrCP (56.6%), and for those using a LAMA/LABA inhaler (n = 217), tiotropium/olodaterol (2.5 mug/2.5 mug) soft mist inhaler had the highest PrCP (42.3%).	Budesonide	52-62	prolylcarboxypeptidase	Homo sapiens	271-275
31974913-1	2020	BACKGROUND: New formulations for topical treatment of ulcerative colitis with budesonide inclusion complex (BUDHP-beta-CD) and poloxamers (PL) were developed for future clinical use.	Budesonide	78-88	ACD, shelterin complex subunit and telomerase recruitment factor	Rattus norvegicus	114-121
31974913-12	2020	CONCLUSION: Novel budesonide inclusion complex formulations improved microscopic damage and reduced colonic MPO activity and TNF-alpha levels.	Budesonide	18-28	myeloperoxidase	Rattus norvegicus	108-111
31974913-12	2020	CONCLUSION: Novel budesonide inclusion complex formulations improved microscopic damage and reduced colonic MPO activity and TNF-alpha levels.	Budesonide	18-28	tumor necrosis factor	Rattus norvegicus	125-134
33057953-9	2020	RESULTS: Plasma budesonide concentrations showed that budesonide was absorbed significantly faster from BOS 2 mg than from ENTOCORT EC 9 mg, with peak concentrations reached at 1.5 and 4 h, respectively (p < 0.001).	Budesonide	54-64	BOS2	Homo sapiens	104-109
33057953-10	2020	Systemic exposure to budesonide after a single oral dose of BOS 2 mg was lower than that observed after a single oral dose of ENTOCORT EC 9 mg; the least squares geometric mean maximum plasma concentration and the area under the concentration-time curve from the time of dosing to infinity and from the time of dosing to the last measurable concentration of budesonide after BOS 2 mg were 71.1%, 33.5%, and 33.6% of those after ENTOCORT EC 9 mg, respectively.	Budesonide	21-31	BOS2	Homo sapiens	60-65
33057953-12	2020	CONCLUSIONS: This study demonstrated that systemic exposure to budesonide after a single oral dose of BOS 2 mg was lower than that after a single oral dose of ENTOCORT EC 9 mg.	Budesonide	63-73	BOS2	Homo sapiens	102-107
32878016-5	2020	At the end of the article, they concluded that the best formulation of oral viscous budesonide was the one already being used in hospitals, based on xanthan gum.	Budesonide	84-94	OTU deubiquitinase with linear linkage specificity	Homo sapiens	157-160
32899549-8	2020	The in vivo tumor-necrosis-factor (TNF)-alpha secretion in an acute lung inflammation mouse model was significantly reduced (p < 0.001) following a prophylactic treatment with Budesolv compared to Rhinocort  aqua 64.	Budesonide	197-206	tumor necrosis factor	Mus musculus	12-45
32994594-1	2020	AIM: In the PRACTICAL study, as-needed budesonide/formoterol reduced the rate of severe exacerbations compared with maintenance budesonide plus as-needed terbutaline.	Budesonide	39-49	PRAC1 small nuclear protein	Homo sapiens	12-21
32913546-12	2020	Budesonide treatment also resulted in increased HDAC2 expression and decreased IL-8 and VEGF expression.	Budesonide	0-10	histone deacetylase 2	Homo sapiens	48-53
32913546-12	2020	Budesonide treatment also resulted in increased HDAC2 expression and decreased IL-8 and VEGF expression.	Budesonide	0-10	C-X-C motif chemokine ligand 8	Homo sapiens	79-83
32913546-12	2020	Budesonide treatment also resulted in increased HDAC2 expression and decreased IL-8 and VEGF expression.	Budesonide	0-10	vascular endothelial growth factor A	Homo sapiens	88-92
32842201-0	2020	[The role of budesonide on CD8+CD25+Foxp3+ Treg cells in neutrophilic nasal polyps].	Budesonide	13-23	CD8a molecule	Homo sapiens	27-30
32164488-6	2020	The levels of IL-6, IL-8, and MDA in BLAF and pulmonary MPO content in the COPD mice were effectively increased, while the levels of SOD and CAT in BLAF were decreased, which could be reversed by budesonide and hesperidin.	Budesonide	196-206	interleukin 6	Mus musculus	14-18
32164488-6	2020	The levels of IL-6, IL-8, and MDA in BLAF and pulmonary MPO content in the COPD mice were effectively increased, while the levels of SOD and CAT in BLAF were decreased, which could be reversed by budesonide and hesperidin.	Budesonide	196-206	chemokine (C-X-C motif) ligand 15	Mus musculus	20-24
32164488-6	2020	The levels of IL-6, IL-8, and MDA in BLAF and pulmonary MPO content in the COPD mice were effectively increased, while the levels of SOD and CAT in BLAF were decreased, which could be reversed by budesonide and hesperidin.	Budesonide	196-206	myeloperoxidase	Mus musculus	56-59
32164488-7	2020	Moreover, the addition of budesonide or hesperidin reliably accelerated the expression levels of PGC-1alpha and SIRT1 but suppressed the phosphorylation of p65 in COPD mice.	Budesonide	26-36	peroxisome proliferative activated receptor, gamma, coactivator 1 alpha	Mus musculus	97-107
32164488-7	2020	Moreover, the addition of budesonide or hesperidin reliably accelerated the expression levels of PGC-1alpha and SIRT1 but suppressed the phosphorylation of p65 in COPD mice.	Budesonide	26-36	sirtuin 1	Mus musculus	112-117
32164488-7	2020	Moreover, the addition of budesonide or hesperidin reliably accelerated the expression levels of PGC-1alpha and SIRT1 but suppressed the phosphorylation of p65 in COPD mice.	Budesonide	26-36	v-rel reticuloendotheliosis viral oncogene homolog A (avian)	Mus musculus	156-159
32842201-0	2020	[The role of budesonide on CD8+CD25+Foxp3+ Treg cells in neutrophilic nasal polyps].	Budesonide	13-23	interferon stimulated exonuclease gene 20	Homo sapiens	31-35
32842201-0	2020	[The role of budesonide on CD8+CD25+Foxp3+ Treg cells in neutrophilic nasal polyps].	Budesonide	13-23	forkhead box P3	Homo sapiens	36-41
32723439-0	2020	Mechanisms of effect of early inhalation of budesonide on pulmonary function, osteopontin and alpha-SMA in asthmatic rats.	Budesonide	44-54	secreted phosphoprotein 1	Rattus norvegicus	78-89
32944330-2	2020	In this study, we investigated the therapeutic effect of high-dose budesonide/formoterol (320/9 microg bid) in patients with BOS after HSCT already using low-dose budesonide/formoterol (160/4.5 microg bid).	Budesonide	67-77	BH3 interacting domain death agonist	Homo sapiens	103-106
32016376-9	2020	RESULTS: Using qPCR and RNA-seq, we identified loss of AQP8 expression as a hallmark of active CC, which was reverted by budesonide treatment in steroid-responsive but not refractory patients.	Budesonide	121-131	aquaporin 8	Homo sapiens	55-59
32378535-0	2020	Remarkable Improvement in Clinical Course and Serum KL-6 Levels after Initiation of High-Dose Inhaled Budesonide in Pulmonary Sarcoidosis.	Budesonide	102-112	mucin 1, cell surface associated	Homo sapiens	52-56
32378535-3	2020	The patient was started on high-dose inhaled budesonide because of high serum levels of angiotensin-converting enzyme (ACE) and KL-6.	Budesonide	45-55	angiotensin I converting enzyme	Homo sapiens	88-117
32378535-3	2020	The patient was started on high-dose inhaled budesonide because of high serum levels of angiotensin-converting enzyme (ACE) and KL-6.	Budesonide	45-55	angiotensin I converting enzyme	Homo sapiens	119-122
32378535-3	2020	The patient was started on high-dose inhaled budesonide because of high serum levels of angiotensin-converting enzyme (ACE) and KL-6.	Budesonide	45-55	mucin 1, cell surface associated	Homo sapiens	128-132
32590815-2	2020	We sought to evaluate the efficacy of targeting the mucosal immune system dysregulation underlying IgAN pathogenesis with a pH-modified formulation of budesonide with a maximum release of active compound in the distal ileum and proximal colon.We did a retrospective study evaluating the efficacy of budesonide (Budenofalk) in the treatment of IgAN.	Budesonide	151-161	IGAN1	Homo sapiens	99-103
32590815-3	2020	From a retrospective cohort of 143 patients with IgAN followed in our department we identified 21 patients that received treatment with budesonide.	Budesonide	136-146	IGAN1	Homo sapiens	49-53
32590815-10	2020	Treatment with budesonide was well tolerated with minimal side effects.Budesonide (Budenofalk) was effective in the treatment of patients with IgAN at high-risk of progression in terms of reducing proteinuria, hematuria and preserving renal function over 24 months of therapy.	Budesonide	15-25	IGAN1	Homo sapiens	143-147
32590815-10	2020	Treatment with budesonide was well tolerated with minimal side effects.Budesonide (Budenofalk) was effective in the treatment of patients with IgAN at high-risk of progression in terms of reducing proteinuria, hematuria and preserving renal function over 24 months of therapy.	Budesonide	71-81	IGAN1	Homo sapiens	143-147
32590815-10	2020	Treatment with budesonide was well tolerated with minimal side effects.Budesonide (Budenofalk) was effective in the treatment of patients with IgAN at high-risk of progression in terms of reducing proteinuria, hematuria and preserving renal function over 24 months of therapy.	Budesonide	83-93	IGAN1	Homo sapiens	143-147
32253054-1	2020	PURPOSE: The triple combination therapy budesonide/glycopyrrolate/formoterol fumarate in a metered dose inhaler (BGF MDI), formulated by using innovative co-suspension delivery technology, is a new inhaled corticosteroid/long-acting muscarinic antagonist/long-acting beta2-agonist fixed-dose combination for the maintenance treatment of COPD.	Budesonide	40-50	ATPase H+ transporting V0 subunit a2	Homo sapiens	267-272
32378169-11	2020	There was decline of IKK-beta and NF-kappaB-P65 and elevation of IkappaB-alpha in the N-acetylcysteine group, which was even significantly in the Budesonide group (P < 0.01).	Budesonide	146-156	conserved helix-loop-helix ubiquitous kinase	Mus musculus	21-29
32378169-11	2020	There was decline of IKK-beta and NF-kappaB-P65 and elevation of IkappaB-alpha in the N-acetylcysteine group, which was even significantly in the Budesonide group (P < 0.01).	Budesonide	146-156	nuclear factor of kappa light polypeptide gene enhancer in B cells inhibitor, alpha	Mus musculus	65-78
32210313-7	2020	We found that like dexamethasone, budesonide inhibits adipogenesis induced by insulin in sub-confluent FAPs.	Budesonide	34-44	insulin	Homo sapiens	78-85
32135492-8	2020	CpG-ODNs and budesonide were found to synergistically inhibit inflammatory cell recruitment in the lung, airway remodeling, IgE synthesis, and Th17/Th2 associated cytokines.	Budesonide	13-23	heart and neural crest derivatives expressed 2	Mus musculus	148-151
32135492-9	2020	Mechanistically, CpG-ODNs and budesonide acted synergistically on BMDCs via downregulation of TSLP receptor (TSLPR) and IL-23 production, and subsequently contributed to dampen Th17/Th2 polarization in CS-associated asthma.	Budesonide	30-40	cytokine receptor-like factor 2	Mus musculus	94-107
32135492-9	2020	Mechanistically, CpG-ODNs and budesonide acted synergistically on BMDCs via downregulation of TSLP receptor (TSLPR) and IL-23 production, and subsequently contributed to dampen Th17/Th2 polarization in CS-associated asthma.	Budesonide	30-40	cytokine receptor-like factor 2	Mus musculus	109-114
32135492-9	2020	Mechanistically, CpG-ODNs and budesonide acted synergistically on BMDCs via downregulation of TSLP receptor (TSLPR) and IL-23 production, and subsequently contributed to dampen Th17/Th2 polarization in CS-associated asthma.	Budesonide	30-40	interleukin 23, alpha subunit p19	Mus musculus	120-125
32135492-9	2020	Mechanistically, CpG-ODNs and budesonide acted synergistically on BMDCs via downregulation of TSLP receptor (TSLPR) and IL-23 production, and subsequently contributed to dampen Th17/Th2 polarization in CS-associated asthma.	Budesonide	30-40	heart and neural crest derivatives expressed 2	Mus musculus	182-185
32135492-10	2020	In conclusion, combined administration of CpG-ODNs and budesonide, in a synergistic manner, inhibits airway inflammation, and tissue remodeling mediated by BMDCs by regulating IL-23 secretion and blocking TSLP signaling, which subsequently contribute to alleviate Th17/Th2 imbalance in CS-associated asthma.	Budesonide	55-65	interleukin 23, alpha subunit p19	Mus musculus	176-181
32135492-10	2020	In conclusion, combined administration of CpG-ODNs and budesonide, in a synergistic manner, inhibits airway inflammation, and tissue remodeling mediated by BMDCs by regulating IL-23 secretion and blocking TSLP signaling, which subsequently contribute to alleviate Th17/Th2 imbalance in CS-associated asthma.	Budesonide	55-65	thymic stromal lymphopoietin	Mus musculus	205-209
32135492-10	2020	In conclusion, combined administration of CpG-ODNs and budesonide, in a synergistic manner, inhibits airway inflammation, and tissue remodeling mediated by BMDCs by regulating IL-23 secretion and blocking TSLP signaling, which subsequently contribute to alleviate Th17/Th2 imbalance in CS-associated asthma.	Budesonide	55-65	heart and neural crest derivatives expressed 2	Mus musculus	269-272
32394927-0	2020	Successful treatment of a patient with posttransplant IgA nephropathy with targeted release formulation of budesonide.	Budesonide	107-117	CD79a molecule	Homo sapiens	54-57
32394927-3	2020	The NEFIGAN trial demonstrated that Target Release Formulation (TRF) of budesonide is a specific treatment for IgA nephropathy targeting intestinal mucosal immunity upstream of disease manifestation with favorable safety profile.	Budesonide	72-82	CD79a molecule	Homo sapiens	111-114
32394927-4	2020	We are reporting a case of successful treatment of a patient with posttransplant IgA nephropathy with TRF of budesonide.	Budesonide	109-119	CD79a molecule	Homo sapiens	81-84
32158443-6	2020	Through a series of inhibition and add-back studies, we determined budesonide acts synergistically with spheroid MSC-produced PGE2 to suppress T cell proliferation through the PGE2 receptors EP2 and EP4.	Budesonide	67-77	prostaglandin E receptor 2	Homo sapiens	191-194
32158443-6	2020	Through a series of inhibition and add-back studies, we determined budesonide acts synergistically with spheroid MSC-produced PGE2 to suppress T cell proliferation through the PGE2 receptors EP2 and EP4.	Budesonide	67-77	prostaglandin E receptor 4	Homo sapiens	199-202
30614939-4	2020	METHODS: Prospectively collected serum samples of 17 EoE patients before and after 8 weeks of therapy with budesonide (1 mg BID) were analyzed for total and antigen-specific IgG4 and IgE levels.	Budesonide	107-117	BH3 interacting domain death agonist	Homo sapiens	124-127
31964393-6	2020	At pH 7.4, EAC-Bud-Lip underwent significant size reduction and exhibited drug release profiles similar to that from AC-Bud-Lip, implying the pH-dependent removal of the outer coating layer.	Budesonide	15-18	CCAAT/enhancer binding protein (C/EBP), beta	Mus musculus	19-22
31964393-7	2020	Compared to free Bud solution, EAC-Bud-Lip achieved a higher drug uptake in Caco-2 cells and exhibited a stronger inhibition of TNF-alpha and IL-6 secretion in LPS-stimulated Raw264.7 cells.	Budesonide	17-20	SMG1 nonsense mediated mRNA decay associated PI3K related kinase	Homo sapiens	39-42
31964393-7	2020	Compared to free Bud solution, EAC-Bud-Lip achieved a higher drug uptake in Caco-2 cells and exhibited a stronger inhibition of TNF-alpha and IL-6 secretion in LPS-stimulated Raw264.7 cells.	Budesonide	17-20	tumor necrosis factor	Homo sapiens	128-137
31964393-7	2020	Compared to free Bud solution, EAC-Bud-Lip achieved a higher drug uptake in Caco-2 cells and exhibited a stronger inhibition of TNF-alpha and IL-6 secretion in LPS-stimulated Raw264.7 cells.	Budesonide	17-20	interleukin 6	Homo sapiens	142-146
31964393-7	2020	Compared to free Bud solution, EAC-Bud-Lip achieved a higher drug uptake in Caco-2 cells and exhibited a stronger inhibition of TNF-alpha and IL-6 secretion in LPS-stimulated Raw264.7 cells.	Budesonide	35-38	SMG1 nonsense mediated mRNA decay associated PI3K related kinase	Homo sapiens	39-42
31964393-7	2020	Compared to free Bud solution, EAC-Bud-Lip achieved a higher drug uptake in Caco-2 cells and exhibited a stronger inhibition of TNF-alpha and IL-6 secretion in LPS-stimulated Raw264.7 cells.	Budesonide	35-38	tumor necrosis factor	Homo sapiens	128-137
31964393-7	2020	Compared to free Bud solution, EAC-Bud-Lip achieved a higher drug uptake in Caco-2 cells and exhibited a stronger inhibition of TNF-alpha and IL-6 secretion in LPS-stimulated Raw264.7 cells.	Budesonide	35-38	interleukin 6	Homo sapiens	142-146
31743968-0	2020	Reversal of Olfactory Disturbance in Allergic Rhinitis Related to OMP Suppression by Intranasal Budesonide Treatment.	Budesonide	96-106	olfactory marker protein	Mus musculus	66-69
31743968-22	2020	In the intranasal budesonide group, the olfactory lesions and OMP expression had improved substantially.	Budesonide	18-28	olfactory marker protein	Mus musculus	62-65
31835979-1	2020	BACKGROUND: Recent studies have shown that oral budesonide can be used to improve albumin level in patients with protein-losing enteropathy (PLE) following Fontan procedure.	Budesonide	48-58	albumin	Homo sapiens	82-89
31835979-8	2020	In random-effects model, there was a statistically significant difference in albumin level between before and after budesonide treatment (weighted mean difference = 1.28, 95% confidence interval: 0.76-1.79).	Budesonide	116-126	albumin	Homo sapiens	77-84
31835979-10	2020	CONCLUSIONS: The results of this systematic review and meta-analysis show that budesonide can be used to increase albumin level in patients with PLE following Fontan operation.	Budesonide	79-89	albumin	Homo sapiens	114-121
31848500-10	2019	The expression of AQP5 in the budesonide group was not significantly different from that in the normal control group 1, 2 and 4 weeks after drug intervention (P>0.05), but there was significant difference between the budesonide group and the model control group (P<0.05).	Budesonide	30-40	aquaporin 5	Rattus norvegicus	18-22
31948528-12	2020	Compared with the model group, the low-, middle-, and high-dose asiaticoside groups and the budesonide group had significant improvement in the above symptoms of bronchopulmonary dysplasia, significant reductions in MLI, MDA level in lung tissue, serum levels of IL-6 and TNF-alpha, and miR-155 level in lung tissue (P<0.05), and significant increases in RAC, SOD level, and mRNA and protein expression of SOCS1 in lung tissue (P<0.05).	Budesonide	92-102	interleukin 6	Rattus norvegicus	263-267
31948528-12	2020	Compared with the model group, the low-, middle-, and high-dose asiaticoside groups and the budesonide group had significant improvement in the above symptoms of bronchopulmonary dysplasia, significant reductions in MLI, MDA level in lung tissue, serum levels of IL-6 and TNF-alpha, and miR-155 level in lung tissue (P<0.05), and significant increases in RAC, SOD level, and mRNA and protein expression of SOCS1 in lung tissue (P<0.05).	Budesonide	92-102	tumor necrosis factor	Rattus norvegicus	272-281
31948528-12	2020	Compared with the model group, the low-, middle-, and high-dose asiaticoside groups and the budesonide group had significant improvement in the above symptoms of bronchopulmonary dysplasia, significant reductions in MLI, MDA level in lung tissue, serum levels of IL-6 and TNF-alpha, and miR-155 level in lung tissue (P<0.05), and significant increases in RAC, SOD level, and mRNA and protein expression of SOCS1 in lung tissue (P<0.05).	Budesonide	92-102	microRNA 155	Rattus norvegicus	287-294
31948528-12	2020	Compared with the model group, the low-, middle-, and high-dose asiaticoside groups and the budesonide group had significant improvement in the above symptoms of bronchopulmonary dysplasia, significant reductions in MLI, MDA level in lung tissue, serum levels of IL-6 and TNF-alpha, and miR-155 level in lung tissue (P<0.05), and significant increases in RAC, SOD level, and mRNA and protein expression of SOCS1 in lung tissue (P<0.05).	Budesonide	92-102	suppressor of cytokine signaling 1	Rattus norvegicus	406-411
31848500-10	2019	The expression of AQP5 in the budesonide group was not significantly different from that in the normal control group 1, 2 and 4 weeks after drug intervention (P>0.05), but there was significant difference between the budesonide group and the model control group (P<0.05).	Budesonide	217-227	aquaporin 5	Rattus norvegicus	18-22
31848500-11	2019	The expression of AQP5 mRNA in the budesonide group was significantly different from that in the normal control group and the model control group (P<0.05).After 2 weeks of intervention, the expression of AQP5 in each dose group of methyleugenol was not significantly different from that in the budesonide group (P>0.05).	Budesonide	35-45	aquaporin 5	Rattus norvegicus	18-22
31848500-11	2019	The expression of AQP5 mRNA in the budesonide group was significantly different from that in the normal control group and the model control group (P<0.05).After 2 weeks of intervention, the expression of AQP5 in each dose group of methyleugenol was not significantly different from that in the budesonide group (P>0.05).	Budesonide	35-45	aquaporin 5	Rattus norvegicus	204-208
31858575-0	2019	Budesonide and Poractant Alfa prevent bronchopulmonary dysplasia via triggering SIRT1 signaling pathway.	Budesonide	0-10	sirtuin 1	Homo sapiens	80-85
31269587-15	2019	Conclusion: Penicillin,erythromycin and budesonide can alleviate inflammation by increasing SIRT-1, alleviate tracheal scar hyperplasia induced by TGF-beta/mTOR pathway, and reduce the degree of tracheal stenosis in rabbits.	Budesonide	40-50	NAD-dependent protein deacetylase sirtuin-1	Oryctolagus cuniculus	92-98
31858575-14	2019	Compared with NRDS group, when treated with budesonide and Poractant Alfa, ROS levels decreased, SENP1 decreased, nuclear SIRT1 increased (p<0.01).	Budesonide	44-54	SUMO specific peptidase 1	Homo sapiens	97-102
31858575-14	2019	Compared with NRDS group, when treated with budesonide and Poractant Alfa, ROS levels decreased, SENP1 decreased, nuclear SIRT1 increased (p<0.01).	Budesonide	44-54	sirtuin 1	Homo sapiens	122-127
31858575-15	2019	CONCLUSIONS: Budesonide combining Poractant Alfa can prevent BPD in preterm infants by activating the SIRT1 signaling pathway.	Budesonide	13-23	sirtuin 1	Homo sapiens	102-107
31806959-8	2019	In mice subjected to dextran sulfate sodium-induced colitis, oral administration of BDS-entrapped KO liposomes suppressed tumor necrosis factor-alpha production (by 84.1%), interleukin-6 production (by 35.3%), and the systemic level of endotoxin (by 96.8%), and slightly reduced the macroscopic signs of the disease.	Budesonide	84-87	interleukin 6	Mus musculus	173-186
31636329-7	2019	Budesonide strongly suppressed the production of neutrophil attractant CXCL8, and promoted epithelial integrity in A549 wild-type cells, while A549 Rho-0 cells displayed reduced corticosteroid sensitivity compared to wild-type cells.	Budesonide	0-10	C-X-C motif chemokine ligand 8	Homo sapiens	71-76
31737193-9	2019	However, the IFN-gamma concentration for the Catalpol and BUD groups were higher than the model group.	Budesonide	58-61	interferon gamma	Rattus norvegicus	13-22
31737193-10	2019	After treatment with Catalpol+BUD, the eosinophils and neutrophils of the rats were further reduced, asthma-associated inflammation was obviously inhibited, IL-4 level was further decreased and IFN-gamma level was further increased comparing the Catalpol group and the BUD group.	Budesonide	30-33	interleukin 4	Rattus norvegicus	157-161
31737193-10	2019	After treatment with Catalpol+BUD, the eosinophils and neutrophils of the rats were further reduced, asthma-associated inflammation was obviously inhibited, IL-4 level was further decreased and IFN-gamma level was further increased comparing the Catalpol group and the BUD group.	Budesonide	30-33	interferon gamma	Rattus norvegicus	194-203
31605597-6	2019	Furthermore, the porous structure of hybrid silica particles loaded with budesonide was examined under TEM.	Budesonide	73-83	MFT2	Homo sapiens	103-106
31572383-8	2019	Budesonide inhibited airway hyperreactivity, eosinophil counts in the lung and bronchoalveolar lavage (BAL) and CCL11, IL-13, and IL-23p19 release in the BAL of mice sensitized and challenged with Af (p < 0.05).	Budesonide	0-10	chemokine (C-C motif) ligand 11	Mus musculus	112-117
31572383-8	2019	Budesonide inhibited airway hyperreactivity, eosinophil counts in the lung and bronchoalveolar lavage (BAL) and CCL11, IL-13, and IL-23p19 release in the BAL of mice sensitized and challenged with Af (p < 0.05).	Budesonide	0-10	interleukin 13	Mus musculus	119-124
31572383-10	2019	O3 stimulated release of pro-neutrophilic mediators including CCL20 and IL-6 into the airways and impaired the inhibitory effects of budesonide on CCL11, IL-13 and IL-23.	Budesonide	133-143	chemokine (C-C motif) ligand 11	Mus musculus	147-152
31572383-10	2019	O3 stimulated release of pro-neutrophilic mediators including CCL20 and IL-6 into the airways and impaired the inhibitory effects of budesonide on CCL11, IL-13 and IL-23.	Budesonide	133-143	interleukin 13	Mus musculus	154-159
31572383-10	2019	O3 stimulated release of pro-neutrophilic mediators including CCL20 and IL-6 into the airways and impaired the inhibitory effects of budesonide on CCL11, IL-13 and IL-23.	Budesonide	133-143	interleukin 23, alpha subunit p19	Mus musculus	164-169
31572383-13	2019	Dexamethasone and budesonide induced sftpd transcription and translation in human type II alveolar epithelial cells in a glucocorticoid receptor and STAT3 (an IL-6 responsive transcription factor) dependent manner.	Budesonide	18-28	nuclear receptor subfamily 3 group C member 1	Homo sapiens	121-144
31572383-13	2019	Dexamethasone and budesonide induced sftpd transcription and translation in human type II alveolar epithelial cells in a glucocorticoid receptor and STAT3 (an IL-6 responsive transcription factor) dependent manner.	Budesonide	18-28	signal transducer and activator of transcription 3	Homo sapiens	149-154
31572383-13	2019	Dexamethasone and budesonide induced sftpd transcription and translation in human type II alveolar epithelial cells in a glucocorticoid receptor and STAT3 (an IL-6 responsive transcription factor) dependent manner.	Budesonide	18-28	interleukin 6	Homo sapiens	159-163
31269587-15	2019	Conclusion: Penicillin,erythromycin and budesonide can alleviate inflammation by increasing SIRT-1, alleviate tracheal scar hyperplasia induced by TGF-beta/mTOR pathway, and reduce the degree of tracheal stenosis in rabbits.	Budesonide	40-50	serine/threonine-protein kinase mTOR	Oryctolagus cuniculus	156-160
30741829-10	2019	CONCLUSIONS: This study suggested that LL-37 could improve the anti-inflammatory activity of budesonide in cigarette smoke and LPS-induced COPD rat model by enhancing the expression and activity of HDAC2.	Budesonide	93-103	histone deacetylase 2	Rattus norvegicus	198-203
31112386-1	2019	BACKGROUND: In double-blind, placebo-controlled trials, budesonide-formoterol used on an as-needed basis resulted in a lower risk of severe exacerbation of asthma than as-needed use of a short-acting beta2-agonist (SABA); the risk was similar to that of budesonide maintenance therapy plus as-needed SABA.	Budesonide	56-66	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	200-205
31092255-14	2019	TRPC1 intervention treatment showed similar anti-remodeling therapeutic effect with budesonide.	Budesonide	84-94	transient receptor potential cation channel subfamily C member 1	Homo sapiens	0-5
30535958-13	2019	Budesonide reduced histopathological injury in the proximal (P = 0.0401) and distal colon (P = 0.027) and increased anti-inflammatory IL-4 tissue concentration (ileum; P = 0.0026, colon; P = 0.031) compared to rats treated with neratinib alone.	Budesonide	0-10	interleukin 4	Rattus norvegicus	134-138
30535958-14	2019	In the distal ileum, while budesonide decreased ErbB1 mRNA expression compared to controls (P = 0.018) (PCR), an increase in total ErbB1 protein was detected (P = 0.0021) (Western Blot).	Budesonide	27-37	epidermal growth factor receptor	Rattus norvegicus	48-53
30704470-8	2019	Budesonide-induced genes showed GO term enrichment for positive and negative regulation of transcription, signaling, proliferation, apoptosis, and movement, as well as FOXO and PI3K-Akt signaling pathways.	Budesonide	0-10	AKT serine/threonine kinase 1	Homo sapiens	182-185
30937316-0	2019	Intranasal Application of Budesonide Attenuates Lipopolysaccharide-Induced Acute Lung Injury by Suppressing Nucleotide-Binding Oligomerization Domain-Like Receptor Family, Pyrin Domain-Containing 3 Inflammasome Activation in Mice.	Budesonide	26-36	interferon activated gene 208	Mus musculus	172-197
30937316-14	2019	Additionally, budesonide dramatically reduced TNF-alpha and MCP-1 expression in the BALF and serum of mice with ALI.	Budesonide	14-24	tumor necrosis factor	Mus musculus	46-55
30937316-14	2019	Additionally, budesonide dramatically reduced TNF-alpha and MCP-1 expression in the BALF and serum of mice with ALI.	Budesonide	14-24	chemokine (C-C motif) ligand 2	Mus musculus	60-65
30937316-15	2019	Budesonide significantly suppressed NLRP3 and pro-caspase-1 expression in the lung and reduced IL-1beta content in the BALF, indicating that budesonide inhibited the activation of the NLRP3 inflammasome.	Budesonide	0-10	NLR family, pyrin domain containing 3	Mus musculus	36-41
30937316-15	2019	Budesonide significantly suppressed NLRP3 and pro-caspase-1 expression in the lung and reduced IL-1beta content in the BALF, indicating that budesonide inhibited the activation of the NLRP3 inflammasome.	Budesonide	0-10	interleukin 1 beta	Mus musculus	95-103
30937316-15	2019	Budesonide significantly suppressed NLRP3 and pro-caspase-1 expression in the lung and reduced IL-1beta content in the BALF, indicating that budesonide inhibited the activation of the NLRP3 inflammasome.	Budesonide	0-10	NLR family, pyrin domain containing 3	Mus musculus	184-189
30937316-15	2019	Budesonide significantly suppressed NLRP3 and pro-caspase-1 expression in the lung and reduced IL-1beta content in the BALF, indicating that budesonide inhibited the activation of the NLRP3 inflammasome.	Budesonide	141-151	NLR family, pyrin domain containing 3	Mus musculus	36-41
30937316-15	2019	Budesonide significantly suppressed NLRP3 and pro-caspase-1 expression in the lung and reduced IL-1beta content in the BALF, indicating that budesonide inhibited the activation of the NLRP3 inflammasome.	Budesonide	141-151	interleukin 1 beta	Mus musculus	95-103
30937316-15	2019	Budesonide significantly suppressed NLRP3 and pro-caspase-1 expression in the lung and reduced IL-1beta content in the BALF, indicating that budesonide inhibited the activation of the NLRP3 inflammasome.	Budesonide	141-151	NLR family, pyrin domain containing 3	Mus musculus	184-189
30937316-17	2019	Conclusion: Suppression of NLRP3 inflammasome activation in mice via budesonide attenuated lung injury induced by LPS in mice with ALI.	Budesonide	69-79	NLR family, pyrin domain containing 3	Mus musculus	27-32
31204163-0	2019	Budesonide up-regulates vitamin D receptor expression in human bronchial fibroblasts and enhances the inhibitory effect of calcitriol on airway remodeling.	Budesonide	0-10	vitamin D receptor	Homo sapiens	24-42
31204163-7	2019	RESULTS: Both budesonide and calcitriol down-regulated miR-21 expression in human bronchial fibroblasts, up-regulated Smad7 expression, and inhibited the expression of airway remodeling-related proteins.	Budesonide	14-24	microRNA 21	Homo sapiens	55-61
31204163-7	2019	RESULTS: Both budesonide and calcitriol down-regulated miR-21 expression in human bronchial fibroblasts, up-regulated Smad7 expression, and inhibited the expression of airway remodeling-related proteins.	Budesonide	14-24	SMAD family member 7	Homo sapiens	118-123
31204163-8	2019	Both budesonide and calcitriol up-regulated the low expression of VDR induced by TGFbeta1 in human bronchial fibroblasts.	Budesonide	5-15	vitamin D receptor	Homo sapiens	66-69
31204163-8	2019	Both budesonide and calcitriol up-regulated the low expression of VDR induced by TGFbeta1 in human bronchial fibroblasts.	Budesonide	5-15	transforming growth factor beta 1	Homo sapiens	81-89
31204163-9	2019	The expression of VDR in the combined treatment group (budesonide plus calcitriol) was significantly higher than that in the calcitriol treatment group.	Budesonide	55-65	vitamin D receptor	Homo sapiens	18-21
31204163-12	2019	Budesonide can up-regulate the expression of VDR in human bronchial fibroblasts and enhance the inhibitory effect of calcitriol on airway remodeling.	Budesonide	0-10	vitamin D receptor	Homo sapiens	45-48
30867367-4	2019	RESULTS: SHC increased internal resistance by 2.8 times in TBH, 1.0 in DKS, and 1.28 (incomplete obstruction) and 1.86 (complete) in EPT.	Budesonide	59-62	SHC adaptor protein 1	Homo sapiens	9-12
30867367-6	2019	SHC suppressed drug release from TBH but statistical significance was not obtained.	Budesonide	33-36	SHC adaptor protein 1	Homo sapiens	0-3
30867367-10	2019	CONCLUSION: SHC severely inhibited drug release from TBH, but almost no effects on DKS.	Budesonide	53-56	SHC adaptor protein 1	Homo sapiens	12-15
30368448-1	2018	OBJECTIVES: Budesonide/formoterol (BF) Spiromax   is an inhaled corticosteroid/long-acting beta2-agonist fixed-dose combination (FDC) inhaler, designed to minimise common inhaler errors and provide reliable and consistent dose delivery in asthma and chronic obstructive pulmonary disease (COPD).	Budesonide	12-22	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	91-96
30236840-8	2018	Further, we show that the budesonide NS enema treated mice had a significantly reduced number of inflammatory macrophages and IL-beta producing CD11b + cells in colon tissue compared to untreated controls or mice treated with the budesonide MS enema.	Budesonide	26-36	integrin subunit alpha M	Homo sapiens	144-149
30236840-8	2018	Further, we show that the budesonide NS enema treated mice had a significantly reduced number of inflammatory macrophages and IL-beta producing CD11b + cells in colon tissue compared to untreated controls or mice treated with the budesonide MS enema.	Budesonide	230-240	integrin subunit alpha M	Homo sapiens	144-149
30471087-0	2018	Protective Effects of Astragaloside IV Combined with Budesonide in Bronchitis in Rats by Regulation of Nrf2/Keap1 Pathway.	Budesonide	53-63	NFE2 like bZIP transcription factor 2	Rattus norvegicus	103-107
30471087-0	2018	Protective Effects of Astragaloside IV Combined with Budesonide in Bronchitis in Rats by Regulation of Nrf2/Keap1 Pathway.	Budesonide	53-63	Kelch-like ECH-associated protein 1	Rattus norvegicus	108-113
30471087-8	2018	The levels of Nrf2, Keap1, and Bcl-2 proteins were increased and the levels of Bach1 and Bax were decreased after treatment with Budesonide and Astragaloside IV.	Budesonide	129-139	NFE2 like bZIP transcription factor 2	Rattus norvegicus	14-18
30471087-8	2018	The levels of Nrf2, Keap1, and Bcl-2 proteins were increased and the levels of Bach1 and Bax were decreased after treatment with Budesonide and Astragaloside IV.	Budesonide	129-139	Kelch-like ECH-associated protein 1	Rattus norvegicus	20-25
30471087-8	2018	The levels of Nrf2, Keap1, and Bcl-2 proteins were increased and the levels of Bach1 and Bax were decreased after treatment with Budesonide and Astragaloside IV.	Budesonide	129-139	BCL2, apoptosis regulator	Rattus norvegicus	31-36
30471087-8	2018	The levels of Nrf2, Keap1, and Bcl-2 proteins were increased and the levels of Bach1 and Bax were decreased after treatment with Budesonide and Astragaloside IV.	Budesonide	129-139	BTB domain and CNC homolog 1	Rattus norvegicus	79-84
30471087-8	2018	The levels of Nrf2, Keap1, and Bcl-2 proteins were increased and the levels of Bach1 and Bax were decreased after treatment with Budesonide and Astragaloside IV.	Budesonide	129-139	BCL2 associated X, apoptosis regulator	Rattus norvegicus	89-92
30471087-9	2018	CONCLUSIONS Astragaloside IV combined with budesonide can ameliorate the lesions caused by bronchitis in rats through activating the Nrf2/Keap1 pathway, which plays a protective role on anti-oxidative stress injury.	Budesonide	43-53	NFE2 like bZIP transcription factor 2	Rattus norvegicus	133-137
30471087-9	2018	CONCLUSIONS Astragaloside IV combined with budesonide can ameliorate the lesions caused by bronchitis in rats through activating the Nrf2/Keap1 pathway, which plays a protective role on anti-oxidative stress injury.	Budesonide	43-53	Kelch-like ECH-associated protein 1	Rattus norvegicus	138-143
30306750-3	2018	We investigate a potentially useful relatively non-invasive biomarker, eosinophil-derived neurotoxin (EDN), to predict favorable responses to budesonide or montelukast, common treatment for children with asthma.	Budesonide	142-152	ribonuclease A family member 2	Homo sapiens	71-100
30306750-3	2018	We investigate a potentially useful relatively non-invasive biomarker, eosinophil-derived neurotoxin (EDN), to predict favorable responses to budesonide or montelukast, common treatment for children with asthma.	Budesonide	142-152	ribonuclease A family member 2	Homo sapiens	102-105
30306750-13	2018	CONCLUSIONS: EDN is a useful relatively non-invasive biomarker for predicting responses to montelukast and budesonide treatment of preschool children with beta2-agonist responsive recurrent wheeze and multiple-trigger wheeze (Trial registry at UMIN Clinical Trials Registry, UMIN000008335).	Budesonide	107-117	ribonuclease A family member 2	Homo sapiens	13-16
30306750-13	2018	CONCLUSIONS: EDN is a useful relatively non-invasive biomarker for predicting responses to montelukast and budesonide treatment of preschool children with beta2-agonist responsive recurrent wheeze and multiple-trigger wheeze (Trial registry at UMIN Clinical Trials Registry, UMIN000008335).	Budesonide	107-117	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	155-160
30405619-0	2018	The Combination Therapy of Dietary Galacto-Oligosaccharides With Budesonide Reduces Pulmonary Th2 Driving Mediators and Mast Cell Degranulation in a Murine Model of House Dust Mite Induced Asthma.	Budesonide	65-75	heart and neural crest derivatives expressed 2	Mus musculus	94-97
30405619-7	2018	Both 1 w/w% and 2.5 w/w% GOS and/or budesonide suppressed serum mMCP-1 concentrations.	Budesonide	36-46	mast cell protease 1	Mus musculus	64-70
30405619-8	2018	However, budesonide nor GOS alone was capable of reducing Th2 driving chemokines CCL17, CCL22 and IL-33 protein levels in supernatants of lung homogenates of HDM allergic mice, whereas the combination therapy did.	Budesonide	9-19	chemokine (C-C motif) ligand 17	Mus musculus	81-86
30405619-8	2018	However, budesonide nor GOS alone was capable of reducing Th2 driving chemokines CCL17, CCL22 and IL-33 protein levels in supernatants of lung homogenates of HDM allergic mice, whereas the combination therapy did.	Budesonide	9-19	chemokine (C-C motif) ligand 22	Mus musculus	88-93
30405619-8	2018	However, budesonide nor GOS alone was capable of reducing Th2 driving chemokines CCL17, CCL22 and IL-33 protein levels in supernatants of lung homogenates of HDM allergic mice, whereas the combination therapy did.	Budesonide	9-19	interleukin 33	Mus musculus	98-103
30405619-9	2018	Moreover, IL-13 concentrations were only significantly suppressed in mice treated with budesonide while fed GOS.	Budesonide	87-97	interleukin 13	Mus musculus	10-15
30066185-3	2018	The effectiveness of budesonide/formoterol inhalation therapy in daily clinical practice, delivered via the Bufomix Easyhaler , was evaluated in patients with asthma, chronic obstructive pulmonary disease (COPD) and asthma-COPD overlap (ACO).	Budesonide	21-31	COPD	Homo sapiens	206-210
29654433-0	2018	CpG-ODNs and Budesonide Act Synergistically to Improve Allergic Responses in Combined Allergic Rhinitis and Asthma Syndrome Induced by Chronic Exposure to Ovalbumin by Modulating the TSLP-DC-OX40L Axis.	Budesonide	13-23	serine (or cysteine) peptidase inhibitor, clade B, member 1, pseudogene	Mus musculus	155-164
29654433-0	2018	CpG-ODNs and Budesonide Act Synergistically to Improve Allergic Responses in Combined Allergic Rhinitis and Asthma Syndrome Induced by Chronic Exposure to Ovalbumin by Modulating the TSLP-DC-OX40L Axis.	Budesonide	13-23	thymic stromal lymphopoietin	Mus musculus	183-187
29654433-0	2018	CpG-ODNs and Budesonide Act Synergistically to Improve Allergic Responses in Combined Allergic Rhinitis and Asthma Syndrome Induced by Chronic Exposure to Ovalbumin by Modulating the TSLP-DC-OX40L Axis.	Budesonide	13-23	tumor necrosis factor (ligand) superfamily, member 4	Mus musculus	191-196
29654433-3	2018	This study aimed to assess the therapeutic effects of CpG-ODNs combined with budesonide (BUD) on upper and lower-airway inflammation and remodeling in mice with CARAS induced by chronic exposure to ovalbumin (OVA), exploring the possible underlying molecular mechanisms.	Budesonide	89-92	serine (or cysteine) peptidase inhibitor, clade B, member 1, pseudogene	Mus musculus	198-207
29998120-10	2018	TRF budesonide, additionally to optimized RAS blockade, reduced proteinuria and maintained eGFR in IgAN patients, suggesting a reduced risk of future progression to ESRD.	Budesonide	4-14	epidermal growth factor receptor	Homo sapiens	91-95
30078282-14	2018	The expression of E-cadherin of Model, MSCs and Budesonide group rats was significantly lower than Control group, while the expression of alpha-SMA and Fn were significantly higher.	Budesonide	48-58	cadherin 1	Rattus norvegicus	18-28
29998120-10	2018	TRF budesonide, additionally to optimized RAS blockade, reduced proteinuria and maintained eGFR in IgAN patients, suggesting a reduced risk of future progression to ESRD.	Budesonide	4-14	IGAN1	Homo sapiens	99-103
28730856-0	2018	In vitro drug-drug interactions of budesonide: inhibition and induction of transporters and cytochrome P450 enzymes.	Budesonide	35-45	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	92-107
28730856-4	2018	This study aimed to evaluate the potential of budesonide to act as a perpetrator or a victim of transporter- or CYP-mediated drug-drug interactions (DDIs).	Budesonide	46-56	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	112-115
28730856-7	2018	Changes in mRNA expression in human hepatocytes and enzyme activity in human liver microsomes by budesonide were determined for CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6 and <protein-id="1576">CYP3A.	Budesonide	97-107	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	128-134
28730856-7	2018	Changes in mRNA expression in human hepatocytes and enzyme activity in human liver microsomes by budesonide were determined for CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6 and <protein-id="1576">CYP3A.	Budesonide	97-107	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	136-142
28730856-7	2018	Changes in mRNA expression in human hepatocytes and enzyme activity in human liver microsomes by budesonide were determined for CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6 and <protein-id="1576">CYP3A.	Budesonide	97-107	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	144-150
28730856-9	2018	The data indicated that budesonide is a substrate of P-gp but is not a substrate or an inhibitor of the other transporters investigated.	Budesonide	24-34	phosphoglycolate phosphatase	Homo sapiens	53-57
28730856-11	2018	The effect of P-gp on budesonide disposition is anticipated to be low owing to CYP3A-mediated clearance.	Budesonide	22-32	phosphoglycolate phosphatase	Homo sapiens	14-18
29854030-7	2018	Results: Monotherapy with budesonide or calcitriol inhibited the high expression of collagen type I protein and upregulated the low expression of Smad7 in asthmatic mice.	Budesonide	26-36	SMAD family member 7	Mus musculus	146-151
29773947-1	2018	Purpose: This study investigated the efficacy, safety, and pharmacokinetics of the inhaled corticosteroid/long-acting beta2-agonist fixed-dose combination budesonide/formoterol fumarate (BFF) metered dose inhaler (MDI), compared with the monocomponents budesonide (BD) MDI and formoterol fumarate (FF) MDI, in patients with moderate-to-severe COPD.	Budesonide	155-165	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	118-123
29127842-8	2018	Dynamic compliance was significantly improved in the budesonide group on days 3 (p=0.018) and 5 (p=0.011) The levels of CXCL-8 and IL-6 diminished on days 3-5 after start of budesonide (p&lt;0.05).	Budesonide	53-63	C-X-C motif chemokine ligand 8	Homo sapiens	120-126
29127842-8	2018	Dynamic compliance was significantly improved in the budesonide group on days 3 (p=0.018) and 5 (p=0.011) The levels of CXCL-8 and IL-6 diminished on days 3-5 after start of budesonide (p&lt;0.05).	Budesonide	53-63	interleukin 6	Homo sapiens	131-135
29127842-9	2018	CONCLUSION: In COPD patients on MV, nebulized budesonide was associated with reduced BAL CXCL8 and IL-6 levels and neutrophil numbers as well as an improvement in ventilatory mechanics and facilitated weaning.	Budesonide	46-56	C-X-C motif chemokine ligand 8	Homo sapiens	89-94
29127842-9	2018	CONCLUSION: In COPD patients on MV, nebulized budesonide was associated with reduced BAL CXCL8 and IL-6 levels and neutrophil numbers as well as an improvement in ventilatory mechanics and facilitated weaning.	Budesonide	46-56	interleukin 6	Homo sapiens	99-103